Simula 1993 ~ Kasalukuyan
Domestic na mga proyekto
LAYUNIN NAMIN ANG MAGIGING MAHUSAY !Domestic na mga proyekto
I-click ang pamagat para sa mga detalye .
CSFB
| Company | Project | Language |
|---|---|---|
CSFB |
Financial proposals | Korean ->English |
CSFB |
Financial proposals | Korean->English Proofreading |
CSFB |
Hyundai Glovis Co., Ltd. financial data | Korean ->English |
CSFB |
CSFB/TREMONT INVESTABLE HEDGE FUND INDEX | English->Korean |
CSFB |
JINRO CO.,LTD. M&A Proposals | Korean ->English |
CSFB |
JINRO CO.,LTD. M&A Proposals | Korean->English Proofreading |
CSFB |
Dispatch at the Seoul Finance Center (translation service support) | Korean ->English Interpreting |
CSFB |
Daewoo Heavy Industries & Machinery Ltd. M&A Proposals | Korean ->English |
CSFB |
Daewoo Heavy Industries & Machinery Ltd. M&A Proposals | Korean ->English |
CSFB |
Daewoo Heavy Industries & Machinery Ltd. M&A Proposals | Korean ->English |
CSFB |
Daewoo Heavy Industries & Machinery Ltd. M&A Proposals | Korean->English Proofreading |
CSFB |
Donghae Pulp Co., Ltd. MOU Data | Korean->English Proofreading |
CSFB |
Hyundai Glovis Co., Ltd. financial data | Korean->English Proofreading |
CSFB |
Korean railway structural reform data | Korean ->English |
CSFB |
Dongah Construction Industrial Co., Ltd. M&A Prososals | Korean ->English |
CSFB |
Korea Express Co., Ltd. M&A Proposals | Korean ->English |
CSFB |
Hana Bank Financial data | Korean ->English |
CSFB |
Hana Bank Financial data | Korean ->English |
CSFB |
Hana Bank financial statements | Korean ->English |
CSFB |
SK Telecom Co., Ltd. financial statements | Korean ->English |
CSFB |
Pan Ocean Shipping Co., Ltd. M&A Proposals | Korean ->English |
CSFB |
Hyundai Glovis Co., Ltd. financial data | Korean ->English |
CSFB |
Kookmin Bank M&A Project data | Korean ->English |
CSFB |
Kookmin Bank M&A Project data | Korean->English Proofreading |
CSFB |
JINRO CO.,LTD. financial statements | Korean ->English |
CSFB |
LG Card M&A proposals | Korean ->English |
CSFB |
Daewoo Heavy Industries & Machinery Ltd. M&A Proposals | Korean->English Proofreading |
CSFB |
Ssangyong Motor M&A Proposals | Korean ->English |
CSFB |
Ssangyong Motor M&A Proposals | Korean->English Proofreading |
CSFB |
LG Chem, Ltd. financial statements | Korean ->English |
CSFB |
LG Chem, Ltd. financial statements | Korean->English Proofreading |
CSFB |
KAMCO consulting data | English->Korean |
CSFB |
Samyoung Express Newsletter | Korean ->English |
CSFB |
Samyoung Express Newsletter | Korean->English Proofreading |
CSFB |
Muhak soju M&A Proposals | Korean ->English |
CSFB |
Muhak soju M&A Proposals | Korean->English Proofreading |
CSFB |
Kumbokju M&A Proposals | Korean ->English |
CSFB |
Kumbokju M&A Proposals | Korean->English Proofreading |
CSFB |
C&M Communication Audit report | Korean ->English |
CSFB |
C&M Communication Audit report | Korean->English Proofreading |
CSFB |
Conditions of listing stocks | Korean ->English |
CSFB |
Conditions of listing stocks | Korean->English Proofreading |
CSFB |
CASH FLOW | Korean ->English |
CSFB |
LG Powercom Corp. Financail statements | Korean ->English |
CSFB |
LG Powercom Corp. Financail statements | Korean->English Proofreading |
CSFB |
Dacom M&A Proposals | Korean->English Proofreading |
CSFB |
Dacom M&A Proposals | Korean->English Proofreading |
CSFB |
TPS business project strategy | Korean ->English |
CSFB |
TPS business project strategy | Korean->English Proofreading |
CSFB |
Minimum Cash Policy | Korean ->English |
CSFB |
Minimum Cash Policy | Korean->English Proofreading |
CSFB |
Company Organization Chart | Korean ->English |
CSFB |
Company Organization Chart | Korean->English Proofreading |
CSFB |
Dacom business plan | Korean ->English |
CSFB |
Dacom business plan | Korean->English Proofreading |
CSFB |
Gravity Cross-border listing proposals - a global online game company | Korean ->English |
CSFB |
Gravity Cross-border listing proposals - a global online game company | Korean->English Proofreading |
CSFB |
Kookmin Bank RFP data | Korean ->English |
CSFB |
Kookmin Bank RFP data | Korean->English Proofreading |
CSFB |
Korean Peasants League profile | Korean ->English |
CSFB |
Korean Peasants League profile | Korean->English Proofreading |
CSFB |
Credit Suisse Group - the bylaw of a business company | English->Korean |
CSFB |
Doosan Infracore Co., Ltd. M&A Proposals | Korean ->English |
CSFB |
Doosan Infracore Co., Ltd. M&A Proposals | Korean->English Proofreading |
CSFB |
JINRO CO.,LTD. M&A newsletter | Korean ->English |
CSFB |
JINRO CO.,LTD. M&A newsletter | Korean->English Proofreading |
CSFB |
Dacom Financial Project | Korean ->English |
CSFB |
Dacom Financial Project | Korean->English Proofreading |
CSFB |
Dacom goods and services flow chart | Korean ->English |
CSFB |
Dacom goods and services flow chart | Korean->English Proofreading |
CSFB |
Financial transactions steps | Korean ->English |
CSFB |
Financial transactions steps | Korean->English Proofreading |
CSFB |
JINRO CO.,LTD. financial statements additional data | Korean ->English |
CSFB |
JINRO CO.,LTD. financial statements additional data | Korean->English Proofreading |
CSFB |
New York IR Framework - cross-border listing | Korean ->English |
CSFB |
New York IR Framework - cross-border listing | Korean->English Proofreading |
CSFB |
Oriental Chemical Industries M&A Proposas | Korean ->English |
CSFB |
Oriental Chemical Industries M&A Proposas | Korean->English Proofreading |
CSFB |
Railroad construction agreement | Korean ->English |
CSFB |
Railroad construction agreement | Korean->English Proofreading |
CSFB |
Issue of bonds documents | Korean ->English |
CSFB |
Issue of bonds documents | Korean->English Proofreading |
CSFB |
JINRO CO.,LTD. Audit report | Korean ->English |
CSFB |
JINRO CO.,LTD. Audit report | Korean->English Proofreading |
CSFB |
Conversation between the management and employees - CSFB | English->Korean |
CSFB |
DHIM Supplementary Agreement | English->Korean |
CSFB |
Fund Raising data | Korean ->English |
CSFB |
Fund Raising data | Korean->English Proofreading |
CSFB |
Structuring Menorendom data | Korean ->English |
CSFB |
Structuring Menorendom data | Korean->English Proofreading |
CSFB |
Economy Outlook | Korean ->English |
CSFB |
Text of a speech | Korean ->English |
CSFB |
Economy Outlook | Korean->English Proofreading |
CSFB |
Mortgage Loan Approval (Revised) | Korean ->English |
CSFB |
Mortgage Loan Approval (Revised) | Korean->English Proofreading |
CSFB |
Resume of Manangement | Korean ->English |
CSFB |
Resume of Manangement | Korean->English Proofreading |
CSFB |
Daehan Investment Trust Securities M&A business progress reports | Korean ->English |
CSFB |
Daehan Investment Trust Securities M&A business progress reports | Korean->English Proofreading |
CSFB |
Dongah Construction Industrial Co., Ltd. M&A Proposals | Korean ->English |
CSFB |
Dongah Construction Industrial Co., Ltd. M&A Proposals | Korean->English Proofreading |
CSFB |
Risk management data | Korean ->English |
CSFB |
Risk management data | Korean->English Proofreading |
CSFB |
S&P RATING Data | Korean ->English |
CSFB |
S&P RATING Data | Korean->English Proofreading |
CSFB |
The steel industry report | English->Korean |
CSFB |
SK Telecom Co., Ltd. financial statements | Korean ->English |
CSFB |
SK Telecom Co., Ltd. financial statements | Korean->English Proofreading |
CSFB |
Wage negotiation requirements | Korean ->English |
CSFB |
Wage negotiation requirements | Korean->English Proofreading |
CSFB |
Incorporated subsidiary plan | Korean ->English |
CSFB |
Incorporated subsidiary plan | Korean->English Proofreading |
CSFB |
Lucky Life Insurance Co., Ltd. M&A Proposals | Korean ->English |
CSFB |
Lucky Life Insurance Co., Ltd. M&A Proposals | Korean->English Proofreading |
CSFB |
Funds borrowing agreement | Korean ->English |
CSFB |
Funds borrowing agreement | Korean->English Proofreading |
CSFB |
Business plan & board of directors profiles | Korean ->English |
CSFB |
Business plan & board of directors profiles | Korean->English Proofreading |
CSFB |
Korea National Oil Corporation M&A due diligence qustionnare | Korean ->English |
CSFB |
Korea National Oil Corporation M&A due diligence qustionnare | Korean->English Proofreading |
CSFB |
Hynix Semiconductor Inc. Report | English->Korean |
CSFB |
New loan credit approval report | Korean ->English |
CSFB |
New loan credit approval report | Korean->English Proofreading |
CSFB |
Origination process manual | Korean ->English |
CSFB |
Origination process manual | Korean->English Proofreading |
CSFB |
Hana Bank Financial data - read estate | Korean ->English |
CSFB |
Hana Bank Financial data - read estate | Korean->English Proofreading |
CSFB |
Industry analysis data | Korean ->English |
CSFB |
Delinquent loan management manual | Korean ->English |
CSFB |
Delinquent loan management manual | Korean->English Proofreading |
CSFB |
APLO Provisional settlement of accounts report | Korean ->English |
CSFB |
APLO Provisional settlement of accounts report | Korean->English Proofreading |
CSFB |
Loan transaction agreements | Korean ->English |
CSFB |
Loan transaction agreements | Korean->English Proofreading |
CSFB |
POSCO stock public offering proposals | Korean ->English |
CSFB |
POSCO stock public offering proposals | Korean->English Proofreading |
CSFB |
SK TELECOM reserve proposals | Korean ->English |
CSFB |
SK TELECOM reserve proposals | Korean->English Proofreading |
CSFB |
Meeting data between the Korea National Oil Corporation & Moody's Corporation | English->Korean |
CSFB |
Meeting data between the Korea National Oil Corporation & Moody's Corporation | Korean->English Proofreading |
CSFB |
Bond, Universe report | Korean ->English |
CSFB |
Bond, Universe report | Korean->English Proofreading |
CSFB |
Samsung Total Corp. report | Korean ->English |
CSFB |
Samsung Total Corp. report | Korean->English Proofreading |
CSFB |
Woori Bank business stratedy report | Korean ->English |
CSFB |
Woori Bank business stratedy report | Korean->English Proofreading |
CSFB |
BAMBOO confrontational strategy report | Korean ->English |
CSFB |
BAMBOO confrontational strategy report | Korean->English Proofreading |
CSFB |
Daewoo Electronics proposals | Korean ->English |
CSFB |
Daewoo Electronics proposals | Korean->English Proofreading |
CSFB |
Financial derivatives peaked data | Korean ->English |
CSFB |
Financial derivatives peaked data | Korean->English Proofreading |
CSFB |
Korea Stock Exchange financial statements | Korean ->English |
CSFB |
Korea Stock Exchange financial statements | Korean->English Proofreading |
CSFB |
RBC Program management plan | Korean ->English |
CSFB |
RBC Program management plan | Korean->English Proofreading |
CSFB |
DAEWOO ENGINEERING & CONSTRUCTION CO., LTD. financial statements | Korean ->English |
CSFB |
DAEWOO ENGINEERING & CONSTRUCTION CO., LTD. financial statements | Korean->English Proofreading |
CSFB |
DAEWOO ENGINEERING & CONSTRUCTION CO., LTD. Sale - Company presentation data | Korean ->English |
CSFB |
DAEWOO ENGINEERING & CONSTRUCTION CO., LTD. Sale - Company presentation data | Korean->English Proofreading |
CSFB |
00 life insurance company - promotion testimonial plan | Korean ->English |
CSFB |
00 life insurance company - promotion testimonial plan | Korean->English Proofreading |
CSFB |
Korea's construction market Q&A data | Korean ->English |
CSFB |
Investment briefing presentation data | Korean ->English |
CSFB |
Investment briefing presentation data | Korean->English Proofreading |
CSFB |
C&M Project Appraisal report | Korean ->English |
CSFB |
C&M Project Appraisal report | Korean->English Proofreading |
CSFB |
Potential Buyer Profiles | English->Korean |
CSFB |
Korea Development Bank report | Korean ->English |
CSFB |
Korea Development Bank report | Korean->English Proofreading |
CSFB |
Hyundai Steel report | Korean ->English |
CSFB |
Hyundai Steel report | Korean->English Proofreading |
CSFB |
Hyundai Motor M&A consultation paper | Korean ->English |
CSFB |
Hyundai Motor M&A consultation paper | Korean->English Proofreading |
CSFB |
DAEWOO ENGINEERING & CONSTRUCTION CO., LTD. financial statements | Korean ->English |
CSFB |
DAEWOO ENGINEERING & CONSTRUCTION CO., LTD. financial statements | Korean->English Proofreading |
CSFB |
Promotion testimonial plan | Korean ->English |
CSFB |
Promotion testimonial plan | Korean->English Proofreading |
CSFB |
00 life insurance company - promotion testimonial plan | Korean ->English |
CSFB |
00 life insurance company - promotion testimonial plan | Korean->English Proofreading |
CSFB |
Hana Bank Financial data | Korean ->English |
CSFB |
Hana Bank Financial data | Korean->English Proofreading |
CSFB |
Daewoo Heavy Industries & Machinery Ltd. M&A Proposals | Korean ->English |
CSFB |
Daewoo Heavy Industries & Machinery Ltd. M&A Proposals | Korean ->English |
CSFB |
Hyundai Glovis Co., Ltd. financial data | Korean ->English |
CSFB |
Hyundai Glovis Co., Ltd. financial data | Korean->English Proofreading |
CSFB |
LG Chem, Ltd. financial statements | Korean ->English |
CSFB |
LG Chem, Ltd. financial statements | Korean->English Proofreading |
CSFB |
LG Card the third quarter account material | Korean ->English |
CSFB |
LG Card the third quarter account material | Korean ->English Interpreting |
CSFB |
C&M Communication Audit report | Korean ->English |
CSFB |
C&M Communication Audit report | Korean ->English |
CSFB |
Daehan Investment Trust Securities M&A business progress reports | Korean ->English |
CSFB |
Daehan Investment Trust Securities M&A business progress reports | Korean ->English Interpreting |
CSFB |
Hynix Semiconductor Inc. M&A Proposals | Korean ->English |
CSFB |
Hynix Semiconductor Inc. M&A Proposals | Korean->English Proofreading |
CSFB |
Hynix Semiconductor Inc. financial statements | Korean ->English |
CSFB |
Hynix Semiconductor Inc. financial statements | Korean->English Proofreading |
CSFB |
Himart M&A Proposals | Korean ->English |
CSFB |
Himart M&A Proposals | Korean->English Proofreading |
CSFB |
Pan Ocean Shipping Co., Ltd. financial statements | Korean ->English |
CSFB |
Pan Ocean Shipping Co., Ltd. financial statements | Korean->English Proofreading |
CSFB |
Risk management data | Korean ->English |
CSFB |
Risk management data | Korean->English Proofreading |
CSFB |
Samsung Total Corp. finalcial statements | Korean ->English |
CSFB |
Samsung Total Corp. finalcial statements | Korean->English Proofreading |
CSFB |
Ssangyong Motor financial statements | Korean ->English |
CSFB |
Ssangyong Motor financial statements | Korean->English Proofreading |
CSFB |
Hana Bank financial statements | Korean ->English |
CSFB |
Hana Bank financial statements | Korean->English Proofreading |
CSFB |
Gravity Strategic Report for Global Game Market - a global online game company | Korean ->English |
CSFB |
Gravity Strategic Report for Global Game Market - a global online game company | Korean->English Proofreading |
CSFB |
MKE statement of accounts for the first half year | Korean ->English |
CSFB |
LG Card the second quarter account material | Korean ->English |
CSFB |
Glovis Co., Ltd M&A Proposal | Korean ->English |
CSFB |
Gravity Strategic Report for Global Game Market - a global online game company | Korean ->English |
CSFB |
Dispatch at the Seoul Finance Center (translation service support) | Korean ->English |
CSFB |
Management Presentation questionnaire | Korean ->English |
CSFB |
Management Presentation questionnaire | Korean->English Proofreading |
CSFB |
KIA moters Investor Q&A data | Korean ->English |
CSFB |
KIA moters Investor Q&A data | Korean->English Proofreading |
CSFB |
KEC business analysis report | English->Korean |
CSFB |
Consolidated RFI Review by Workstream | Korean ->English |
CSFB |
Phoenix project | Korean ->English |
CSFB |
Phoenix project | Korean->English Proofreading |
CSFB |
Due diligence regulation & procedure data | Korean ->English |
CSFB |
Due diligence regulation & procedure data | Korean->English Proofreading |
CSFB |
Phoenix MOU | Korean ->English |
CSFB |
Phoenix MOU | Korean->English Proofreading |
CSFB |
Bid application | Korean ->English |
CSFB |
Bid application | Korean->English Proofreading |
CSFB |
MOU Data | Korean ->English |
CSFB |
MOU Data | Korean->English Proofreading |
CSFB |
Data Room | Korean ->English |
CSFB |
Donghae Pulp Co., Ltd. MOU Data | Korean ->English |
CSFB |
Donghae Pulp Co., Ltd. MOU Data | Korean->English Proofreading |
CSFB |
Information Memorandum | Korean ->English |
CSFB |
Information Memorandum | Korean->English Proofreading |
CSFB |
Donghae Pulp Co., Ltd. due diligence interpreting - dispatch at Ulsan, Korea | Korean ->English Interpreting |
CSFB |
Execution drawing data | Korean ->English |
CSFB |
Product Instruction | Korean ->English |
CSFB |
U-City plan | Korean ->English |
CSFB |
Chelton Hotel observation platform Website G17N | Korean ->English |
Goldman Sachs Asset Management
| Company | Project | Language |
|---|---|---|
Goldman Sachs Asset Management |
US Equity Portfolio | English ->Korean |
Goldman Sachs Asset Management |
Global fixed income outlook | English ->Korean |
Goldman Sachs Asset Management |
RFP Korea Post FOHF Draf t2, October 2007 | English ->Korean |
Goldman Sachs Asset Management |
AIMA Fund of Hedge Funds Managers RFP | English ->Korean |
Goldman Sachs Asset Management |
Copy of Korea Post_GS GED plc Returns and Contributions | English ->Korean |
Goldman Sachs Asset Management |
Final Korea Post RFP Oct 2007(Update) | English ->Korean |
Goldman Sachs Asset Management |
Korea Post Global CORE 09 Oct 07 | English ->Korean |
Goldman Sachs Asset Management |
Global CORE Performance | English ->Korean |
Goldman Sachs Asset Management |
Korea Post Global Core | English ->Korean |
Goldman Sachs Asset Management |
Offshore fund menu July 2007 | English ->Korean |
Goldman Sachs Asset Management |
Distribution of property ordinance | Korean ->English |
Goldman Sachs Asset Management |
Distribution of property ordinance | Korean->English Proofreading |
Goldman Sachs Asset Management |
Asset portfolio data | English ->Korean |
Goldman Sachs Asset Management |
Global Financial pitchbook | English ->Korean |
Goldman Sachs Asset Management |
Global Equity pitchbook | English ->Korean |
Goldman Sachs Asset Management |
Global EM Leaders pitchbook | English ->Korean |
Goldman Sachs Asset Management |
Global BRICs pitchbook | English ->Korean |
Goldman Sachs Asset Management |
Korean Equity Fund Aug 2008 | English ->Korean |
Goldman Sachs Asset Management |
Financials Product Focus v3, GFS LEAFLET COPY | English ->Korean |
Goldman Sachs Asset Management |
2Q 08 Offshore Inst.Value REVISED | English ->Korean |
Goldman Sachs Asset Management |
EDUCATION FORMATTED | English ->Korean |
Goldman Sachs Asset Management |
US Equity Strategy - SA offshore 2Q08 | English ->Korean |
Goldman Sachs Asset Management |
Disclaimer (GSAM) | English ->Korean |
Goldman Sachs Asset Management |
4Q 08 GlS | English ->Korean |
Goldman Sachs Asset Management |
Market Pulse October 2008 | English ->Korean |
Goldman Sachs Asset Management |
Monthly Review (Sep08)) | English ->Korean |
Goldman Sachs Asset Management |
the Ministry of Information and Communication, postal service headquarters RFP | English->Korean |
Samsung Securities Co., Ltd.
| Company | Project | Language |
|---|---|---|
Samsung Securities Co., Ltd. |
Duke Street Capital - December 2012 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
Harbourvest Dover VIII Year End Letter - Korea Post Savings Bureau, 31,12,2012 | English ->Korean |
Samsung Securities Co., Ltd. |
PEF Proposal for KTCU ( MezzVest) & Partners Group Direct Mezzanine 2013, L.P. Inc.』Fund Documents - Partners Group Direct Mezzanine 2013, L.P. Inc. Fund Proposal, 23 January 2013 | English ->Korean |
Samsung Securities Co., Ltd. |
Korea Post RFP Final Draft | English ->Korean |
Samsung Securities Co., Ltd. |
Korea Post Questionnaire(2-1) | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - June 2009 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
Partners Group PPM/LPA | English ->Korean |
Samsung Securities Co., Ltd. |
Industry Outlook | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - March 2009 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street No.5 PEF Performance Report (As of Dec. 31, 2008) | Korean->English Proofreading |
Samsung Securities Co., Ltd. |
Partners Group Secondary 2008 May 2008 | English ->Korean |
Samsung Securities Co., Ltd. |
Partners Group Private Equity and Private Debt General Information Q2 2008 | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - September 2008 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street No.5 PEF Performance Report (As of Dec. 31, 2008) | Korean ->English |
Samsung Securities Co., Ltd. |
articles of incorporation. | Korean ->Chinese |
Samsung Securities Co., Ltd. |
Duke December 2007 Quarterly report | English ->Korean |
Samsung Securities Co., Ltd. |
Korea Post, Ministry of Information and Communications, Republic of Korea - Savings - Duke Street Capital VI No. 1 Limited Partnership | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - March 2008 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
DSC VI FUND SUMMARY, Unrealised Investment Review, Financial Statements , Notes to the Financial Statements, DSC VI Fund Cashflow History Schedule | English ->Korean |
Samsung Securities Co., Ltd. |
Brookfield Confidential Due Diligence Questionnaire - Brookfield Infrastructure Fund II Brookfield’s Flagship Private Infrastructure Fund | English ->Korean |
Samsung Securities Co., Ltd. |
Partners Group Direct Mezzanine 2013, L.P. Inc., Seoul l 25 January 2013 - Korea Post Proj. | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Parabis Summary, 17.12.12 | English ->Korean |
Samsung Securities Co., Ltd. |
Meetings with Duke Street JV | English ->Korean |
Samsung Securities Co., Ltd. |
LGT RFP Summary Sheet - Final Version | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - December 2008 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street VI qtrly report 31 December | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - December 2009 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street No.6 PEF Annual Report As of Dec. 31 2009 | English ->Korean |
Samsung Securities Co., Ltd. |
ANNUAL REPORT 2009 - PARTNERS GROUP SECONDARY 2008, L.P. | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - March 2010 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
PARTNERS GROUP SECONDARY 2008, L.P. QUARTERLY REPORT Q1 2010 | English ->Korean |
Samsung Securities Co., Ltd. |
Request for Proposal to Korea Post - Baillie Gifford Global Alpha & Baillie Gifford North American Equities | English ->Korean |
Samsung Securities Co., Ltd. |
American Equities GIPS June 2010 | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - June 2010 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
Partners Group Secondary 2008 - PORTFOLIO OVERVIEW | English ->Korean |
Samsung Securities Co., Ltd. |
Korea Post Special Report_201006. | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - September 2010 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
Asia Pacific Equity Strategy (Citi) 18 November 2010 | English ->Korean |
Samsung Securities Co., Ltd. |
PARTNERS GROUP SECONDARY 2008, L.P. QUARTERLY REPORT Q3 2010 | English ->Korean |
Samsung Securities Co., Ltd. |
JONES LANG LASALLE IP, INC - Global Market Perspective November 2010, Real Estate Outlook for 2011 | English ->Korean |
Samsung Securities Co., Ltd. |
JONES LANG LASALLE IP, INC - Indian Real Estate An Outlook on industry trends | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - December 2010 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
PARTNERS GROUP SECONDARY 2008, L.P. QUARTERLY REPORT Q4 2010 | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Korea Post Special Reoprt-31 December 2010 & PG - Korea Post Special Report | English ->Korean |
Samsung Securities Co., Ltd. |
Korea Post RFP_9 May - Application Documents of Tunstall RCP II Fund, L.P. | English ->Korean |
Samsung Securities Co., Ltd. |
Korea Post Supplemental Information | English ->Korean |
Samsung Securities Co., Ltd. |
Distressed Investments Solution for Korea Post | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - March 2011 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street VII, Portfolio Review May 2011 | English ->Korean |
Samsung Securities Co., Ltd. |
PARTNERS GROUP SECONDARY 2008, L.P. QUARTERLY REPORT Q1 2011 | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - Duke Street Private Equity Inspiring the ambitious | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - Leveraged Buyouts How Do They Work? | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - June 2011 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
PARTNERS GROUP SECONDARY 2008, L.P. QUARTERLY REPORT Q2 2011 | English ->Korean |
Samsung Securities Co., Ltd. |
AMP Capital Investors - Global REIT update : Week ending Friday, 23 September 2011 | English ->Korean |
Samsung Securities Co., Ltd. |
Korea Teachers Pension - QUESTIONNAIRE (1) FOR DUE DILIGENCE OF Dover Street VIII L.P. | English ->Korean |
Samsung Securities Co., Ltd. |
HARBOURVEST Korea Teachers Pension Dover Street VIII L.P. Due Diligence – Part 2 & Dover Street VIII L.P. Due Diligence – Part 3 | English ->Korean |
Samsung Securities Co., Ltd. |
LGT Capital Partners Crown Global Secondaries III (“CGS III”) A program focusing on global secondary transactions October 2011 | English ->Korean |
Samsung Securities Co., Ltd. |
HarbourVest Partners Secondary Program Korea Post Savings – Request for Proposal OCTOBER 2011 | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - September 2011 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
LGT Capital Partners' secondary strategy & HARBOURVEST Korea Post Potential Impact of European Financial Crisis on Dover Street VIII | English ->Korean |
Samsung Securities Co., Ltd. |
LGT Capital Partners - Presentation to Korea Post Savings Crown Global Secondaries III (“CGS III”) A program focusing on global secondary transactions 12 December 2011 | English ->Korean |
Samsung Securities Co., Ltd. |
PARTNERS GROUP SECONDARY 2008, L.P. QUARTERLY REPORT Q3 2011 | English ->Korean |
Samsung Securities Co., Ltd. |
HARBOURVEST Korea Post– Implications of the Global Macroeconomic Environment on HarbourVest Partners Secondary Investment Strategy | English ->Korean |
Samsung Securities Co., Ltd. |
Dover Street VIII L.P. Summary of Major Terms and Conditions | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street VI Fund Investor Letter | English ->Korean |
Samsung Securities Co., Ltd. |
HARBOURVEST Korea Post– Answers to DDQ | English ->Korean |
Samsung Securities Co., Ltd. |
PARTNERS GROUP SECONDARY 2008, L.P. QUARTERLY REPORT Q4 2011 | English ->Korean |
Samsung Securities Co., Ltd. |
Dover Street VIII L.P. Investment Program to Purchase Limited Partnership Interests on the Secondary Market, May 2011 & HarbourVest_Staff_2012_03(1) | English ->Korean |
Samsung Securities Co., Ltd. |
HarbourVest – Overview of Controls | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Presentation to Korea Post 29 May 2012 & Additional request from Korea Post | English ->Korean |
Samsung Securities Co., Ltd. |
PARTNERS GROUP SECONDARY 2008, L.P. QUARTERLY REPORT Q1 2012 | English ->Korean |
Samsung Securities Co., Ltd. |
PARTNERS GROUP SECONDARY 2008, L.P. - Portfolio update | as of 31 March 2012 | English ->Korean |
Samsung Securities Co., Ltd. |
MORGAN STANLEY Monthly Commentary June 2012 | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - June 2012 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
HARBOURVEST Dover Street Investment Program Case Studies | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Summary for Korea Post | English ->Korean |
Samsung Securities Co., Ltd. |
PARTNERS GROUP SECONDARY 2008, L.P. QUARTERLY REPORT Q2 2012 | English ->Korean |
Samsung Securities Co., Ltd. |
HARBOURVEST Dover Street Investment Program, AUGUST 2012 | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - DUKE STREET MAKES INVESTMENT IN LEADING PROVIDER OF LEGAL AND CLAIMS MANAGEMENT SERVICES | English ->Korean |
Samsung Securities Co., Ltd. |
Special Reporting for Korea Post (Insurance) Appendix, PG Secondary 2008, L.P. | English ->Korean |
Samsung Securities Co., Ltd. |
ADVISORY COMMITTEE NOTE OF MEETING OF 5 SEPTEMBER | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Portfolio Review, September 2012 | English ->Korean |
Samsung Securities Co., Ltd. |
Brand name firm built over 20 years operating in Western European mid-market operation out of offices in London and Paris | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - September 2012 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
Partners Group Direct Mezzanine 2013 | English ->Korean |
Samsung Securities Co., Ltd. |
PARTNERS GROUP SECONDARY 2008, L.P. QUARTERLY REPORT Q3 2012 | English ->Korean |
Samsung Securities Co., Ltd. |
Partners Group Foreign Account Tax Compliance Act (FATCA) November 2012 | English ->Korean |
Samsung Securities Co., Ltd. |
DS VI Minutes of the Advisory Committee Meeting, 28 February 2013 at Nations House, 103 Wigmore Street, London W1U 1QS | English ->Korean |
Samsung Securities Co., Ltd. |
Brookfield Infrastructure Fund II Request for Information Public Officials Benefit Association (“POBA”), March 2013 | English ->Korean |
Samsung Securities Co., Ltd. |
HARBOURVEST Minutes of the Dover Street Advisory Committee Meeting, February 12, 2013 | English ->Korean |
Samsung Securities Co., Ltd. |
HarbourVest KTCU Due Diligence Check List - March 2013 | English ->Korean |
Samsung Securities Co., Ltd. |
PARTNERS GROUP SECONDARY 2008, L.P. QUARTERLY REPORT Q4 2012 | English ->Korean |
Samsung Securities Co., Ltd. |
HarbourVest Dover Street VIII Due Diligence Check List - Korea Post – April 2013 | English ->Korean |
Samsung Securities Co., Ltd. |
KKR North America Fund XI L.P. Executive Summary Prepared for and at the request of: Korea Post, April 2013 | English ->Korean |
Samsung Securities Co., Ltd. |
Korea Post Buyout RFP_(ENG) vF | English ->Korean |
Samsung Securities Co., Ltd. |
HarbourVest –2012 DIRECT - KP, APRIL 2013 | English ->Korean |
Samsung Securities Co., Ltd. |
Korea Post Buyout RFP_(ENG) v2 | English ->Korean |
Samsung Securities Co., Ltd. |
CANACCORD Genuity Project Spring Overview of portfolio companies, April 2013 | English ->Korean |
Samsung Securities Co., Ltd. |
KKR A Balanced Portfolio: The Case for Mega-Buyout Funds, 2013 | English ->Korean |
Samsung Securities Co., Ltd. |
KKR Details of probation | English ->Korean |
Samsung Securities Co., Ltd. |
HarbourVest Secondary Investment Types, KTP – June 2012 | English ->Korean |
Samsung Securities Co., Ltd. |
PARTNERS GROUP SECONDARY 2008, L.P. QUARTERLY REPORT Q1 2013 | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - March 2013 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
Harbourvest Dover VIII Quarterly Report Letter - Samsung Securities Co., Ltd., 31,03,2013 | English ->Korean |
Samsung Securities Co., Ltd. |
HarbourVest Dover Street VIII Update - Korea Post – JULY | 2013 | English ->Korean |
Samsung Securities Co., Ltd. |
Arkadin Transscirpt, Tuesday, 6 August 2013 | English ->Korean |
Samsung Securities Co., Ltd. |
KOREA POST: Notice on the follow-up action plan for the post management of POST deposit alternative investments | Korean ->English |
Samsung Securities Co., Ltd. |
KOREA POST: Notice on the follow-up action plan for the post management of POST deposit alternative investments | Korean->English Proofreading |
Samsung Securities Co., Ltd. |
PARTNERS GROUP SECONDARY 2008, L.P. QUARTERLY REPORT Q2 2013 | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - June 2013 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - DUKE STREET OPPORTUNITIES FUND I, 20.11.13 | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - September 2013 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
CFA Level 2 Schweser Study Notes 2010 - Book 1 | English ->Korean |
Samsung Securities Co., Ltd. |
PARTNERS GROUP SECONDARY 2008, L.P. QUARTERLY REPORT Q3 2013 | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - DUKE STREET OPPORTUNITIES FUND I £100M TARGET TO SUPPORT £500M INVESTMENT OVER 3 YEARS | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - FUND RETURNS & DEAL ATTRIBUTION - KIO Summary & Forecas, 20.01.14 | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - December 2013 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
PARTNERS GROUP SECONDARY 2008, L.P. QUARTERLY REPORT Q4 2013 | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - 2013 Financial Statements - Duke Street VI No.1 Limited Partnership | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street VI Investor Update Call, 6 March 2014 | English ->Korean |
Samsung Securities Co., Ltd. |
KTP RFP PROPOSAL_vFINAL | English ->Korean |
Samsung Securities Co., Ltd. |
DS VI Minutes of the Advisory Committee Meeting, 5 March 2014 at Nations House, 103 Wigmore Street, London W1U 1QS | English ->Korean |
Samsung Securities Co., Ltd. |
GoldPoint Partners - GoldPoint Partners Co-Investment V, LP - Presentation to Teachers’ Pension, April 1, 2014 | English ->Korean |
Samsung Securities Co., Ltd. |
HarbourVest Dover Street VIII 2013 Annua Report and Audited Fiinancial Stattements - Korrea Post Saviings Bureau– May 2014 | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - March 2014 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
PARTNERS GROUP SECONDARY 2008, L.P. QUARTERLY REPORT Q1 2014 | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - Duke Street VI Fund Investor Update Call, Tuesday 20 May 2014 | English ->Korean |
Samsung Securities Co., Ltd. |
Harbourvest Dover VIII Quarterly Report Letter - Korea Post Savings Bureau, 31.03.2014 | English ->Korean |
Samsung Securities Co., Ltd. |
Harbourvest Dover VIII Quarterly Report Update Letter - Korea Post Savings Bureau, 30.06.2014 | English ->Korean |
Samsung Securities Co., Ltd. |
Viking Press Release: Partners Group and Duke Street/Tikehau to lead GBP 375 million acquisition of Voyage Care from HgCapital, 6 August 2014 | English ->Korean |
Samsung Securities Co., Ltd. |
TGP Capital - VII Disclaimer and Forward Looking Statements, August 2014 | English ->Korean |
Samsung Securities Co., Ltd. |
PARTNERS GROUP SECONDARY 2008, L.P. QUARTERLY REPORT Q2 2014 | English ->Korean |
Samsung Securities Co., Ltd. |
Brookfield Brookfield Infrastructure Fund II – Investor Update August 2014 | English ->Korean |
Samsung Securities Co., Ltd. |
MS GCM Grosvenor SEMA Multi Strategy Proposal Presentation - Client Composition by Hedge Fund Assets Under Management | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - September 2014 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
PARTNERS GROUP SECONDARY 2008, L.P. QUARTERLY REPORT Q3 2014 | English ->Korean |
Samsung Securities Co., Ltd. |
BROOKFIELD INFRASTRUCTURE FUND II 2014 Third Quarter Report | English ->Korean |
Samsung Securities Co., Ltd. |
AMP Capital Investors - AMP Capital Global Infrastructure Fund (GIF) Prepared for Korea Post, JANUARY 2015 | English ->Korean |
Samsung Securities Co., Ltd. |
AMP Capital Global Infrastructure Fund RFP FINAL DRAFT, 15.01.2015 | English ->Korean |
Samsung Securities Co., Ltd. |
Harbourvest Dover VII Dover VIII Year End Update Letter - Korea Post Savings Bureau, JANUARY 2015 | English ->Korean |
Samsung Securities Co., Ltd. |
Harbourvest Dover VIII Quarterly Report Letter - Korea Post Savings Bureau, DECEMBER 2014 | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - wagamama maps out fresher way for noodle Peach Report, 23 February 2015 | English ->Korean |
Samsung Securities Co., Ltd. |
PARTNERS GROUP SECONDARY 2008, L.P. QUARTERLY REPORT Q4 2014 | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - December 2014 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
Brookfield Infrastructure Fund II – Investor Update February 2015 | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - Duke Street realises its investment in Payzone Ireland with sale to Carlyle joint venture, 9 March 2015 | English ->Korean |
Samsung Securities Co., Ltd. |
BROOKFIELD INFRASTRUCTURE FUND II, 2014 Annual Report | English ->Korean |
Samsung Securities Co., Ltd. |
BROOKFIELD INFRASTRUCTURE FUND II, 2015 First Quarter Report | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - March 2015 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
PARTNERS GROUP SECONDARY 2008, L.P. QUARTERLY REPORT Q1 2015 | English ->Korean |
Samsung Securities Co., Ltd. |
HarbourVest Dover Street VIII L.P. A Semi-Annual Report 2015 | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - DUKE STREET CO-INVESTMENT, 17 July 2015 | English ->Korean |
Samsung Securities Co., Ltd. |
PARTNERS GROUP SECONDARY 2008, L.P. QUARTERLY REPORT Q2 2015 | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - June 2015 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
Brookfield Real Estate Finance Fund IV, 2015 Second Quarter Report, August 2015 | English ->Korean |
Samsung Securities Co., Ltd. |
Oaktree Capital Management, L.P. - It’s Not Easy | English ->Korean |
Samsung Securities Co., Ltd. |
HarbourVest Dover Street VIII L.P. 2015 A Semi-Annual Report | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - Annual Investor Meeting 2015 | English ->Korean |
Samsung Securities Co., Ltd. |
BROOKFIELD INFRASTRUCTURE FUND II, 2015 Third Quarter Report | English ->Korean |
Samsung Securities Co., Ltd. |
BROOKFIELD Private Funds Annual Investor Conference, 17-18.November. 2015 - Brookfield Infrastructure Fund II (BIF II) | English ->Korean |
Samsung Securities Co., Ltd. |
Harbourvest Dover Street L.P. VIII Q3 2015 Querterly Report, December 2015 | English ->Korean |
Samsung Securities Co., Ltd. |
PARTNERS GROUP SECONDARY 2008, L.P. QUARTERLY REPORT Q3 2015 | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - December 2015 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
PARTNERS GROUP SECONDARY 2008, L.P. QUARTERLY REPORT Q4 2015 | English ->Korean |
Samsung Securities Co., Ltd. |
Brookfield Infrastructure Fund II – Investor Update, Q4 2015 | English ->Korean |
Samsung Securities Co., Ltd. |
Brookfield Real Estate Finance Fund IV, 2015 Fourth Quarterly Report, 15.04.2015 | English ->Korean |
Samsung Securities Co., Ltd. |
HarbourVest Dover Street VIII L.P. 2015 Annual Report - EXECUTIVE SUMMARY | English ->Korean |
Samsung Securities Co., Ltd. |
BROOKFIELD INFRASTRUCTURE FUND II 2015 First Quarter Report | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - March 2016 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
InfraRed Capital Partners - InfraRed Active Real Estate Fund IV - Confidential Private Placement Memorandum | English ->Korean |
Samsung Securities Co., Ltd. |
InfraRed Capital Partners - European Real Estate Markets And value-add investing in Europe with InfraRed, May 2016 | English ->Korean |
Samsung Securities Co., Ltd. |
InfraRed Capital Partners - European Real Estate Markets And value-add investing in Europe with InfraRed, Appendix 1 Active Fund III – Case Studies | English ->Korean |
Samsung Securities Co., Ltd. |
DS VI Minutes of the Advisory Committee Meeting, 24 May 2016 at Nations House, 103 Wigmore Street, London W1U 1QS | English ->Korean |
Samsung Securities Co., Ltd. |
HarbourVest – Investor Update, Thursday, June 23, 2016 | English ->Korean |
Samsung Securities Co., Ltd. |
Brookfield Real Estate Finance Fund IV, 2016 First Quarter Report, 26.06.2015 | English->Korean |
Samsung Securities Co., Ltd. |
DS VI Minutes of the Advisory Committee Meeting, 24 May 2016 at Nations House, 103 Wigmore Street, London W1U 1QS | English ->Korean |
Samsung Securities Co., Ltd. |
Oaktree Capital Management, L.P. - EU Referendum, June 24, 2016 | English ->Korean |
Samsung Securities Co., Ltd. |
GEPS_Response v5 - Investment Performance of Private Debt Fund (Mezzanine and related strategy) | English ->Korean |
Samsung Securities Co., Ltd. |
Global Private Debt Fund Proposal for GEPS (Fund name : GoldPoint Mezzanine Partners IV, LP), 15.07.2016 | English ->Korean |
Samsung Securities Co., Ltd. |
Harbourvest Dover Street L.P. VIII Q1 2016 Querterly Report, July 2016 | English ->Korean |
Samsung Securities Co., Ltd. |
Brookfield Real Estate Finance Fund IV, 2016 Second Quarter Report, August 2016 | English ->Korean |
Samsung Securities Co., Ltd. |
AMP Capital Investors - Have you overlooked opportunities in Australia’s real estate and infrastructure?, SEMTEMBER 2016 | English ->Korean |
Samsung Securities Co., Ltd. |
AMP Capital Investors - AMP Capital Samsung Seminar_Draft 2, AUGUST 2016 | English ->Korean |
Samsung Securities Co., Ltd. |
InfraRed Capital Partners - The Property Environment post Brexit Global Alternative Investments Seminar, Samsung Securities, September 2016 | English ->Korean |
Samsung Securities Co., Ltd. |
Brookfield Infrastructure Fund II – Investor Update, Q2 2016 | English ->Korean |
Samsung Securities Co., Ltd. |
BROOKFIELD INFRASTRUCTURE FUND II 2016 SECOND QUARTER REPORT, AUGUST 23, 2016 | English ->Korean |
Samsung Securities Co., Ltd. |
PARTNERS GROUP SECONDARY 2008, L.P. QUARTERLY REPORT Q2 2016 | English ->Korean |
Samsung Securities Co., Ltd. |
HarbourVest – Investor Update, September 12, 2016 | English ->Korean |
Samsung Securities Co., Ltd. |
GoldPoint Partners - RESPONSES TO PUBLIC OFFICIALS BENEFIT ASSOCIATION, JULY 2016 | English ->Korean |
Samsung Securities Co., Ltd. |
GoldPoint Partners - MARKET ENVIRONMENT OVERVIEW FOR POBA, OCTOBER 2016 | English ->Korean |
Samsung Securities Co., Ltd. |
HarbourVest Dover Street VIII L.P. 2016 A Semi Annual Report EXECUTIVE SUMMARY, | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - June 2016 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - DS Re Investment Fund Term Sheet v3 | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - September 2016 Quarterly Report | English ->Korean |
Samsung Securities Co., Ltd. |
DS VI Minutes of the Advisory Committee Meeting, 18 November @ 1.30pm (UK time) Via telephone conference | English ->Korean |
Samsung Securities Co., Ltd. |
HarbourVest – Investor Letter, 25 November 2016 - Korea Post Insurance | English ->Korean |
Samsung Securities Co., Ltd. |
Brookfield Infrastructure Fund II – Investor Update, Q3 2016 | English ->Korean |
Samsung Securities Co., Ltd. |
Duke Street Capital - Project Arrow Advisory Committee, 18 November 2016 | English ->Korean |
Samsung Securities Co., Ltd. |
GOLDPOINT MEZZANINE PARTNERS IV, LP - SECOND AMENDED AND RESTATED LIMITED PARTNERSHIP AGREEMENT, CONFORMED AS OF AUGUST 1, 2016 | English ->Korean |
Actelion Pharmaceuticals Korea
| Company | Project | Language |
|---|---|---|
Actelion Pharmaceuticals Korea |
Allpack Group AG - RHI Regionales Heilmittelinspektorat der Nordwestschweiz - Inspektionsbericht - Datum der Inspektion : 25.-27.02. und 03.03.2014 | German->Korean |
Actelion Pharmaceuticals Korea |
Selexipag: An oral, selective IP prostacyclin receptor agonist - MEDICAL PLATFORM November 2014 | English ->Korean |
Actelion Pharmaceuticals Korea |
Selexipag (ACT-293987): Investigator's Brochure - Version 9 – May 2014 | English ->Korean |
Actelion Pharmaceuticals Korea |
COMPANY CORE DATA SHEET - UPTRAVI® (SELEXIPAG) VERSION 2 - 11 December 2014 | English ->Korean |
Actelion Pharmaceuticals Korea |
Selexipag (ACT-293987) 2.2 INTRODUCTION TO MODULE 2 - 12 November 2014 | English ->Korean |
Actelion Pharmaceuticals Korea |
Selexipag Film-coated tablet QOS-A 2.3 QUALITY OVERALL SUMMARY (APPENDICES) | English ->Korean |
Actelion Pharmaceuticals Korea |
Selexipag Film-coated tablet 2.3 QUALITY OVERALL SUMMARY (REGIONAL) | English ->Korean |
Actelion Pharmaceuticals Korea |
Selexipag (ACT-293987) 2.4 NONCLINICAL OVERVIEW - Prostacyclin Receptor Agonist For Treatment of Pulmonary Arterial Hypertension - 23 October 2014 | English ->Korean |
Actelion Pharmaceuticals Korea |
Selexipag (ACT-293987) 2.5 CLINICAL OVERVIEW FOR SELEXIPAG (ACT-293987) IN PULMONARY ARTERIAL HYPERTENSION - 25 November 2014 | English ->Korean |
Actelion Pharmaceuticals Korea |
Selexipag (ACT-293987) 2.6.1 INTRODUCTION - 12 November 2014 | English ->Korean |
Actelion Pharmaceuticals Korea |
Selexipag (ACT-293987) 2.6.2 PHARMACOLOGY WRITTEN SUMMARY - Prostacyclin Receptor Agonist For Treatment of Pulmonary Arterial Hypertension - 23 October 2014 | English ->Korean |
Actelion Pharmaceuticals Korea |
Selexipag (ACT-293987) 2.6.4 PHARMACOKINETICS WRITTEN SUMMARY - Prostacyclin Receptor Agonist For Treatment of Pulmonary Arterial Hypertension - 2 October 2014 | English ->Korean |
Actelion Pharmaceuticals Korea |
Selexipag (ACT-293987) 2.6.6 TOXICOLOGY WRITTEN SUMMARY - IP Receptor Agonist - 21 October 2014 | English ->Korean |
Actelion Pharmaceuticals Korea |
Selexipag (ACT-293987) 2.7.1 SUMMARY OF BIOPHARMACEUTIC STUDIES AND ASSOCIATED ANALYTICAL METHODS FOR SELEXIPAG (ACT-293987) - 3 October 2014 | English ->Korean |
Actelion Pharmaceuticals Korea |
Selexipag (ACT-293987) 2.7.3 SUMMARY OF CLINICAL EFFICACY FOR SELEXIPAG (ACT-293987) IN PULMONARY ARTERIAL HYPERTENSION - 19 November 2014 | English ->Korean |
Actelion Pharmaceuticals Korea |
Selexipag (ACT-293987) 2.7.2 SUMMARY OF CLINICAL PHARMACOLOGY STUDIES FOR SELEXIPAG (ACT-293987) - 14 November 2014 | English ->Korean |
Actelion Pharmaceuticals Korea |
Selexipag (ACT-293987) 2.7.4 SUMMARY OF CLINICAL SAFETY FOR SELEXIPAG (ACT-293987) IN PULMONARY ARTERIAL HYPERTENSION - 14 November 2014 | English ->Korean |
Actelion Pharmaceuticals Korea |
Selexipag (ACT-293987) 2.7.6 SYNOPSES OF INDIVIDUAL STUDIES SELEXIPAG (ACT-293987) IN PULMONARY ARTERIAL HYPERTENSION - 21 October 2014 | English ->Korean |
Actelion Pharmaceuticals Korea |
ACT-293987 Response to MFDS Supplemental Requests - 25 August 2015 | English ->Korean |
Actelion Pharmaceuticals Korea |
Pulmonary Arterial Hypertension - Epidemiology and Observational Studies Tracking Number (Protocol AC-Number) - Post Marketing Surveillance in Korea by local regulation - Study (patient) population or database (source population) being investigated | Korean ->English |
Actelion Pharmaceuticals Korea |
OPS CRF V1 draft1 ACT | Korean ->English |
Actelion Pharmaceuticals Korea |
1.1.1.1 Adverse event or adverse experience 1.1.1.2 Intensity of adverse events 1.1.1.3 Serious adverse events 1.2 Safety Reporting Requirements 1.2.1 Reconciliation | English ->Korean |
Actelion Pharmaceuticals Korea |
TITRATION GUIDE - TITRATION PACK | English ->Korean |
Actelion Pharmaceuticals Korea |
Allpack Group AG - RHI Regionales Heilmittelinspektorat der Nordwestschweiz- Inspektionsbericht - Datum der Inspektion : 25.-27.02. und 03.03.2014 | German->Korean |
Actelion Pharmaceuticals Korea |
Allpack Group AG - STANDARD OPERATING PROCEDERE A04-007-04 - Mikrobiologische Überwachungder Luft und Oberflächen in der C-, D- und E- Zone - 25.02.2013 | German->Korean |
Actelion Pharmaceuticals Korea |
Allpack Group AG - STANDARD OPERATING PROCEDERE A06-006-03- Qualifizierung und Bewertung von Lieferanten - 13.12.2013 | German->Korean |
Actelion Pharmaceuticals Korea |
Allpack Group AG - STANDARD OPERATING PROCEDERE A01-014-02- Product Quality Report und Annual Product Review - 11.11.2013 | German->Korean |
Actelion Pharmaceuticals Korea |
Allpack Group AG - Annual Product Review (APR) SOP A01-014-01 ANLAGE 2 V01 - Annual Product Review Tracleer 62.5mg 10er Blister Japan I Korea fur Actelion Pharmaceuticals Ltd. - 17.10.2016 | German->Korean |
Actelion Pharmaceuticals Korea |
Allpack Group AG - STANDARD OPERATING PROCEDERE A10-014-03- Umarbeitung (Reworking) von Chargen - 12.12.2013 | German->Korean |
Actelion Pharmaceuticals Korea |
Allpack Group AG - Testplan/-protokoll der Operational Qualification -PrOfung der Grundfunktionen Version: 01- Blistering of Tracleer 62.5mg Japan, blisters containing 10 FCT on the Klockner CP3 Blistering Machine- 16.06.2015 | German->Korean |
Actelion Pharmaceuticals Korea |
Allpack Group AG - STANDARD OPERATING PROCEDERE A01-005-02- Vorgehen zur Beurteilung von neuen Präparaten bezüglich der Reinigungsvalidierung (Risk Assessment)- 09/2011 | German->Korean |
Actelion Pharmaceuticals Korea |
Allpack Group AG - Massnahmenplan zur RHI Version: 01 - lnspektion vom 25. - 27.02. und 03.03.2014 - Standorte Kägenstrasse 17 und Pfeffingerstrasse 45 | German->Korean |
Actelion Pharmaceuticals Korea |
A.1 AC-055-302 (SERAPHIN) Patient demographics and exposure B. Macitentan post-marketing experience in children C. Endothelin receptor antagonist experience in children D. Nonclinical data of macitentan in juvenile animals | English ->Korean |
Actelion Pharmaceuticals Korea |
Allpack Group AG - STANDARD OPERATING PROCEDERE A05-005-04 - Reinigung produktberührender Maschinenteile und diverser Herstellungsutensilien - 30/11/2016 | German->Korean |
Actelion Pharmaceuticals Korea |
Allpack Group AG - STANDARD OPERATING PROCEDERE A04-001-04 - Reinigungspläne für die Produktionsräume (Zone C, D und E) und die angrenzenden Räumlichkeiten (Lager, Technik und Werkstatt) - 30.11.2016 | German->Korean |
Actelion Pharmaceuticals Korea |
Allpack Group AG - STANDARD OPERATING PROCEDERE A04-002-02 - Kennzeichnung der Produktionsräume und Maschinen, Dokumentation der Belegung der Räume - 08/ 2009 | German->Korean |
Actelion Pharmaceuticals Korea |
Allpack Group AG - STANDARD OPERATING PROCEDEREA04-003-03 - Bekleidungs- und Hygienekonzept - 27.12.2016 | German->Korean |
Actelion Pharmaceuticals Korea |
Allpack Group AG - STANDARD OPERATING PROCEDERE A04-004-01 - Pflege der persönlichen Hygiene - 01.06.2004 | German->Korean |
Actelion Pharmaceuticals Korea |
Allpack Group AG - Prüfprotokoll FS und VK SOP A01-007-05 ANLAGE 9 V01 - 11.11.2013 - 1406P155 6 | German->Korean |
Actelion Pharmaceuticals Korea |
Allpack Group AG - Prüfprotokoll FS und VK SOP A01-007-05 ANLAGE 9 V01 - 11.11.2013 - 1412P128 6 | German->Korean |
Actelion Pharmaceuticals Korea |
Allpack Group AG - Prüfprotokoll FS und VK SOP A01-007-05 ANLAGE 9 V01 - 11.11.2013 - 1511P140 6 | German->Korean |
Actelion Pharmaceuticals Korea |
Allpack Group AG - STANDARD OPERATING PROCEDERE A01-Q03-03 - Complaint Management - 01.12.2011 | German->Korean |
Actelion Pharmaceuticals Korea |
Allpack Group AG - Assessment zur Reinigung von dedicated Zuführungen betreffend Rückständen von Reinigungsmitteln und mikrobiologischen Verunreinigungen BRV-007-01- 02.06.2017 | German->Korean |
Actelion Pharmaceuticals Korea |
Allpack Group AG - CHNAGE CONTROL SQP A01-009 Version vom 07.08.2004 - Anderungsgegenstand | German->Korean |
Actelion Pharmaceuticals Korea |
ALMEDICA GMP DOKUMENTATION REINIGUNGSVALlDIERUNG SRV-001-01 - Schlussbericht Reinigungsvalidierung - 30.04.2002 | German->Korean |
Actelion Pharmaceuticals Korea |
ALMEDICA GMP DOKUMENTATION REINIGUNGSVALlDIERUNG 8MT.00ι02 - Bericht zur Validierung vom Musteαug und der Testmethode - 19.04.2002 | German->Korean |
Actelion Pharmaceuticals Korea |
Mfr. Control Number: A-CH2017-159696 - ADDITIONAL INFORMATION | English ->Korean |
Bayer Korea Ltd.
| Company | Project | Language |
|---|---|---|
Bayer Korea Ltd. |
Bayer Magazine, December 2016 | Korean ->English |
Bayer Korea Ltd. |
10th Congress of the Asia-Pacific Vitreo-Retina Society (APVRS) 2016: One Year Results Demonstrate Effectiveness of EYLEA® as Monotherapy in Patients with Polypoidal Choroidal Vasculopathy | English ->Korean |
Bayer Korea Ltd. |
DIGITAL FARMING: MORE EFFICIENT AGRICULTURE, MORE RELIABLE HARVESTS - The networked farm, Bayer research 30 November 2016 | English ->Korean |
Bayer Korea Ltd. |
TRUST & COLLABORATION & EXPERIMENTATION & CUSTOMER FOCUS | Korean->English Proofreading |
Bayer Korea Ltd. |
Stivarga (regorafenib) Tablets 2.7.4 Summary of Clinical Safety, 20 October 2016 | English ->Korean |
Bayer Korea Ltd. |
The Future Has Just Begun" A book celebrating 100th anniversary of Asprin | English ->Korean |
Bayer Korea Ltd. |
The Dept. of Radiology at Seoul National University Hospital (SNUH) Intoduction data | Korean ->English |
Bayer Korea Ltd. |
CARTOON Collaboration script EN_680 | English ->Korean |
Bayer Korea Ltd. |
RA Newsletter Volume 5 │ Oct 2016 | Korean ->English |
Bayer Korea Ltd. |
Bayer Magazine, September 2016 | Korean ->English |
Bayer Korea Ltd. |
CARTOON Customer Focus script, CARTOON Experimentation script & Smart Cartoon TRUST script | English ->Korean |
Bayer Korea Ltd. |
Update: Global transfer of HR services - Relaunch of BayerNet | myServices | English ->Korean |
Bayer Korea Ltd. |
30 to 40% stock-out revives only market sale | Korean ->English |
Bayer Korea Ltd. |
Bayer Increases Monsanto Offer and Provides Certainty on Financing and Regulatory Matters | English ->Korean |
Bayer Korea Ltd. |
RA News Letter Volume 4 │ July 2016 | Korean ->English |
Bayer Korea Ltd. |
Bayer Magazine, May 2016 | Korean ->English |
Bayer Korea Ltd. |
Mosquito-borne diseases prevention and control, Learning module | English ->Korean |
Bayer Korea Ltd. |
The right culture for the new structure - Video script translation | English ->Korean video translation |
Bayer Korea Ltd. |
Innovation Powerhouse to Deliver Integrated Solutions for the Next Generation of Farming: Bayer Offers to Acquire Monsanto to Create a Global Leader in Agriculture | English ->Korean |
Bayer Korea Ltd. |
Werner Baumann: Portrait and Interview Video: Interview with the New Bayer CEO | English ->Korean video translation |
Bayer Korea Ltd. |
Welcome to your seminar EPFC 2.0 – High Performance through Developmental Feedback | English ->Korean |
Bayer Korea Ltd. |
EPFC 2.0 – High Performance through Developmental Feedback Development Dialogue - Course of a development dialogue | English ->Korean |
Bayer Korea Ltd. |
EPFC 2.0 – High Performance through Developmental Feedback - Creating a climate of appreciation | English ->Korean |
Bayer Korea Ltd. |
EPFC 2.0 – High Performance through Developmental Feedback - Practice simulation | English ->Korean |
Bayer Korea Ltd. |
EPFC 2.0 – High Performance through Developmental Feedback - My Personal 6 Months Diary | English ->Korean |
Bayer Korea Ltd. |
Kyung Nong and Bayer seem to have a disagreement with regard to the contract term. | Korean ->English |
Bayer Korea Ltd. |
KVALIFIOINNIN RAPORTTI, KVALIFIOINNIN LOPPURAPORTTI, KVALIFIOINNIN YHTEENVETORAPORTTI, 9 cases | Finnish ->Korean |
Bayer Korea Ltd. |
Elevit Pronatal Tab - |
Korean ->English |
Bayer Korea Ltd. |
[Hot Issue Diagnosed] Foreign companies supplying raw materials for agricultural chemicals in controversy over its gabjil (power harassment) | Korean ->English |
Bayer Korea Ltd. |
Shareholders of membership-based wholesale corporations or crop protection agent marketing cooperatives - Business letter | Korean ->English |
Bayer Korea Ltd. |
BAYER LOYALTY PROGRAM 2015 - Registeation Form - | English ->Korean |
Bayer Korea Ltd. |
Bayer Magazine, March 2016 | Korean ->English |
Bayer Korea Ltd. |
SBR Message proofreading | Korean->English Proofreading |
Bayer Korea Ltd. |
CLOSE OF THE SALE OF BAYER DIABETES CARE TO CREATE NEW STAND-ALONE COMPANY, ASCENSIA DIABETES CARE | English ->Korean |
Bayer Korea Ltd. |
CONCEPT SCLC study 14615 Investigator Letter final, Feb 2016 | English ->Korean |
Bayer Korea Ltd. |
Conglomerates begin to look at agriculture as a higher value-added business & "Working to strengthen the industry's competency, and to disseminate residual pesticide analysis technology" | Korean ->English |
Bayer Korea Ltd. |
Purchase & Delivery Agreement of Agricultural Chemicals | Korean ->English |
Bayer Korea Ltd. |
Outlook for the Non-Selective Herbicide Market in Korea - Is the heyday of Basta coming to an end? Suppliers engaged in a cutthroat battle due to excessive supply | Korean ->English |
Bayer Korea Ltd. |
Aflibercept in DME (Week 148) 2.5 Clinical Overview, 08 December 2015 | English ->Korean |
Bayer Korea Ltd. |
Amended Clinical Study Report No. PH-38460 Synopsis - amended | English ->Korean |
Bayer Korea Ltd. |
Clinical Study Report VGFT-OD-1009 (Year 3) CLINICAL STUDY REPORT SYNOPSIS | English ->Korean |
Bayer Korea Ltd. |
Bayer Magazine, December 2015 | Korean ->English |
Bayer Korea Ltd. |
DISTRIBUTION AGREEMENT | English ->Korean |
Bayer Korea Ltd. |
SBR message Q4 Proofreading | Korean->English Proofreading |
Bayer Korea Ltd. |
Left in the rain (5) | English ->Korean |
Bayer Korea Ltd. |
Fascinating Image: A Shoal of Fish with a Remarkable Story | English ->Korean |
Bayer Korea Ltd. |
A Vegetable Garden on the Roof, New and unconventional perspectives | English ->Korean |
Bayer Korea Ltd. |
Employer Branding Image - Researchers on the Arctic Circle | English ->Korean |
Bayer Korea Ltd. |
Image Motifs for Employer Branding - Food for a Hungry Planet | English ->Korean |
Bayer Korea Ltd. |
Employer Branding Images - Singapore’s Supertrees | English ->Korean |
Bayer Korea Ltd. |
Monitoringbericht - Reinigung der Frewitt-Granuliermaschinen | German->Korean |
Bayer Korea Ltd. |
GMP - Inspektionsbericht FIRMENNAME DES INSPIZIERTEN BETRIEBES | German->Korean |
Bayer Korea Ltd. |
Bayer Magazine, Oct 2015 | Korean ->English |
Bayer Korea Ltd. |
Bayer Schering Pharma AG: Batch Record (BR), Media Fill Vials 6 ml | German->Korean |
Bayer Korea Ltd. |
Bayer Schering Pharma AG: Batch Record (BR), Media Fill Ansatz | German->Korean |
Bayer Korea Ltd. |
Bayer Pharma AG: Batch Record (BR), Media Fill Vials 6 ml | German->Korean |
Bayer Korea Ltd. |
Bayer Pharma AG: Batch Record (BR), Media Fill Vials 6 ml (BK: GO/SW) | German->Korean |
Bayer Korea Ltd. |
Bayer Magazine, September 2015 | Korean ->English |
Bayer Korea Ltd. |
Disposal of Dongbu Farm Hannong and TERRAD'OR & Chemical industries look to agriculture and life science for their survival | Korean ->English |
Bayer Korea Ltd. |
Life first began four billion years ago when the Earth had finally cooled to a temperature of below 100 degrees Celsius. | English ->Korean video translation |
Bayer Korea Ltd. |
Bayer Healthcare: Anweisung Supply Center Berlin Version 12.0 - SOP Media Fill PL06 | German->Korean |
Bayer Korea Ltd. |
Abweichungsmeldung Production Supply Certer Berlin HL2_2011_94_2 | German->Korean |
Bayer Korea Ltd. |
Bayer Healthcare: Revalidierungsplan Nr. A10217D120 Streng vertraulich - Revalidierung der Reinigungsverfahren nach Herstellung von Hormonölampullen | German->Korean |
Bayer Korea Ltd. |
Pesticide Purchase and Supply Agreement (Draft) | Korean ->English |
Bayer Korea Ltd. |
SBR Q3 letter | Korean ->English |
Bayer Korea Ltd. |
This is Daniel. As a Bayer CropScience employee, he also wants to contribute to making his company the No. 1. But he doesn’t really know how he can support this major goal in practice. | English ->Korean video translation |
Bayer Korea Ltd. |
EYLEA Learning Resource: BRVOTRAINING Background and epidemiology of BRVO Training Manual | English ->Korean |
Bayer Korea Ltd. |
EYLEA Learning Resource: Pathophysiology and natural history of BRVO Training Manual | English ->Korean |
Bayer Korea Ltd. |
EYLEA Learning Resource: BRVOTRAINING Management approaches in BRVO Training Manual | English ->Korean |
Bayer Korea Ltd. |
EYLEA Learning Resource: BRVOTRAINING Key clinical trials in BRVO Training Manual | English ->Korean |
Bayer Korea Ltd. |
EYLEA Learning Resource: BRVOTRAINING EYLEA clinical trials in BRVO Training Manual | English ->Korean |
Bayer Korea Ltd. |
EYLEA Learning Resource: BRVOTRAINING EYLEA’s Contribution to the Management of BRVO Training Manual | English ->Korean |
Bayer Korea Ltd. |
EYLEA Learning Resource: CRVOTRAINING Background and epidemiology of CRVO Training Manual | English ->Korean |
Bayer Korea Ltd. |
EYLEA Learning Resource: CRVOTRAINING EYLEA clinical trials in CRVO Training Manual | English ->Korean |
Bayer Korea Ltd. |
EYLEA Learning Resource: CRVOTRAINING EYLEA’s contribution to the management of CRVO Training Manual | English ->Korean |
Bayer Korea Ltd. |
EYLEA Learning Resource: CRVOTRAINING Key clinical trials in RVO Training Manual | English ->Korean |
Bayer Korea Ltd. |
EYLEA Learning Resource: CRVOTRAINING Management approaches in RVO Training Manual | English ->Korean |
Bayer Korea Ltd. |
EYLEA Learning Resource: CRVOTRAINING Pathophysiology and natural history of CRVO Training Manual | English ->Korean |
Bayer Korea Ltd. |
Dongbu Farm Hannong engages in a sales offensive with pesticide and fertilizer & How can we set a supply of Glyposate by company? | Korean ->English |
Bayer Korea Ltd. |
Please Visit the Bayer Korea Live Webcast at 9:00 AM, Wednesday, on July 8, 2015. | Korean ->English |
Bayer Korea Ltd. |
CONTRATO DE DISTRIBUCIÓN , En Valencia, a ….. de …….. de 2014 | Spanish->Korean |
Bayer Korea Ltd. |
Bayer Healthcare Korea, Animal Health Division: Sterility Test | English ->Korean |
Bayer Korea Ltd. |
SBR Q2_YEK_490 | Korean ->English |
Bayer Korea Ltd. |
Bayer CropScience holds rice transplanting event to wish for a good harvest - - At Pyeongtaek lab with Bayer employees and foreign children | Korean ->English |
Bayer Korea Ltd. |
Late Breaking Clinical Trial Session at Heart Rhythm 2015: New Data on Bayer’s Xarelto® Versus Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation | English ->Korean |
Bayer Korea Ltd. |
A new kind of herbicide, Terrad’or, agreed on patent technology transfer | Korean ->English |
Bayer Korea Ltd. |
Dongbu Farm Hannong accomplishes the highest first quarter sales figures this year 250 billion won in sales and 46.3 billion won in operating profit | Korean ->English |
Bayer Korea Ltd. |
“Protecting pollinators in Korea through active support” | Korean ->English |
Bayer Korea Ltd. |
TOPPS-Training for Shift supervisors & Production technicians, craftsmen … - Rules and Regulations | English ->Korean |
Bayer Korea Ltd. |
TOPPS- Training for Cat. 2 - Process Hazard Analysis (PHA/HAZOP) | English ->Korean |
Bayer Korea Ltd. |
TOPPS- Training for Level 2 - Safety Relevant Utilities | English ->Korean |
Bayer Korea Ltd. |
TOPPS- Training for - Site Managers, HSE-Managers, - Production Supervisors and -Experts, Technicians, - Shift Supervisors, Production Operators and Craftsmen / Consequence Analysis | English ->Korean |
Bayer Korea Ltd. |
Dear Members of Sales Headquarters: April 2015 | Korean ->English |
Bayer Korea Ltd. |
Dongbu Group, puts forward an application for separating an affiliated company, Dongbu Farm Hannong … promoting its sale & Dongbu Farm Hannong to be sold to ORIX? | Korean ->English |
Bayer Korea Ltd. |
Dongbu Farm Hannong to Receive KRW60bn in Emergency Funds & One Week to Define Dongbu’s Destiny… Stopping the 100-to-1 Capital Reduction | Korean ->English |
Bayer Korea Ltd. |
Procedure Third Party Due Diligence Process Group Regulation No. 2083, Effective: February 1, 2015 | English ->Korean |
Bayer Korea Ltd. |
Dongbu CNI considers selling stake in Dongbu Farm Hannong & Dongbu Group to sell Dongbu Farm Hannong, making electronics its only manufacturing business | Korean ->English |
Bayer Korea Ltd. |
Negotiations for disposal of the chemicals unit of Dongbu Farm Hannong break down - Repayment crisis growing & [Issue & News] 'Agriculture in crisis' - Does corporate participation in agriculture do good or harm? | Korean ->English |
Bayer Korea Ltd. |
BASIC LEGAL PRINCIPLES FOR BUSINESS RELATIONSHIPS WITH RETAILERS AND AGENTS | English ->Korean |
Bayer Korea Ltd. |
Ingrid U. Drechsel Appointed as New SBR/CEO of Bayer Korea, Hosted Compliance Challenge Golden Bell Welcoming the Lunar New Year, Fruit-full Monday | Korean ->English |
Bayer Korea Ltd. |
Pyeongtaek Branch of Suwon District Court Table of Allowance | Korean ->English |
Bayer Korea Ltd. |
COMPLIANCE WITH INTERNATIONAL SANCTIONS AND EXPORT CONTROL & Compliance Letter | English ->Korean |
Bayer Korea Ltd. |
Sales Agreement | Korean ->English |
Bayer Korea Ltd. |
Employee Newsletter: New SBR Interview / Feb 26, 2015 | Korean ->English |
Bayer Korea Ltd. |
Dongbu Farm Hannong's new herbicide enters overseas markets through Japan | Korean ->English |
Bayer Korea Ltd. |
Bayer Healthcare:Integrated Clinical Study Protocol - A randomized, double-blind Phase III study of copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin’s lymphoma (iNHL) – CHRONOS-2 | English ->Korean |
Bayer Korea Ltd. |
BHC Anti-Corruption Compliance Manual - BHC Regulation No. 700 Module: Animal Health | English ->Korean |
Bayer Korea Ltd. |
Bayer Healthcare: Directive BHC Price Reporting Compliance BHC Regulation No. 1043 (Edition: 1), Effective: November 15, 2014 | English ->Korean |
Bayer Korea Ltd. |
Functional Processes Referenced document Price Reporting Compliance Corporate Price Database SOP Version 1.0 | English ->Korean |
Bayer Korea Ltd. |
Layoffs at Bayer Korea, the labor-management conflict continues | Korean ->English |
Bayer Korea Ltd. |
Email Tips Daily Note: Hold on for 2 seconds when e-mailing | Korean ->English |
Bayer Korea Ltd. |
Bayer Branding with Bayer04Leverkusen Category: Best Integrated Campaign | Korean ->English |
Bayer Korea Ltd. |
Bayer Healthcare: Directive Business and Private Use of Electronic Communication Systems Group Regulation No. 2080 (Edition: 1): Effective: December 1, 2014 | English ->Korean |
Bayer Korea Ltd. |
BNC Bayer Holds Bayer Health Day to Help Seniors Live a Better Life | Korean ->English |
Bayer Korea Ltd. |
Clinical Study Report: A Phase II/III, multicenter, partially randomized, open label trial investigating safety and efficacy of on-demand and prophylactic treatment with BAY 94-9027 in Severe Hemophilia A | English ->Korean |
Bayer Korea Ltd. |
SBR Message Q4 2014 | Korean ->English |
Bayer Korea Ltd. |
Bayer Healthcare: Procedure BHC Anti-Corruption Compliance Manual BHC Regulation No. 700 (Edition: 1), Effective: May 15, 2014 | English ->Korean |
Bayer Korea Ltd. |
Future Leader Development Center: Concept Development – Assessment Aid for Observers | English ->Korean |
Bayer Korea Ltd. |
Future Leader Development Center: Concept Development – Instructions for participants | English ->Korean |
Bayer Korea Ltd. |
Future Leader Development Center: Direct Report – Instruction for participants | English ->Korean |
Bayer Korea Ltd. |
Future Leader Development Center: Direct Report – Instruction for role players | English ->Korean |
Bayer Korea Ltd. |
Future Leader Development Center: Dialogue with a Peer – Instructions for role players | English ->Korean |
Bayer Korea Ltd. |
Future Leader Development Center: Dialogue with a Peer – Instructions for participants | English ->Korean |
Bayer Korea Ltd. |
Bayer Interview Manual - Competency Based Interview / Passion to Innovate, Power to Change | English ->Korean |
Bayer Korea Ltd. |
1. Align Your Top Management, 2. Build Awareness and Skills for All Managers, 3. Empower All Talents, 4. Include Customers and Markets, 5. Review HR Systems & Processes, What YOU Say, | English ->Korean |
Bayer Korea Ltd. |
Step 2: Discover HCP Point of View - Purpose: To visually introduce Step 2: Discover HCP Point of View. | English ->Korean |
Bayer Korea Ltd. |
Supplementary Terms and Conditions of Bayer AG and its Affiliated Companies for the Award and Execution of Construction Services - Edition: 08/2008 | English ->Korean |
Bayer Korea Ltd. |
Bayer Korea Holds Welcome Reception to Celebrate Head Office Renovation: Renovated to Offer a More Open and Practical Space, the Integrated Head Office Now Accommodates BCS Staff As Well | Korean ->English |
Bayer Korea Ltd. |
Notification of Important Information for Radium Ra 223 Dichloride Study Patients | English ->Korean |
Bayer Korea Ltd. |
PS1 Content Translations: Breadcrumb title: Product Safety First - Website L10N | English ->Korean |
Bayer Korea Ltd. |
Sales Incentive Agreement for **** | Korean ->English |
Bayer Korea Ltd. |
BiK Authorization, Approval, Signature and Seal Directive, October 1, 2014 | English ->Korean |
Bayer Korea Ltd. |
BiK Contract Management Directive Preparation, Execution and Archiving of Contracts, October 1, 2014. | English ->Korean |
Bayer Korea Ltd. |
Vaccination of Piglets up to 1 Week of Age with a Single-Dose Mycoplasma hyopneumoniae Vaccine Induces Protective Immunity within 2 Weeks against Virulent Challenge in the Presence of Maternally Derived Antibodies | English ->Korean |
Bayer Korea Ltd. |
Investigator’s Brochure BAY 1187982 Version:1.0 Date: 11 SEP 2014 | English ->Korean |
Bayer Korea Ltd. |
POSITION STATEMENT Hormonal Contraception and Risk of Venous Thromboembolism (VTE), 19 February 2013 | English ->Korean |
Bayer Korea Ltd. |
INVESTIGATOR’S BROCHURE Oncology, 11 SEP 2014 | English ->Korean |
Bayer Korea Ltd. |
Clinical Study Protocol No. BAY 1187982 / 16897 , 01 Oct 2014 | English ->Korean |
Bayer Korea Ltd. |
Patient Information & Informed Consent Form - Study number: 16897 | English ->Korean |
Bayer Korea Ltd. |
Late-Breaking Presentation at European Society of Medical Oncology (ESMO) 2014 Congress: | English ->Korean |
Bayer Korea Ltd. |
Customer Complaints Handling QA-700-07 Rev.02 | Korean ->English |
Bayer Korea Ltd. |
Bayer MaterialScience AG - Dear (name of customer) | English ->Korean |
Bayer Korea Ltd. |
Integrated Clinical Study Protocol Roniciclib / 14615 Version 3.0, 03 SEP 2014 | English ->Korean |
Bayer Korea Ltd. |
PATIENT INFORMATION & INFORMED CONSENT FORM - RONICICLIB/14615 | English ->Korean |
Bayer Korea Ltd. |
Study No. 14615 roniciclib/placebo DOSING DIARY | English ->Korean |
Bayer Korea Ltd. |
Bayer Magazine, Semtember 2014 - Make a good use of refurbished Shindaebang-dong workplace of Bayer Korea when you know it well | Korean ->English |
Bayer Korea Ltd. |
Contract Template for the Conduct of an Observational Study - Observational Study Agreement | English ->Korean |
Bayer Korea Ltd. |
Bayer CEO Message - Dear colleagues, | Korean ->English |
Bayer Korea Ltd. |
Foreign firms pay over 80 percent of net profits as dividends with employment and investment going down | Korean ->English |
Bayer Korea Ltd. |
What is the impact of BCS’s “Commercial Excellence” project on distribution? | Spanish->English |
Bayer Korea Ltd. |
Purchase ERP Resource Data: IACR_C 20140818 | English ->Korean |
Bayer Korea Ltd. |
Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism, Draft: Aug 5, 2014 | English ->Korean |
Bayer Korea Ltd. |
Bayer Healthcare: Standard Operating Procedure - Archiving and Retrieval of Regulatory Affairs Documents | English ->Korean |
Bayer Korea Ltd. |
Bayer Healthcare: Procedure BHC Anti-Corruption Group Regulation No. 2041 (Edition: 1), Effective: January 1, 2012 | English ->Korean |
Bayer Korea Ltd. |
Bayer Healthcare: BHC Anti-Corruption Compliance Manual BHC Regulation No. 700, Effective: May 15, 2014 | English ->Korean |
Bayer Korea Ltd. |
Bayer Healthcare: ERP Resource Data 5 Cases | English ->Korean |
Bayer Korea Ltd. |
Charta: New Directions, Yulia Melikova, General Counsel Office | English ->Korean |
Bayer Korea Ltd. |
Bayer HealthCare Animal Health - Held the first LIVE Webinar in Korea aimed at clinical veterinarians | Korean ->English |
Bayer Korea Ltd. |
Bayer HealthCare Product Supply Ansung plant selected as Fire Safety Excellence Building | Korean ->English |
Bayer Korea Ltd. |
DuPont Moves from Chemicals and Textiles to Agriculture as a Future Growth Engine | Korean ->English |
Bayer Korea Ltd. |
The wholesalers will not win the margin war against multinational pharmaceuticals | Korean ->English |
Bayer Korea Ltd. |
Bayer Healthcare: ERP Resource Data 2 Cases | English ->Korean |
Bayer Korea Ltd. |
SkillCamp FOUNDATIONAL TRAINING Version 3.0 data 13 Cases | English ->Korean |
Bayer Korea Ltd. |
Bayer Magazine, July 2014 - Renovation work at headquarter offices starts from July. | Korean ->English |
Bayer Korea Ltd. |
PS1 KOREA page comments - MAIN PAGE We Help Customers Minimize Risk | English ->Korean |
Bayer Korea Ltd. |
UTT Leasing Agreement | English ->Korean |
Bayer Korea Ltd. |
TAEYOUNG CHEMICAL CO., LTD. - Agreement | Korean ->English |
Bayer Korea Ltd. |
Global First-Line Sales Manager Field Coaching Program Participant Workbook | English ->Korean |
Bayer Korea Ltd. |
Global First-Line Sales Manager Field Coaching Program Instructor’’s’ Guide | English ->Korean |
Bayer Korea Ltd. |
Print: Min Yun-gi/ Free Trade Agreement Division No. 3 (05-08-2014 10:29:12) Seoul Main Customs - Information on Voluntary Review of Korea-EU FTA Certified Exporter Number | Korean ->English |
Bayer Korea Ltd. |
Integrated Clinical Study Protocol No. BAY no. 88-8223 / 15397, 17 APR 2014 | English ->Korean |
Bayer Korea Ltd. |
Radimetrics 2.2 User Guide | English ->Korean |
Bayer Korea Ltd. |
PATIENT INFORMATION & INFORMED CONSENT FORM - RONICICLIB/14615 | English ->Korean |
Bayer Korea Ltd. |
Dong-A ST’s Submission of NDA to FDA for its Super Bacteria Antibiotics | Korean ->English |
Bayer Korea Ltd. |
STUDY 16349 – PART B PATIENT’S BLOOD GLUCOSE MONITORING DIARY NON- DIABETIC PATIENT | English ->Korean |
Bayer Korea Ltd. |
Clinical Study Protocol Roniciclib / 14615 | English ->Korean |
Bayer Korea Ltd. |
[Appendix 8] Guidelines to Establishment of Maximum Residue Limits of Pesticides in Food and Veterinary Pharmaceuticals | Korean ->English |
Bayer Korea Ltd. |
[Appendix] Toxicity Test Methods for Veterinary Pharmaceuticals, etc. (relating to Article 3) | Korean ->English |
Bayer Korea Ltd. |
[Appendix] Residue Test Methods for Veterinary Pharmaceuticals, etc. (relating to Article 3) | Korean ->English |
Bayer Korea Ltd. |
Regulations on the Review of Safety and Efficacy for Veterinary Pharmaceuticals, etc. - [Enforced 8 Jan. 2014] [Animal and Plant Quarantine Agency Notification No. 2014-2, 8 Jan. 2014, Partial Amendment] | Korean ->English |
Bayer Korea Ltd. |
Bayer Healthcare: Standard Operating Procedure - Management of Safety Relevant Local Studies, BAH-RD-SOP#0221 | English ->Korean |
Bayer Korea Ltd. |
Bayer Healthcare: Supplement- Flowchart "Management of safety relevant local studies", BAH-RD-SOP#0221 | English ->Korean |
Bayer Korea Ltd. |
Appendix 14.6 “study part B” to Integrated Clinical Study Protocol No. BAY 80-6946 / 16349, 28 Mar 2013 | English ->Korean |
Bayer Korea Ltd. |
Phase II PI3K inhibitor in relapsed, indolent or aggressive NHL (Part B) | English ->Korean |
Bayer Korea Ltd. |
PATIENT INFORMATION AND INFORMED CONSENT - Dose Modification 16349 | English ->Korean |
Bayer Korea Ltd. |
DECLARATION OF CONSENT - Active Assessment Follow-up period | English ->Korean |
Bayer Korea Ltd. |
Integrated Clinical Study Protocol No. BAY 80-6946 / 16349, 17 Feb 2014 | English ->Korean |
Bayer Korea Ltd. |
RFID/USN User Technology Consulting Result Report - Bayer CropScience: Feasibility analysis for developing advanced distribution system for RFID-based crop protection product, Jan. 2014 (NIPA) | Korean ->English |
Bayer Korea Ltd. |
CONFIDENTIALITY AGREEMENT - Nifco Korea Inc. | English ->Korean |
Bayer Korea Ltd. |
Patent Specification - LIGHT DIFFUSION PLATE - <0001> The invention relates to a light diffusion plate. | Korean ->English |
Bayer Korea Ltd. |
Integrated Clinical Study Protocol No. BAY 86-9766 / 16553, 27 Nov 2013 | Korean ->English |
Bayer Korea Ltd. |
Patient Information & Informed Consent Form, Study number: 16553 | Korean ->English |
Bayer Korea Ltd. |
The Journal of Obstetrics and Gynaecology Research, January 2014: Recurrence of ovarian endometrioma after laparoscopic excision: Risk factors and prevention | English ->Korean |
Bayer Korea Ltd. |
JMIG Original Article: Efficacy of Dienogest in Thinning the Endometrium Before Hysteroscopic Surgery | English ->Korean |
Bayer Korea Ltd. |
FAU Busan campus from Germany below expectations | Korean ->English |
Bayer Korea Ltd. |
PI / IC for Study Updates, Study number: 16728 | English ->Korean |
Bayer Korea Ltd. |
COOPERATION AGREEMENT, Ecoplastic Corp. | English ->Korean |
Bayer Korea Ltd. |
Bayer Healthcare: Best Practice IT Security for Users Group No. 1473 (Edition: 3), Effective: October 1, 2013 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine)
| Company | Project | Language |
|---|---|---|
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
24 006 PTW Attachment 5 Form General Work Permit v2 (1), 24 011 PTW Attachment 3 Form FSI v2 & HOT WORK PERMIT 3 files | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Johnson & Johnson Global Health Services - Healthy News - August | 2017 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Johnson & Johnson Global Health Services - Healthy News - June | 2017 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Johnson & Johnson Global Health Services - Healthy News - July | 2017 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Global Benefits and Health Resources - CHEMICAL AGENTS & API MEDICAL SURVEILLANCE QUESTIONNAIRE - (For new employees to this surveillance) - April 25, 2011 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Johnson & Johnson Global Health Services - PERIODIC CHEMICAL AGENTS & API MEDICAL SURVEILLANCE QUESTIONNAIRE | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Johnson & Johnson Global Health Services - ERGONOMIC SURVEILLANCE QUESTIONNAIRE To be completed by employee - April 13, 2011 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Global Benefits and Health Resources - GENERAL HEALTH QUESTIONNAIRE & SURVEILLANCE ASSESSMENT - HEALTH EVALUATION QUESTIONNAIRE - April 25, 2011 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Johnson & Johnson Global Health Service - Johnson & Johnson PRE-PLACEMENT HEALTH QUESTIONNAIRE - | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Housekeeping & 5S Training Guide - Version 3.0 (Feb. 2015) QE2 Team - February 2015 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Johnson & Johnson Worldwide Environment Health & Safety - Technical Standard - Hazard Identification and Risk Assessment- Job Safety Analysis - Issue Date: 01 Jan 2017 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
JSC Global - Standard Operating Procedure DS-SOP-1348 - Management of GMP Pharma R&D and Janssen Supply Chain (JSC) Global Documents - Effective Date: 01-Feb-2016 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
JSC Global - Standard - Pharma Supply Chain Standard DS-STA-43 - FACILITY MAINTENANCE - Effective Date: 20-Apr-2015 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
JSC Global - Standard - Pharma Supply Chain Standard DS-STA-47 - WATER AND STEAM SYSTEMS - Effective Date: 12-Mar-2012 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
JSC Global - Standard - Pharma Supply Chain Standard DS-STA-48 - COMPRESSED GAS SYSTEMS - Effective Date: 01-Apr-2013 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
JSC Global - Standard - Pharma Supply Chain Standard DS-STA-64 - BUILDING MANAGEMENT SYSTEMS - Effective Date: 27-Aug-2013 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
JSC Global - Standard - Pharma Supply Chain Standard PSGA-DOC-232294 - HEATING, VENTILATION AND AIR CONDITIONING (HVAC) SYSTEMS - Effective Date: 9/27/2010 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Johnson & Johnson Global - 4.0 Physical Security Overview - Minimum Security Standards (MSS) - 4.1 Perimeter 4.2 Gatehouses 4.3 Site Lighting 4.4 Parking Control 4.5 Building Surface Openings 4.6 Protective Barriers | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
The Netherlands (“Rhein Biotech”), and GreenCross Vaccine Corporation, a company incorporated in the Republic of Korea - BULK SUPPLY AGREEMENT EXECUTION VERSION - April 30, 2001 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
The Netherlands (“Rhein Biotech”), and GreenCross Vaccine Corporation, a company incorporated in the Republic of Korea - COLLABORATION AGREEMENT EXECUTION VERSION - April 30, 2001 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
SCHEDULE G - EXISTING ROYALTY AGREEMENTS - Chiron Royalty Obligations and Estimated Financial Impact - 1- Amgen 2- Tejin 3- Novartis 4- Aceullar Pertussis 5- Hib | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Crucell [Berna Biotech Korea Corp., formerly GreenCross Vaccine Corporation] and Novartis [Novartis Vaccines and Diagnostics GmbH, formerly Chiron Behring GmbH & Co] - Amendment Agreement - Effective Date: June 15, 2013 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
The Netherlands (“Rhein Biotech”), and GreenCross Vaccine Corporation, a company incorporated in the Republic of Korea - SUPPLY AND MANUFACTURING AGREEMENT EXECUTION VERSION - April 30, 2001 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
SCHEDULE G TO SUPPLY AND MANUFACTURING AGREEMENT - Transfer Pricing - 1 Definitions 2 Initial Period Transfer Price Calculation 3 Subsequent Period Transfer Price Calculation 4 Maximum Protected Average Net Sales Price 5 Minimum Projected Average Net Sale | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
WWRIM Program Assessment Interview - WWRIM (Worldwide Records & Infomation Management) - The documented process that will educate associates on managing their records and information during the normal course of business | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
MODURO Solutions for GRC - WWRIM (Worldwide Records & Infomation Management) Modulo Risk Assessment Tool Toolkit Manual | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
BIOMEVA GmbH Document Control - BIOMEVA MANUFACTURING - Bestimmung der Lebendzellzahl von Hansenula polymorpha - 14. Nov. 2012 | German->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Energy Profile - Profile (Page 1 of 7) Comments Audit Demographics - Please answer the following questions by selecting the option that most closely reflects your answer. Place your mouse arrow over the number rating to read the text associated with that | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Johnson & Johnson Global Health Services - Ebola Update - The Ebola virus disease (EVD) outbreak in West Africa and recent cases in other countries have caused intense media attention and questions about potential risks to J&J employees. A team of experts | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Johnson & Johnson Global Health Services - live for life™ News - OCTOBER | 2014 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Johnson & Johnson Global Health Services - live for life™ News - JULY | 2014 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Johnson & Johnson Global Health Services - live for life™ - World No Tobacco Day May 31, 2014 - E-cigarettes: What You Need to Know - To: Employees | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Johnson & Johnson Global Health Services - live for life™ - World No Tobacco Day May 31, 2014 - E-cigarettes: What You Need to Know - Presentation | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Johnson & Johnson Global Health Services - live for life™ News - MAY | 2014 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Berna Biotech Korea Corp. External Auditor’s Report on Financial Statement - Financial Statements Statement of Financial Position & Statement of Profit and Loss - March 23, 2013 | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
RISK ASSESSMENT AND CONTROL MASTER LIST - SMART Uniject Fill & Finish Facility - System/Process Name: Preparation for Filling (Washing/Sterilization/Bulk preparation) | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Berna Biotech Korea - External Auditor’s Report on Financial Statement - Financial Statements, Statement of Profit and Loss, Statement of Changes in Stockholders' Equity, Statement of Cash Flows -Review Report on Internal Control over Financial Reporting | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
RISK ASSESSMENT AND CONTROL MASTER LIST - SMART Uniject Fill & Finish Facility - System/Process Name: FHS | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
RISK ASSESSMENT AND CONTROL MASTER LIST - SMART Uniject Fill & Finish Facility - System/Process Name: HVLI | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
RISK ASSESSMENT AND CONTROL MASTER LIST - SMART Uniject Fill & Finish Facility - System/Process Name: LCI | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
RISK ASSESSMENT AND CONTROL MASTER LIST - SMART Uniject Fill & Finish Facility - System/Process Name: TRM | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
RISK ASSESSMENT AND CONTROL MASTER LIST - SMART Uniject Fill & Finish Facility - System/Process Name: 2nd HVLI | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Crucell Holland B.V. - Remuneration Round 2013 - Date: January 28, 2013 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Crucell Berna Biotech Ltd - Appartement-Wechsel und Vertragsverlängerung / MIETVERTRAG - Bern 19, April. 2010 | German->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Crucell Berna Biotech Ltd für Herr YongDon KIM - Appartement MIETVERTRAG -01.12.2009 ~ 31.01.2010 | German->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Crucell - Leadership Competency Evaluation By Peer Group | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Berna Biotech Korea Corp. - Post Marketing Surveillance Report - (Epaxal® Berna Prefilled Syringe Inj., Purified Hepatitis A virus (Inactivated) antigen ) (Apr 17, 2006 ~ Apr 16, 2012) | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Berna Biotech Korea Corp. - Post Marketing Surveillance Report - (Epaxal® Berna Prefilled Syringe Inj., Purified Hepatitis A virus (Inactivated) antigen ) Ⅴ. Lists of the Study Result Ⅵ. Discussion and Conclusion Ⅶ. Shipment Records (domestic) Ⅷ. Use in | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Crucell’s Performance Management System (PMS) - EMPLOYEE ONBOARDING PROGRAM & TOOLKIT FOR MANAGERS | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Crucell’s Performance Management System (PMS) - Performance Improvement Plan – Final Review | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Crucell’s Performance Management System (PMS) - New Performance Improvement Plan – 02.16.2012 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Crucell - INFORMATION FOR EMPLOYEES AROUND GCF LEVELING SYSTEM - 1. What is the Global Compensation Framework? | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Crucell - DURING PROBATION PERIOD – FEEDBACK FRAME - Preliminary Remarks | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Crucell - Feedback-Questionnaire – after 4 weeks | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Crucell - On-boarding Checklist – This checklist will assist you in welcoming and training new staff members. Be creative and resourceful in making your new hire feel part of the team. The goal is to provide an optimal work environment for the new employe | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Crucell - Probation period report | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Criminal History Information Record - No. 1004 -Criminal History, Investigation Result(including an actual penalty) - Incheon Yesonsu Police Station Chief - June 15, 2009 | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Johnson & Johnson Family Companies - Hotline for the Johnson & Johnson Family of Companies (Credo Hotline) – Frequently Asked Questions | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Johnson & Johnson Family Companies - CredoHotline.com for the reporting of ethical and legal concerns - Presentation | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Crucell - Introducing GCF (Global Compensation Framework) Leveling at Crucell - Human Resources, April 2012 / Presentation | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Crucell - Power of Attorney - Date: May 04, 2012 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Crucell Holland B.V - Status of your options in Crucell N.V. - February 23, 2011 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Circular de Información sobre Antecedentes de Crimen y de Pesquisa Núm. 1146 - Antecedentes de crimen y de pesquisa(incluso la penalidad efectuada) - 13 de abril de 2012 - Comisario de Policía de Namdong de Incheon | Korean ->Spanish |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
KFDA Regulation - Standards for Reexamination of New Drug, Etc. - Notification No. 2011-60 Korea Food & Drug Administration (Amended on Oct. 10, 2011) | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Berna Biotech Korea Corp. - 就業規則(취업규칙) / 附則(부칙) - Translation of Chinese characters into Korean Characters [Translation of Chinese ideogram into Korean phonogram] | Chinese characters->Korean Characters |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Steuerungsverwaltung des Kantons Bern - Verfügungen: Definitive Veranlagungen (Direkte Bundessteuer, Kantons- und Gemeindesteuern) und Schlussabrechnungen 2010 - 16.01.2012 | German->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Steuerungsverwaltung des Kantons Bern - Verfügungen: Dieses Schreiben umfasst folgende Dokumente (siehe Beilagen), Einzahlungsscheine (sofern vorhanden), Definitive Veranlagung und Schlussabrechnung Kantons- und Gemeindesteuern 2010 | German->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Steuerungsverwaltung des Kantons Bern - Verfügungen: Anderungen I Ergänzungen Kantons- und Gemeindesteuern 2010, Definitive Veranlagung und Schlussabrechnung Direkte Bundessteuer2010, Anderungen I Ergänzungen Direkte Bundessteuer 2010, Steuerausscheidung | German->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Steuerungsverwaltung des Kantons Bern - Verfügungen: Definitive Veranlagungen (Direkte Bundessteuer, Kantons- und Gemeindesteuern) und Schlussabrechnungen 2010 - 09.01.2012 | German->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Certificate of Foreign-Invested Enterprise - Registration No. 11625 (April 11th, 2000) - 1. Foreign Investor BERNA RHEIN B.V. - Netherlands 2. Foreign-Invested Enterprise Berna Biotech Korea -Head of Deutsche Bank July 14th 2011 | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Certificado analítico - Rector de Universidad de CHUNGBUK - Se certifica que los datos mencionados arriba son auténticos. 1 de febrero de 2012 | Korean ->Spanish |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Crucell - POWER OF ATTORNEY Template - Director and Legal Representative of Berna Biotech Korea Corp. - February 01, 2012 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
CERTIFICADO DE DATOS FUNDAMENTALES DE PERSONA, CERTIFICADO DE MATRIMONIO | Korean ->Spanish |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
UNIVERSIDAD NACIONAL DE CHUNGBUK Certificado de Graduación, Curriculum Vitae | English->Spanish |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
CERTIFICATE OF FAMILY RELATIONSHIP - The Chief of Dongjak-gu Office, Seoul - February 1, 2010 | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
CERTIFICATE OF FAMILY RELATIONSHIP - The Chief of Yeonsu-gu office, Incheon - January 12, 2012 | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Standard Certificate - The Chief of Yeonsu-gu office, Incheon - January 12, 2012 | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Marriage Certificate - The Chief of Yeonsu-gu office, Incheon - January 12, 2012 | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
NOVARTIS VACCINES - Standard Operating Procedure SOP 201434 (GVC 11101) - Monika Griot- Crucell La documentazione richiesta è - Rosia, 12 Oicembre 2011 | Italian ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
NOVARTIS VACCINES - Metodo Analitico/ Analytical Method SOP 202626-07 CQS 07.103 - DETERMINAZIONE DEL KD IN CAMPIONI GLICOCONIUGATI METODO HPLC - 23. 08. 2010 | Italian ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Johnson & Johnson Quality Standard STD - 005 - Pallet Management - Issue Date: August 3, 2011 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Crucell - PQ.0804.1-A - Validation Summary Report - Performance Qualification Report of Automatic Vial Inspector (PI-40) - Approved Date Aug 8, 2011 | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
NOVARTIS VACCINES - Metodo Analitico/ Analytical Method 201740 - 06 VGH 07.006 - Determinazione della percentuale di CRM 197 libero in campioni di glicoconiugati, metodo elettroforetico - 24. 11. 2011 | Italian ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Green Cross Corporation - Agreement - the collaborative use of the e-CRF system to carry out the research on use results after marketing of a GC Flu syringe product (undiluted solution of vaccine for splitting and inactivating influenza). - 07.07.2011 | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Medical Headquarters, Green Cross Corporation - Annex - Development Expenses of the e-CRF System for PMS Progression - Jul. 7, 2011 | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Samsung Medical Center & Asan Medical Center - A result of a clinical study - Test drug : Epaxal Berna pre-filled syringe inj. Control drug : Havrix Phase IV - July 2008 | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Berna Biotech Korea Corp. & Health Road Co., Ltd. - Bernaflu inj (Influenza Split Vaccine) PMS e-CRF System - Development Agreement - July 5, 2011 | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Berna Biotech Korea Corp. & Dream CIS Inc. - Bernaflu inj. PMS AGREEMENT - July 2011 | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Specific Guidance for APls Manufactured by Cell Culture/Fermentation - PE 009-9 (Paη 11) - 1 September 2009 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Crucell - Expected Q&As regarding the Results of the Investigation by KFTC (Korea Fair Trade Commission) - Version 6 | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Process Validation Equivalence Report - Process Validation Equivalence Report for Hepavax-Gene Stock Solutions Manufactured from the Singal Factory and Incheon Factory - April 2011 | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Bosch - An Overview of Barrier Isolation Technology - FDA regulatory guidelines, namely the agency’s guidance, “Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice.” Equally influential is the U.S. Pharmacopeia Conve | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Crucell Global Contract Approval Procedure - This electronic and centralized sign-off procedure is the only means for approval and signing of agreements. | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Validation summary report - Hepavax-Gene Drug Substance manufacturing process - March 2011 | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
GREEN CROSS VACCINE CORP & RHEIN BIOTECH GmbH - EXCLUSIVE LICENSE AGREEMENT - Supervax Exclusive Lic:ense Closing - 21 st day of April 2006 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Berna Biotech Korea Corp. GMP V54-0136-0 - Manual foreign body analysis Method - January 2011 | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Berna Biotech Korea Corp. GMP V55-0154-4 - Educational Method of Bottle Inspection - January 2011 | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Health Korea News articles - [Exclusive] Repercussions from Contamination in Berna Biotech’s Vaccine Manufacturing Factory in Shingal are Intensifying - January 2011 | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Berna Biotech Korea Corp. GMP V55-0039-7 - OOS Handling - January 2011 | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Berna Biotech Korea Corp. GMP V55-0039-7 - Manual No. V55-0039-7, Attachment 3 "OOS Handling". Flow Chart of OOS Processing - January 2011 | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Berna Biotech Korea Corp. GMP V55-0039-7 - Manual No. V55-0039-7, Attachement 4 "OOS Handling". - Flow Chart of OOS Processing for Sterility Test - January 2011 | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Berna Biotech Korea Corp. GMP V55-0096-12 - Validation of aseptic manipulation - January 2011 | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Cilag - Code: WI-SCH-2014 Version 3.0 - ARBEITSANWEISUNG - Filtertestgeräte Palltronic AquaWIT - 24 Jun 2010 | German->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Cilag - Code: WI-SCH-2014 Version 3.0 - ARBEITSANWEISUNG - Filtertestgeräte Palltronic AquaWIT - 24 Jun 2010 | German->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
The Minister of Health - Warsaw, Poland - To Berna Biotech Italia S.r.l. - Decision - Hepavax-Gene TF Vaccinum hepatitidis B (ADNr) Hepatitis B vaccine (rDNA) Injection slurry, 20µg of hepatitis B surface antigen (HbsAg)/ml; 1 dosage (1ml), dosage for adu | Polish ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Crucell and JNJ - Strategic Rationale Q&A | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Korea Food Drug Administration - Certificate of Good Manufacturiml Practice & Certificate of Pharmaceutical Manufacturim! License - Manufacturer: BERNA BIOTECH KOREA CORP- Issued date : Apr. 12. 2010 | English->Arabic |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
رقم الاصدار : يوم 12 من شهر أبريل في عام 2010 - شهادة رخصة تصنيع الأدوية - هيئة كيونغ ان الاقليمي للغذاء والدواء - شهادة ممارسة التصنيع الجيد - الهيئة الكورية للغذاء والدواء | English->Arabic Proofreading |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
A series of adverse events related to Hepatitis B vaccines. “Is it not because of the vaccine?” - Berna Biotech is checking the distribution channel of vaccines with the same batch number. - July 31, 2010 by Medical Today | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Incheon Free Economic Zone New Release - IFEZ signs land lease agreement with Berna Biotech Korea for expanded site - July 19, 2010 | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Crucell MINUTES- Results from Meeting about Quinvaxem CMO - 22 June 2010 | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
1 Recombinant Hepatitis B Vaccine(Hansenula polymorpha) - 재조합 B형 간염 백신 (한세눌라 폴리모르파) - Chinese into Korean Translation | Chinese ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
2 Recombinant Hepatitis B Vaccine(Saccharomyces cerevisiae) - 재조합 B형 간염 백신 (사카로미세스 세레비시아) - Chinese into Korean Translation | Chinese ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
3 Ⅳ C - 부록Ⅳ C SDS-폴리아크릴아미드 겔 전기영동법 - Chinese into Korean Translation | Chinese ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
4 IX B - 부록IX B Exogenous DNA 잔류량 측정법 - Chinese into Korean Translation | Chinese ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
5 Ⅸ E - 부록 Ⅸ E 효모 공정균 균체 단백질 잔류량 측정법 - Chinese into Korean Translation | Chinese ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
6 Ⅵ L - 부록Ⅵ L 유리형 포름알데하이드 측정법 - Chinese into Korean Translation | Chinese ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
7 Ⅹ A - 부록Ⅹ A 재조합 B형 간염백신(효모) 체외 상대적 효력 검사법 - Chinese into Korean Translation | Chinese ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
8 Ⅻ A - 부록 Ⅻ A 무균검사법 - Chinese into Korean Translation | Chinese ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
9 Ⅰ A - 부록 Ⅰ 제제 총칙 부록 Ⅰ A 주사제 - Chinese into Korean Translation | Chinese ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
10 Ⅲ D - 부록 Ⅲ D 분자배제 크로마토그래피법 - Chinese into Korean Translation | Chinese ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
10 Ⅲ D - 부록 Ⅲ D 분자배제 크로마토그래피법 - Chinese into Korean Translation | Chinese ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
11 Ⅴ A - 부록 Ⅴ A pH 측정법 - Chinese into Korean Translation | Chinese ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
12 Ⅴ H - 부록 Ⅴ H 삼투압 측정법 - Chinese into Korean Translation | Chinese ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
13 Ⅵ B - 부록 Ⅵ B 단백질 측정법 - Chinese into Korean Translation | Chinese ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
14 Ⅵ G - 부록 Ⅵ G 폴리에틸렌글리콜 잔류량 측정법 - Chinese into Korean Translation | Chinese ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
15 VI H - 부록 Ⅵ H 폴리소르베이트(Tween)80 잔류량 측정법 - Chinese into Korean Translation | Chinese ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
16 Ⅶ B - 부록 Ⅶ B 티메로살 측정법 - Chinese into Korean Translation | Chinese ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
17 Ⅶ F - 부록 Ⅶ F 수산화알루미늄(또는 인산알루미늄) 측정법 - Chinese into Korean Translation | Chinese ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
18 Ⅻ E - 부록 Ⅻ E 균체 내 독소 검사법 - Chinese into Korean Translation | Chinese ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
BOSCH Pharmatec GmbH -Operating Instructions 1233_CIPFI-100-00-1000_R1-0 - Project 1.233 „ New Vaccines Manufacturing Facility (Filling CIP System)“ - 24.03.2010 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
BOSCH Pharmatec GmbH - Operating manual automation 1233_CIPFI-100-02-1000_R2-0 - Project „New Vaccines Manufacturing Facility” Filling CIP for Berna Biotech Korea Corp. - 27.04.2010 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
BOSCH Pharmatec GmbH - Operating Instructions 1233_CIPFO-100-00-1000_R1-0 - Project 1.233 „ New Vaccines Manufacturing Facility (Formulation CIP System)“ - 24.03.2010 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
BOSCH Pharmatec GmbH - Operating manual automation 1233_CIPFO-100-02-1000_R2-0 - Project „New Vaccines Manufacturing Facility” Formulation CIP for Berna Biotech Korea Corp. - 27.04.2010 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
BOSCH Pharmatec GmbH - Operating instructions 1233_FS-100-00-1000_R1-0 - Project 1.233 „ New Vaccines Manufacturing Facility (Formulation System)“ - 22.10.2009 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
BOSCH Pharmatec GmbH - Operating manual automation 1233_FS-100-02-1000_R2-0 - Project „New Vaccines Manufacturing Facility” Formulation System for Berna Biotech Korea Corp.- 27.04.2010 | English ->Korean |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Commissioner of IFEZ (Incheon Free Economic Zone) and CEO of BernaBiotech Korea Corp. - Land Lease Agreement (Amendment) - June 22. 2010 | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Korea Food & Drug Administration - Request for supplementary of information (Berna Biotech Korea Co., Ltd, - HEPA BOX - Gene TF inj [Hepatitis Type B Vaccine (gene recombination) Thimerosa – free] (Export name: 박세푸르비) and two more items) 05.14 2010 | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
KFDA -Approval of change in the medicine manufacturing items [Berna Biotech Korea Co., Ltd ‘Quinvaxem inj (for export) (Diphtheria, Tetanus Toxoid, Whooping cough, Hepatitis B Vaccine (gene recombination), and Haemophilus influenza type b strain, Coryneba | Korean ->English |
Bernabiotech Korea (Crucell - Present Janssen Vaccine) |
Berna Biotech Korea Co., Ltd & C&R Research Inc. - Contract for Audit Service -Contract for Audit Service of Phase III Clinical Trial of “Hepavax Gene - TF inj.” (Hepatitis B Vaccine) - Feb. 2010 | Korean ->English |
Boehringer Ingelheim Korea
| Company | Project | Language |
|---|---|---|
Boehringer Ingelheim Korea |
Summary of the Memo from CD Purchasing - RE: Agency Holding Agreementsl Strategy for Selecting Agencies -> CD 구매부 메모 요약 - 답신: 에이전시 선정을 위한 에이전시 보유 계약/전략 | English ->Korean |
Boehringer Ingelheim Korea |
Vendor Management Policy - Effective Date: Jan. 2008 -> 벤더(공급업체) 관리 규정 - 효력발생일: 2008년 1월 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim - Checklist for Preparation of Local Contracts - September 2005 -> 베링거인겔하임 - 현지 계약 작성을 위한 체크리스트 - 2005년 8월 | English ->Korean |
Boehringer Ingelheim Korea |
CD Purchasing CORPORATE PROCEDURE - Title : Corporate Procedure Procurement of Agency Services -> CD 구매부 회사 절차 - 제목: 에이전시 서비스 조달을 위한 회사 절차 | English ->Korean |
Boehringer Ingelheim Korea |
CD Purchasing CORPORATE PROCEDURE - Title : Corporate Procedure for Contractual Liability Arrangements with Suppliers -> CD 구매부 회사 절차 - 제목: 공급업체와 계약상 책임 조정을 위한 회사 절차 | English ->Korean |
Boehringer Ingelheim Korea |
Adaptation of "BI Global Supply Regulation" (Version 2009) -> “BI 글로벌 공급 규정”의 개정 (2009 버전) | English ->Korean |
Boehringer Ingelheim Korea |
WUNSCH Preis | German->Korean |
Boehringer Ingelheim Korea |
TIA Lancet Neurology Press Release | English ->Korean |
Boehringer Ingelheim Korea |
Rocket AF toolkit & QA | English ->Korean |
Boehringer Ingelheim Korea |
Interview with Dr Jonas Oldgren Coverage | Korean ->English |
Boehringer Ingelheim Korea |
Subject Information - Single rising dose with BI 135585 XX in healthy Asian volunteers -> 피험자 정보 - 신체 건강한 아시아계 지원자에서의 BI 135585 XX 단 회 상승 투여 | English ->Korean |
Boehringer Ingelheim Korea |
Subject Information - Single rising dose with BI 135585 XX in healthy Asian volunteers -> 主题信息 - 单剂量BI 135585 XX在健康亚洲自愿者 | English ->Chinese |
Boehringer Ingelheim Korea |
Subject Information - Single rising dose with BI 135585 XX in healthy Asian volunteers -> 被験者情報シート - アジア人健常ボランティアにおけるBI 135585 XX用量漸増・単回投与 | English->Japanese |
Boehringer Ingelheim Korea |
Press Release - New subgroup analysis of the LUX-Lung 1 trial suggests benefit from afatinib* in lung cancer patients likely to have EGFR mutations -> 보도자료 - LUX-Lung 1 시험의 새로운 부분군 분석을 통해, EGFR 변이가 있을 가능성이 높은 폐암 환자에서 아파티닙(afatinib)* 효용성이 확인되었다 | English ->Korean |
Boehringer Ingelheim Korea |
External Social Media Guidelines 2011 -> 2011년 사외 소셜 미디어 관련 지침 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim Signature Policy (“four-eyes-principle") & Quality Policy December 2010 -> Boehringer Ingelheim 서명정책 ("2인 인증원칙") & 품질 정책 2010년 12월 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim Vetmedica Korea - Plan for PRRS Area Regional Control in Jeju 2011. Jan. | Korean ->English Proofreading |
Boehringer Ingelheim Korea |
Boehringer Ingelheim and Eli Lilly and Company Announce Strategic Alliance to Bring New Diabetes Treatments to Patients Worldwide - January 11, 2011 -> Boehringer Ingelheim과 Eli Lilly and Company, 전세계 당뇨병 환자들에게 새로운 치료제를 제공하기 위한 전략적 제휴 발표 2011년 1월 11일 | English ->Korean |
Boehringer Ingelheim Korea |
COMBINED VACCINES FOR PIGS - Are combined vaccines as suitable for pigs as individual vaccines? -> 돼지용 배합백신 - 혼합백신이 개별 백신만큼 돼지용으로 적합한가? | English ->Korean |
Boehringer Ingelheim Korea |
CLINICAL TRIAL PROTOCOL SYNOPSIS - Objectives: To investigate safety, tolerability, and pharmacokinetics of BI 207127 -> 임상시험 프로토콜 개요 - 목적: BI 207127의 안전성, 내약성 및 약동학을 연구 | English ->Korean |
Boehringer Ingelheim Korea |
Subject Informed Consent Form - Single rising dose with BI 207127 NA in healthy male Asian and Caucasian volunteers -> 피험자 동의서 - 건강한 남성 아시아인 및 백인 지원자에서의 BI 207127 NA 단회 상승 투여 | English ->Korean |
Boehringer Ingelheim Korea |
Subject Information - Single rising dose with BI 20712NA in healthy male Asian and Caucasian volunteers -> 피험자 정보 - 건강한 남성 아시아인 및 백인 지원자에서의 BI 20712NA 단회 상승 투여 | English ->Korean |
Boehringer Ingelheim Korea |
Subject Information sheet for pharmacogenetic testing - Single rising dose with BI 207127 NA in healthy male Asian and Caucasian volunteers -> 약물유전체검사에 관한 피험자 정보지 - 건강한 남성 아시아인 및 백인 지원자에서의 BI 207127 NA 단 회 상승 용량 | English ->Korean |
Boehringer Ingelheim Korea |
Patient Information and Consent Form - combination with pegylated interferon-α and ribavirin -> 환자 정보 및 사전 동의서 - 페그인터페론- α(pegylated interferon- α) 및 리바비린(ribavirin)과 병용 | English ->Korean |
Boehringer Ingelheim Korea |
A case of PRRS control in Korea | Korean ->English Proofreading |
Boehringer Ingelheim Korea |
Clinical Trial Protocol - Investigational Product(s): BI 207127 NA -> 임상시험 연구계획서 - 시험 제품(들): BI 207127 NA | English ->Korean |
Boehringer Ingelheim Korea |
ELSEVIER Virus Research - Review - Control and elimination of porcine reproductive and respiratory syndrome virus -> 바이러스 조사 - 검토 - 돼지 생식기 및 호흡기 증후군 바이러스의 관리 및 제거 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim Key Messages 2011 - PR-KEY Messages on Brands -> 베링거인겔하임(Boehringer Ingelheim) 주요 내용(KEY Messages) 2011년 - 브랜드 홍보 – 주요 내용(KEY Messages) | English ->Korean |
Boehringer Ingelheim Korea |
Commentary - Peer reviewed - Terminology for classifying swine herds by porcine reproductive and respiratory syndrome virus status -> 해설 - 상호 검토문 - 돼지 생식기 및 호흡기 증후군 바이러스 상태에 의한 돈군 분류 용어 | English ->Korean |
Boehringer Ingelheim Korea |
Research Agreement - Research Project Name: Experiment on the Effect and Safety of Pimobendan <- 연구계약서 - 연구과제명: 피모벤단의 효능과 안전성 실험 | Korean ->English |
Boehringer Ingelheim Korea |
Jeju PRRS ARC TFT TC Minute | Korean ->English |
Boehringer Ingelheim Korea |
PRADAXA® (dabigatran etexilate) QUESTIONS & ANSWERS RESOURCE - Bayer/J&J ROCKET AF results -> PRADAXA® (다비가트란 이텍실레이트) 질문 & 답변 자료 - Bayer/J&J ROCKET AF 결과 | English ->Korean |
Boehringer Ingelheim Korea |
Chronic Obstructive Pulmonary Disease (COPD) Media backgrounder March 2011 -> 만성 폐쇄성 폐질환(COPD) 배경설명 자료 2011년 3월 | English ->Korean |
Boehringer Ingelheim Korea |
Early Diagnosis and Management of Chronic Obstructive Pulmonary Disease (COPD) Media backgrounder March 2011 -> 만성폐쇄성폐질환(COPD)의 조기진단 및 관리 배경설명 자료 2011년 3월 | English ->Korean |
Boehringer Ingelheim Korea |
COPD Exacerbations Media backgrounder March 2011 -> COPD의 악화 배경설명 자료 - 2011년 3월 | English ->Korean |
Boehringer Ingelheim Korea |
The POET-COPD® study (The Prevention Of Exacerbations with Tiotropium) Media backgrounder March 2011 -> POET-COPD® 시험 (The Prevention Of Exacerbations with Tiotropium) 배경설명 자료 2011년 3월 | English ->Korean |
Boehringer Ingelheim Korea |
The POET-COPD® Study (The Prevention Of Exacerbations with Tiotropium) Reactive Media Q&A 24 March, 2011 -> POET-COPD® 연구 (티오트로퓸(Tiotropium)으로 악화 예방) 반응 매체 Q&A 2011년 3월 24일 | English ->Korean |
Boehringer Ingelheim Korea |
SPIRIVA® (tiotropium)* Media backgrounder March 2011 -> 스피리바® (티오트로퓸)* 배경설명 자료 2011년 3월 | English ->Korean |
Boehringer Ingelheim Korea |
The Economic Burden of Chronic Obstructive Pulmonary Disease (COPD) Media backgrounder March 2011 -> 만성 폐쇄성 폐질환(COPD)의 경제적 부담 배경설명 자료 2011년 3월 | English ->Korean |
Boehringer Ingelheim Korea |
For medical media outside the USA and Canada -The POET-COPD® study results demonstrate superiority of Spiriva® (tiotropium) over long-acting beta agonist salmeterol in reducing the risk for COPD exacerbations -> Korean | English ->Korean |
Boehringer Ingelheim Korea |
미국 및 캐나다 외 지역 의학 매체용 -POET-COPD® 연구 결과, COPD(만성폐쇄성폐질환) 악화 위험을 감소시키는 지속성 베타 작용제 살메테롤(salmeterol)에 대해 스피리바® (티오트로퓸)의 우수성을 증명 <- English | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Sustained Viral response achieved in 83% of Hepatitis C infected patients with new HCV protease inhibitor from Boehringer Ingelheim -> 보도자료 - 베링거 인겔하임의 새로운 HCV 단백질분해효소 억제제로 치료 받은 C형 간염 감염 환자의 83%가 지속 바이러스 반응을 보였다. | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Dabigatran etexilate is cost-effective for stroke prevention in atrial fibrillation, particularly in real-world clinical practice-> 보도자료 -다비가트란 이텍실레이트는 특히 실제 임상 진료에서 비판막성 심방세동 환자의 뇌졸중 예방에 있어 비용효과적이다. | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New SPIRIVA® RESPIMAT® Soft MistTM Inhaler now available for the management of COPD - Patients to benefit from easy-to-use inhaler with enhanced drug delivery-> 보도자료 -COPD 관리를 위한 새로운 스피리바® (SPIRIVA®) 레스퍼매트® (RESPIMAT) ® Soft MistTM 흡입기- 환자 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Breakthrough therapy dabigatran provides consistent benefit across all atrial fibrillation types and stroke risk groups-> 보도자료 - 획기적인 치료인 다비가트란은 모든 심방세동 유형 및 뇌졸중 위험군에 걸쳐 일관된 효용을 제공한다 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim’s lead hepatitis C compound moves into phase III – the first within the BI HCV portfolio -> 보도자료 - Boehringer Ingelheim이 C형 간염 화합물의 III 단계를 향한 움직임을 선도 - BI HCV 최초 | English ->Korean |
Boehringer Ingelheim Korea |
JEJU PRRS ARC Meeting Apr. 1, 2011 (Friday) <- 제주 PRRS ARC 간담회 2011년 4월 1일(금요일) | Korean ->English |
Boehringer Ingelheim Korea |
Boehringer Ingelheim Korea Supply Agreement <- 한국베링거인겔하임㈜ 공급계약서 | Korean ->English |
Boehringer Ingelheim Korea |
Cosmetic Product Data Sheet, ANTISTAX Leg Cooling Spray -> 화장품 데이터시트 ANTISTAX Leg Cooling Spray | English ->Korean |
Boehringer Ingelheim Korea |
Clinical Trial Report for Cosmetics - Test Substance: Antistax® Spray -> 화장품 임상시험 보고서 - 검사성분: Antistax® Spray | English ->Korean |
Boehringer Ingelheim Korea |
ANTISTAX Leg Cooling Spray Homepage Contents translation | English ->Korean |
Boehringer Ingelheim Korea |
Birthday thank-you letter - Hello, everyone. I'm La In Gang. <- 생일 감사 편지 - 안녕하세요, 라인강입니다. | Korean ->English |
Boehringer Ingelheim Korea |
Corporate Procedure for Handling Technical Complaints of Veterinary Products - Effective Date: 02-Feb-2004 -> 수의학 제품 관련 기술적 불만 처리 절차 - 발효일자: 2004년 2월 2일 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Dabigatran etexilate now approved in eight Asia Pacific countries for stroke prevention in atrial fibrillation-> 보도자료 - 다비가트란 이텍실레이트(Dabigatran etexilate), 심방세동 환자의 뇌졸중 예방 목적으로 아시아 태평양 8개국에서 허가 | English ->Korean |
Boehringer Ingelheim Korea |
Origin of the UK Foot and Mouth Disease epidemic in 2001 - Department for Environment, Food and Rural Affairs June 2002 -> 2001년 영국 구제역 유행의 원인 - 영국 환경농식품부 2002년 6월 | English ->Korean |
Boehringer Ingelheim Korea |
The Regulations on New Accounts and the Termination of Contract - Date of Execution: April 1, 2011 <- 거래처 신규 및 계약종료에 관한 규정 - 실시일 : 2011.04.01 | Korean ->English |
Boehringer Ingelheim Korea |
Control of foot and mouth disease: lessons from the experience of Ireland - Rev. sci. tech. Off. int. Epiz., 2002, 21 (3), 739-750 -> 구제역(foot and mouth disease) 관리: 아일랜드 경험으로부터의 교훈 | English ->Korean |
Boehringer Ingelheim Korea |
Control of foot and mouth disease: lessons from the experience of the outbreak in Great Britain in 2001 - Rev. sci. tech. Off. int. Epiz., 2002, 21 (3), 699-710 -> 구제역 관리: 2001년 영국(Great Britain)에서의 구제역 발생으로부터의 교훈 - 영국 SW1P 4PQ, 런던 1A Page가, 주 수의학 서비스, 환경 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim/Pfizer position regarding the recent publication by Singh et. al., in British Medical Journal, June 15, 2011 -> 보도자료 - 2011년 6월 15일 British Medical Journal의 Singh 등 최근 발표 관련 베링거 인겔하임/화이자 측 입장 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New data confirm superior blood pressure reductions in diabetic patients treated with TWYNSTA® compared to amlodipine alone -> 보도자료 - 암로디핀(amlodipine) 단독 투여 대비 TWYNSTA®투여 당뇨환자에서 우월한 혈압 강하 효능 확인 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New data for linagliptin* show clinically meaningful efficacy similar to glimepiride but with fewer cardiovascular events -> 보도자료 - 리나글립틴*, 글리메피리드 대비 유효성은 유사하나 심혈관 사건 발생률은 더 낮아 | English ->Korean |
Boehringer Ingelheim Korea |
Case report: Effect of mass vaccination with Ingelvac® PRRS MLV on sow performance <- Korean | Korean ->English |
Boehringer Ingelheim Korea |
Press Release - Breakthrough therapy PRADAXA® (dabigatran etexilate) first drug in 50 years to gain approval for stroke prevention in atrial fibrillation in Europe -> 보도자료 - PRADAXA® (dabigatran etexilate), 50년 만에 최초로 심방세동환자의 뇌졸중 예방을 위한 혁신적 치료법으로 유럽에서 승인 | English ->Korean |
Boehringer Ingelheim Korea |
1st Conference of MAF for the |
Korean ->English |
Boehringer Ingelheim Korea |
FMD Planning RFP - Project Name Development of technology for the production of a recombinant FMD vaccine <- 구제역 기획과제 제안요구서 RFP - 과제명: 유전자 재조합 구제역 백신 생산 기술개발 | Korean ->English |
Boehringer Ingelheim Korea |
2nd Conference of the FMD Planning Group at the Ministry for Food, Agriculture, Forestry and Fisheries (MAF) for [2011.4.26] <- 제2차 농림수산식품 구제역 기획단 회의자료 [2011.4.26] | Korean ->English |
Boehringer Ingelheim Korea |
Overall Project Milestone Plan - G. Considerations related to technology development - 5. Research Period and Research Budget <- 전체 추진 마일스톤 - 사. 기술개발과 관련된 검토사항 - 5. 연구기관 및 연구 예산 규모 | Korean ->English |
Boehringer Ingelheim Korea |
PROJECT ②: Development of Production Technology for a Recombinant Vaccine for Foot-and-Mouth Disease (FMD) <- 기획과제 ② : 유전자 재조합 구제역 백신 생산 기술개발 | Korean ->English |
Boehringer Ingelheim Korea |
Mortality associated with tiotropium mist inhaler? A critical appraisal of the authors' selection and use of previously communicated tiotropium Respimat data -> 티오트로피움 분무흡입기 관련 사망: 이전에 알려진 티오트로피움 Respimat 자료의 저자 선정 및 사용 비평 | English ->Korean |
Boehringer Ingelheim Korea |
World Hepatitis Day 2011 and our commitment to hepatitis C patients worldwide | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Dabigatran etexilate protects against recurrent venous thromboembolic (VTE) events 92% reduction in risk of VTE with dabigatran etexilate compared to placebo (RE-SONATE trial)-> 보도자료 -다비가트란 이텍실레이트는 재발성 정맥 혈전색전증(VTE)을 방지한다 다비가트란 이텍실레이트는 VTE | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Trajenta® (linagliptin) receives approval for the treatment of type 2 diabetes in Europe -> 보도자료 - 트라젠타® (리나글립틴), 유럽에서 제 2형 당뇨병 치료약으로 승인 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Pradaxa® (dabigatran etexilate, 150mg bid) shows significant reduction in the risk of stroke over warfarin in patients with atrial fibrillation taking antiplatelet or other concomitant therapies -> 보도자료 - 프라닥사® (다비가트란 에텍실레이트) 150mg 1일 2회 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Pradaxa® (dabigatran etexilate) revolutionizes stroke prevention in atrial fibrillation -> 보도자료 - 프라닥사®(다비가트란 에텍실레이트) 심방세동환자 뇌졸중 예방의 혁신을 이루다 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New data for once-daily linagliptin show durable efficacy over two years -> 보도자료 - 리나글립틴 1일 1회 투여 시 유효성이 2년 동안 지속된다는 새로운 자료 발표돼 | English ->Korean |
Boehringer Ingelheim Korea |
Bericht zur Leistungsqualifizierung (PQ) - TZL 18, PQ-Überprüfungslauf nach Umzug der Linie ins LogiPack Center -> 적격 검사(PQ) 보고서 - 가열성형라인 18, LogiPack Center로의 라인 이동에 따른 PQ-심사과정 | German->Korean |
Boehringer Ingelheim Korea |
Bericht zur Leistungsqualifizierung (PQ) - TZL 19, PQ-Überprüfungslauf nach Umzug der Linie ins LogiPack Center-> 적격 검사(PQ) 보고서 - 가열성형라인 19, LogiPack Center로의 라인 이동에 따른 PQ-심사과정 | German->Korean |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim implements additional guidance supporting appropriate use of Pradaxa® (dabigatran etexilate) in Europe -> 보도자료 - 베링거인겔하임, 프라닥사®(다비가트란 이텍실레이트)의 적절한 사용을 위한 추가지침 시행 | English ->Korean |
Boehringer Ingelheim Korea |
Bericht zur Leistungsqualifizierung (PQ) - TZL23 - Kombilinie- Format: Micardis Mono 10er Blister- ínit Perforation -> 적격 검사(PQ) 보고서 - 가열성형라인 23-조합라인-유형: 절취선이 있는 미카르디스 10정용 블리스터 | German->Korean |
Boehringer Ingelheim Korea |
Bericht zur Leistungsqualifizierung (PQ) - Tiefziehli nie 26 I Qualifizierung 10er-Blisterformate (Micardis Plus I Twynsta und Micardis Mono)-> 적격 검사(PQ) 보고서 -가열성형라인 26/10정용 블리스터의 제품 유형에 대한 적격 검사 | German->Korean |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim gains approval of the extended 4.5 hour time-window for Actilyse® (Alteplase) in acute ischaemic stroke for majority of EU countries* -> 보도자료 - Boehringer Ingelheim, 대다수의EU 국가에서 급성 허혈성 뇌졸중에 대해 Actilyse® (Alteplase)의 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim enrols first patient in Phase III program for new once-daily fixed-dose combination of tiotropium plus olodaterol in COPD -> 보도자료 - Boehringer Ingelheim, 만성폐쇄성 폐질환(COPD)에서의 새로운 하루 1회 고정용량 티오트로피움 및 올로다테롤 조합에 대한 제3상 프로그 | English ->Korean |
Boehringer Ingelheim Korea |
Applying PRRS Risk Assessment v2.3 to Jeju PRRS Area Regional Control and Analysis of Results <- PRRS Risk Assessment v2.3의 제주 PRRS Area Regional Control에의 적용 및 결과 분석 | Korean ->English |
Boehringer Ingelheim Korea |
Application of PRRS Area Regional Control in Jeju <- 대한민국 제주도에서의 PRRS 지역 관리(Area Regional Control)의 적용 | Korean ->English |
Boehringer Ingelheim Korea |
Meeting Report of the Jeju PRRS ARC TFT Meeting, dated 27 Sep, 2011 Place: Jeju Grand Hotel <- 2011년 9월 27일 제주 PRRS ARC TFT 미팅 결과 보고 - 장소: 제주 그랜드호텔 | Korean ->English |
Boehringer Ingelheim Korea |
Press Release - New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis -> 보도자료 - 뉴잉글랜드 저널 오브 메디슨 지(New England Journal of Medicine | English ->Korean |
Boehringer Ingelheim Korea |
Cases of Using Ileitis Vaccine in the Korean Field: Increasing Productivity through the Ileitis Vaccine <- 회장염 백신의 국내 필드 사용 사례: 회장염 백신을 통한 농장 생산성 증가 | Korean ->English |
Boehringer Ingelheim Korea |
The Efficacy and Safety Evaluation of 3FLEX in Jeju Island <- Korean | Korean ->English |
Boehringer Ingelheim Korea |
The labor cost saving after using mixed PCV2 and Mycoplasma hyopneumonia vaccine in Korea <- Korean | Korean ->English |
Boehringer Ingelheim Korea |
SECTION 8 VACCINATION Article 49 Use, manufacture, sales and controls of foot-and-mouth Article 50 Decision on introducing emergency vaccination Article 51 Conditions for emergency vaccination -> SECTION 8 백신 접종 제49조 구제역 백신의 사용, 제조, 판매 및 관리 제50조 긴급 백신 접종 | English ->Korean |
Boehringer Ingelheim Korea |
Manuscript checklist (space for manuscript ID) - 원고(Manuscript) 체크리스트 (원고 ID 기입 공백) | English ->Korean |
Boehringer Ingelheim Korea |
Analysis of Correlations between PRRS Monitoring Results Using the Risk Factors of the Risk Assessment and Blood on Korean Farms <- 대한민국 농장에서의 Risk Assessment의 Risk Factor와 혈액을 이용한 PRRS 모니터링 결과간의 상관관계 분석 | Korean ->English |
Boehringer Ingelheim Korea |
Final Report of PRRS Research Group Field Trial - Analysis Result of PRRS Risk Assessment <- Korean | Korean ->English |
Boehringer Ingelheim Korea |
PHOENYX is effective for respiratory organ diseases caused by PRRS viruses by activating innate immunity (IFN – α, β, TNF – α). Find the effectiveness yourself by injecting PHOENYX on atrophic pigs or infected pigs! <- Korean | Korean ->English |
Boehringer Ingelheim Korea |
PRADAXA® (dabigatran etexilate) - QUESTIONS & ANSWERS RESOURCE Direct Healthcare Professional Communication on the importance of assessing renal function in patients treated with Pradaxa® (dabigatran etexilate) in Europe-> 프라닥사® (다비가트란 이텍실레이트) - 질문 & 답변 , | English ->Korean |
Boehringer Ingelheim Korea |
Pharmaton Web Translation Document - 1.1.1.A.d. FAQ 1. What are the main advantages of taking Pharmaton® Vitality? -> 1.1.1.A.d. 자주 묻는 질문 1. Pharmaton® Vitality 복용의 주요 장점은 무엇인가요? | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim GmbH ABCD Consumer Health Care Basic Medical Information - Product: Standardised Panax ginseng G115® extract, vitamins and minerals -Pharmaton ® Core (Soft gelatine capsules, effervescents, and caplets) | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim GmbH COMPANY CORE DATA SHEET GERIATRIC PHARMATON * (Pharmaton capsules, Geriavit Pharmaton, Gericomplex, Pharmaton Caplets) * -> 게리아트릭 파마톤 (GERIATRIC PHARMATON) * (Pharmaton capsules, Geriavit Pharmaton, Gericomplex, Pharmaton Caplets | English ->Korean |
Boehringer Ingelheim Korea |
Fachinformation des Arzneimittel-Kompendium der Schweiz® - Pharmaton® Vital Tabletten -> 파마톤® 바이탈 정 | German->Korean |
Boehringer Ingelheim Korea |
Press Release - BI 201335 demonstrates potential to shorten HCV treatment duration while achieving high sustained virological response rates in difficult to treat patients -> 보도자료 - BI 201335, 치료가 어려운 환자들에서 HCV치료 기간 단축과 높은 지속적 바이러스 반응 비율 입증1,2 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Hepatitis C: Interferon-free combination of BI 201335 plus BI 207127 and ribavirin shows up to 76% of patients achieve a virological response at week 12, and 63% achieve SVR12 with 16 weeks treatment 1-> 보도자료 - C형 간염: 인터페론이 포함되지 않는 BI 2013 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Patients with atrial fibrillation should continue to protect themselves against the risk of stroke -> 보도자료 - 심방세동 환자는 뇌졸중 위험으로부터 지속적으로 스스로를 지켜야 한다 | English ->Korean |
Boehringer Ingelheim Korea |
ABCD Patient Information and Consent Form - Inje University Busan Paik Hospital -> ABCD Өвчтөний Мэдээлэл ба Зөвшөөрлийн Маягт - Инже Их Сургуулийн дэргэдэх Бусан Пайк Эмнэлэг | English ->Mongolian |
Boehringer Ingelheim Korea |
PATIENT IDENTIFICATIOM CARD CLINICAL TRIAL: 1220.47 - Front: Trial Identification Card For EMERGENCY Back: Visit 8 and 9 are only for patients in 48 weeks -> ӨВЧТӨНИЙ ТАНИХ КАРТ КЛИНИКИЙН ТУРШИЛТ: 1220.47 Урд: ЯАРАЛТАЙ ТҮРГЭН ТУСЛАМЖ-д зориулсан Судалгаан | English ->Mongolian |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim completes patient entry for Phase III trial programme in Hepatitis C -> 보도자료 - 베링거인겔하임, C형 간염 제 3상 임상프로그램을 위한 환자 모집 완료해 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim Moves into Phase III for its Head and Neck Cancer Trial Programme for Afatinib* -> 보도자료 - 베링거인겔하임, 아파티닙에 대한 제 3상 두경부암 임상시험프로그램 시작해 | English ->Korean |
Boehringer Ingelheim Korea |
First of all, I would like to congratulations on your promotion to the Head of Global Swine Marketing. <- 먼저 Head of Global Swine Marketing으로의 영전을 축하 드립니다. | Korean ->English |
Boehringer Ingelheim Korea |
Ministry of Health and Welfare [Attached Table 20 Form] |
Korean ->English |
Boehringer Ingelheim Korea |
Ministry of Health and Welfare [Attached Table 20 Form] |
English ->Mongolian |
Boehringer Ingelheim Korea |
Boehringer Ingelheim Korea Consumer Health Care (CHC) Greeting Letter <- 한국베링거인겔하임 일반의약품 CHC(Consumer Health Care) 인사 서신 | Korean ->English |
Boehringer Ingelheim Korea |
Reactive Global Media Q&A SPIRIVA® AND THE REVISED GOLD GUIDELINES SUMMARY Date Issued: xx January 2012 -> Reactive Global Media Q&A SPIRIVA®와 개정된 GOLD 가이드라인 요약 발행 일자: 2012년 1월 xx | English ->Korean |
Boehringer Ingelheim Korea |
1-1-02-05 The standard for screening inactivated vaccine for staphylococcus aureus mastitis of dairy cows <- 1- 1- 02- 05 젖소 황섹포도상구균 유방염 불활화백신 검정기준 | Korean ->English |
Boehringer Ingelheim Korea |
XI. General Screening Standard for Veterinary Biological Medicines 1-11-20-01 Characteristic test 1-11-20-02 Vacuum test 1-11-20-03 Hydrogen ion concentration test <- X I. 동물용 생물학적제제 일반검정기준 1- 11- 20-01 특성 시 험 1-11- 20- 02 진공도 시험 1-11-20- 03 수소 이온 농도 시험 | Korean ->English |
Boehringer Ingelheim Korea |
XI. General Screening Standard for Veterinary Biological Medicines 1-11-20-04 Moisture content test 1-11-20-05 Purity test 1-11-20-06 Sterility test 1-11-20-07 Mycoplasma test 1-11-20-08 Bacteria test 1-11-20-09 Preservative quantity test <- Korean | Korean ->English |
Boehringer Ingelheim Korea |
X I. 동물용 생물학적제제 일반검정기준1- 11-20 - 04 함습도 시험 1- 11-20- 05 순수 시험 1- 11-20- 06 무균 시험 1-11-20-07 마이코플라즈마 부정시험 1- 11- 20-08 세균 시험 1- 11-20-09 방부제 정량시험 -> English | Korean ->English |
Boehringer Ingelheim Korea |
Press Release - Revised GOLD Guidelines highlight - Long-acting anticholinergics supported by new guidelines as the only therapeutic class recommended for every patient requiring maintenance therapy -> 보도자료 - 개정 GOLD 가이드라인, 악화 위험성과 COPD 증상 강조 - 새로운 가이드라 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim/Pfizer’s Spiriva Has Earned Decision Resources’ Proprietary Clinical Gold Standard Status for the Treatment of Chronic Obstructive Pulmonary Disease-> 보도자료 - 베링거인겔하임/화이자의 스피리바, Decision Resources로부터 만성 폐쇄성 폐질환의 치료에 대한 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer lngelheim Corporate Policy on Purchαsing at Boehringer lngelheim Group of Companies -> 베링거인겔하임 그룹에서 그룹 차원의 구매에 관한 회사 정책 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim GmbH Corporate Division Purchasing Procedure - Ident.-No PCP-001 Version No: 03 -> 베링거인겔하임 회사 구매 절차 - 식별번호 PCP-001 버전 번호: 03 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Combination Therapy with Insulin -> 트라드젠타 (리나글립틴) 정제 인슐린과의 병용 요법 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Add-on Combination Therapy with Metformin -> 트라드젠타 (리나그립틴) 정제 메트포르민과의 추가적 병용 요법 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Combination with Pioglitazone -> 트라드젠타 (리나그립틴) 정제 피오글리타존(Pioglitazone)과의 병용 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Combination with Alpha Glucosidase Inhibitors -> 트라드젠타 (리나그립틴) 정제 알파 글루코시데이스 억제제와의 병용 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Combination with Sulfonylurea & Sulfonylurea/Metformin -> 트라드젠타 (리나글립틴) 정제 술포닐우레아 및 술포닐우레아/메트포르민과의 병용 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Drug Interactions -> 트라드젠타 (리나글립틴) 정제 약물상호작용 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Drug-Drug Interactions with Bile Acid Sequestrants (Welchol®) -> 트라드젠타 (리나그립틴) 정제 담즙산 결합수지(Welchol®)와의 약물-약물 상호작용 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Drug-Drug Interactions with Transplant Drugs (CellCept®, Sandimmune® and Prograf®) -> 트라드젠타 (리나글립틴) 정제 이식 거부반응 예방약과의 약물-약물 상호작용 (CellCept®, Sandimmune® and Prograf®) | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Use with Glucagon-like Peptide 1 (GLP-1) Agonist Therapy -> 트라드젠타 (리나글립틴) 정제 글루카곤-유사 펩티드 1(GLP-1) 작용제 요법과의 병용 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Use with Meglitinides -> 트라드젠타 (리나글립틴) 정제 메글리티나이드계와의 병용 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Use with Pramlintide -> 트라드젠타 (리나글립틴) 정제 프람린티드와의 병용 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Use with SGLT-2 Inhibitors -> 트라드젠타 (리나그립틴) 정제 SGLT-2 억제제와의 병용 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Alternative dosing -> 트라드젠타 (리나글립틴) 정제 대체 용법 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Dosage and Administration -> 트라드젠타 (리나글립틴) 정제 용량 및 투여법 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Switching from another DPP-4 Inhibitor to TRADJENTA -> 트라드젠타 (리나글립틴) 정제 다른 DPP-4 억제제에서 트라드젠타로의 전환 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Switching from Glucagon Like Peptide -1 (GLP-1) Agonist Therapy to TRADJENTA -> 트라드젠타 (리나글립틴) 정제 글루카곤-유사 펩티드-1 (GLP-1) 작용제 요법에서 트라드젠타로의 전환 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Comparison to Alpha Glucosidase Inhibitors -> 트라드젠타 (리나그립틴) 정제 알파 글루코시데이즈 억제제와의 비교 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Comparison to Glucagon-like Peptide-1 (GLP-1) Agonist Therapy -> 트라드젠타 (리나글립틴) 정제 글루카곤-유사 펩티드 1(GLP-1) 작용제 요법과의 비교 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Comparison with Januvia® -> 트라드젠타 (리나그립틴) 정제 Januvia®와의 비교 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Comparison with ONGLYZATM (saxagliptin) -> 트라드젠타 (리나글립틴) 정제 ONGLYZATM (삭사글립틴)와의 비교 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Comparison with Sulfonylureas -> 트라드젠타 (리나글립틴) 정제 술포닐우레아계와의 비교 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Effect on Indicators of β-cell function -> 트라드젠타 (리나글립틴) 정제 β-세포 기능 지표에 대한 효과 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Summary of Efficacy and Safety -> 트라드젠타 (리나글립틴) 정제 유효성 및 안전성 요약 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Monotherapy -> 트라드젠타 (리나글립틴) 정제 단독요법 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Glycemic Endpoints across 6 TRADJENTA Pivotal Trials -> 트라드젠타 (리나글립틴) 정제 6건의 트라드젠타 중추적 시험에서의 혈당 평가변수들 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Elimination Half-Life -> 트라드젠타 (리나그립틴) 정제 제거 반감기 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Mechanism of Action and Pharmacodynamics -> 트라드젠타 (리나글립틴) 정제 작용기전과 약역학 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Onset of Action -> 트라드젠타 (리나글립틴) 정제 작용발현 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Pharmacokinetics -> 트라드젠타 (리나그립틴) 정제 약동학 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Cardiovascular Safety -> 트라드젠타 (리나글립틴) 정제 심혈관 안전성 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Effect on Body Weight -> 트라드젠타 (리나글립틴) 정제 체중에 대한 효과 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Effect on Laboratory Tests -> 트라드젠타 (리나글립틴) 정제 실험실 검사에 대한 효과 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Hyperlipidemia/Effect on Triglycerides -> 트라드젠타 (리나글립틴) 정제 고지질혈증/중성지방에 대한 효과 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Hyperuricemia, Nephrolithiasis (Kidney Stones), and Gout -> 트라드젠타 (리나글립틴) 정제 고요산혈증, 신장결석증(신장결석), 통풍 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Hypoglycemia -> 트라드젠타 (리나글립틴) 정제 저혈당증 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Incidence of Malignancy -> 트라드젠타 (리나글립틴) 정제 암 발생률 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Nasopharyngitis -> 트라드젠타 (리나글립틴) 정제 비인두염 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Overdosage / Removal by Dialysis -> 트라드젠타 (리나글립틴) 정제 과량투여/투석에 의한 제거 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Incidence of Pancreatitis -> 트라드젠타 (리나글립틴) 정제 이자염 발생률 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Rash, Hypersensitivity and Skin Lesions -> 트라드젠타 (리나글립틴) 정제 발진, 과민 및 피부 병터 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Use in Geriatric Patients -> 트라드젠타 (리나글립틴) 정제 노인 환자들에서의 사용 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Pediatric Use -> 트라드젠타 (리나글립틴) 정제 소아 사용 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Use in Pregnancy and Lactation -> 트라드젠타 (리나글립틴) 정제 임신 및 수유중 사용 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Use in Alcoholic Patients -> 트라드젠타 (리나글립틴) 정제 알코올중독 환자들에서의 사용 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Use in American Indian Patients -> 트라드젠타 (리나글립틴) 정제 아메리카 인디언 환자들에서의 사용 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Use in Asian Patients -> 트라드젠타 (리나글립틴) 정제 아시아 환자들에서의 사용 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Use in Black/African American Patients -> 트라드젠타 (리나글립틴) 정제 흑인/아프라카계 미국인 환자들에서의 사용 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Use in Hepatic Impairment -> 트라드젠타 (리나글립틴) 정제 간 장애에서의 사용 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Use in Hispanic / Latino Patients -> 트라드젠타 (리나글립틴) 정제 히스패닉계/라틴계 환자들에서의 사용 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Use in Males versus Females -> 트라드젠타 (리나그립틴) 정제 남성과 여성에서의 사용 비교 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Use in Obese Patients -> 트라드젠타 (리나그립틴) 정제 비만 환자들에서의 사용 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Use in Renally Impaired Patients -> 트라드젠타 (리나글립틴) 정제 신장 장애가 있는 환자들에서의 사용 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Bibliography -> 트라드젠타 (리나글립틴) 정제 참고문헌 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Measuring GLP-1 Levels in the Clinical Trials -> 트라드젠타 (리나글립틴) 정제 임상 시험들에서 GLP-1 수준의 측정 | English ->Korean |
Boehringer Ingelheim Korea |
TRADJENTA (linagliptin) tablets Storage and Stability -> 트라드젠타 (리나글립틴) 정제 보관 및 안정성 | English ->Korean |
Boehringer Ingelheim Korea |
ABCD 피험자 설명문 건강한 아시아 남성 자원자에서 BI 1021958 단회 증량 (BI) 임상시험 번호: 1310.3 -> ABCD 试验对象说明书 以健康的亚洲男性志愿者为对象进行的BI1021958单次递增剂量给药试验 (BI) 临床试验编号: 1310.3 | Korean ->Chinese |
Boehringer Ingelheim Korea |
ABCD 피험자 설명문 건강한 아시아 남성 자원자에서 BI 1021958 단회 증량 (BI) 임상시험 번호: 1310.3 -> ABCD 受试者说明书 以健康的亚洲男性志愿者为对象进行的BI1021958单次递增剂量给药试验 (BI) 临床试验编号： 1310.3 | Korean ->Chinese |
Boehringer Ingelheim Korea |
ABCD 피험자 설명문 건강한 아시아 남성 자원자에서 BI 1021958 단회 증량 (BI) 임상시험 번호: 1310.3 -> ABCD 被験者説明文書 健康なアジア人男性志願者における BI 1021958の単回増量 (BI) 治験番号: 1310.3 | Korean->Japanese |
Boehringer Ingelheim Korea |
ABCD 피험자 설명문 건강한 아시아 남성 자원자에서 BI 1021958 단회 증량 (BI) 임상시험 번호: 1310.3 -> ABCD 被験者説明文書 健康なアジア人男性ボランティアを対象とする BI 1021958の単回増量 (BI) 治験番号: 1310.3 | Korean->Japanese |
Boehringer Ingelheim Korea |
Subsequently, Korea’s first PRRS ARC project, J-PAP, was promoted to 18 piggeries in the eastern Jeju-do, although there are 60% to 70% of concentrated piggeries in the west. <- 제주도는 양돈장이 서쪽에 60~70% 집중되어 있지만 분석 결과 동쪽지역 18농장을 대상으로 J-PAP이라는 프로젝트명으로 한국 최초의 P | Korean ->English |
Boehringer Ingelheim Korea |
ABCD Patient Information BI Trial No: 1220.47 Inje University Busan Paik Hospital -> ABCD Өвчтөний Мэдээлэл BI Туршилтын No: 1220.47 Инже Их Сургуулийн дэргэдэх Бусан Пайк Эмнэлэг | English ->Mongolian |
Boehringer Ingelheim Korea |
Clinical Trial Protocol Final Protocol Date: 09 February 2012 CLINICAL TRIAL PROTOCOL SYNOPSIS Name of finished product: Tiotropium Inhalation Solution - Respimat® Inhaler -> 임상시험 계획서 최종 임상시험계획서 날짜: 2012년 2월 9일 임상시험계획서 개요 완제품명: 티오트로피움 흡입액- Respimat® 흡입기 | English ->Korean |
Boehringer Ingelheim Korea |
Subject Information and Consent Form - Tiotropium in children with moderate persistent asthma - INFORMATION FOR PATIENTS -> 피험자 정보 및 동의서 - 중등도 지속 천식이 있는 아동들에서 티오트로피움 - 환자를 위한 정보 | English ->Korean |
Boehringer Ingelheim Korea |
Purchasing Script - 1. Scope of work 2. Process and Regulation & We will support purchasing with better quality based on our purchasing missions, purchasing ethics, profits, and efficiency. <- 구매 스크립트 - 1. 업무 범위 2. 프로세스와 규정 & 우리는 구매 미션인 구매윤리, 이익, 효율을 바탕으로 | Korean ->English |
Boehringer Ingelheim Korea |
Press Release - First ever data investigating interferon-free treatment in cirrhotic hepatitis C patients shows high viral cure rate -> 보도자료 - 간경변이 있는 C형 간염 환자들에게 인터페론(interferon)이 없는 치료를 임상시험한 데이터에서 높은 바이러스 치유율이 나타나 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Viral cure achieved without interferon in up to 82% of hepatitis C patients (GT-1a & -1b*) -> 보도자료 - C형 간염 환자의 82%에서 인터페론 없이 달성된 바이러스 치유 (GT-1a & -1b*) | English ->Korean |
Boehringer Ingelheim Korea |
Niemals Geht Man So Ganz -> No one is gone forever | German->English |
Boehringer Ingelheim Korea |
Niemals Geht Man So Ganz -> 영원히 떠나는 이는 없네 | German->Korean |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim HCV Clinical Trials Overview -> 보도자료 - 베링거인겔하임 HCV 임상시험 개요 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Research & Development in Hepatitis C -> 보도자료 - C형 간염 분야의 연구개발 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Hepatitis C Virus (HCV) What is Hepatitis C? -> 보도자료 - C형 간염 바이러스 (HCV) , C형 간염이란? | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim Vetmetrica Korea Inc. Special Contract 2012 <- 베링거인겔하임동물약품㈜ 2012년 특약사항 | Korean ->English |
Boehringer Ingelheim Korea |
1-2-02-07 Guideline for Validation of Inactivated Vaccines for Porcine Pleuropneumonia <- 1- 2- 02-07 돼지 흉막 폐렴 불활화벡신 검정기준 | Korean ->English |
Boehringer Ingelheim Korea |
1-2-01-03 Guideline for the Validation of Dried Live Vaccines for Porcine Proliferative Ileitis <- 1-2-01 - 03 돼지 증식성 회장염 생건조백신 검정기준 | Korean ->English |
Boehringer Ingelheim Korea |
1-2-02-03 Guideline for the Validation of Porcine Mycoplasma Pneumonia Inactivated Vaccines <- 1-2- 02- 03 돼지 마이코플라즈마성 폐렴 불활화벡신 검정기준 | Korean ->English |
Boehringer Ingelheim Korea |
1-2-02-21 Guideline for the Validation of Inactivated Mixing Vaccines of Porcine Atrophic Rhinitis, Atrophic Rhinitis Toxoid and Pasteurella Toxoid <- 1-2- 02- 21 돼지 위축성비염，위축성비염 톡소이드，파스튜렐라 톡소이드 불활화혼합백신 검정기준 | Korean ->English |
Boehringer Ingelheim Korea |
1-2-04-03 Guideline for the Validation of Porcine Circovirus Type 2 Genetic Recombination Inactivated Vaccines <- 1- 2- 04-03 돼지 써코바이러스 type 2 유전자제 조합 불활 화백신 검정기준 | Korean ->English |
Boehringer Ingelheim Korea |
14P5.20 PO - OUTLINE OF PRODUCTION CANINE CORONA VIRUS V ACCINE, KILLED VIRUS - U.S. Veterinary License No. 124 VS Code No. 14P5.20 January 20, 2011 -> 14P5.20 PO - 바이러스 치료제 개 코로나바이러스에 대한 제품 개요 - 미국 수의사법 124조 VS Code No. 14P5.20 2011년 1월 20일 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Pivotal study on afatinib may challenge current standard first line treatment for lung cancer patients with EGFR mutations -> 보도자료 - EGFR-활성변이가 있는 진전된 폐샘암종 환자의 일차 치료로서의 페메트렉시드/시스플라틴과 아파티닙을 비교하기 위한 무작위배정, 공개라벨 제3상 시험) | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim announces positive phase II results for once-daily -> 보도자료 - 베링거인겔하임, 천식 대상 1일 1회 티오트로피움(tiotropium)의 제2상 임상시험에서 긍정적인 결과를 얻었다고 발표 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Afatinib* delivers unprecedented first line efficacy in patients with EGFR mutation positive lung cancer in registration trial -> 보도자료 - 아파티닙*, EGFR 변이 양성 폐암 등록 시험에서 1차 요법으로서의 유효성 시사 | English ->Korean |
Boehringer Ingelheim Korea |
Core target consumer for MUCOPECT in Korea - Presentation data <- Korean | Korean ->English |
Boehringer Ingelheim Korea |
Mucoangin® lozenges for relieving the pain of sore throat The active ingredient ambroxol and its local anaesthetic properties By Horst Wunderer -> 인후염의 통증 완화를 위한 뮤코안진® 로젠지(Mucoangin® lozenges) 주성분 암브록솔과 국소마취 속성 Horst Wunderer 저 | English ->Korean |
Boehringer Ingelheim Korea |
PRESCRIPCIÓN DE ANÁLISIS (PA) lNGELV AC APP X Especificaciones de p roducto terminado Bac!erina con!ra Ac!inobacillus pleuroneumoniae Sinonimo: Ingelvac HI APPI APPx -> 분석 처방(PA) lNGELV AC APP X 완제품 사양 -흉막폐렴균 퇴치균 동의어: Ingelvac H/ APP/APPx | Spanish->Korean |
Boehringer Ingelheim Korea |
AGENCY EVALUATION -> 에이전시 평가 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Phase III results: Tiotropium Respimat® significantly reduces exacerbations in asthma patients still symptomatic despite ICS/LABA treatment -> 보도자료 - 티오트로피움 레스피맷® 3상 임상시험 결과, ICS/LABA 치료 요법으로도 증상이 지속되는 천식 환자들의 증상 악화를 크게 감소시킴 | English ->Korean |
Boehringer Ingelheim Korea |
Asthma Media Backgrounder - What is asthma? -> 천식 언론매체용 배경설명 - 천식이란? | English ->Korean |
Boehringer Ingelheim Korea |
Are Pharmaceutical Companies in Korea becoming Multinational Wholesalers? Written: 2012-07-26 17:46 Revised: 2012-07-26 17:50 <- 국내제약사, 다국적 도매상 전락? 기사 입력 2012-07-26 17:46 기사 수정 2012-07-26 17:50 | Korean ->English |
Boehringer Ingelheim Korea |
Mucosolvan Triple effect/Three way action 1. Loosens and thins - SECRETOLYTIC Effect 2. Frees/Clears - SECRETOMOTORIC Effect 3. Protects - PROTECTIVE Effect -> 3중 효과 /3가지 작용 1. 느슨하고 얇게 – 점액용해작용 2. 떨어지고 배설되게 - 분비촉진작용 3. 보호- 보호 작용 | English ->Korean |
Boehringer Ingelheim Korea |
ABCD Mucosolvan® (ambroxol) Standard Presentation -> ABCD 뮤코솔반®(암브록솔) 표준 프리젠테이션 | English ->Korean |
Boehringer Ingelheim Korea |
Mucosolvan® Medico-Marketing package Key messages / claims May 2012 -> 뮤코솔반® 의약시판 포장 주요 메세지/ 주장 2012년 5월 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim Mucosolvan® (ambroxol), CHC, Basic Medical Information December 17, 2008-> 베링거인겔하임 뮤코솔반(암브록솔) CHC, 기본 의학 정보 2008년 12월 17일 | English ->Korean |
Boehringer Ingelheim Korea |
Korean Academy of Medical Sciences - Wunsch Medical Award Introduction - Enactment of the Wunsch Medical Award <- 대한의학회 - 분쉬의학상 소개 자료 - 분쉬의학상 제정 | Korean ->English |
Boehringer Ingelheim Korea |
Understanding COPD - MEDIA BACKGROUNDER -> COPD의 이해 - 언론매체용 배경설명 | English ->Korean |
Boehringer Ingelheim Korea |
SPIRIVA® (tiotropium) Milestone Trials - MEDIA BACKGROUNDER -> 스피리바® (티오트로피움) 중요시험 - 언론매체용 배경설명 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - SPIRIVA celebrates 10 years of ongoing commitment to patients and advancing clinical innovation in COPD -> 보도자료 - 환자 치료제로 사용되어 왔고 COPD 치료 혁신을 촉진한 스피리바, 10주년을 맞아 | English ->Korean |
Boehringer Ingelheim Korea |
SPIRIVA (tiotropium) - MEDIA BACKGROUNDER -> 스피리바 (티오트로피움) - 언론매체용 배경설명 | English ->Korean |
Boehringer Ingelheim Korea |
Ministry of Health and Welfare - Revision of Standards for Decision and Adjustment for Drugs (Draft) <- 보건복지부 - 약제의 결정 및 조정 기준 중 개정(안) | Korean ->English |
Boehringer Ingelheim Korea |
Press Release - Cost effectiveness and clinical efficacy of Pradaxa® (dabigatran etexilate) versus rivaroxaban analysed. -> 보도자료 - 리바록사반 대비 프라닥사® 의 (다비가트란 에텍실레이트)의 비용 효과 및 임상효용 분석. | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New data show significant improvements in lung function using combination of tiotropium and olodaterol in COPD patients -> 보도자료 - 티오트로피움과 올로다테롤 의 조합으로 COPD 환자의 폐 기능 크게 향상 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim in Respiratory - Media Backgrounder -> 호흡기 질환 분야의 베링거인겔하임 - 언론매체용 배경설명 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Key results from new tiotropium studies in COPD and asthma to be presented at ERS 2012 -> 보도자료 - ERS 2012에서 COPD와 천식에 대한 신규 티오트로피움 연구의 주요 결과 발표 | English ->Korean |
Boehringer Ingelheim Korea |
Chronic Obstructive Pulmonary Disease (COPD) Media backgrounder August 2012 -> 만성 폐쇄성 폐질환(COPD) 배경설명 자료 2012년 8월 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Worldwide, one in ten patients presenting in the emergency department with atrial fibrillation will die within one year-> 보도자료 - 전세계적으로, 응급실 내 심방세동 환자 10명 중 1명이 1년 이내에 사망하는 것으로 알려져 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Clinical experience with Pradaxa® crosses one million patient-years of treatment -> 보도자료 - 프라닥사® 임상경험이 100만 환자-치료년수를 넘어 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim submits first oncology compound, afatinib* for European approval -> 보도자료 - 베링거인겔하임, 최초 항암제인 아파티닙* 유럽 허가를 위한 신청서 제출 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Analyses presented at EASD support Trajenta™ (linagliptin) as effective and well-tolerated for patients with type 2 diabetes with different background therapies -> 보도자료 - EASD, 상이한 기본요법을 받는 제 2형 당뇨병 환자에게 Trajenta™ (linagliptin)의 유효성과 내약성을 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim Corp. Div. Internal Auditing / Audit Report No. 2012-15 -> 베링거인겔하임 기업 부서 내부 감사 / 감사 보고 No. 2012-15 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim BeNeLux Purchasing Policy - Effective date: 1st July 2012-> 베링거인겔하임 BeNeLux 구매정책 - 유효일자: 2012년 7월 1일 | English ->Korean |
Boehringer Ingelheim Korea |
External/Internal Social Media Guidelines for All Boehringer Ingelheim Employees -> 베링거 인겔하임 전 직원용 사내/사외 소셜 미디어에 대한 지침 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Asian populations with atrial fibrillation (AF) benefit from better stroke prevention with Pradaxa® (dabigatran etexilate) compared to warfarin-> 보도자료 - 아시아인 심방세동 환자에서 와파린 대비 프라닥사®(성분명: 다비가트란 에텍실레이트)의 뇌졸중 예방 효과가 더 우수한 것으로 나타나 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Recruitment complete for two pivotal Phase III studies of nintedanib* in patients with idiopathic pulmonary fibrosis -> 보도자료 - 특발성 폐섬유증 환자에서 닌테다닙*의 핵심 제 3상 시험 2건에 대한 환자 모집이 완료돼 | English ->Korean |
Boehringer Ingelheim Korea |
2by 2020 internal calendar comment <- Korean | Korean ->English |
Boehringer Ingelheim Korea |
Press Release - Unprecedented progression-free survival benefit with afatinib* associated with clinically meaningful improvements in life-limiting lung cancer symptoms and better quality of life -> 아파티닙*의 전례없는 무진행 생존률 효용으로 임상적으로 유의한 생활을 제한하는 폐암 증상 및 삶의 질 | English ->Korean |
Boehringer Ingelheim Korea |
Medico-Marketing Package, Version 03, February 01, 2008 Antistax®, Clinical Trials -> 안티스탁스(Antistax)-임상시험 | English ->Korean |
Boehringer Ingelheim Korea |
Efficacy of Orally Administered Extract of Red Vine Leaf AS 195 (folia vitis viniferae) in Chronic Venous Insufficiency (Stages I-II) A randomized, double-blind, placebo-controlled trial -> Korean | English ->Korean |
Boehringer Ingelheim Korea |
Improvement of Cutaneous Microcirculation and Oxygen Supply in Patients with Chronic Venous Insufficiency by Orally Administered Extract of Red Vine Leaves of AS 195 - A randomized, Double-Blind, Placebo-Controlled, Crossover Study -> Korean | English ->Korean |
Boehringer Ingelheim Korea |
만성정맥부전(I-II 단계)에서 Red Vine Leaf AS 195(folia vitis viniferae)의 경구용 추출물 효능 -무작위배정, 이중맹검, 위약대조 시험 <- English | English ->Korean |
Boehringer Ingelheim Korea |
경구용 레드바인잎 AS 195 추출물에 의한 만성정맥부전 혼자에서의 피부 미세순환과 산소공급 개선 - 무작위배정, 이중맹검, 위약대조, 교차시험 <- English | English ->Korean |
Boehringer Ingelheim Korea |
Zusammenfassung -> 요약 - 적색 포도 잎 추출물인 경구용 AS195(folia vitis viniferae)의 만성 정맥 부전(1~2기)에 대한 효능/ 무작위 더블 블라인드 위약 대조 연구. | German->Korean |
Boehringer Ingelheim Korea |
Press Release - NICE recommends treatment with alteplase is started as early as possible, within 4.5 hours of onset of ischaemic stroke symptoms-> 보도자료 - NICE, 허혈성 뇌졸중 증상 개시 후 최대 4.5시간 이내에 조속히 알테플라제 투여를 시작하도록 권고해 | English ->Korean |
Boehringer Ingelheim Korea |
The LUCK study: Laxative Usage in patients with GP-diagnosed Constipation in the UK, within the general population and in pregnancy. An epidemiological study using the General Practice Research Database (GPRD) -> Korean | English ->Korean |
Boehringer Ingelheim Korea |
LUCK 시험: 영국 일반집단 및 임산부 중 GP가 진단한 변비 환자에 완하제 사용. 일반진료연구데이터베이스(GPRD)를 이용한 역학 연구. <- English | English ->Korean |
Boehringer Ingelheim Korea |
Wunsch speech Andreas Barner 2012 -> 분쉬의학상 연설문 - 2012년 안드레아스 바너 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - The Respimat® success story: Boehringer Ingelheim doubles its production capacity -> 보도자료 - 레스피맷® 성공 스토리: 베링거인겔하임의 생산 능력 배가 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim presents robust pipeline highlighting its Respiratory R&D -> 보도자료 - 베링거인겔하임, 호흡기 R&D를 중심으로 한 탄탄한 파이프라인 발표 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - RELY-ABLE®: Unprecedented long-term data confirm favourable safety profile and sustained efficacy of Pradaxa® for stroke prevention in AF -> 보도자료 - RELY-ABLE®: 전례 없는 장기간 자료를 통해 심방세동환자의 뇌졸중 예방에 대한 프라닥사®(Pradaxa®)의 양호한 안전성 프로파일과 지속적인 효능 확인 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim’s interferon-free all-oral hepatitis C treatment+ shows up to 85% viral cure in Phase IIb study including patients with advanced liver disease-> Korean | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - 진행성 간질환 환자가 포함된 제 2b상 시험에서 베링거인겔하임의 무 인터페론, 경구용 C형 간염치료제+의 바이러스 치료율이 최대 85%인 것으로 나타나 <- English | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - U.S. FDA Grants Priority Review to Boehringer Ingelheim’s Afatinib* NDA for EGFR Mutation-Positive Advanced NSCLC -> 보도자료 - 미국 FDA, EGFR 변이 양성 진행성 NSCLC를 위한 베링거인겔하임 아파티닙(Afatinib)* 의 NDA에 우선심사권 부여 | English ->Korean |
Boehringer Ingelheim Korea |
Local Service Agreement Template -> 로컬 서비스 계약 템플릿 | English ->Korean |
Boehringer Ingelheim Korea |
Master Agreement for Media Service MINDSHARE / BI - Master Agreement for Planning and Buying Media Services -> 미디어 서비스 MINDSHARE/BI 를 위한 마스터계약 - 미디어 서비스 기획 및 구매를 위한 마스터계약 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New findings from two studies support substantial benefit of Pradaxa® for prevention of recurrent deep vein thrombosis and pulmonary embolism -> 보도자료 - 두 연구를 통해 심부정맥 혈전증 및 폐색전증 재발 예방을 위한 프라닥사®의 상당한 효과가 새로이 드러나 | English ->Korean |
Boehringer Ingelheim Korea |
Enforcement Regulations for the Act on Bioethics and Safety [Annex Form No. 34] - Informed Consent for Human Derivatives Research <- 생명윤리 및 안전에 관한 법률 시행규칙 [별지 제34호서식] - 인체유래물 연구 동의서 | Korean ->English |
Boehringer Ingelheim Korea |
ABCD I. TITULO DEL PROTOCOLO (PROTOCOL TITLE): Determinación del punto protectivo para Actinobacillus pleuropneumoniae serotipos 1,2,3,4,5 y 7, en Ingelvac H -> ABCD I. 실험계획서 제목 (PROTOCOL TITLE): Ingelvac H에서의 흉막폐렴균 혈청형 1,2,3,4,5,7의 방어 정도 확인 | English ->Korean |
Boehringer Ingelheim Korea |
Harvard Business School - 9-393-012 September 8, 1992 - ACCOR (A) Introduction -> 하버드 비지니스 스쿨 - 9-393-012 1992년 9월 8일 - 아코르그룹(ACCOR) 소개 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Phase III results: tiotropium Respimat® is effective in symptomatic asthma patients irrespective of their allergic status -> 보도자료 - 제 3상 시험결과: 티오트로피움 레스피맷®은 알레르기 상태와 무관하게 증상이 지속되는 천식환자에 효과적 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Preventing disease: One billion pigs vaccinated with Ingelvac CircoFLEX® -> 보도자료 - 질병 예방: 10억 마리 돼지, 인겔백 써코플렉스®로 접종 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Rare disease day: Boehringer Ingelheim announces initiation of pivotal trial investigating volasertib* in patients with acute myeloid leukaemia -> 보도자료 - 희귀질환의 날: 베링거 인겔하임, 급성 골수성 백혈병 환자 대상 volasertib* 연구를 위한 핵심 임상시험 시작 발표 | English ->Korean |
Boehringer Ingelheim Korea |
The new england journal of medicine - Extended Use of Dabigatran, or Placebo in Venous Thromboembolism -> 영국 최신 의학 저널 - 정맥 혈전색전증에서 다비가트란, 와파린, 위약의 연장 사용 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim announces interim results from a Phase III trial in HIV patients co-infected with chronic hepatitis C -> 보도자료 - 베링거인겔하임, 만성 C형 간염과 HIV의 중복감염 환자를 대상으로 한 제3상 임상연구의 중간 결과 발표 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim and Lilly initiate MARLINA™ clinical trial to evaluate use of Trajenta® (linagliptin) in patients with type 2 diabetes and albuminuria-> 보도자료 - 베링거인겔하임과 릴리, 제 2형 당뇨병 및 알부민뇨증 환자에서의 Trajenta® (linagliptin) 사용 평가를 위한MARLI | English ->Korean |
Boehringer Ingelheim Korea |
2013 CHC Brand Convention for Wholesalers Welcome Speech President <- Korean | Korean ->English |
Boehringer Ingelheim Korea |
Press Release - FDA perspective published in the New England Journal of Medicine reinforces safety of Pradaxa® (dabigatran etexilate) -> 보도자료 - FDA, NEJM에서 프라닥사® (다비가트란 에텍실레이트)의 안전성에 대한 견해 재확인 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Investigational compound faldaprevir+ shows high viral cure and early treatment success in treatment-naïve patients with genotype-1 hepatitis C -> 보도자료 - 임상연구용 의약품 팔다프레비어+, 치료 경험이 없는 유전자 1형 C형 간염 환자에서 바이러스 치유 및 조기 치료 성공 | English ->Korean |
Boehringer Ingelheim Korea |
CHRISTOPHER A . BARTLETT ANDREW N . McLEAN - GE's Talent Machine: The Making of a CEO -> CHRISTOPHER A . BARTLETT ANDREW N . McLEAN - GE의 인재 육성 기계(Talent Machine): CEO 양성하기 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Phase III results: tiotropium Respimat® effective in symptomatic asthma patients irrespective of their age, allergic status, smoking status and bronchodilator response -> 보도자료 - 제3상 결과: 티오트로피움 레스피맷®, 나이, 알레르기와 흡연 여부 및 기관지확장제 반응에 상관없이 증상이 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New European survey highlights ischaemic stroke protection as treatment priority for patients with atrial fibrillation-> 보도자료 - 유럽의 새로운 연구, 심방세동 환자의 우선적 치료로 허혈성 뇌졸중 예방 강조 | English ->Korean |
Boehringer Ingelheim Korea |
Trial identification card Korea V1.0 English 14 May 2013 -> Korean | English ->Korean |
Boehringer Ingelheim Korea |
Trial identification card Korea V1.0 English 14 May 2013 -> Chinese / 研究编号. 1293.8 试验应急识别证 | English ->Chinese |
Boehringer Ingelheim Korea |
Press Release - New long-term data reinforce safety profile of Pradaxa® for stroke prevention in AF -> 보도자료 - 심방세동 환자의 뇌졸중 예방에 대한 프라닥사®의 안전성을 보강하는 새로운 장기간의 자료 | English ->Korean |
Boehringer Ingelheim Korea |
American Journal of Gastroenterology - Myths and misconceptions about chronic constipation_muller lissner -> 만성 변비에 대한 미신과 오해 | English ->Korean |
Boehringer Ingelheim Korea |
Studies assessing bisacodyl and sodium picosulfate in chronic patients can be used to support their use in chronic and acute constipation -> 만성 환자에서의 비사코딜과 소듐 피코설페이트를 평가한 연구 결과는 만성 및 급성 변비에 대한 이들의 사용을 뒷받침한다 | English ->Korean |
Boehringer Ingelheim Korea |
Stimulant laxatives do not impair normal colonic function or increase the risk of habituation, tolerance and dependency -> 자극성 완하제는 정상적인 대장기능을 손상시키거나 습관화, 내성 및 의존성 위험을 증가시키지 않는다. | English ->Korean |
Boehringer Ingelheim Korea |
Use of laxatives in recommended doses does not cause electrolyte or metabolic disturbances or renal impairment -> 권장 용량의 완하제 사용은 전해질 장애, 대사 장애 또는 신장 손상을 유발하지 않는다. | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Application submitted to the European Medicines Agency (EMA) for use of Pradaxa® in treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE-> 심부정맥 혈전증(DVT) 및 폐색전증(PE) 치료와 재발성 심부정맥 혈전증 및 폐색 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - U.S. FDA approves Gilotrif™ (afatinib) as first-line treatment for lung cancer patients with EGFR mutations-> 보도자료 - 지오트립™(Afatinib; 항암제(비소세포폐암)) , 미국 FDA로부터 EGFR 변이 폐암 환자의 우선 치료제로 승인 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Benefits of Pradaxa maintained in difficult to treat patients with atrial fibrillation and symptomatic heart failure-> 보도자료 - 프라닥사, 치료가 어려운 심방세동 및 증후성 심부전 환자에서도 혜택 유지 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Volasertib* receives FDA Breakthrough Therapy designation for treatment of patients with acute myeloid leukaemia-> 보도자료 - FDA, 급성 골수성 백혈병 환자를 위한 획기적인 치료법으로 볼라설팁(Volasertib*) 지정 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - First patient enrolled in new cardiovascular and renal outcomes trial for linagliptin in Type 2 Diabetes -> 보도자료 - 제2형 당뇨병 환자 대상 새로운 심혈관계 및 신장 결과에 관한 리나글립틴 임상 연구에 첫 환자 등록 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Afatinib* shows benefits for EGFR mutation positive non-small cell lung cancer patients across various efficacy endpoints-> 보도자료 - 아파티닙*, 다양한 유효성 종점에서 EGFR 변이 양성 비소세포폐암 환자에게 효과 증명 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim Korea Human Resources - Guideline for Overseas Business Trip -> 한국베링거인겔하임 HR - 해외 비지니스 여행 가이드라인 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Phase III safety and efficacy data of Trajenta® (linagliptin) in elderly people with Type 2 Diabetes published in The Lancet -> 보도자료 - 의학저널 란셋(The Lancet)에 제2형 노인 당뇨병 환자에서 트라젠타®(성분명: 리나글립틴)의 안전성과 유효성에 관한 3상 임상 연구 결과 게재 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New Phase III data presented for first time demonstrate: tiotropium Respimat® significantly improves lung function and provides sustained bronchodilation in asthma patients who remain symptomatic despite ICS treatment1-> Korean | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - 티오트로피움 레스피맷® 새로운 3상 임상 연구 결과, 유의한 폐기능 개선과 ICS 치료1에도 증상이 지속되는 천식 환자에게 지속적인 기관지 확장 효과 최초 입증 <- English | English ->Korean |
Boehringer Ingelheim Korea |
Advertisement - Winter-time is cough time - Get rid of your cold-related cough – fast -> 광고 - 겨울은 기침의 계절 - 추위와 관련된 기침에서 빨리 벗어나세요 | English ->Korean |
Boehringer Ingelheim Korea |
Reactive Global Media Q&A for TIOSPIRTM trial - Date: 30 August 2013 -> TIOSPIRTM 시험에 대한 전세계 매체 대응용 Q&A - 날짜: 2013년 8월 30일 | English ->Korean |
Boehringer Ingelheim Korea |
Security Abroad - Guidance for Business Travelers -> 해외 여행에서의 보안 - 비지니스 여행자용 가이드라인 | English ->Korean |
Boehringer Ingelheim Korea |
Security Risk Avoidance - Emergency for Guide Business Trips abroad -> 보안 위험 방지 - 해외 출장 중 비상 상황 안내 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Pradaxa® (dabigatran etexilate) drives Boehringer Ingelheim’s innovation promise in cardiovascular diseases-> 보도자료 - 베링거인겔하임, 프라닥사® (다비가트란 에텍실레이트)로 심혈관계 질환에 대한 혁신 약속 실현 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Landmark TIOSPIRTM trial reinforces importance of SPIRIVA in both available formulations as the world’s leading maintenance therapy for chronic obstructive pulmonary disease (COPD) -> 보도자료 -획기적 임상시험 TIOSPIRTM으로 만성폐쇄성폐질환 (COPD)의 세계적인 주요 유지 | English ->Korean |
Boehringer Ingelheim Korea |
100-PCP-00011_1.0_Corporate Procedure for Contractual Liability Arrangements with Suppliers -> 공급사와의 계약상의 배상책임 협정에 대한 회사 절차 | English ->Korean |
Boehringer Ingelheim Korea |
Exceptional Bidding Items, Out of scope of Purchasing & Standard Operating Procedure - Purchasing Standard Operating Procedure for BIK <- 입찰 예외 항목들, 구매 예외 범위, 표준 운영 절차서 - 한국베링거인겔하임용 표준 구매 운영 절차 | Korean ->English |
Boehringer Ingelheim Korea |
Press Release - GIOTRIF® (afatinib) approved in Europe for patients with EGFR mutation positive lung cancer -> 보도자료 - 지오트립® (아파티닙) , EGFR 변이 양성 폐암 환자 치료제로 유럽에서 승인 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Data presented at EASD support safety profile of Trajenta® (linagliptin) in broad range of adults with Type 2 Diabetes -> 보도자료 - EASD에서 발표된 결과, 광범위한 제2형 당뇨병 성인 환자에서 트라젠타®(리나글립틴)의 안전성 프로파일 뒷받침 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim Animal Health achieves milestone: 500 million pigs benefit from Mycoplasma vaccination -> 보도자료 - 베링거인겔하임, 동물 건강의 중요 단계 달성: 5억 마리의 돼지, 마이코플라즈마 백신 혜택 받아 | English ->Korean |
Boehringer Ingelheim Korea |
THE COMPOUND AFATINIB BACKGROUNDER Date: September 2013 -> 화합물 아파티닙 배경 설명 날짜:2013년 9월 | English ->Korean |
Boehringer Ingelheim Korea |
LUNG CANCER BACKGROUNDER Date: September 2013 -> 폐암 배경설명 날짜: 2013년 9월 | English ->Korean |
Boehringer Ingelheim Korea |
Targeted Therapies for Lung Cancer Backgrounder Date: September 2013 -> 폐암을 위한 표적치료 배경설명 날짜: 2013년 9월 | English ->Korean |
Boehringer Ingelheim Korea |
EGFR Mutation Testing Backgrounder Date: September 2013 -> ErbB FAMILY 배경설명 - 진행성 NSCLC와 ErbB FAMILY와의 관련성 - 날짜: 2013년 9월 | English ->Korean |
Boehringer Ingelheim Korea |
AFATINIB* – THE FIRST APPROVED IRREVERSIBLE ERBB FAMILY BLOCKER -> 아파티닙*-최초 허가된 비가역적 ErbB Family 차단제 | English ->Korean |
Boehringer Ingelheim Korea |
LUX-Lung Clinical Trial Programme: Afatinib* is being studied in a comprehensive lung cancer clinical trial programme -> LUX-Lung 임상시험 프로그램: 아파티닙*은 포괄적인 폐암 임상시험 프로그램에서 연구 중이다. | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Better outcome in case of major bleed for patients taking the anticoagulant Pradaxa® compared to warfarin -> 보도자료 - 항응고제 프라닥사® 치료군, 와파린 치료군에 비해 대출혈 발생 후 더 나은 결과 보여 | English ->Korean |
Boehringer Ingelheim Korea |
SGLT2 Inhibition Media Fact Sheet - 1. Type 2 Diabetes (T2D) 2. Sodium glucose cotransporter 2 (SGLT2) 3. What is SGLT2 inhibition? 4. Why is SGLT2 inhibition important? -> SGLT2 억제제 미디어 자료 - 1. 제2형 당뇨병 (T2D) 2. 나트륨 포도당 공동수송체 2 (SGLT2) 3. SGLT2 억제제란 무엇인가? | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New efficacy and safety data adds to evidence supporting treatment with afatinib*(GIOTRIF®) in Asian and non-Asian lung cancer patients-> 보도자료 - 아시아 및 비 아시아인 폐암 환자 대상, 아파티닙* (지오트립®) 치료 효과를 입증하는 새로운 유효성 및 안전성 결과 추가 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New data presented at AASD further demonstrate benefits of Trajenta® (linagliptin) efficacy and safety in specific patient populations -> 보도자료 - AASD에서 발표된 새로운 결과, 특정 환자군에서 트라젠타® (리나글립틴)의 유효성과 안전성 추가 입증 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Micardis crosses 50 million patient-years of experience on 15th anniversary -> 보도자료 - 미카르디스 15주년 기념일에 5천만 환자 년 수 경험 달성 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New survey in four major Asian countries reveals complexity of managing Type 2 Diabetes is currently underestimated1-> 보도자료 - 새로운 아시아 주요 4개국 연구 결과, 제2형 당뇨병 관리의 복잡성이 현재 과소평가되고 있다고 밝혀1 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Global Lung Cancer Coalition to identify patient challenges and improve support strategies in partnership with Boehringer Ingelheim -> 보도자료 - 국제폐암연맹, 베링거인겔하임과 협력을 통한 환자의 어려움 파악, 지원전략 개선 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New long-term treatment data confirms consistent benefit and safety profile of Pradaxa® beyond 6 years -> 보도자료 - 새로운 장기 치료 결과, 6년 이상 프라닥사®의 일관적인 효과와 안전성 프로파일 확인 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Largest global survey investigating early Type 2 Diabetes conversations launched by Boehringer Ingelheim and Eli Lilly and Company in partnership with the International Diabetes Federation -> Korean | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - 베링거인겔하임과 일라이릴리, 국제당뇨병연맹과 협력을 통해 초기 제2형 당뇨병 환자와의 대화를 조사하는 세계 최대 규모의 설문 착수 <- English | English ->Korean |
Boehringer Ingelheim Korea |
AUSTRALIA - PET HEALTHCARE RECORD (Passport) - > 호주- 애완동물 건강관리 기록 (패스포트) | English ->Korean |
Boehringer Ingelheim Korea |
Canine Parvovirus (CPV) Vaccination: Comparison of Neutralizing Antibody Responses in Pups after Inoculation with CPV2 or CPV2b Modified Live Virus Vaccine -> 개 파보바이러스(CPV) 백신: CPV2 또는 CPV2b 변형 생바이러스 백신으로 접종한 후 새끼 강아지들의 중화항체반응 비교 | English ->Korean |
Boehringer Ingelheim Korea |
Adverse events diagnosed within three days of vaccine administration in dogs -> 개에게 백신 투여 3일 내 진단된 이상 반응 | English ->Korean |
Boehringer Ingelheim Korea |
Evolution of canine parvovirus—A need for new vaccines? -> 개 파보바이러스(canine parvovirus)의 진화 – 새로운 백신이 필요한가? | English ->Korean |
Boehringer Ingelheim Korea |
Lung Cancer in Asia Infographic -> 아시아에서의 폐암 인포메이션 그래픽 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Pradaxa® (dabigatran etexilate) 150mg bid continues to be the only oral anticoagulant which showed superior ischaemic stroke reduction vs. warfarin in its pivotal study RE-LY® – Results of the ENGAGE AF-TIMI 48 trial published for edoxaban | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - 프라닥사®(다비가트란 에텍실레이트) 150mg 1일 2회 투여 요법, 중추적 연구 RE-LY® 에서 계속하여 와파린 대비 허혈성뇌졸중을 월등하게 감소시키는 유일한 경구용 항응고제로 남아 - 와파린 대비 에독사반을 연구한 ENGAGE AF-TIMI 48 임상 결과에도 프라닥사®의 입지에는 변화 없어<- English | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim Animal Health - Received award for the excellent voluntary inspection company from the Animal and Plant Quarantine Agency in 2013! <- 베링거인겔하임동물약품㈜ - 2013년 농림축산검역본부 자율점검 우수업체 우수상 수상! | Korean ->English |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim planning two new Global Clinical Trials for Pradaxa® (dabigatran etexilate) in expanded patient populations -> 보도자료 - 베링거인겔하임, 환자군을 확대하여 프라닥사®(다비가트란 에텍실레이트) 대상 2개의 새로운 글로벌 임상 연구 계획 | English ->Korean |
Boehringer Ingelheim Korea |
External Statement re. decision to terminate development programme for Boehringer Ingelheim’s investigational interferon free hepatitis C regimen containing deleobuvir. -> 베링거인겔하임의 델레오부비르를 함유한, 인터페론이 포함되지 않은 C형 간염 치료 요법 연구 개발 프로그램의 종료 결정에 대한 외부 성명 | English ->Korean |
Boehringer Ingelheim Korea |
Trial data in Hepatitis C below expectations - Based on Phase III trial data for combination of deleobuvir and faldaprevir the difficult decision was taken to halt all further development efforts and investment into our interferon free Hepatits C combinat | English ->Korean |
Boehringer Ingelheim Korea |
기대 이하의 C형 간염 대상 임상시험 데이터 - 델레오부비르와 팔다프레비어의 병용 요법을 연구한 제3상 임상시험 데이터를 기반으로 인터페론이 포함되지 않은 C형 간염 병용 요법에 대해 추가적인 모든 개발 노력과 투자를 중단한다는 어려운 결정을 내렸습니다. <- English | English ->Korean |
Boehringer Ingelheim Korea |
VTI Award Recommendation - How to recommend? <- VTI 상 권장사항 - 추천방법 | Korean ->English |
Boehringer Ingelheim Korea |
Press Release - New data on safety and efficacy of Pradaxa® in treatment of acute deep vein thrombosis and pulmonary embolism -> 보도자료 - 급성 심부정맥혈전증과 폐색전증 치료에서 프라닥사®의 안전성 및 효능에 관한 새로운 결과 | English ->Korean |
Boehringer Ingelheim Korea |
Corporate Quality Manual of the Pharmaceutical Quality System -> 의약품 품질관리 시스템 기업 품질 매뉴얼 | English ->Korean |
Boehringer Ingelheim Korea |
Quality Management Review -> 품질관리 평가 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim GmbH - Quality & Environmental Health and Safety CORPORATE PROCEDURE -> 품질 및 환경 보건 및 안전 기업 절차서 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim GmbH - Corporate Division Quality MANDATORY REFERENCE DOCUMENT-> 기업 부문 품질 - 의무 관련 문서 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim GmbH - Quality & Environmental Health and Safety - MANDATORY REFERENCE DOCUMENT -> 품질 및 환경 보건과 안전 - 의무 관련 문서 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim GmbH - Preparing for Audits and dealing with Audit Findings -> 감사준비 및 감사결과 처리 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim GmbH - BI Material Service Supplier Qualification -> BI 재료/서비스 공급자 적격성 평가 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim GmbH - Certification by a Qualified Person and Batch Release -> 배치 인증 및 출하 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim GmbH - Product Quality Review -> 제품 품질 검토 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim GmbH - Management of Contracts with Quality relevant content -> 품질 관련 계약 관리 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim GmbH - BI Material _ Service supplier selection -> BI 재료/서비스 공급자 선정 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim GmbH - BI Material _ Service Supplier Performance Evaluation -> BI 재료/서비스 공급자 성과 평가 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim GmbH - BI system for Quality- and EHS-audits -> 품질 및 EHS 감사를 위한 BI 시스템 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim GmbH - BI Material_Service Supplier Audits (Quality and EHS) -> BI 재료/서비스 공급자 감사(품질 및 EHS) | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim GmbH - Management of Contracts with Quality relevant content -> 품질관련 계약 관리 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim GmbH - Storage of Chemical Pharmaceutical, Biopharmaceutical and Veterinary Products -> 화학제품, 의약품, 생물의약품, 동물제품 보관 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim GmbH - Working document_ Annex 9 to WHO Technical Support Series, No 908, 2003, Guide to Good Storage Practices for pharmaceuticals -> 의약품의 모범 보관 관행을 위한 지침 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim GmbH - Hazardous and Pharmaceutical Waste -> 위험 폐기물 및 약제 폐기물 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim GmbH - Warehouse Performance Standard - Safety and GMP in Warehouse -> 창고운영 표준 EHS 측면 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim GmbH - Handling of Market Returns -> 시장 반품 제품 취급 | English ->Korean |
Boehringer Ingelheim Korea |
Internal update and reactive statement in relation to documents unsealed as part of litigation process and New York Times article -> 소송과정에서 공개된 문서들과 뉴욕타임즈 기사에 관련한 최신 내부 대응 진술문 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - AAAAI 2014 ASTHMA: New Phase III data show tiotropium Respimat® effective across asthma severities-> 보도자료 - AAAAI 2014 천식: 새로운 제3상 결과, 천식 중증도 전반에서 티오트로피움 레스피맷®의 효과 입증 | English ->Korean |
Boehringer Ingelheim Korea |
Pradaxa® litigation in the U.S. - RESPONSIVE STATEMENT FOR BLOOMBERG ARTICLE ON SELECTION OF DATA FOR FDA -> 보도자료 - 미국 내 프라닥사® 소송 - FDA용 데이터 선정 관련 블룸버그 기사에 대한 대응 진술문 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Pradaxa® (dabigatran etexilate) now approved in more than 100 countries for stroke prevention in atrial fibrillation-> 보도자료 - 프라닥사®(다비가트란 에텍실레이트), 현재 심방세동 환자의 뇌졸중 예방에 대해 100개국 이상에서 승인 | English ->Korean |
Boehringer Ingelheim Korea |
Unilateral cancellation of the planned Boehringer Ingelheim seminar scheduled on Mar. 12 in Gangwon-do <- 12일에 있을 예정이었던 베링거 강원도 세미나 일방적인 취소 | Korean ->English |
Boehringer Ingelheim Korea |
Press Release - 10,000 patients with atrial fibrillation now enrolled in innovative GLORIA™-AF Registry-> 보도자료 - 10,000명의 심방세동 환자, 혁신적 GLORIA™-AF 등록 임상 프로그램에 등록 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim GmbH - 028-OCP-00109-RD01-Appendix-017E (3.0) QAA for Warehouses, 028-OCP-00109-RD01-Appendix-019E (1.0) Analytical Service QAA-Template | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim GmbH - 028-OCP-00109-RD01-Appendix-033E (1.0) Packaging Material QAA-Template, 028-OCP-00109-RD01-Appendix-034E (1.0) Template QAA for Repackaging | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim GmbH - 028-OCP-00109-RD01-Appendix-035E (2.0) QAA for Freight Forwarders | English ->Korean |
Boehringer Ingelheim Korea |
Interview Briefing Document - Mr. David B. Gocken, BIVK Sales & Marketing President <- 축산 경제 D.Gocken 사장님 인터뷰 답변서 | Korean ->English |
Boehringer Ingelheim Korea |
Opening remark_Focus SPAF_2014_1 | Korean ->English |
Boehringer Ingelheim Korea |
Temperature MonitoringTest Protocole – During Delivery Service <- 배송시 온도 모니터링 절차 | Korean ->English |
Boehringer Ingelheim Korea |
Temperature Mapping Test Procedure in Warehouse <- 창고 온도 Mapping 절차 | Korean ->English |
Boehringer Ingelheim Korea |
Boehringer Ingelheim VETMEDICA - Procedure for Training - For Warehouse <- 교육 규정 - 창고용 | Korean ->English |
Boehringer Ingelheim Korea |
Boehringer Ingelheim VETMEDICA - Procedure for re-packaging in ware house - For Warehouse <- 재포장 작업규정- 창고용 | Korean ->English |
Boehringer Ingelheim Korea |
Boehringer Ingelheim VETMEDICA - Warehouse Control for Product and Other materials - For Warehouse <- 제품 및 자재 보관관리 기준 - 창고용 | Korean ->English |
Boehringer Ingelheim Korea |
Press Release - American Diabetes Association Announces Research Collaboration with Boehringer Ingelheim Awards will focus on chronic kidney disease and renal insufficiency in diabetes-> 미국당뇨병협회, 베링거인겔하임과의 연구 협력 발표 -상은 당뇨병에서의 만성 신장 질환과 신부전에 초점을 둘 것이다 | English ->Korean |
Boehringer Ingelheim Korea |
4 eLearning - Seven Steps to Effective Customer Engagement - Video script translation | English ->Korean video script translation |
Boehringer Ingelheim Korea |
Agenda FLM – Workshop, 7 Steps to Excellence in Customer Engagement - Roadmap FLM Workshop, FLM 3 Workshop Presentation, FLM 4 Seven Steps Poster | English ->Korean |
Boehringer Ingelheim Korea |
5 Video - Sales Call Trajenta - Video script translation | English ->Korean video script translation |
Boehringer Ingelheim Korea |
FLM 5_1 Handout 1 Facilitator_Review Game, FLM 5_2 Handout 2 Facilitator_Video Guide, FLM 6_1 Handout 3 Participant_Observer Form, FLM 6_2 Handout 4 Participant_Proficiency Rating Scale | English ->Korean |
Boehringer Ingelheim Korea |
FLM 6_3 Handout 5 Participant_Round 1 Coach, FLM 6_4 Handout 6 Participant_Round 1 Sales Rep, FLM 6_5 Handout 7 Participant_Round 2 Coach, FLM 6_6 Handout 8 Participant_ Round 2_Sales Rep | English ->Korean |
Boehringer Ingelheim Korea |
FLM 6_7 Handout 9 Participant_Roleplay SPAF_A, FLM 6_8 Handout 10 Participant_Roleplay SPAF_B, FLM 6_9 Handout 11 Participant_Roleplay SPAF_C, FLM 6_10 Handout 12 Participant_Insight & Action | English ->Korean |
Boehringer Ingelheim Korea |
FLM 6_11 Handout 13 Participant_Own Role Play, FLM 6_12 Handout 14 Participant_Preparation Practice Session, FLM 7_1 Printer Spread - Seven Steps Quick Reference Guide | English ->Korean |
Boehringer Ingelheim Korea |
FLM 7_2 Printer Cover - Seven Steps Quick Reference Guide | English ->Korean |
Boehringer Ingelheim Korea |
FLM 7_2 Printer Cover - Seven Steps Quick Reference Guide - Video script translaion | English ->Korean video script translation |
Boehringer Ingelheim Korea |
SR 1_Agenda Sales Rep, SR 2 Roadmap new, SR 3 Workshop Presentation, SR 4 Seven Steps Poster, SR 5_1 Handout 1 - Roleplay SPAF_A, SR 5_2 Handout 2 - Roleplay SPAF_B | English ->Korean |
Boehringer Ingelheim Korea |
SR 5_3 Handout 3 - Roleplay SPAF_C, SR 5_4 Handout 4 - Insight & Action, SR 5_5 Handout 5 - TriFold, SR 6_1 Printer Spread - Seven Steps Quick Reference Guide | English ->Korean |
Boehringer Ingelheim Korea |
SR 6_2 Printer Cover - Seven Steps Quick Reference Guide, SR 7 Certificate | English ->Korean |
Boehringer Ingelheim Korea |
3 Seven Steps Quick Reference Guide | English ->Korean |
Boehringer Ingelheim Korea |
CfE 1 Coaching for Excellence Presentation, CfE 2 Coaching for Excellence User Guide & CfE 3 Coaching for Excellence Quick Reference Card | English ->Korean |
Boehringer Ingelheim Korea |
1 CEE Toolkit Contents, 2 CEE Trainer Tips | English ->Korean |
Boehringer Ingelheim Korea |
Security Crisis Manual -> 보안 위기 대응 매뉴얼 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim GmbH - 028-OCP-00109-RD01-Appendix-017E (3.0) QAA for Warehouses & 028-OCP-00109-RD01-Appendix-019E (1.0) Analytical Service QAA-Template | English ->Korean |
Boehringer Ingelheim Korea |
Title : Quality Assurance Regulation ID No: SOP-Vet-04-001-General Provisions <- ID No : SOP-Vet-04-001총칙 | Korean ->English |
Boehringer Ingelheim Korea |
Boehringer Ingelheim Korea Title of the SOP/Guideline | Korean ->English |
Boehringer Ingelheim Korea |
Press Release - FDA approves Pradaxa® for treatment and reduction in risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) -> 보도자료 - FDA, 심부정맥혈전증(DVT)과 폐색전증(PE)의 치료 및 재발 위험 감소에 대하여 프라닥사® 승인 | English ->Korean |
Boehringer Ingelheim Korea |
NINTEDANIB CONSUMER MEDIA MESSAGES -> 닌테다닙 소비자 미디어 메시지 | English ->Korean |
Boehringer Ingelheim Korea |
NINTEDANIB MEDICAL MEDIA MESSAGES -> 닌테다닙 의료 미디어 메시지 | English ->Korean |
Boehringer Ingelheim Korea |
BMC Family Practice - Efficacy of Ambroxol lozenges for pharyngitis: a meta-analysis & BI internal review - Efficacy of Ambroxol lozenges for pharyngitis: a meta-analysis by Chenot JF, Weber P, Friede T | English ->Korean |
Boehringer Ingelheim Korea |
Recall of Voren® Suspension for Injection - Date: April 11, 2014 -> 주사용 보렌® 현탁액 리콜 - 날짜: 2014년 4월 11일 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Volasertib, Boehringer Ingelheim´s investigational treatment of acute myeloid leukaemia, is granted ‘orphan drug designation’ in the EU and the US-> 보도자료 - 베링거인겔하임의 급성 골수성 백혈병 연구 치료제인 볼라설팁, EU와 미국에서 '희귀의약품 지정' 승인받아 | English ->Korean |
Boehringer Ingelheim Korea |
PRADAXA® LITIGATION COMMUNICATIONS - TOOLKIT FOR OPU IMPLEMENTATION -> 프라닥사® 소송 커뮤니케이션 - OPU 이행에 관한 툴키트 | English ->Korean |
Boehringer Ingelheim Korea |
Tiotropium Respimat® in asthma* Media backgrounder -> 천식에서의 티오트로피움 레스피맷®* 미디어 배경 설명 | English ->Korean |
Boehringer Ingelheim Korea |
Innovative SOLUTIONS TO HELP MILLIONS BREATHE EASIER - About asthma -> 수많은 사람이 편하게 숨쉴 수 있도록 돕는 혁신적인 솔루션 - 천식에 관하여 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Positive CHMP opinion for Pradaxa® in treatment of deep vein thrombosis and pulmonary embolism and prevention of repeat blood clots-> 보도자료 - 심부정맥혈전증(DVT)과 폐색전증(PE) 치료 및 반복성 혈전 예방 관련 프라닥사®에 대한 CHMP의 긍정적인 견해 | English ->Korean |
Boehringer Ingelheim Korea |
New analysis shows Boehringer Ingelheim’s Giotrif® (afatinib) is the first treatment to demonstrate significant overall survival benefit for patients with a specific type of lung cancer -> 새로운 분석 결과는 베링거인겔하임의 지오트립®(아파티닙)이 특정 유형의 폐암 환자에게 전체 생존율에 유의미한 혜택을 주 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New study to investigate dabigatran etexilate for prevention of recurrent stroke in high-risk patients-> 보도자료 - 고위험 환자의 재발성 뇌졸중 예방을 위한 새로운 다비가트란 에텍실레이트 연구 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New registry data highlight substantial global differences in stroke prevention for patients with an irregular heart beat-> 보도자료 - 새로운 등록 임상 결과, 불규칙한 심장박동 환자의 뇌졸중 예방에서 상당한 세계적 차이 강조 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim will make detailed clinical trial data available to the scientific community-> 보도자료 - 베링거인겔하임, 과학계가 상세한 임상시험 데이터를 이용할 수 있도록 할 예정 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - IPF Phase III results published in NEJM show nintedanib* slows disease progression-> 보도자료 - NEJM에서 발표된 IPF 제3상 임상 결과, 닌테다닙*, 질병 진행을 늦추는 것으로 나타나 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - ATS 2014 COPD: First Phase III data show lung function benefits of tiotropium + olodaterol fixed-dose combination go beyond tiotropium (Spiriva®) alone-> 보도자료 - COPD: 최초 3상 임상 결과, 폐기능에서 티오트로피움+올로다테롤 병용 고정 용량이 티오트로피움(스피리바®) 단독 용량 이상의 효과 보여 | English ->Korean |
Boehringer Ingelheim Korea |
Social Media General Mgmt Guide Jan 2013 Final -> 소셜 미디어 관리 안내 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Antidote for rapid reversal of Pradaxa® (dabigatran etexilate) progresses into next stage of clinical investigation with study in patients-> 보도자료 - 프라닥사®(다비가트란 에텍실레이트)의 빠른 역전 해독제, 환자 대상 임상 연구의 다음 단계로 나아가 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - EMA accepts marketing authorisation application for nintedanib* in IPF -> 보도자료 - EMA, 특발성 폐섬유화증(IPF)에 대한 닌테다닙*의 시판허가 신청 승인 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Type 2 Diabetes: Physicians worldwide agree early conversations are crucial in the management of condition -> 보도자료 - 제2형 당뇨병: 전 세계 의료진, 초기 대화가 질병 관리에 매우 중요하다는 점에 동의 | English ->Korean |
Boehringer Ingelheim Korea |
5 Video - Sales Call Trajenta & 6 Video - Seven Steps Pradaxa - Video Subtitling | English ->Korean Video Subtitling |
Boehringer Ingelheim Korea |
Press Release - Pradaxa® gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism -> 보도자료 - 프라닥사®, 심부정맥혈전증(DVT) 및 폐색전증(PE) 치료와 재발 예방에 대한 EU 승인 획득 | English ->Korean |
Boehringer Ingelheim Korea |
Mucopect® prospect <- 뮤코펙트 전망 | Korean ->English |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim’s volasertib showed in a Phase II study an improvement in overall survival in older AML patients-> 보도자료 - 베링거인겔하임의 볼라설팁, 제2상 임상연구에서 고령의 급성골수성백혈병 환자의 전체 생존율 개선 입증 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New survey in five European countries reveals urgent need to improve education about Acute Myeloid Leukaemia -> 보도자료 - 유럽 5개국에서의 새로운 설문, 급성골수성백혈병에 대한 교육 개선이 시급히 필요함을 밝혀 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New Pradaxa® clinical study to explore practical management of patients with atrial fibrillation undergoing ablation-> 보도자료 - 프라닥사®에 대한 새로운 임상 연구, 절제술을 받은 심방세동 환자의 실용적 관리 탐구 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - U.S. FDA grants Breakthrough Therapy Designation to Pradaxa® (dabigatran etexilate) specific investigational antidote-> 보도자료 - 미 FDA, 프라닥사® (다비가트란 에텍실레이트) 전용 연구용 해독제, 획기적인 치료법으로 지정(BTD) 승인 | English ->Korean |
Boehringer Ingelheim Korea |
A fresh look at asthma - Media resource -The 3 facts you need to know about asthma -> 천식에 대하여 알아야 할 세 가지 사실 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim’s investigational therapy nintedanib* receives the first FDA breakthrough therapy designation in IPF -> 보도자료 - 베링거인겔하임의 연구용 치료제 닌테다닙*, 특발성 폐섬유화증(IPF)에서 최초로 FDA의 획기적 치료법으로 지정받아 | English ->Korean |
Boehringer Ingelheim Korea |
Position statement concerning recently published clinical data on extended-release (ER) guaifenesin (Mucinex®) | English ->Korean |
Boehringer Ingelheim Korea |
Inquiries about the blood test at Gasi farm on Jeju Island <- 제주도 소재 가시농장 채혈검사에 대한 의문사항 문의 | Korean ->English |
Boehringer Ingelheim Korea |
Monopoly Regulation and Fair Trade Act <- 독점규제 및 공정거래에 관한 법률 | Korean ->English |
Boehringer Ingelheim Korea |
[1]Interview Transcript Barner-Baum July 29 2014 EN & [2]Interview transcript Barner-Baum July 1 2014 ENG | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - First patients enrolled in study to evaluate dabigatran etexilate after PCI with stenting-> 보도자료 - 베링거인겔하임, 더 넓은 환자군의 뇌졸중 예방 치료에서 프라닥사® 임상적 혜택을 평가하는 두 가지 대규모 글로벌 임상 연구 계획 발표 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Asthma: new indication for Spiriva® (tiotropium) Respimat® in the EU may offer millions of adults a significant advance in asthma care -> 보도자료 - 천식: 유럽 연합 내에서 스피리바* 레스피맷® (티오트로피움)에 대한 새로운 적응증, 수백만의 성인 환자에게 천식 치료의 상당한 진전 제공 전망 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - ESC Congress 2014 Hot Line Session: Favourable effect of Pradaxa® on kidney function over time compared to warfarin-> 보도자료 - 2014 ESC 학회 핫라인 세션: 프라닥사®, 시간에 따른 신장 기능에서 와파린 대비 유리한 효과 보여 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Extensive experience in clinical practice and expanding research programme support use of Pradaxa® for clot prevention -> 보도자료 - 광범위한 임상 실습 경험과 연구 프로그램 확대, 혈전 예방을 위한 프라닥사® 사용 뒷받침 | English ->Korean |
Boehringer Ingelheim Korea |
BIK_Working Instruction on Handling and distribution of promotional material <- Korean | Korean ->English |
Boehringer Ingelheim Korea |
Press Release - ERS INTERNATIONAL CONGRESS 2014 TONADO™ - further lung function and quality of life benefits with tiotropium + olodaterol Respimat® FDC in COPD-> 보도자료 - 2014 유럽 호흡기학회 국제회의: TONADO™ - 만성폐쇄성폐질환(COPD) 환자에서 티오트로피움+올로다테롤 레스피맷® FDC 를 통한 폐 기능과 삶 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Nintedanib* slowed disease progression in IPF independent of patients’ lung function impairment at baseline -> 보도자료 - 닌테다닙*, 기저선에서 환자의 폐 기능 장애와 관계없이 질병 진행 지연 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim’s afatinib achieves primary endpoint in global Phase III study in recurrent/metastatic head and neck squamous cell cancer-> 보도자료 - 베링거인겔하임 아파티닙, 재발성/전이성 두경부 편평세포암 대상 글로벌 제3상 시험에서 일차 평가변수 달성 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Head-to-head Phase III trial results demonstrate superior progression-free survival for afatinib compared to erlotinib in patients with advanced squamous cell carcinoma of the lung -> Korean | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - 제3상 직접 비교 임상시험 결과, 아파티닙, 진행성 폐 편평세포암 환자 대상 엘로티닙과 비교하여 우수한 무진행 생존기간 보여 <- English | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy-> 보도자료 - 베링거인겔하임과 큐어백(CureVac), 차세대 폐암 면역 요법 개발 협력 발표 | English ->Korean |
Boehringer Ingelheim Korea |
The understanding and application of the Personal Information Protection Act <- 개인정보 보호법의 이해 및 적용 | Korean ->English |
Boehringer Ingelheim Korea |
Media Factsheet - How are symptoms and lung function evaluated? -> 증상과 폐 기능은 어떻게 평가되는가? | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim’s OFEV® (nintedanib*) is approved by the FDA for the treatment of idiopathic pulmonary fibrosis-> 보도자료 - 베링거인겔하임의 OFEV® (닌테다닙*), 특발성 폐섬유화증(IPF) 치료제로 FDA 승인 받아 | English ->Korean |
Boehringer Ingelheim Korea |
BOEHRINGER INGELHEIM Animal Health GmbH - STANDARD OPERATING PROCEDURES SOP No. 00-05-01 - “Stndy numbering" -> 베링거인겔하임동물약품(BOEHRINGER INGELHEIM Animal Health GmbH) - 표준 운영 절차 SOP No. 00-05-01 - “연구 번호 붙이기” | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim Korea - Working Instruction on Event Management - Effective date: 5 Jan. 2015 | Korean ->English |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim and Lilly Revising Operational Structure of Diabetes Alliance in Certain Countries-> 보도자료 - 베링거인겔하임과 일라이 릴리, 특정 국가 내 당뇨병 제휴의 운영 구조 수정 | English ->Korean |
Boehringer Ingelheim Korea |
Issue: Restructuring of Lilly-BI Diabetes Alliance Agreement -> 주제: 릴리-베링거인겔하임 당뇨병 합의 개편 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New subgroup analysis shows Asian non-small cell lung cancer patients with most common EGFR mutation (del19) lived significantly longer with first line GIOTRIF® (afatinib) compared to chemotherapy -> Korean | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - 새로운 하위그룹 분석, 화학요법과 비교한 일차 치료법으로 지오트립®(아파티닙) 치료를 받은 가장 흔한 EGFR 변이(del19) 양성 아시아 비소세포폐암 환자의 생존 기간이 유의하게 연장되었음을 입증 <- English | English ->Korean |
Boehringer Ingelheim Korea |
Healthcare compliance_v1.1, Anti-Corruption_v2.0, Anti-Discrimination _v2.0_1104, Anti-Trust_v1.0_1030_FB, nsider Trading_v1.1_1028, Trade Compliance_v1.0_1107, Case Study | Korean ->English |
Boehringer Ingelheim Korea |
Press Release - Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa® than with warfarin-> 보도자료 - 두 개의 새로운 대규모 실제 분석 결과, 와파린 대비 프라닥사® 치료의 대출혈 및 뇌졸중 발생 감소 입증 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Vargatef® (nintedanib*) approved in the EU for lung cancer patients with advanced adenocarcinoma after first-line chemotherapy -> 보도자료 - Vargatef® (닌테다닙*), EU에서 일차 화학요법 후 진행성 폐선암 환자 대상 승인 | English ->Korean |
Boehringer Ingelheim Korea |
Dulcolax® Brand Marketing data | Korean ->English |
Boehringer Ingelheim Korea |
Press Release - New data show specific antidote idarucizumab reverses dabigatran-induced anticoagulation also in elderly and renally impaired volunteers-> 보도자료 - 특이적 해독제 이다루시주맙 , 새로운 데이터를 통해 노인과 신장 장애를 가진 지원자에서도 다비가트란 유도 항응고제의 역전 효과 입증해 | English ->Korean |
Boehringer Ingelheim Korea |
My Honorary Public Official ID Card - Became a One-day Public Official <- 명예공무원증을 받으며... - 일일공무원이 되다 | Korean ->English |
Boehringer Ingelheim Korea |
Press Release - The Lancet Oncology publishes Phase III data showing Giotrif® (afatinib*) significantly extended overall survival of lung cancer patients with the most common EGFR mutation over chemotherapy -> Korean | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - 란셋 온콜로지(The Lancet Oncology), 지오트립® (아파니팁*)이 화학요법과 비교하여 가장 흔한 EGFR 변이 폐암 환자의 전체 생존기간을 유의하게 연장했음을 입증하는 제3상 임상 결과 발표 <- English | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - OFEV® (nintedanib*) approved in the EU for the treatment of IPF-> 보도자료 - OFEV® (닌테다닙*), EU 내 특발성 폐섬유화증(IPF) 치료제로 승인받아 | English ->Korean |
Boehringer Ingelheim Korea |
Mucopect Digital Viral Film script translation <- Korean | Korean ->English Video translaion |
Boehringer Ingelheim Korea |
Press Release - New large-scale study to investigate effect of tiotropium + olodaterol Respimat® on exacerbations in COPD -> 보도자료 - COPD 환자 악화에 대한 티오트로피움+올로다테롤 레스피맷® 효과 연구를 위한 새로운 대규모 임상 | English ->Korean |
Boehringer Ingelheim Korea |
Antistax - ‘Transformation' MOA Video script translation -> 안티스탁스 - ‘변형' MOA 비디오 스크립트 번역 | English ->Korean video script translation |
Boehringer Ingelheim Korea |
Press Release -Boehringer Ingelheim and Sanofi enter into a strategic contract manufacturing alliance to produce biopharmaceuticals-> 보도자료 - 베링거인겔하임ㆍ사노피, 생물의약품 생산 제휴 전략적 계약 체결 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim Korea (CEO: Dirk Van Niekerk) announced that, since February 1st, 2015, the patients’ share for the thrombolytic treatment, Actilyse® (Ingredients: Alteplase, rt-PA), has been reduced from previous 20 percent to 5 percent. <- Korean | Korean ->English |
Boehringer Ingelheim Korea |
Press Release - First trial of a novel oral anticoagulant starts in prevention of recurrent stroke due to a blood clot of undetermined source -> 보도자료 - 새로운 글로벌 프라닥사® 연구, 급성 심부정맥혈전증(DVT) 및 폐색전증(PE) 관리에 대한 실질적 증거 추가 제공 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New global Pradaxa® study to provide additional real-world evidence on the management of acute Deep Vein Thrombosis and Pulmonary Embolism -> 보도자료 - 베링거인겔하임, EMA, FDA, 캐나다 보건부에 다비가트란 에텍실레이트(프라닥사®)에 특이적인 역전제인 이다루시주맙* 승인 신청 제출 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim submits applications for approval of idarucizumab, specific reversal agent to dabigatran etexilate (Pradaxa®), to EMA, FDA and Health Canada ->베링거인겔하임, EMA, FDA, 캐나다 보건부에 다비가트란 에텍실레이트(프라닥사®)에 특이적인 역전제인 이다루시주맙 승인 신청 제출 | English ->Korean |
Boehringer Ingelheim Korea |
Mucosolvan GP DA_v12 & Mucosolvan Pharmacist DA_v15 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Many Atrial Fibrillation patients at high risk of stroke fail to receive guideline-recommended oral anticoagulant treatment-> 보도자료 -뇌졸중 위험이 높은 심방세동 환자 다수가 가이드라인에서 권고되는 경구용 항응고제로 치료받지 못해 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New international survey of lung cancer oncologists highlights underutilization of personalized treatments -> 보도자료 - 폐암 종양학자가 발표한 새로운 국제적 설문조사, 개인 맞춤형 치료법의 불충분한 사용 강조 | English ->Korean |
Boehringer Ingelheim Korea |
AN INTERNATIONAL SURVEY ASSESSED EGFR MUTATION TESTING RATES AND TREATMENT PRACTICES IN A SPECIFIC TYPE OF LUNG CANCER -> 국제적 설문조사는 폐암의 특이적 유형에서 EGFR 변이 검사 비율과 진료를 평가했다. | English ->Korean |
Boehringer Ingelheim Korea |
Buscopan HCP Detailing app screengrabs 11.03.15_REV_5000 | English ->Korean |
Boehringer Ingelheim Korea |
2015_Dulcolax training ToolKit (CHC portal) - 2015 듈코락스 교육 툴킷 (CHC 포털) | English ->Korean |
Boehringer Ingelheim Korea |
Dulcolax claim compendium, Stimulant laxatives are effective in chronic constipation: multi-center, 4-week, double-blind, randomized, placebo-controlled trial of bisacodyl -> 듈코락스 주장 개요서, 자극성 완화제 만성변비에 효과적: 다기간, 4주, 이중눈가림, 무작위배정, 위약대조 비사코딜 시험 & | English ->Korean |
Boehringer Ingelheim Korea |
Stimulant laxatives do not impair normal colonic function or increase the risk of habituation, tolerance and dependency -> 자극성 완하제는 정상적인 대장 기능을 손상시키거나 습관화, 내성, 의존성 위험을 증가시키지 않는다. | English ->Korean |
Boehringer Ingelheim Korea |
Clinical Trial Protocol - BI Trial No.: 1311.16 -> 임상시험계획서 - BI Trial No.: 1311.16 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - ASCO 2015: Superior overall survival for afatinib compared to erlotinib demonstrated in head-to-head trial in patients with previously treated advanced squamous cell carcinoma of the lung -> Korean | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - ASCO 2015: 폐의 진행성 편평상피암(SCC)으로 이전에 치료받은 환자를 대상으로 한 직접 대면 시험, 에를로티닙과 비교하여 아파티닙의 우수한 전체 생존 기간 입증 <- English | English ->Korean |
Boehringer Ingelheim Korea |
Lung Cancer Backgrounder_1.0 & GIOTRIF backgrounder_1.0 | English ->Korean |
Boehringer Ingelheim Korea |
LUX-Lung 8 infographic_FINAL, LUX-Lung3&6 infographic_1.0 & Lung Cancer Infographic | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New data and analyses confirm the efficacy and safety of OFEV® (nintedanib*) for the treatment of IPF beyond 52 weeks and for distinct subgroups-> 보도자료 - 새로운 연구 결과와 분석, 52주간의 특발성 폐섬유화증(IPF) 치료와 별개 하위 그룹에서 OFEV® (닌테다닙*)의 효능과 안전성 확인 | English ->Korean |
Boehringer Ingelheim Korea |
2011 AAHA Canine Vaccination Guidelines -> 2011년 AAHA 개 예방접종 가이드라인 | English ->Korean |
Boehringer Ingelheim Korea |
BI In Oncology Backgrounder_1.0 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New data show benefit of tiotropium/ olodaterol Respimat® from the start of COPD maintenance therapy -> 보도자료 - 새로운 연구 결과, 만성폐쇄성폐질환(COPD) 유지요법 시작부터 티오트로퓸/올로다테롤 레스피맷®의 효과 입증 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - First patient enrolled in dabigatran study comparing anticoagulation strategies during AF ablation-> 보도자료 - 심방세동(AF) 절제술 중 항응고 전략을 비교하는 다비가트란 연구에 첫 번째 환자 등록 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - FDA approves Boehringer Ingelheim’s Stiolto® Respimat® as once-daily maintenance treatment for COPD-> 보도자료 - 미국식품의약국(FDA), 만성폐쇄성폐질환(COPD)을 위한 1일 1회 유지요법으로서 베링거인겔하임의 Stiolto® 레스피맷® 승인 | English ->Korean |
Boehringer Ingelheim Korea |
Core Trial Subject Information -> 핵심 임상시험대상자 동의설명서 | English ->Korean |
Boehringer Ingelheim Korea |
Trial identification Card For EMERGENCY -> 응급용 임상시험 ID카드 | English ->Korean |
Boehringer Ingelheim Korea |
Clinical Trial Protocol - BI Trial No.: 1311.16 updated data-> 임상시험계획서 - BI Trial No.: 1311.16 업데이트 자료 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Respimat® success story: Boehringer Ingelheim invests EUR 72 million in production capacity in Ingelheim-> 보도자료 - 레스피맷®의 성공 스토리: 베링거인겔하임, 인겔하임의 생산 시설에 7천 2백만 유로 투자 | English ->Korean |
Boehringer Ingelheim Korea |
Spiolto® Respimat® fact sheet -> Spiolto® 레스피맷® 팩트 시트 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New advance in COPD maintenance treatment, Spiolto® Respimat®, approved in first European countries -> 보도자료 -COPD 유지요법의 새로운 진전, Spiolto® 레스피맷, 유럽 국가에서 최초 승인 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release -New publication in The Lancet describes effective reversal of Pradaxa® in healthy volunteers-> 보도자료 - 란셋(The Lancet) 의 새로운 연구 논문, 건강한 지원자에서 프라닥사®의 효과적인 역전 효과 설명 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Idarucizumab* reverses the anticoagulant effect of dabigatran within minutes in patient study -> 보도자료 - 이다루시주맙*, 환자 대상 연구에서 몇 분 만에 다비가트란의 항응고 효과 역전 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim Korea Dirk van Niekerk Business letter - MERS crisis | Korean ->English |
Boehringer Ingelheim Korea |
Respimat® fact sheet - Respimat® is the propellant free platform inhaler for Boehringer Ingelheim’s COPD and Asthma product family. -> 레스피맷® Fact Sheet - 레스피맷®은 베링거인겔하임의 COPD와 천식 제품군을 위한 압축가스가 함유되지 않은 플랫폼 흡입기이다. | English ->Korean |
Boehringer Ingelheim Korea |
TOviTO® infographic - Spiolto® Respimat® TOviTO® Phase III Clinical Trial Programme -> TOviTO® 인포그래픽 - 스피올토® 레스피맷® TOviTO® 3상 임상시험 프로그램 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim Welcomes the Inclusion of OFEV® (nintedanib*) in the Updated International Treatment Guidelines for Idiopathic Pulmonary Fibrosis (IPF)-> 베링거인겔하임, 특발성 폐섬유화증(IPF)의 최신 국제 치료 가이드라인에 오페브® (닌테다닙*) 포함 환영 | English ->Korean |
Boehringer Ingelheim Korea |
Transcript: David Wright Video on Winning | English ->Korean video script translation |
Boehringer Ingelheim Korea |
Bi Interview (Mr. Marc Doetze) Video Dictation & Translation | English ->Korean video dictation & translation |
Boehringer Ingelheim Korea |
Press Release - Phase III data published in The Lancet Oncology shows a significant overall survival benefit of Giotrif® (afatinib) compared to Tarceva® (erlotinib) in patients with previously treated advanced squamous cell carcinoma of the lung -> Korean | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - 란셋 온콜로지에 게재된 3상 임상 결과, 이전에 치료 경험이 있는 진행성 편평세포 폐암 환자에서 타쎄바®(엘로티닙) 대비 지오트립®(아파티닙)의 우수한 전체 생존 효과 보여 <- English | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New data show Spiolto® Respimat® provides meaningful quality of life improvements in COPD-> 보도자료 - 새로운 연구 결과, 만성폐쇄성폐질환(COPD) 환자 대상 스피올토® 레스피맷®의 유의한 삶의 질 개선 효과 입증 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - CHMP recommends label update for Giotrif® with addition of data demonstrating overall survival benefit for patients with EGFR mutation-positive lung cancer-> 보도자료 - CHMP, EGFR 변이 양성 폐암 환자에서 전체 생존 기간 연장 혜택을 입증한 연구 결과를 추가하여 지오트립®의 라벨 업데이트 권고 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - COPD: New data support role of Spiolto® Respimat® as 1st-line maintenance therapy and show superiority over LABA/ICS -> 보도자료 - 만성폐쇄성폐질환(COPD): 새로운 연구 결과, 일차 유지 요법으로서 스피올토® 레스피맷®의 역할과 LABA/ICS 대비 우수성 입증 | English ->Korean |
Boehringer Ingelheim Korea |
UNDERSTANDING COPD - MEDIA BACKGROUNDER -> 만성폐쇄성폐질환(COPD) - 미디어 참고자료(MEDIA BACKGROUNDER) | English ->Korean |
Boehringer Ingelheim Korea |
Pivotal phase III studies for tiotropium + olodaterol Respimat® FDC -> 티오트로퓸+올로다테롤 레스피맷® FDC에 관한 중추적 3상 임상 연구 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events -> 보도자료 - 자디앙®, 심혈관계 질환 발생 위험이 높은 2형 당뇨병 환자의 심혈관 위험 감소 입증 | English ->Korean |
Boehringer Ingelheim Korea |
Cardiovascular disease in type 2 diabetes backgrounder -> 제2형 당뇨병 환자의 심혈관계 질환에 관한 배경 자료 | English ->Korean |
Boehringer Ingelheim Korea |
Cardiovascular Disease in Type 2 Diabetes -> 제2형 당뇨병에서 심혈관계 질환 | English ->Korean |
Boehringer Ingelheim Korea |
EMPA-REG OUTCOME® trial design backgrounder -> EMPA-REG OUTCOME® 임상 설계 배경 자료 | English ->Korean |
Boehringer Ingelheim Korea |
EMPA-REG OUTCOME® trial design -> EMPA-REG OUTCOME® 임상 설계 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - ESC launches new concept for driving innovation in cardiovascular research with exclusive support from Boehringer Ingelheim-> 보도자료 - ESC, 베링거인겔하임의 특별 지원으로 심혈관계 연구의 혁신을 이끄는 새로운 연구 지원 사업 시작 | English ->Korean |
Boehringer Ingelheim Korea |
SPIOLTO® guide to addressing Questions and Perceptions -> 스피올토®에 관한 질문 및 인식 해결에 대한 가이드 | English ->Korean |
Boehringer Ingelheim Korea |
Buscopan-Country_template_language-file - Buscopan Website L10N Project | English ->Korean |
Boehringer Ingelheim Korea |
Basic Service Agreement -> 기본 서비스 계약 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - ECC 2015: GIOTRIF® (afatinib) demonstrates superior survival compared to Tarceva® (erlotinib) for patients with previously treated advanced squamous cell carcinoma of the lung, independent of EGFR mutation status-> Korean | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - ECC 2015: 지오트립® (아파티닙), EGFR 변이 상태와는 상관없이 이전에 치료받은 진행성 편평세포 폐암 환자에서 타쎄바® (엘로티닙) 대비 우수한 생존 기간 입증 <- English | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim Vetmedica Korea - Agreement - Ingelvac CircoFLEX -> 베링거인겔하임동물약품 주식회사 - 합의서 - 인겔백 써코플렉스 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New analysis shows idarucizumab enables rapid initiation of emergency surgery in dabigatran-treated patients -> 보도자료 - 새로운 분석 결과, 다비가트란 치료 환자에 대한 이다루시주맙의 빠른 응급 수술 개시 가능성 보여 | English ->Korean |
Boehringer Ingelheim Korea |
Clinical Trial Protocol - BI Trial No.: 1320.23 -> 임상시험 계획서 - BI Trial No.: 1320.23 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate)-> 보도자료 - FDA, 프라닥사®(다비가트란 에텍실레이트)의 특이적 역전제, Praxbind® (이다루시주맙) 승인 | English ->Korean |
Boehringer Ingelheim Korea |
INFORMATION AND CONSENT FORM FOR TRIAL PARTICIPANTS - TRIAL PARTICIPANT No.: 1320.23 -> 시험 참가자에 대한 정보 및 사전 동의서 - 시험 참가자 번호: 1320.23 | English ->Korean |
Boehringer Ingelheim Korea |
Informed Consent Form for Clinical Trial Subjects - Trial No. : 1320.23 -> 임상시험대상자 설명문 및 동의서 - 시험 번호 : 1320.23 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Real-World Analysis of more than 44,000 Patients Reinforces Safety and Effectiveness of Pradaxa® in Routine Clinical Care-> 보도자료 - 44.000명 이상의 환자를 대상으로 한 실제 분석 결과, 일상적인 진료에서 프라닥사®의 안전성과 효과 입증 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - CHEST: New Sub-Analyses Show Improvement in Patient-Reported Outcomes with Spiolto® Respimat® -> 보도자료 - CHEST: 새로운 하위 분석, 스피올토® 레스피맷®에 대한 환자 보고 결과 개선 입증 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim partners withleading scientific institutions in inflammatory bowel disease research -> 보도자료 - 베링거인겔하임, 염증성 장 질환 연구의 유수 과학 기관과 제휴 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline -> 보도자료 - 새로운 자디앙®(엠파글리플로진) 연구, 베이스라인에서의 심부전 상태와 관계없이 심혈관 연구결과 개선 보여 | English ->Korean |
Boehringer Ingelheim Korea |
US FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors to include warnings about risk of ketoacidosis and serious urinary tract infections ->미국 FDA 의약품 안전성 공고 : FDA, SGLT-2 억제제의 라벨을 개정하여 케토산증 및 중대한 요로감염 위험에 대한 경고를 포함시키다. | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - LUX-Lung 7 trial reveals that the second-generation EGFR tyrosine kinase inhibitor significantly improved PFS in naive patients with advanced mutated lung cancer compared to gefitinib-> Korean | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - 베링거인겔하임의 지오트립®/질로트립®(아파티닙), 이레사®(제피티닙) 대비 EGFR 변이 양성 진행성 비소세포폐암(NSCLC) 환자의 일차 치료제로써 우수한 무진행 생존기간(PFS) 및 치료 실패까지의 시간 입증 <- English | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Phase III data show significant reductions in blood glucose with investigational compound empagliflozin used as monotherapy in adults with Type 2 Diabetes-> 제III상 데이터 분석 결과, 제2형 당뇨병 환자에게 단일요법으로 활용되는 임상시험용 화합물인 엠파글리플로진이 혈당을 유의하게 낮춰 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Phase III data show investigational compound empagliflozin reduced blood glucose in adults with Type 2 Diabetes treated with basal insulin-> 보도자료 - 제III상 데이터 분석 결과, 임상시험용 화합물인 엠파글리플로진이 기저 인슐린 치료를 받은 제2형 당뇨병 환자의 혈당을 낮춰 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulphonylurea in adults with Type 2 Diabetes-> Korean | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - 제 III상 데이터 분석 결과, 제 2형 당뇨병 성인 환자에서 메트포르민 또는 메트포르민+설포닐우레아에 추가한 임상시험용 화합물인 엠파글리플로진이 혈당을 유의하게 낮춰 <- English | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations -> 보도자료 - OFEV® (닌테다닙), 특발성 폐섬유화증(IPF) 질병 진행 지연과 급성 악화 위험을 감소시켜 | English ->Korean |
Boehringer Ingelheim Korea |
Cushman & Wakefield (Korea) Limited - AGREEMENT -> 쿠시먼웨이크필드코리아 - 합의서 | English ->Korean |
Boehringer Ingelheim Korea |
LUX-Lung 7: providing guidance for the treatment of lung cancer patients by comparing two important current treatments -Boehringer Ingelheim - Ongoing Commitment to Oncology->LUX-Lung 7: 2가지 최신 주요 치료제의 비교를 통해 폐암 환자의 치료에 대한 지침 제공 -베링거인겔하임 –종양학에 대한 지속적 헌신 | English ->Korean |
Boehringer Ingelheim Korea |
The treatment landscape for patients with EGFR mutation-positive NSCLC -> EGFR 변이 양성 비소세포폐암(NSCLC) 환자의 치료 배경 | English ->Korean |
Boehringer Ingelheim Korea |
LUX-Lung 7: providing guidance for the treatment of lung cancer patients by comparing two important current treatments - Unveiling LUX-Lung 7 -> LUX-Lung 7: 2가지 최신 주요 치료제의 비교를 통해, 폐암 환자의 치료에 대한 지침 제공 - LUX-Lung 7 공개 | English ->Korean |
Boehringer Ingelheim Korea |
PRAXBIND® (IDARUCIZUMAB) – KEY MESSAGE DOCUMENT -> 프락스바인드® (이다루시주맙) 핵심 메시지 문서 | English ->Korean |
Boehringer Ingelheim Korea |
PRAXBIND® – THE SPECIFIC REVERSAL AGENT TO DABIGATRAN -> 프락스바인드® – 다비가트란에 특이적인 역전제 | English ->Korean |
Boehringer Ingelheim Korea |
REVERSING THE ANTICOAGULANT EFFECTS OF DABIGATRAN ETEXILATE (PRADAXA®) - EXECUTIVE SUMMARY -> 다비가트란 에텍실레이트(프라닥사®)의 항응고 효과 역전 - 핵심 요약 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New Analyses: Adding SPIRIVA® Respimat® Effective for Uncontrolled Asthma – Regardless of Allergy Subtype -> 보도자료 - 새로운 분석: 스피리바® 레스피맷®, 알레르기 하위 유형과 관계없이 통제되지 않는 천식에 효과 보여 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim Internal Q&A, Version 2.0, March 2016 - FINAL -> 베링거인겔하임 내부용 Q&A, 버전 2.0, 2016년 3월 - 최종 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Landmark head to head study demonstrating Giotrif® (afatinib) significantly improved clinical outcomes compared to Iressa® (gefitinib) in EGFR mutation-positive advanced non-small cell lung cancer published in The Lancet Oncology-> Korean | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - EGFR 변이 양성 진행성 비소세포폐암에서 이레사®(게피티닙) 대비 임상 결과의 유의한 개선을 입증한 지오트립®(아파티닙)에 관하여 직접 비교한 랜드마크 연구, 란셋 온콜로지(The Lancet Oncology)에 게재 <- English | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Boehringer Ingelheim launches RE-COVERY DVT/PE™: global observational study on management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate) -> Korean | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - 베링거인겔하임, 심재성정맥혈전증(DVT)과 폐색전증(PE) 관리에 있어 프라닥사®(다비가트란 에텍실레이트)의 효과를 연구한 글로벌 관찰 연구, RE-COVERY DVT/PE™ 착수 <- English | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Interim Phase III Data Show Praxbind® (idarucizumab) Reverses Dabigatran (Pradaxa®) in Emergency Situations-> 보도자료 - 3상 연구의 중간 결과, 응급 상황에서 프락스바인드®(이다루시주맙)의 다비가트란(프라닥사®) 역전 효과 입증 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Type 2 Diabetes: Jardiance® (empagliflozin) as an add-on therapy significantly reduced blood glucose and body weight in two newly presented Phase III trials-> 제2형 당뇨병: 추가 치료제로서 자디앙® (엠파글리플로진), 새로 발표된 두 개의 3상 임상 연구에서 유의한 혈당 강하와 체중 감소 확인 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release -New analysis demonstrates only minority of COPD patients may benefit from adding ICS to Spiriva®+LABA-> 보도자료 - 새로운 분석 결과, 소수의 만성폐쇄성폐질환(COPD) 환자만이 스피리바®+LABA 에 흡입 코르티코스테로이드(ICS) 추가한 치료법의 효과 얻을 수 있어 | English ->Korean |
Boehringer Ingelheim Korea |
Assignability & Termination clauses -> 양도가능성 및 해지 조항 | English ->Korean |
Boehringer Ingelheim Korea |
50 years of bisacodyl - How to "invent" a laxative? -> 50년 역사의 비사코딜 - 완하제의 “발명” 과정 - 비사코딜(bisacodyl) “발명가”인 Ernst Seeger 박사를 PTAheute가 만나봅니다. | English ->Korean |
Boehringer Ingelheim Korea |
Contractual Matters – Contracts -> 계약 사항 – 계약서 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Pradaxa®: First NOAC to be assessed in prospective study in patients with blood clots in the veins or venous sinuses of the brain-> 보도자료 - 프라닥사® - 최초의 신규 경구용 항응고제(NOAC), 뇌정맥 또는 정맥동 내 혈전 발생 환자를 대상으로 전향적 연구에서 평가 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New Presentations at ATS 2016 Reinforce OFEV® (nintedanib) Efficacy, Safety and Tolerability Across Broad Range of Patients with IPF-> 보도자료 - ATS 2016에서 발표된 새로운 연구 결과, 광범위한 특발성폐섬유화증(IPF) 환자를 대상으로 OFEV® (닌테다닙)의 유효성, 안전성, 내약성 재확인 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - 3 out of 4 people with asthma report reduced productivity at work -> 보도자료 - 천식 환자 4명 중 3명, 업무 생산성 감소 보고 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Study results support potential new asthma treatment for children and adolescents who still have symptoms despite taking treatment-> 보도자료 - 연구 결과, 치료에도 불구하고 여전히 증상이 지속되는 어린이 및 청소년 천식 환자를 위한 새로운 천식 치료제의 가능성 뒷받침해 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - Jardiance® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease -> 자디앙®(엠파글리플로진), 확립된 심혈관계 질환을 가진 제2형 당뇨병 성인 환자에서 진행성 신장 질환 위험의 유의한 감소 확인 | English ->Korean |
Boehringer Ingelheim Korea |
Rosso D, Felice R. Clinico-Pharmacological Review on antispasmodic drugs. Boehringer Ingelheim in-house files 2003 | English ->Korean |
Boehringer Ingelheim Korea |
Pulmonary Pharmacology & Therapeutics 17 (2004) 27–34 - Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial) | English ->Korean |
Boehringer Ingelheim Korea |
IDIOPATHIC PULMONARY FIBROSIS (IPF) MEDIA BACKGROUNDER -> 특발성폐섬유화증 (IDIOPATHIC PULMONARY FIBROSIS, IPF) 미디어 배경 자료 | English ->Korean |
Boehringer Ingelheim Korea |
IDIOPATHIC PULMONARY FIBROSIS (IPF) branded infographic -> 특발성폐섬유화증 (IDIOPATHIC PULMONARY FIBROSIS, IPF) 브랜드 인포그래픽 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New study results show Trajenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment-> 보도자료 - 트라젠타® (성분명: 리나글립틴)의 새로운 연구 결과, 신장 장애의 위험이 있는 제2형 당뇨병 성인 환자들의 혈당 강하 효과를 드러내 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance American Diabetes Association (ADA) 76th Scientific Sessions® MARLINA-T2DTM Trial Talking Points-> 베링거인겔하임-일라이 릴리 당뇨병 연합 미국 당뇨병 학회(ADA) 제 76회 과학 세션® MARLINA-T2DTM 임상 요점사항 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New Jardiance® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes-> 자디앙®(엠파글리플로진)에 대한 새로운 연구 결과, 제2형 당뇨병 성인 환자의 모든 연령 그룹에서 심혈관계(CV) 사망 위험 감소 입증해 | English ->Korean |
Boehringer Ingelheim Korea |
Press Release - New analysis of INPULSIS® trials demonstrates efficacy of OFEV® (nintedanib) across a range of IPF patients using broader diagnostic criteria -> INPULSIS® 임상의 새로운 분석 결과, 광범위한 진단 기준을 사용한 다양한 특발성폐섬유화증(IPF) 환자에서 오페브® (닌테다닙) 유효성 입증 | English ->Korean |
Boehringer Ingelheim Korea |
Clinical Trial Protocol - Multi-centre, open-label, single arm, phase I study to investigate safety, tolerability, pharmacokinetics, pharmacogenomics and efficacy of a single intravenous dose of BI 655130 in patients with active generalized pustular psori | English ->Korean |
Boehringer Ingelheim Korea |
Clinical Trial Protocol (임상시험계획서) - 활동성 전신 농포성 건선 환자들에서 BI 655130의 단회 정맥 투여의 안전성, 내약성, 약동학, 약리유전체학, 유효성을 조사하기 위한 다기관, 공개, 단일군, 제I상 시험 | English ->Korean |
Boehringer Ingelheim Korea |
Clinical Trial Protocol - BI Trial No.: 1368.11 Updated data -> 임상시험계획서- BI Trial No.: 1368.11 업데이트 자료 | English ->Korean |
Boehringer Ingelheim Korea |
270716 Trainer Kit TTT BI AH, 280716 QRC BI_Data Change Request, Trainer notes for EUT- AH_V3_RL, 270716 BI Reference Guide AH V3.5_with comments_RL | English ->Korean |
Boehringer Ingelheim Korea |
Data Steward Ref Guide_V3.3_with comments, DS-Trainer Kit TTT BI AH_DS_V1.2pptx, AH DS Training Exercises_V1.0 | English ->Korean |
Boehringer Ingelheim Korea |
INFORMATION AND CONSENT FORM FOR TRIAL PARTICIPANTS - TRIAL PARTICIPANT No.: 1368.11 & Trial Participant Information and Consent Form (DNA Banking) Version No: 1.0 Version Date: 30 Aug 2016 | English ->Korean |
Boehringer Ingelheim Korea |
BOEHRINGER INGELHEIM GmbH - Clinergize – Corporate Template for Data Protection Information Statement title: USER INFORMED CONSENT (CONSENT TO COLLECTION, PROCESSING AND USE OF PERSONAL DATA FOR |
English ->Korean |
Boehringer Ingelheim Korea |
BOEHRINGER INGELHEIM GmbH - Clinergize – 데이터 보호 정보에 관한 기업 서식 - 진술 제목: 사용자 사전동의(개인 데이터 수집, 처리, 사용에 대한 동의 <한국>용) <- English | English ->Korean |
Boehringer Ingelheim Korea |
Assignment clauses for contracts: Contract Manufacturing Agreements: -> 계약 양도 조항: 위탁 생산 계약: | English ->Korean |
Boehringer Ingelheim Korea |
BI Transfer Contract Express Consent -approved by SAN | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim Supplier Code of Conduct -> 베링거인겔하임 공급자 행동강령 | English ->Korean |
Boehringer Ingelheim Korea |
Boehringer Ingelheim Supplier Code of Conduct (SuCoC ) communication -> 베링거인겔하임 공급자 행동강령(SuCoC) 공지 레터 | English ->Korean |
Boehringer Ingelheim Korea |
Antistax CA Language Template -> 안티스탁스™ 소개 자료 | English ->Korean |
Boehringer Ingelheim Korea |
INFORMATION AND CONSENT FORM FOR TRIAL PARTICIPANTS - PROTOCOL No.: 1346.9 <- 시험 참가자에 대한 정보 및 사전 동의서 - 변경사항 업데이트 번역 및 역번역 | English ->Korean & Back-Translaton |
Boehringer Ingelheim Korea |
Let’s continue driving collaboration and teamwork within our ROPU Team. -> 앞으로도 ROPU 팀 내의 협력과 팀워크 발전이 지속되길 바랍니다. | English ->Korean |
Boehringer Ingelheim Korea |
We ask for your support of the CHC Carve-out and the transfer of a viable business to Sanofi. -> CHC 카브아웃(Carve-out) 및 Sanofi로의 실현 가능성 있는 비즈니스 이전과 관련하여 귀사의 협조를 당부 드립니다. | English ->Korean |
Boehringer Ingelheim Korea |
Strategic Sourcing - Asia RoundTable Meeting Notes 22 September 2016 at the Excelsior Hotel, Hong Kong -> 전략적 소싱 - 2016년 9월 22일 홍콩 엑셀시어 호텔 | English ->Korean |
Boehringer Ingelheim Korea |
Third party notification of assignment -> 제3자 양도 공지 | English ->Korean |
Boehringer Ingelheim Korea |
1368 11 clinical-trial-protocol-revision-01-FINAL TrackChange_2016-11-09 & 1368.11_Main PISICF_Core V2.0_Korea_English_version 1.0_11Nov2016_Track changes | English ->Korean |
Boehringer Ingelheim Korea |
B_Communication_Supplier_POs-10-24_Final_contract_SAN | English ->Korean |
Boehringer Ingelheim Korea |
Move to Sanofi Guide -> 사노피 이전 가이드 | English ->Korean |
Boehringer Ingelheim Korea |
Evaluation of porcine reproductive and respiratory syndrome virus (PRRSV) challenge dose in vaccinated pigs -> 백신접종 돼지에서의 돼지생식호흡기증후군바이러스(PRRSV) 공격접종 평가 | English ->Korean |
Boehringer Ingelheim Korea |
Transition of Purchase Orders -> 발주서 인계 | English ->Korean |
Eisai Korea
| Company | Project | Language |
|---|---|---|
Eisai Korea |
Eisai Medical Research Inc. Clinical Study Report - Phase II Clinical Study of E7389 Locally Advanced or Metastatic Breast Cancer | English ->Korean |
Eisai Korea |
Eisai Medical Research Inc. Clinical Study Report - Phase I Clinical Study of E7389 for Solid Tumors - A stepwise dose-ascending, single-center, non-randomized, open-label study | English ->Korean |
Eisai Korea |
Eisai Medical Research Inc. Clinical Study Report - A Phase I Dose-Finding Study of E7389 (Halichondrin B Analog) Administered Once Every Three Weeks in Patients with Advanced Solid Tumors | English ->Korean |
Eisai Korea |
Eisai Medical Research Inc. Clinical Study Report - A Phase I Dose-Finding Study of E7389 (Halichondrin B Analog) in Patients with Advanced Solid Tumors | English ->Korean |
Eisai Korea |
Eisai Medical Research Inc. Clinical Study Report - E7389-G000-305 | English ->Korean |
Eisai Korea |
E7389 CLINICAL STUDY PROGRESS REPORT - A Phase Ib Open-Label, Two-Arm, Dose-Finding Study of E7389 in Combination with Carboplatin in Patients with Solid Tumors | English ->Korean |
Eisai Korea |
Eisai Medical Research Inc. E7389 (eribulin mesylate) Amended CSR E7389-A001-201- Amended Clinical Study Report | English ->Korean |
Eisai Korea |
Eisai Medical Research Inc. E7389 (eribulin mesylate) Amended CSR - STUDY SYNOPSIS | English ->Korean |
Eisai Korea |
Eisai Medical Research Inc. E7389 (eribulin mesylate) Amended CSR E7389-A001-202 - Amended Clinical Study Report | English ->Korean |
Eisai Korea |
Eribulin mesylate Solution for Injection 0.5mg/mL 2.6 Nonclinical Written and Tabulated Summaries 2.6.2 Pharmacology Written Summary | English ->Korean |
Eisai Korea |
Study Report - TIME COURSE OF CELL CYCLE EFFECTS GENERATED BY E7389 IN U937 HUMAN HISTIOCYTIC LYMPHOMA CELLS REPORT NUMBER: PPC2005-02 | English ->Korean |
Eisai Korea |
Study Report - ANTIPROLIFERATIVE EFFECTS OF E7389, PACLITAXEL AND VINBLASTINE IN HUMAN CANCER CELLS REPORT NUMBER: PPC2005-03 | English ->Korean |
Eisai Korea |
Study Report - ANTIPROLIFERATIVE EFFECTS OF E7389 AGAINST PACLITAXEL-RESISTANT HUMAN CANCER CELLS IN VITRO REPORT NUMBER: PPC2005-04 | English ->Korean |
Eisai Korea |
Study Report - E7389: EFFECTS OF E7389 ON TUBULIN POLYMERIZATION IN VITRO REPORT NUMBER: PPC2005-05 | English ->Korean |
Eisai Korea |
Study Report - ANTIPROLIFERATIVE EFFECTS OF E7389 AGAINST PGLYCOPROTEIN-OVEREXPRESSING MULTIDRUG RESISTANT HUMAN CANCER CELLS IN VITRO REPORT NUMBER: PPC2006-06 | English ->Korean |
Eisai Korea |
Study Report - ANTIPROLIFERATIVE EFFECTS OF E7389, PACLITAXEL AND VINBLASTINE AGAINST HUMAN SMALL CELL LUNG CANCER AND HEAD AND NECK CANCER CELLS IN VITRO REPORT NUMBER: PPC2006-07 | English ->Korean |
Eisai Korea |
STUDY REPORT & AMENDMENT NO. 1 - RESPONSE OF SC MDA-MB-435 MAMMARY TUMOR TO TREATMENT WITH E7389 REPORT NUMBER: PPC2003-03A | English ->Korean |
Eisai Korea |
STUDY REPORT & AMENDMENT NO. 1 - RESPONSE OF SC NCI-H522 LUNG TUMOR TO COMBINATION TREATMENT WITH E7389 AND GEMZAR REPORT NUMBER: PPC2003-04A | English ->Korean |
Eisai Korea |
Study Report - Response of SC MDA-MB-435 Mammary Tumor to Combination Treatment with E7389 and Doxorubicin REPORT NUMBER: PPC2003-05A | English ->Korean |
Eisai Korea |
Study Report - Response of SC PANC-l Pancreatic Tumor to Treatment with E7389 REPORT NUMBER: PPC2003-02A | English ->Korean |
Eisai Korea |
FINAL REPORT - RESPONSE OF SC NCI-H82 LUNG TUMOR XENOGRAFTS TO TREATMENT WITH E7389 Study No. ERI-74 | English ->Korean |
Eisai Korea |
Final Report To Eisai Research Institute On RESPONSE OF INTRACRANIALLY IMPLANTED U251 HUMAN GLIOBLASTOMA CELLS TO TREATMENT WITH E7389 (Study No.ERI-89A) | English ->Korean |
Eisai Korea |
Final Report To Eisai Research Institute On RESPONSE OF SC U251 GLIOBLASTOMA XENOGRAFTS TO TREATMENT WITH E7389 (Study No. ERI-90A) | English ->Korean |
Eisai Korea |
Final Report To Eisai Research Institute On RESPONSE OF INTRACRANIALLY IMPLANTED U251 HUMAN GLIOBLASTOMA CELLS TO TREATMENT WITH E7389 (Study No. ERI-95A) | English ->Korean |
Eisai Korea |
Final Report To Eisai Research Institute On RESPONSE OF INTRACRANIALLY IMPLANTED U251 HUMAN GLIOBLASTOMA CELLS TO TREATMENT WITH E7389 (Study No. ERI-97A) | English ->Korean |
Eisai Korea |
Final Report To Eisai Research Institute On RESPONSE OF INTRACRANIALLY IMPLANTED U251 HUMAN GLIOBLASTOMA CELLS TO TREATMENT WITH E7389 (Study No. ERI-98A) | English ->Korean |
Eisai Korea |
FINAL REPORT - RESPONSE OF SC SR475 HEAD AND NECK TUMOR XENOGRAFTS TO TREATMENT WITH E7389 Study No. ERI-99A | English ->Korean |
Eisai Korea |
Final Report To Eisai Research Institute On RESPONSE OF INTRACRANIALLY IMPLANTED U251 HUMAN GLIOBLASTOMA CELLS TO TREATMENT WITH E7389 (Study No. ERI-I00A) | English ->Korean |
Eisai Korea |
Final Report To Eisai Research Institute On RESPONSE OF INTRACRANIALLY IMPLANTED SF-295 HUMAN GLIOBLASTOMA TO TREATMENT WITH E7389 (Study No. ERI-I06A) | English ->Korean |
Eisai Korea |
Final Report To Eisai Research Institute On RESPONSE OF INTRACRANIALLY IMPLANTED SF-295 HUMAN GLIOBLASTOMA TO TREATMENT WITH E7389 (Study No. ERI-ll1A) | English ->Korean |
Eisai Korea |
FINAL REPORT - EVALUATION OF THE ANTITUMOR EFFICACY OF E7389 WHEN ADMINISTERED IN COMBINATION WITH XELODA AGAINST S.C. MX-1 HUMAN MAMMARY TUMOR XENOGRAFTS IN FEMALE ATHYMIC NCR-NU/NU MICE Study No. ERI-118 | English ->Korean |
Eisai Korea |
STUDY REPORT & AMENDMENT NO. 1 - Evaluation of the antitumor efficacy of E7389 when administered in combination with XELODA against S.C. UISO-BCA-1 Human Mammary Tumor Xenografts in female Athymic NCR-NU/NU MICE Study Number: ERI 119 | English ->Korean |
Eisai Korea |
STUDY REPORT & AMENDMENT NO. 1 - Evaluation of the antitumor efficacy of E7389 when administered in combination with TARCEVA or ARIMITA against S.C. NCI-H322M Human Lung Tumor Xenografts in female Athymic NCR-NU/NU MICE Study Number: ERI 120 | English ->Korean |
Eisai Korea |
FINAL REPORT - EVALUATION OF THE ANTITUMOR EFFICACY OF ERLOTINIB, PEMETREXED, AND E7389 AGAINST S.C. NCI-H522 HUMAN LUNG TUMOR XENOGRAFTS IN FEMALE ATHYMIC NCR-NU/NU MICE Study No. ERI-121 | English ->Korean |
Eisai Korea |
FINAL REPORT- EVALUATION OF THE ANTITUMOR EFFICACY OF E7389 WHEN ADMINISTERED IN COMBINATION WITH PEMETREXED AND ERLOTINIB AGAINST S.C. NCI-H322M HUMAN LUNG TUMOR XENOGRAFTS IN FEMALE ATHYMIC NCR-NU/NU MICE Study No. ERI-122 | English ->Korean |
Eisai Korea |
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth - Mary Ann Jordan,1 Kathryn Kamath,1 Tapas Manna,1 Tatiana Okouneva,1 Herbert P. Miller,1 Celia Davis,1 Bruce A. Littlefield,2 and Leslie | English ->Korean |
Eisai Korea |
Induction of Morphological and Biochemical Apoptosis following Prolonged Mitotic Blockage by Halichondrin B Macrocyclic Ketone Analog E7389 - Galina Kuznetsov,1 Murray J. Towle,2 Hongsheng Cheng,2 Takanori Kawamura,6 Karen TenDyke,1 Diana Liu,2 Yoshito Ki | English ->Korean |
Eisai Korea |
STUDY REPORT - ANTITUMOR EFFECTS OF E7389 AGAINST S.C. HT-1080 HUMAN FIBROSARCOMA XENOGRAFTS IN VIVO Revision No. 1 REPORT NUMBER: PPC2003-01 | English ->Korean |
Eisai Korea |
Study Report - ANTIPROLIFERATIVE EFFECTS OF E7389 COMBINATIONS WITH DOCETAXEL OR CARBOPLATIN AGAINST HUMAN CANCER CELLS IN VITRO STUDY NUMBER: SA030105 | English ->Korean |
Eisai Korea |
CANCER RESEARCH 61, 1013–1021, February 1, 2001 - In Vitro and In Vivo Anticancer Activities of Synthetic Macrocyclic Ketone Analogues of Halichondrin B1 - Murray J. Towle, Kathleen A. Salvato, Jacqueline Budrow, Bruce F. Wels, Galina Kuznetsov, Kimberley | English ->Korean |
Eisai Korea |
Study Report - E7389-INDUCED NEUROPATHY EVALUATION IN MICE: The Effects of E7389 on nerve conduction velocity (NCV), amplitude and morphology in the BALB/c Mouse STUDY NUMBER: PPC-2009-01 | English ->Korean |
Eisai Korea |
Final Report - E7389: Effects on HERG Tail Currents Recorded from Stably Transfected HEK293 Cells Quintiles, Inc. Report No.: QKAN-2003-0272-SPC | English ->Korean |
Eisai Korea |
Final Report - E7389: Effects on General Physical Condition and Behavior by Intravenous Injection in Rats Quintiles, Inc. Report No.: QKAN-2003-0271-SPC | English ->Korean |
Eisai Korea |
Final Report - E7389: Effects on Action Potential Parameters in Isolated Cardiac Purkinje Fibers of Dog Quintiles, Inc. Report No.: QKAN-2003-0441-SPC | English ->Korean |
Eisai Korea |
Final Report - E7389: Effects on Respiratory Function by Intravenous Injection in Rats Quintiles, Inc. Report No.: QKAN-2003-0333-SPC | English ->Korean |
Eisai Korea |
Final Report - E7389: Effects on Cardiovascular System and Body Temperature by Intravenous Infusion in Conscious Dogs Quintiles, Inc. Report No.: QKAN-2003-0471-SPC | English ->Korean |
Eisai Korea |
Eisai Research Institute - Pharmacokinetics of Halichondrin B Analog NSC 707389-D Following Three 1-Hour CIV Infusions in Rats REPORT NO.: DSD2001-30 | English ->Korean |
Eisai Korea |
Eisai Research Institute - Pharmacokinetics of E7389 in Mice, Rats, and Dogs REPORT NUMBER: DSD2002-42 | English ->Korean |
Eisai Korea |
STUDY REPORT - PHARMACOKINETICS OF E7389 IN MICE AND RATS FOLLOWING SINGLE INTRAVENOUS AND ORAL ADMINISTRATIONS STUDY NUMBERS: DDDP2005-090 TO DDDP2005-095, DDDP2005-097, DDDP2005-153, AND DDDP2005-163 | English ->Korean |
Eisai Korea |
STUDY REPORT - TUMOR AND BRAIN PENETRATION OF E7389 IN LOX XENOGRAFT MICE FOLLOWING SINGLE AND MULTIPLE INTRAVENOUS ADMINISTRATIONS STUDY NUMBERS: DDDP2005-098 AND DDDP2005-135 | English ->Korean |
Eisai Korea |
STUDY REPORT - QUANTITATIVE TISSUE DISTRIBUTION OF DRUGRELATED MATERIAL USING WHOLE-BODY AUTORADIOGRAPHY FOLLOWING A SINGLE IV DOSE OF [14C]E814058 (1.5 mg/kg, as the salt form) TO MALE LONG-EVANS AND SPRAGUE DAWLEY RATS STUDY NUMBER: QPS45-0403 | English ->Korean |
Eisai Korea |
REPORT AMENDMENT - Quantitative Tissue Distribution and Human Dosimetry Predictions of Drug-Related Material Using Whole-Body Autoradiography Following a Single IV Dose of [14C]E814058 (0.75 mg/kg, as the salt form) to Male Long-Evans and Sprague Dawley R | English ->Korean |
Eisai Korea |
STUDY REPORT AND AMENDMENT NO. 1 - [14C]E-814058 METABOLITE IDENTIFICATION AND PROFILING IN PLASMA, URINE, BILE AND FECES FROM SPRAGUE-DAWLEY RATS FOLLOWING A SINGLE INTRAVENOUS ADMINISTRATION OF [14C]E-814058 (REVISION NO. 1) STUDY NUMBER: 45N-0405 | English ->Korean |
Eisai Korea |
STUDY REPORT & AMENDMENTS NO. 1, 2, & 3 - [14C]E-814058 METABOLITE IDENTIFICATION AND PROFILING IN PLASMA, URINE AND FECES FROM BEAGLE DOGS FOLLOWING A SINGLE INTRAVENOUS ADMINISTRATION OF [14C]E-814058 STUDY NUMBER: 45N-0406 | English ->Korean |
Eisai Korea |
STUDY REPORT AND AMENDMENT #2 - MASS BALANCE AND EXCRETION OF RADIOACTIVITY IN SPRAGUE-DAWLEY RATS FOLLOWING A SINGLE INTRAVENOUS BOLUS DOSE OF [14C]E-814058 QPS Project Number: 45-0404 | English ->Korean |
Eisai Korea |
STUDY REPORT - [14C]E-814058: A STUDY OF MASS BALANCE OF RADIOACTIVITY FOLLOWING A SINGLE INTRAVENOUS ADMINISTRATION OF 14C-LABELLED E-814058 TO BEAGLE DOGS STUDY NUMBER: 6212 | English ->Korean |
Eisai Korea |
KFDA Chapter 3 Drug Imprint Code Article 10 (Object of Drug Imprint Code) Article 11 (Drug Imprint Method) Article 12 (Registration of Drug Imprint Code) Article 13 (Drug Imprint Code Registration Authority) | English ->Korean |
Eisai Korea |
KFDA Chapter 3 Drug Imprint Code Article 14 (Coordinating Committee for Drug Imprint Code) Article 15 (Disclosure of Information) Article 16 (Reporting) Article 17 (Miscellaneous Provisions) Article 18 (Deadline for Re-review) | Korean ->English |
Eisai Korea |
Briefing Book - Data for Developing a Compound of Donepezil HCl and Memantine HC Ver. 2 - December, 2011 Daewoong / Eisai Korea, Inc. | Korean ->English |
Eisai Korea |
Journal of Non-Crystalline Solids 52 (1 982) 91-103 North-Holland Publishing Company - CHEMICAL DURABILITY OF GLASSES - H. SCHOLZE Fraunhofer-Institut für Silicatforschung, Würzburg, FRG | English ->Korean |
Eisai Korea |
KOREA PHARMACEUTICAL MANUFACTURERS ASSOCIATION Public Document - Notice of submission of required application documents for preliminary GMP evaluation by item | Korean ->English |
Eisai Korea |
Korea Food and Drug Administration Public Document - Request for GMP inspection result's supplementary data by item [Eisai Korea Inc. - Halaven (eribulin mesylate)] | Korean ->English |
Eisai Korea |
Attachment 1_KFDA_CAP-005_12 - NerPharMa - INSTALLATION & OPERATIONAL QUALIFICATION Protocol about Differential pressure Indicators - Protocol No.: SF. 793 IOQ Rev. 01 - 05.15.2012 | Italian ->Korean |
Eisai Korea |
Attachment 2_KFDA_CAP-005_12 - PHOTO 1 ~ PHOTO 3/b – SOP SF.DB 006 (Management of Solvent and Reagents) with mention of data logger management | Italian ->Korean |
Eisai Korea |
Attachment 4_KFDA_CAP-005_12 - NerPharMa - Eribulin Mesylate (P4114623) MASTER FORMULA SF 1 07SS03*Fa Versione 6 del Giugno 2012 | Italian ->Korean |
Eisai Korea |
NerPharMa - Challenge Test Protocol Doc nOINfCT 001 VERS.01 - Apparecchíatura: Línea dí rípartízíone MAR Matrícola: IN/LR/01 | Italian ->Korean |
Eisai Korea |
NerPharMa - Eribulin Mesylate (P4114623) - Injectables | Italian ->Korean |
Eisai Korea |
The Korean generic drug pharmaceutical industry will cover the costs of KRW 4 billion for the clinical reassessment, and EISAI will defray the additional costs. June 19, 2012 | Korean ->English |
Eisai Korea |
Proposition for joint clinical reassessment of DONEPEZIL HCI - Proposed date: Friday, May 25, 2012 | Korean ->English |
Eisai Korea |
KOREA PHARMACEUTICAL MANUFACTURERS ASSOCIATION Public Document - Korean pharmaceutical industry’s opinion about the joint participation in the clinical reassessment of DONEPEZIL HCI | Korean ->English |
Eisai Korea |
DAEWOONG Pharmaceutical Co., Ltd. - Agreement for Joint Clinical Trail | Korean ->English |
Eisai Korea |
DAEWOONG Pharmaceutical Co, Ltd.- Submission of application form and relevant documents for the drug re-assessment of items subject to the drug clinical trial | Korean ->English |
Eisai Korea |
Astellas Pharma GmbH, Germany / - Akademie der Wissenschaften der DDR Forschungszentrum für Molekularbiologie und Medizin Zentralinstitut für Mikrobiologie und experimentelle Therapie Jena Abt. Pharmakologie und Toxikologie - Subchronische Toxizitatsunter | German->Korean |
Eisai Korea |
Astellas Pharma GmbH, Germany / - CYTOSTASAN - Chrronische Toxizitätsprüfung der Substanz Cytostasan im Vergleich (VS) zu Chlorambuzi1 an der Ratte - August 1985 | German->Korean |
Eisai Korea |
Astellas Pharma GmbH, Germany / - RBM 0011971423 - BENDAMUSTIN HYDROCHLORIDE MAXIMUM TOLERATED DOSE AND FIVE DAY REPEATED DOSE STUDY – IN DOGS BY INTRA VENOUS INFUSION Report No.: 0640.98.C2.01 29 July 1998 | English ->Korean |
Eisai Korea |
Astellas Pharma GmbH, Germany / - RBM 003/974052 - BENDAMUSTIN HYDROCHLORIDE TOXICITY TO DOGS BY DAIL Y INTRA VENOUS INFUSION OVER A MINIMUM OF THREE 4-DAY CYCLES EACH FOLLOWED BY A PERIOD WITHOUT TREATMENT OF UPT031DAYS Report No.: 0640.98.C2.02 27 Jul | English ->Korean |
Eisai Korea |
Ribomustin Test 1 M4/ 4.2.3.3.1.1 Huntingdon-KPG-017-002582-ID639 - BENDAMUSTIN HYDROCHLORIDE BACTERIAL MUTATION ASSAY - Klinge Internal Report No. 0640.00.C4.01 - 12 MAY 2000 | English ->Korean |
Eisai Korea |
Ribomustin Test 1 M4/ 4.2.3.3.1.2 Huntingdon-KGP-018-002634-ID640 - BENDAMUSTIN HYDROCHLORIDE IN VITRO MAMMALIAN CHROMOSOME ABERRATION TEST IN HUMAN LYMPHOCYTES - Klinge Internal Report No. 0640.00.C4.02 - 6 JULY 2000 | English ->Korean |
Eisai Korea |
Astellas Pharma GmbH, Germany / - KGP 014/002753 - BENDAMUSTIN HYDROCHLORIDE PERIVENOUS & INTRA-ARTERIAL TOLERANCE STUDY IN ’fHE RABBIT– Report No.: 0640.00.C14.01 26 September 2000 | English ->Korean |
Eisai Korea |
Korea Food & Drug Administration - Narcotic and Neuropharmacological Drug Team Drug Evaluation Dept. - Guideline on Clinical Investigation of Medical Products for Dementia of Alzheimer’s Type - May 2007 | Korean ->English |
Eisai Korea |
Food and Drug Integrated Information Service Korea Food & Drug Administration (KFDA) - License for drug import item [Halaven (Eribulin mesylate)] Aug. 17, 2012 | Korean ->English |
Eisai Korea |
Alzheimer's research & therapy - Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer’s disease - Steven H Ferris1*, Frederick A Schmitt2, Judith Saxton3, Sharon Richardson4, Joan Mackell5, Yijun Sun6 and Yik | English ->Korean |
Eisai Korea |
RCC - CCR STUDY NUMBER 831200 - CHROMOSOME ABERRATION TEST IN HUMAN L YMPHOCYTES IN VITRO WITH HYDROXY-BENDAMUSTINE (HP1) FINAL REPORT June 28, 2004 | English ->Korean |
Eisai Korea |
FINAL REPORT - Study Title CEP-18083: Rat Bone Marrow Erythrocyte Micronucleus Test - Test Article CEP-18083 Authors Ljubica Krsmanovic, Ph.D. Tawney Huston, B.S. Study Completion Date 03 August 2007 | English ->Korean |
Eisai Korea |
Annals of Oncology 19 (Supplement 8): viii63–viii76, 2008 - breast cancer, advanced | English ->Korean |
Eisai Korea |
Annals of Oncology 21 (Supplement 8): viii96–viii121, 2010 - breast cancer, advanced | English ->Korean |
Eisai Korea |
BREAST CANCER—METASTATIC BREAST CANCER - 1081 General Poster Session (Board #27H), Sat, 2:00 PM - 6:00 PM Efficacy and safety of eribulin in Japanese patients (pts) with advanced breast cancer. 2010 American Society of Clinical Oncology | English ->Korean |
Eisai Korea |
Clinical Breast Cancer April 2010 - Phase III Trials of Eribulin Mesylate (E7389) in Extensively Pretreated Patients With Locally Recurrent or Metastatic Breast Cancer - Clin Cancer Res 2009;15:4207-4212. Published online June 9, 2009. | English ->Korean |
Eisai Korea |
Clinical Breast Cancer 2009 - A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies Sanjay Goel, Alain C. Mita, Monica Mita, et al. Clin Cancer Res 2009;15:420 | English ->Korean |
Eisai Korea |
JOURNAL OF CLINICAL ONCOLOGY ORIGINAL REPORT - Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane - JUNE 20 2009 | English ->Korean |
Eisai Korea |
JOURNAL OF CLINICAL ONCOLOGY ORIGINAL REPORT -Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine SEPTEMBER 1 2010 | English ->Korean |
Eisai Korea |
Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study - Lancet 2011 | English ->Korean |
Eisai Korea |
NICE STA report - 9.3 Appendix 3: Quality assessment of RCT(s) Study name: EMBRACE (Study 305) | English ->Korean |
Eisai Korea |
Seoul Regional Korea Food & Drug Administration - Instructions for submission of imported drugs’ overseas factories history card - 16 Feburary 2012 | Korean ->English |
Eisai Korea |
Korea Food and Drug Administration Biopharmaceuticals Safety Bureau Evaluation Guide for Pharmaceuticals-65 - Guidance for Clinical Pharmacology Studies - in Healthy Adults - November 2011 | Korean ->English |
Eisai Korea |
DAEWOONG Pharmaceutical Co, Ltd.- Packing Instruction and Record Book - Product Name : E2020K082418A | Korean ->English |
Eisai Korea |
DAEWOONG Pharmaceutical Co, Ltd.- Packing Instruction and Record Book - Product Name : E2020K082418O | Korean ->English |
Eisai Korea |
DAEWOONG Pharmaceutical Co, Ltd.- Packing Instruction and Record Book - Product Name : E2020K082418P | Korean ->English |
Eisai Korea |
DAEWOONG Pharmaceutical Co, Ltd.- Packing Instruction and Record Book - Product Name : Aricept Tablet | Korean ->English |
Eisai Korea |
DAEWOONG Pharmaceutical Co, Ltd.- Packing Instruction and Record Book - Product Name : Aricept Tablet 10 mg Placebo | Korean ->English |
Eisai Korea |
DAEWOONG Pharmaceutical Co, Ltd.- Packing Instruction and Record Book - Product Name : Aricept Tablet Placebo | Korean ->English |
Eisai Korea |
4.2.3.2 反復投与毒性試験 - Final Report - 15-Week Intermittent Intravenous Infusion Toxicity and Toxicokinetic Study with CEP-18083 (Bendamustine) in Rats with a 4-Week Recovery Period Thomas E. Ryan, BS Diplomate, ABT - 24 August 2007 | English ->Korean |
Eisai Korea |
4.2.3.2 反復投与毒性試験 - 5-Day Intermittent Intravenous Infusion Dose Range Finding Toxicity Study with CEP-18083 (Bendamustine) in Rats with a 16-Day Recovery Period - Thomas E. Ryan, BS, Diplomate, ABT 22 May 2007 | English ->Korean |
Eisai Korea |
Temmler Werke GmbH - Verpackungsanweisung/-protokoll - SYMBENDA 100 MG | German->Korean |
Eisai Korea |
Temmler Werke GmbH - Technische Hinweise zur Verpackungsvorschrift - SYMBENDA 100 MG 1 DEL/KR RMF 30.09.2011 | German->English |
Eisai Korea |
Temmler Werke GmbH - München - Retrospektive Oualifizierung (10) Hochleistungsdrucker Leibinger Typ JET 2 Serien-Nummer 06210249 - 04.2008 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - Requalifizierung (IQIOQ) Etikettierrnaschine Schðfer SE 180- 08.2009 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - Qualifizierungsplan Etikettiermaschine Schäfer SE 180 - 07.2009 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - Requalifizierung Wiederinbetriebnahme Codelesegerät und Etikettenanwesenheitskontrolle für Schäfer Etikettierer - 07.2010 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - Verkürzte Qualifizierung (10/00) Inspektionsbox Nr. 2 für die visuelle Kontrolle von Bendamustin Vials - 12.2011 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - Prospektive Oualifizierung Kompaktschrumpfgerät Kopp TMC 58 - 07.2012 | German->Korean |
Eisai Korea |
Regulations for Designation of Orphan Drugs - KFDA Notification No. 1998- 23 (established on April 16, 1998) ~ KFDA Notification No. 2013- 127 (revised on April 5, 2013) | Korean ->English |
Eisai Korea |
Form No. 1 - Application Form for Orphan Drug / Application Form for Orphan Drug in the Development Stage | Korean ->English |
Eisai Korea |
Form No. 2 - Letter of Recommendation for Designation of Orphan Drug / Letter of Opinion for Recommendation for Designation of Orphan Drug in the Development Stage | Korean ->English |
Eisai Korea |
Form No. 3 - Designation of Orphan Drug in Development Stage | Korean ->English |
Eisai Korea |
Appendix 1 - Designation of Rare Medications, Appendix 2 - Designation of Rare Medications Under Development | Korean ->English |
Eisai Korea |
Cenexi-laboratoires Thissen - PRELEVEMENTS DE ROUTINE POUR CONTROLES MICROBIOLOGIQUES ET PHYSICO-CHIMIQUES DES EAUX PURIFlEES ET EAUX NON NORMA TIVES SOP S 000-020/06 Date d’application: 0 5 AOUT 2013 - KFDA answers documentation A | French->Korean |
Eisai Korea |
Cenexi-laboratoires Thissen - RECEPTION DES MA TIERES CHIMIQUES, DES PRODUITS VRACS ET SEMI-CONDITIONNES SOP E 2100-001112 Date d’application: 07 AOUT 2013 - KFDA answers documentation C | French->Korean |
Eisai Korea |
Cenexi-laboratoires Thissen - FICHE DE PRELEVEMENT SOP S 000-018 Date d’application: 01 JUIL 2013 - KFDA answers documentation D | French->Korean |
Eisai Korea |
Cenexi-laboratoires Thissen - RECEPTION DU MATERIEL DE CONDlTIONNEMENT SOP E 1000-001110 Date d’application: 07 AOUT 2013 - KFDA answers documentation F | French->Korean |
Eisai Korea |
Cenexi-laboratoires Thissen - Liste des foumisseurs agréés - Date d’application: 3/07//2013 - KFDA answers documentation G | French->Korean |
Eisai Korea |
Agenxia Italiana del Farmaco (AIFA) Roma 03 augusto 2012 - Registri Farmaci sottoposti a Monitoraggio - Procedura di Gestione Rimborsi Payment by result - Specialità HALAVEN® | Italian ->Korean |
Eisai Korea |
Cenexi-laboratoires Thissen - QUALIFICATION DE L’AERAULIQUE DES ZONES CLASSEES SOP G 000-143/04 - Date d’application: 21 DEC 2012 - KFDA answers documentation B | French->Korean |
Eisai Korea |
Cenexi-laboratoires Thissen - P&ID production et distribution equ zone 900 - 2010/0007-J | French->Korean |
Eisai Korea |
Cenexi-laboratoires Thissen - PRELEVEMENTS DE ROUTINE POUR CONTROLES lICROBIOLOGIQUES ET PHYSICO-CHIMIQUES DES EAUX PURIFIEES ET EAUX NON NORMATIVES SOP S 000-020/06 Date d’application: 05 AOUT 2013 - KFDA answers documentation | French->Korean |
Eisai Korea |
Cenexi-laboratoires Thissen - RECEPTION DES MATIERES CHIMIQUES, DES PRODUITS VRACS ET SEMI-CONDITIONNES SOP E 2100-001112 - Date d’application: 07 AOUT 2013 - KFDA answers documentation | French->Korean |
Eisai Korea |
Clinical Trial Materials - E2007 SYNOPSIS 53 Files | English ->Korean |
Eisai Korea |
Cenexi-laboratoires Thissen - CONTROLE DELAVAPEURPROPRE SOP : C 000-029/07 - Date d’application: 15 NOV. 2013 - KFDA answers documentation E2-c | French->Korean |
Eisai Korea |
Cenexi-laboratoires Thissen - CONTRÔLE DES DÉSINFECT ANTS UTILISÉS EN PRODUCTION CLASSE A ET B SOP C 000-082/01 Date d’application: 4 NOV. 2013 - KFDA answers documentation F1 | French->Korean |
Eisai Korea |
Summary of the main contents of suggestion - 1. Opinions of pre-announcement of legislation and administration 2. Suggestion for the risk sharing system 3. Rationalization method for the value of new medicine | Korean ->English |
Eisai Korea |
Study Protocol - Protocol ver 1.0 27 Sep 2013 - A predictive capacity of power Doppler for patients presenting persistent arthritis | English ->Korean |
Eisai Korea |
Clinical Study Report - A Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) Phase 3 Study C18083/3070 | English ->Korean |
Eisai Korea |
Cenexi-laboratoires Thissen - QUALIFICATION DE L'’'AERAULIQUE DES ZONES CLASSEES SOP G 000-143/04 Date d’application: 21 DEC 2012 - #F2b - smoke test report. | French->Korean |
Eisai Korea |
Cenexi-laboratoires Thissen - Results of sterility tests on disinfectants - ESSAIS DE STERILlTE SOP MC 940-001/10 Date d’application: 17 JUIN 2013 - KFDA answers documentation | French->Korean |
Eisai Korea |
Cenexi-laboratoires Thissen - F2b Smoke test qualification report | French->Korean |
Eisai Korea |
Cenexi-laboratoires Thissen - ESSAIS DE STERILlTE SOP MC 940-001/11 Date d’application: 06 JAM 2014 - KFDA answers documentation | French->Korean |
Eisai Korea |
Activity Test Materials - E2007 SYNOPSIS 75 Files | English ->Korean |
Eisai Korea |
Korea Food & Drug Administration Public Document - Notice of civil petitions processing measure related to itemized pre-GMP evaluation check of imported drug products | Korean ->English |
Eisai Korea |
Temmler Werke GmbH - München - Steuerung von Produktänderungen (Regulatory Change Control) SOP Nr. 02.014 - 01.07.2012 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - Ablaufschema bei Produktänderungen Anlage 2 zu SOP 02.014 vom 01.07.2012 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - Personalhygiene in Produktion und CTM (Personnel hygiene in production and CTM) SOP Nr. 03.010 - 01.09.2013 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - Pausenordnung Bulkherstellung BT 56 und Abfüllung & Verpackung BT 30 SOP Nr. 03.010_a2 - September 2013 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - INTERNER SCHRIFTVERKEHR QS-Bearbeitungs-Nr.: TÄ Anlage 1 zur SOP 04.040 vom 01.01.2010 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - Handverpackung (Manual Packaging) SOP Nr. 07.015 - 01.03.2014 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - Anlage 4 zur SOP 08.011 vom 01.11.2012 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - Bewertungsbogen eines neuen Rohstoffes / Zwischenproduktes Anlage 2 zur SOP 08.029 vom 01.04.2012 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - Aktualisierung des Qualifizierungsstatus eines Lieferanten Anlage 3 zu SOP 08.029 vom 01.04.2012 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - Steuerung von Änderungen bei technischen Anlagen (Change Control of premises, utilities and equipment) SOP Nr. 04.040 - 01.01.2010 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - In Prozess Kontrolle 53: Fertigwarenkontrolle (In process control no. 53: Control of finished goods) SOP Nr. 07.166 - 01.03.2014 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - In Prozess Kontrolle 55: Codeleser – Funktionskontrolle (In process control no. 55: code inspectors -function control) SOP Nr. 07.168 - 01.12.2010 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München -In Prozess Kontrolle 61: Kontrolle Teilfertigpackungen (Flaschen, etikettierte Dosen, Dosen Twist-off, Röhrchen und Vials) (In process control no. 61: Control of partial finished goods (bottles, labelled cans, cans twist-off, | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - Probenahme, Prüfung und Statusvergabe bei Packmitteln (Sampling, testing and approval of packaging material) SOP Nr. 08.027 - 01.04.2012 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - Interner Schriftverkehr Verpackungstechnik (VPT) PC- Fax.-Nr.: 5485 Anlage 4 zur SOP 08.027 vom 01.04.2012, Anlage 5 zur SOP 08.027 vom 01.04.2012 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - Bearbeitung von technischen pharmazeutischen Reklamationen von Produkten von Auftraggebern (Treatment of technical pharmaceutical complaints of products of contractors) SOP Nr. 08.020 - 01.11.2010 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - Lieferantenqualifizierung Rohstoffe und Zwischenprodukte und Festlegung des Prüfumfanges (Supplier assessment raw materials, intermediates and determination of analytical testing scale) SOP Nr. 08.029 - 01.04.2012 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - Freigabe eines neuen Lieferanten (SOP 08.029) Anlage 1 zu SOP 08.029 vom 01.04.2012 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - Vorgehensweise bei der Qualifizierung und Bewertung von Packmittellieferanten (Qualification and evaluation of suppliers for packaging material) SOP Nr. 08.061 - 01.03.2012 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - Fragebogen für Hersteller pharmazeutisch verwendeter Packmittel und Medizinprodukte SOP Nr. 08.061_a1 - 01.03.2012 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - Qualifizierung eines Packmittel-Lieferanten Anlage 2 zu SOP 08.061 vom 01.03.2012 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - Prüfergebnisse außerhalb der Freigabe-Spezifikation (Out-of-Specification results) SOP Nr. 08.038 - 01.09.2013 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - OOS-ERGEBNIS – UNTERSUCHUNGSBERICHT Anlage 2 zur SOP 08.038 vom 01.09.2013, Seite 1 von 5 OOS-Nr.: | English ->Korean |
Eisai Korea |
Temmler Werke GmbH - München - GMP-Training, Training in Arbeitssicherheit und Umweltschutz (Training of personnel) SOP Nr. 03.015 - 01.11.2013 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - Reinigung und Desinfektion in der Produktion, in der Pharmazeutischen Entwicklung, in der Herstellung CTM und im Lager und Versand SOP Nr.04.010 - 01.03.2013 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München -Maßnahmen bei Fehlern und Abweichungen in den Herstellungsbereichen und bei Auftragsherstellern (Measures in case of defects and deviations in the manufacturing areas and at contract manufacturers) SOP Nr.07.029- 01.11.2013 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München -Fehler- und Maßnahmenkatalog Herstellung Anlage 2 zur SOP 07.029 vom 01.11.2013 / Fehler- und Maßnahmenkatalog Verpackung Anlage 3 zur SOP 07.029 vom 01.11.2013 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München -Fehler- und Maßnahmenkatalog Herstellung CTM Anlage 4 zur SOP 07.029 vom 01.11.2013 / LOGBUCH ABWEICHUNGEN TECHNISCHE DEFEKTE |
German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - Vorgehensweise bei der Prüfung und Dokumentation von Rohstoffen (System for the testing and documentation of raw material) SOP Nr. 08.011 - 01.11.2012 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - Prüfergebnisse außerhalb der StabilitätsSpezifikation (Out-of-shelflife specification results) SOP Nr. 08.056 - 01.04.2012 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - INTERNER SCHRIFTVERKEHR QS-Bearbeitungs-Nr. TÄ 10-385 Anlage 1 zur SOP 04.040 vom 01.01.2010 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - In Prozess Kontrolle 53: Fertigwarenkontrolle (In process control no. 53: Control of finished goods) SOP Nr. 07.166 - 01.03.2014 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München - In Prozess Kontrolle 55: Codeleser – Funktionskontrolle (In process control no. 55: code inspectors -function control) SOP Nr. 07.168 - 01.12.2010 | German->Korean |
Eisai Korea |
Temmler Werke GmbH - München -In Prozess Kontrolle 61: Kontrolle Teilfertigpackungen (Flaschen, etikettierte Dosen, Dosen Twist-off, Röhrchen und Vials) SOP Nr. 07.176 - 01.03.2014 | German->Korean |
Eisai Korea |
Clinical Trial Materials - 14C-E2007 SYNOPSIS 24 Files | English ->Korean |
Eisai Korea |
National Institute of Food and Drug Safety Evaluation (NIFDSE) Public Document - The first review results of drug’s prior review [Eisai Korea Inc. – Lenvima | Korean ->English |
Eisai Korea |
National Institute of Food and Drug Safety Evaluation (NIFDSE) Public Document - Appendix 2 - low diagram for determining the necessity of a Bridge study | Korean ->English |
Eisai Korea |
Health Insurance Review & Assessment Service (HIRA) - Valid Drug Barcode Manual - - Relating to serial number inclusion in a prescription drug barcode - May 30, 2014 | Korean ->English |
Eisai Korea |
MHRA GMP INSPECTION REPORT : GMP INSPECTION OF Eisai manufacturing Limited - GMP/GDP/IMP 32301/726219-0004 Inspection date: 10th_12th Julv 2012 | English ->Korean |
Eisai Korea |
Ministry of Government Legislation Korea Law Service Center - Regulations on Drug Identification Labeling [Enforced Dec. 22, 2009] [Food and Drug Safety Administration Notification No. 2009-205, Dec. 22, 2009, Revised by other laws] Food And Drug Safety | Korean ->English |
Eisai Korea |
FULL-LENGTH ORIGINAL RESEARCH - Perampanel for adjunctive treatment of partial-onset seizures: A pooled dose–response analysis of phase III studies - *Lynn D. Krame | English ->Korean |
Eisai Korea |
CNS Drugs (2013) 27:817–827 - Systematic Review and Meta-Analysis of the Efficacy and Safety of Perampanel in the Treatment of Partial-Onset Epilepsy - Warrington W. Q. Hsu • C. W. Sing • Ying He • Alan J. Worsley • Ian C. K. Wong • Esther W. Chan | English ->Korean |
Eisai Korea |
Epilepsia, 54(8):1490–1497, 2013 - FULL-LENGTH ORIGINAL RESEARCH - Concentration–effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures *Barry E. Gidal, †Jim Ferry, ‡Oneeb Majid, and ‡Ziad Hussein | English ->Korean |
Eisai Korea |
Epilepsia, 54(8):1481–1489, 2013 - FULL-LENGTH ORIGINAL RESEARCH -Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies - *Bernhard J. Steinhoff, †Elinor Ben-Menachem, ‡ | English ->Korean |
Eisai Korea |
European Journal of Neurology 2013, 20: 1204–1211 - The adverse event profile of perampanel: meta-analysis of randomized controlled trials - G. Zaccaraa, F. Giovannellia, M. Cincottaa, A. Verrottib and E. Grilloc | English ->Korean |
Eisai Korea |
Epilepsy Research (2013) 103, 31 - 44 : Clinical efficacy and safety of the newer antiepileptic drugs as adjunctive treatment in adults with refractory partial-onset epilepsy: A meta-analysis of randomized placebo-controlled trials - Lan Gaoa, Li Xiab, Fe | English ->Korean |
Eisai Korea |
Neuropsychiatric Disease and Treatment - Dovepress open access to scientific and medical research REVIEW : Profile of perampanel and its potential in the treatment of partial onset seizures – 10 May 2013 | English ->Korean |
Eisai Korea |
Epilepsia, 54(1):126–134, 2013 - FULL-LENGTH ORIGINAL RESEARCH - Perampanel, a selective, noncompetitive a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: Interim results | English ->Korean |
Eisai Korea |
Epilepsia, 54(1):117–125, 2013 - FULL-LENGTH ORIGINAL RESEARCH - Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global phase III study 305 - *Jacqueline A. French, yGregory L. Krauss, zBernhar | English ->Korean |
Eisai Korea |
Supplemental data at www.neurology.org - Adjunctive perampanel for refractory partial-onset seizures - Randomized phase III study 304 Jacqueline A. French, MD Gregory L. Krauss, MD Victor Biton, MD David Squillacote, MD Haichen Yang, MD Antonio Laurenza, | English ->Korean |
Eisai Korea |
American Academy of Neurology - Randomized phase III study 306 - Adjunctive perampanel for refractory partial-onset seizures - G.L. Krauss, MD J.M. Serratosa, MD, PhD V. Villanueva, MD, PhD M. Endziniene, MD, PhD Z. Hong, MD J. French, MD H. Yang, MD D. S | English ->Korean |
Eisai Korea |
Acta Neurol Scand 2012: 125: 8–15 - Tolerability and safety of perampanel: two randomized dose-escalation studies - Krauss GL, Bar M, Biton V, Klapper JA, Rektor I, Vaiciene-Magistris N, Squillacote D, Kumar D. | English ->Korean |
Eisai Korea |
Epilepsy Research (2014) 108, 986 - 988 : A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria Bernhard J. Steinhoffa,∗, Hajo Hamerb, Eugen Trinkac, Andreas Schulze-Bonhaged, Christian Biene, Thomas Mayerf, Chri | English ->Korean |
Eisai Korea |
Epilepsia, 55(Suppl.1):16–18, 2014 - First clinical experiences with perampanel—The Kork experience in 74 patients - Bernhard J. Steinhoff, Matthias Bacher, Thomas Bast, Reinhold Kornmeier, Christoph Kurth, Julia Scholly, Anke M. Staack, and Ilona Wisniew | English ->Korean |
Eisai Korea |
Rote Liste - HALAVEN® 0,44 mg/ml Injektionslösung Zus.: 1 ml enth.: Eribulinmesylat (entspr. 0,44 mg Eribulin) - 2014 by Rote Liste Service GmbH | German->Korean |
Eisai Korea |
Annals of Oncology 23: 1441–1448, 2012 - A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer - K. Aogi1*, H. Iwata2, N. Masuda3, H. Mukai4, M. Yoshida5, Y. Rai6, K. Taguchi7, Y. Sasaki8 & S. Takashima1 | English ->Korean |
Eisai Korea |
Journal of Cancer 2014, Vol. 5 Research Paper - Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study - Teresa Gamucci1*, Andrea Michelotti2*, Laura Pizzuti3, Lucia Mentuccia1, Elisabetta Landucci2, Isabel | English ->Korean |
Eisai Korea |
Journal of Solid Tumors, 2013, Vol. 3, No. 1 CASE REPORT - Eribulin monotherapy in a patient with heavily pretreated metastatic breast cancer: Case study and review of the literature - Fariborz Gorouhi, Stefan Glück | English ->Korean |
Eisai Korea |
Acta Oncologica, 2014; Early Online: 1–3 - Treatment with eribulin (halaven) in heavily pre-treated patients with metastatic breast cancer - MAJA LYNGE RASMUSSEN 1 , GABOR LIPOSITS 2 , SUBETHINI YOGENDRAM 1 , ANDERS BONDE JENSEN 1 , S Ø REN LINNET 2 & SVE | English ->Korean |
Eisai Korea |
Academia-Pharma Intersect: Breast Cancer - Eribulin Monotherapy in Patients Aged 70 Years and OlderWith Metastatic Breast Cancer - HYMANMUSS,a JAVIERCORTES,b LINDA T.VAHDAT,c FATIMACARDOSO,dCHRIS TWELVES,e JANTIENWANDERS,fCORINA E.DUTCUS,g JAYYANG,h SETH | English ->Korean |
Eisai Korea |
Future Oncology RESEARCH ARTICLE - Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital - Paola Poletti*1, Valentina Ghilardi1, Luca Livraghi1, Laura Milesi1, Elena Rota Caremoli1 & C | English ->Korean |
Eisai Korea |
Clinical Study Report E2007-G000-235 - STUDY SYNOPSIS | English ->Korean |
Eisai Korea |
Clinical Study Report E2007-G000-307 - STUDY SYNOPSIS | English ->Korean |
Eisai Korea |
NDA 20-237/S012 - SALAGEN® Tablets (pilocarpine hydrochloride) - Each 5 mg SALAGEN® Tablet for oral administration contains 5 mg of pilocarpine hydrochloride. | English ->Korean |
Eisai Korea |
Novartis Pharmaceuticals UK Ltd - Salagen 5 mg Film Coated Tablets - (eMC) - Summary of Product Characteristics last updated on the eMC: 20/12/2012 | English ->Korean |
Eisai Korea |
e-CPS : e-CPS : Drug Monographs - Salagen (pilocapine HCL) Cholinomimetic Agent Phizer DIN(s): 02216345 Date of Revision: May 27 2013 | English ->Korean |
Eisai Korea |
Salagen® NOVARTIS PHARMA AMZV Filmtabletten à 5 mg. | German->Korean |
Eisai Korea |
30 009 (Novartis Pharma) Salagen 5 mg Filmtabletten Rp ATC: N07AX01 Zus.: 1 Filmtbl. enth.: Pilocarpin HCL | German->Korean |
Eisai Korea |
SALAGEN Altri farmaci del sistema nervoso - Sostanze medicineali pilocarpina cloridrato (FU) ATC N07AX01 | Italian ->Korean |
Eisai Korea |
SALAGEN® pilocarpine FORMES/Présentations | French->Korean |
Eisai Korea |
pilocarpine hydrochloride(JP) [필로카핀염산염] 녹내장 치료제, 구강건조증상 개선제 131, 239 - 정제 살라겐 2013년 10월 개정, 점안액 산필로 2013년 7월 개정 | Japanese->Korean |
Eisai Korea |
Application Form / Compliance Self Check List / Date (yyyy-mm-dd): 2014-10-10 | Korean ->English |
Eisai Korea |
Regulations on Expense and Expenditure Management ̶ Revised on Apr. 1, 2014 | Korean ->English |
Eisai Korea |
Accounting Standards - Amended on Apr, 1, 2014 | Korean ->English |
Eisai Korea |
NDA 20-237/S012 - SALAGEN® Tablets (pilocarpine hydrochloride) - DESCRIPTION: SALAGEN® Tablets contain pilocarpine hydrochloride, a cholinergic agonist for oral use. | English ->Korean |
Eisai Korea |
Fachinformation des Arzneimittel-Kompendium der Schweiz® - Salagen® Novartis Pharma Schweiz AG Galenische Form und Wirkstoffmenge pro Einheit Filmtabletten à 5 mg. | German ->Korean |
Eisai Korea |
CLINICAL STUDY REPORT - Study Protocol Number E2020-J081-341 | English ->Korean |
Eisai Korea |
CLINICAL STUDY REPORT - Study Protocol Number E2020-J081-431 | English ->Korean |
Eisai Korea |
CLINICAL STUDY REPORT - Study Protocol Number E2020-J081-432 | English ->Korean |
Eisai Korea |
E2020 Statistical Analysis Report - Population Pharmacokinetics Analysis (Revised) - Study Title: Population Pharmacokinetics Analysis of E2020 using Data from E202-J081-162 and E2020-J081-231 Trials Protocol Numbers: E202-J081-162, E202-J081-231 | English ->Korean |
Eisai Korea |
Federal Register / Vol. 78, No. 204 / Tuesday, October 22, 2013 / Proposed Rules - DEPARTMENT OF JUSTICE Drug Enforcement Administration - 21 CFR Part 1308 [Docket No. DEA–374] Schedules of Controlled Substances: Placement of Perampanel into Schedule III | English ->Korean |
Eisai Korea |
PinneyAssociates, Inc. - Review of the FDA/DEA Rationale for Placement of Perampanel in Schedule III | English ->Korean |
Eisai Korea |
Global Compliance Survey - CHINA & ASIA: TOTAL 21 QUESTIONS REVISED AS OF JUNE 24, 2015 | English ->Korean |
Eisai Korea |
POPULATION ANALYSIS REPORT - CPMS- E2020-001R-v2 - Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Donepezil in Subjects with Dementia with Lewy Bodies (E2020-J081-341) Date: 5 February 2013 | English ->Korean |
Eisai Korea |
Clinical Study Report E2020-E044-316 - Donepezil (Aricept®) Protocol Number: E2020-E044-316- 16 February 2010 | English ->Korean |
Eisai Korea |
A. Applicant’s Opinion O Regarding the Adequacy of Reimbursement Regarding Insurance Reimbursement Basis O The Requested Price by Pharmaceutical Company B. Evaluation Results O Reimbursement Criteria (Proposal) C. Evaluation Criteria O Necessity for Medic | Korean ->English |
Eisai Korea |
Aricept 2.5 CLINICAL OVERVIEW | English ->Korean |
Eisai Korea |
2016 Guideline for the Handling of Civil Petitions Pertaining to Pre-GMP Assessment for Import Drugs | Korean ->English |
Eisai Korea |
Fachinformation des Arzneimittel-Kompendium der Schweiz® - Ribomustin® Mundipharma Medical Co.- Galenische Form und Wirkstoffmenge pro Einheit Lyophilisat für Infusionslösung. Durchstechflaschen zu 25 mg und 100 mg Bendamustinhydrochlorid. | German ->Korean |
Eisai Korea |
TLV (TANDVÅRDS- OCH LÄKEMEDELSFÖRMÅNSVERKET) SAKEN Ansökan inom läkemedelsförmånerna SÖKANDE Eisai AB - BESLUT - Lenvima Hårda kapslar 4 mg / 10 mg | Swedish->Korean |
Eisai Korea |
Fachinformation des Arzneimittel-Kompendium der Schweiz® - Halaven® Eisai Pharma AG AMZV Indikationen/Anwendungsmöglichkeiten / Dosierung/Anwendung | German ->Korean |
Eisai Korea |
Halaven® E7389 Activity Test materials Abstract - A673 | English ->Korean |
Eisai Korea |
Halaven® E7389 Activity Test materials Abstract - SK-LMS-1 | English ->Korean |
Eisai Korea |
Summary of in Vivo Activity of Eribulin - Phase I - PPTP | English ->Korean |
Eisai Korea |
Summary of in Vivo Activity of Eribulin - Phase II - PPTP | English ->Korean |
Eisai Korea |
Activity Test Materials - E7389 SYNOPSIS 5 Files | English ->Korean |
Eisai Korea |
Korea Food and Drug Administration Drug Evaluation Department - Guideline to Setting Dissolution Specifications for Orally Administered Drug Products - Feb. 2005 | Korean ->English |
Eisai Korea |
Purified Water n.14.PD.001 + 16 files (Drawings) | Italian ->Korean |
Eisai Korea |
BioTrends - Statistische risultati dei Campionamenti 01/01/2015 - 31/12/2015 + 3 files [Air_Class A, PW_ST3_2015, Surfaces_Class A, WFI_ST3_2015] | Italian ->Korean |
Eisai Korea |
ORIGINAL ARTICLE—ALIMENTARY TRACT -Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled tri | English ->Korean |
Eisai Korea |
ORIGINAL ARTICLE - Multinational, double-blind, randomised, placebocontrolled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER* study - Kentaro Sugano, 1 Myung-Gyu Choi,2 J | English ->Korean |
Eisai Korea |
PHARMACOEPIDEMIOLOGY AND PRESCRIPTION - Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan - Choitsu Sakamoto . Kentaro Sugano . Shinichi Ota . Nobuhiro Sakaki .Shin’ichi Takahashi . | English ->Korean |
Eisai Korea |
Thrombosis Research - Impact of CYP2C19 Polymorphism and Proton Pump Inhibitors on Platelet Reactivity to Clopidogrel and Clinical Outcomes Following Stent Implantation - Seiji Hokimoto a,⁎, Michio Mizobe a, Tomonori Akasaka a, Yuichiro Arima a, Koichi Ka | English ->Korean |
Eisai Korea |
Clinical Trial Materials - AKUGAKU ZASSHI 130(12) 1743-1750 (2010) The Pharmaceutical Society of Japan | English ->Korean |
Eisai Korea |
Management Regulation of Fixed Assets - -Revised, October 1, 2016 | Korean ->English |
Eisai Korea |
Document Management Regulation - Revised November 1, 2016 | Korean ->English |
Eisai Korea |
Official Seal Management Regulation - Revised August 1, 2016 | Korean ->English |
Eisai Korea |
Fund Management Regulation - Revised September 1, 2016 | Korean ->English |
Eisai Korea |
National Institute of Food and Drug Safety Evaluation (NIFDSE) Gastroenterology and Antimicrobial Product Division, Drug Evaluation Department - Frequently Asked Questions Regarding Bridging Studies . December, 2015 | Korean ->English |
Eisai Korea |
Rote Liste - HALAVEN® 0,44 mg/ml Injektionslösung Zus.: 1 ml enth.: Eribulinmesylat (entspr. 0,44 mg Eribulin). | German ->Korean |
Eisai Korea |
HALAVEN 0,44 mg/ml sol inj Mise à jour : 19 Octobre 2016 - FORMES et PRÉSENTATIONS Solution injectable IV à 0,44 mg/mL (limpide ; aqueuse ; incolore) : Flacon de 2 mL, boîtes de 1 et de 6. | French->Korean |
Eisai Korea |
INFORMATION TRANSMISE SOUS L’AUTORITE DE L’ANSM - Lettre aux professionnels de santé -> INFORMATION PROVIDED UNDER THE AUTHORITY OF ANSM - Letter to healthcare professionals | French->English |
Eisai Korea |
Expenditure Management Regulations - Revised on November 1, 2016 | Korean ->English |
Eisai Korea |
Accounting Regulations - Revised on May 1, 2017 | Korean ->English |
Eisai Korea |
Levact 2.5 mg/ml powder for concentrate for solution for infusion - 4. Clinical particulars | English ->Korean |
Eisai Korea |
AHFS Drug Information 2017 | English ->Korean |
Eisai Korea |
Ribomustin® Mundipharma Medical Company - Indikationen/Anwendungsmöglichkeiten / Dosierung/Anwendung | German ->Korean |
Eisai Korea |
Drug Facts and Comparisons 2017 | English ->Korean |
Eisai Korea |
Drugs in Japan 2017 | Japanese->Korean |
Eisai Korea |
Linformatore Farmaceutico 2016 | Italian ->Korean |
Eisai Korea |
PDR 2017 - PHYSICIAN'S DESK REFERENCE - Partial translation | English ->Korean |
Eisai Korea |
Rote Liste - Levact® 2,5 mg/ml Pulver für ein Konzentrat zur Herstellung einer Infusionslösung - Zus.: 1 Durchstechfl. enth.: Bendamustin-HCl 25 mg/100 mg | German ->Korean |
Eisai Korea |
LEVACT 2,5 mg/ml pdre p sol diluer p perf Mise à jour : 06 Mars 2017 - Classification pharmacothérapeutique VIDAL : | French->Korean |
Eisai Korea |
Global Compliance Survey Asia - ASIA: TOTAL 66 QUESTIONS July 05, 2017 | English ->Korean |
Eisai Korea |
Newron Pharmaceuticals CTD 2.2 Introduction 2.2 Introduction | English ->Korean |
Eisai Korea |
Newron Pharmaceuticals CTD 2.3.I INTRODUCTION | English ->Korean |
Eisai Korea |
Newron Pharmaceuticals CTD 2.3.P DRUG PRODUCT | English ->Korean |
Eisai Korea |
Newron Pharmaceuticals CTD 2.3.R REGIONAL INFORMATION | English ->Korean |
Eisai Korea |
Newron Pharmaceuticals CTD 2.3.S DRUG SUBSTANCE | English ->Korean |
Eisai Korea |
Newron Pharmaceuticals CTD 2.4 Nonclinical Overview | English ->Korean |
Eisai Korea |
Newron Pharmaceuticals CTD 2.5 CLINICAL OVERVIEW | English ->Korean |
Eisai Korea |
Newron Pharmaceuticals CTD 2.6.1 Nonclinical Summary - Introduction | English ->Korean |
Eisai Korea |
Newron Pharmaceuticals CTD 2.6.2 Pharmacology Written Summary | English ->Korean |
Eisai Korea |
Newron Pharmaceuticals CTD 2.6.4 Pharmacokinetics Written Summary | English ->Korean |
Eisai Korea |
Newron Pharmaceuticals CTD 2.6.6 Toxicology Written Summary | English ->Korean |
Eisai Korea |
Newron Pharmaceuticals CTD 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods | English ->Korean |
Eisai Korea |
Newron Pharmaceuticals CTD 2.7.2 Summary of Clinical Pharmacology Studies | English ->Korean |
Eisai Korea |
Newron Pharmaceuticals CTD 2.7.3 Summary of Clinical Efficacy | English ->Korean |
Eisai Korea |
Newron Pharmaceuticals CTD 2.7.4 SUMMARY OF CLINICAL SAFETY | English ->Korean |
Eisai Korea |
Korea Food and Drug Administration Department of Drug Administration Drug Safety Bureau - Guidance on Drug Advertising and Specialty Medicine Information -For Inquiry- December 2016 | Korean ->English |
Eisai Korea |
Product Approval Transfer Agreement | Korean ->English |
GlaxoSmithKline Korea
| Company | Project | Language |
|---|---|---|
GlaxoSmithKline Korea |
Ovarian cancer; gynecologic cancer; pazopanib; GW786034 - Protocol Amendment Number: 01 - JUL-2010 | English ->Korean |
GlaxoSmithKline Korea |
Informed Consent Form - A Study to Evaluate Efficacy and Safety of Pazopanib Monotherapy in Asian Women Who Have Not Progressed After First-line Chemotherapy for Advanced Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma – An Extension Study to VEG1 | English ->Korean |
GlaxoSmithKline Korea |
GlaxoSmithKline Korea - LOCAL STANDARD OPERATING PROCEDURE - Procedure to update product safety information - LSOP No.. / Version : RA-002/02 - Review Date : Oct. 2012 | Korean ->English |
GlaxoSmithKline Korea |
Konkuk University School of Medicine - Te Korean Society of Gastroenterology DOI: 10.4166/kjg.2010/56/2/117 - A Case of Osteomalacia Related to Adefovir in a Patient with Chronic Hepatitis B | Korean ->English |
GlaxoSmithKline Korea |
Pusan National University School of Medicine - Asthma / Allergy Vol.30, No.2, Jun, 2010 - A Case of Ranitidine-Induced Anaphylaxis | Korean ->English |
GlaxoSmithKline Korea |
Ministry of Health and Welfare KFDA Regulation - 약국 및 의약품 등의 제조업·수입자 및 판매업의 시설기준령 시행규칙 - [시행 2011. 7. 7] [보건복지부령 제69호, 2011. 7. 7, 일부개정] | Korean ->English |
GlaxoSmithKline Korea |
KFDA Guideline - 의약품등의 안정성 시험 기준 / 시험성적서 | Korean ->English |
GlaxoSmithKline Korea |
Paradontax Fluorid data, Paradontax Fluorid Product Shipped Approval and Consumer Consulting contents | Korean ->English |
GlaxoSmithKline Korea |
Korea Testing & Research Institute Report | Korean ->English |
GlaxoSmithKline Korea |
Polident Q&A 保麗淨假牙清潔錠常見問題答問集 (폴리덴트 의치세정제에 관한 Q&A) Traditional Chinese into Korean | Traditional Chinese->Korean |
GlaxoSmithKline Korea |
Denture adhesive Medical Paper abstract (의치접착제 의학 논문 요약 자료) Traditional Chinese into Korean | Traditional Chinese->Korean |
GlaxoSmithKline Korea |
Polident 의치세정제 및 의치접착제 Product brochure - Traditional Chinese into Korean | Traditional Chinese->Korean |
GlaxoSmithKline Korea |
VIASYS Healthcare Clinical Services GmbH - MasterScope® CT - User‘s Manual - FFA109684/FFA109685/FFA109687 | English ->Korean |
GlaxoSmithKline Korea |
GlaxoSmithKline Korea - LOCAL STANDARD OPERATING PROCEDURE - Procurement Procedure - LSOP No./Version : LSOP-FNP-001-v3 - Review Date: January 2010 | Korean ->English |
GlaxoSmithKline Korea |
Nasal Device Leaflet (For GW685698 Nasal Spray Studies) - Patient Instructions for the Study Nasal Device | English ->Korean |
GlaxoSmithKline Korea |
Second Audit Result - 8. Audit Area | Korean ->English |
GlaxoSmithKline Korea |
保麗淨假牙黏著劑 (Polident denture adhesive cream) 對咬力之影響 Presentation data - Traditional Chinese into Korean | Traditional Chinese->Korean |
GlaxoSmithKline Korea |
假牙黏著劑之臨床應用 Presentation data - Traditional Chinese into Korean | Traditional Chinese->Korean |
GlaxoSmithKline Korea |
GlaxoSmithKline Korea - STANDARD OPERATING PROCEDURE - Consumer Healthcare Inventory Management (Inventory Management , Order, Return & Sample)- SOP No. / Version : KCXSCO002- Review Date : July 2008 | Korean ->English |
GlaxoSmithKline Korea |
Polident Adhesive brochure - Polident® Denture Adhesive gives your denture patients the confidence to get on with their lives | English ->Korean |
GlaxoSmithKline Korea |
Polident - 保麗淨假牙清潔錠 (폴리덴트 의치세정제) Presentation - Traditional Chinese into Korean | Traditional Chinese->Korean |
GlaxoSmithKline Korea |
Sensodyne toothpaste product manual - Traditional Chinese->Korean | Traditional Chinese->Korean |
GlaxoSmithKline Korea |
Polident - 保麗淨假牙黏着劑 (폴리덴트 의치접착제) Presentation - Traditional Chinese into Korean | Traditional Chinese->Korean |
GlaxoSmithKline Korea |
Brand Detailing Card & Brand Card - Sensodyne, Paradontax & Polident toothpaste | English ->Korean |
GlaxoSmithKline Korea |
Sensodyne, Paradontax & Polident toothpaste - Pre & Post test( for training) - 05.30.2007 | English ->Korean |
GlaxoSmithKline Korea |
GSK Sensodyne, Paradontax & Polident toothpaste FAQ - 30 May 2007 | English ->Korean |
GlaxoSmithKline Korea |
DENTINAL Hypersensitivity - Etiology, Nature, Diagnosis and Treatment - Brought to you by an Educational Grant from Block Drug Company Inc., makers of Sensodyne® | English ->Korean |
GlaxoSmithKline Korea |
Paradontax Key messages presentation | English ->Korean |
GlaxoSmithKline Korea |
Paradontax Detailing presentation | English ->Korean |
GlaxoSmithKline Korea |
Parodontax – the product Module 2 - January 2007 | English ->Korean |
GlaxoSmithKline Korea |
Paradontax - Disease Background Module 1 - January 2007 | English ->Korean |
GlaxoSmithKline Korea |
GSK DD training: WSFE Approach for DD Presentation data - Prepared on 2 Jun 2007 | English ->Korean |
GlaxoSmithKline Korea |
GSK DD Training: 1st Module – Dental Industry 17 May 2007 | English ->Korean |
GlaxoSmithKline Korea |
Daily FOCUS - Approaching a PI Disaster: “Preparation for Survival” - Dr. Dirk Poelaert, Director of the Influenza Division at GSK Biologicals is explaining previous pandemic influenza outbreaks, such as that of Spanish Influenza. 23-Feb-07 | Korean ->English |
GlaxoSmithKline Korea |
The Hankyoreh 21 - Vaccinations turn out to be human trials - Clinical trials on children by the multinational pharmaceutical giant GlaxoSmithKline (GSK) in the Volgograd Railway Hospital in Russia revealed in court - 10-Apr-07 | Korean ->English |
GlaxoSmithKline Korea |
Medical mensuration & quantitative method data | Korean ->English |
GlaxoSmithKline Korea |
IJSFA Admin Training Contents, IJSFA Full Reference Guide, Welcome IJSFA Admin Training data (Total: 3 files 42,637 Eng. words) | English ->Korean |
GlaxoSmithKline Korea |
GlaxoSmithKline plc (GSK) Survey data | English ->Korean |
GlaxoSmithKline Korea |
GSK Policy Human Biological Samples Policy POL-GSK-410 FINAL 26 March 2008 | English ->Korean |
Janssen Korea
| Company | Project | Language |
|---|---|---|
Janssen Korea |
Centocor Ortho Biotech Inc. - Steroidogenesis and disease progression in castration-resistant prostate canser - Recent insights into underlying celluar and molecular mechanisms for the oncologist | English ->Korean |
Janssen Korea |
Janssen Biotech Inc. - Metastatic Castration-resistant Prostate Canser (mCRPC) : An Androgen-Sensitive Disease | English ->Korean |
Janssen Korea |
How does chronic back pain influence quality of life in Koreans: A cross-sectional study - Yong-Soo Choi, Byung-Joon Shin, Dong-Jun Kim, Kyu-Yeol Lee, Ye-Soo Park, Kyu-Jung Cho, Jae-Hyup Lee | Korean ->English Proofreading |
Janssen Korea |
Risk factors for defervescence and success rate of empirical antifungal therapy in immunocompromised patients treated with intravenous itraconazole: multicenter, prospective, open-label, observational study in Korea - Soo-Jeong Kim1 | Korean ->English Proofreading |
Janssen Korea |
The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and plasma levels of itraconazole in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-l | Korean ->English Proofreading |
Janssen Korea |
Cancer patient pain severity is influenced by physician knowledge and compliance with cancer pain management guidelines: a nationwide survey in Korea | Korean ->English Proofreading |
Janssen Korea |
2017 JK Sales Incentive Policy | Korean ->English |
Janssen Korea |
Consentement éclairé écrit - pour l’utilisation des renseignements personnels | Korean ->French |
Janssen Korea |
Consentement éclairé écrit - pour l’utilisation des renseignements personnels | French->Korean |
Janssen Korea |
Consentement éclairé écrit pour l’étude des dérivés d’origine humaine | Korean ->French |
Janssen Korea |
Consentement éclairé écrit pour l’étude des dérivés d’origine humaine | French->Korean |
Janssen Korea |
INSTALLATION, OPERATIONAL QUALIFICATION PROTOCOL P/IO-LAT 16/040-01, P/IO-LAT 16/041-01, P/IOP-LAT 16/028-01 | Italian ->English |
Janssen Korea |
Protocol & Patient Information and Informed Consent Form | English ->Korean |
Janssen Korea |
Notice d’information et Formulaire de recueil du consentement | Korean ->French proofreading |
Janssen Korea |
Guselkumap Module2/5 sets 22 files | English ->Korean |
Janssen Korea |
MM Current State Patient Experience Map & MM Target State Patient Experience Map | English ->Korean |
Janssen Korea |
Batch Record data - TAPENTADOL PR 200MG FILM COATED TABLETS Blending Lot 1MG6531 etc. 10 files | Spanish->English |
Janssen Korea |
Year of the Fire Rooster - CGC message - final_170126 | English ->Korean |
Janssen Korea |
Consentement éclairé écrit / pour l’utilisation des renseignements personnels, Consentement éclairé écrit pour l’étude des dérivés d’origine humaine, Protocol: 56021927PCR3002 & CARTE PARTICIPANT- Etude Clinique | Korean ->French |
Janssen Korea |
Consentement éclairé écrit / pour l’utilisation des renseignements personnels, Consentement éclairé écrit pour l’étude des dérivés d’origine humaine, Protocol: 56021927PCR3002 & CARTE PARTICIPANT- Etude Clinique | French->Korean Back translation |
Janssen Korea |
Value provided by long-acting therapeutics actually experienced in real | Korean ->English |
Janssen Korea |
Batch Record data - Tapentadol HCl IR 50mg BLENDING SETUP RUN CLOSURE Lot 2AG7082 etc. 31 files | Spanish->English |
Janssen Korea |
MCL3001 Synopsis | English ->Korean |
Janssen Korea |
Janssen Korea - NS Current State Map - 0.1 & Janssen Korea - NS Target State Map - 0.1 | English ->Korean |
Janssen Korea |
Making Your Ideas BIGR Every Day Facilitator Guide FINAL | English ->Korean |
Janssen Korea |
JK innovation framework training_ver1.1/2. innovation ppt & SUN Index Check Sheet | Korean ->English |
Janssen Korea |
Idea Gorilla, http://www.ideagorilla.com Video 9 files dictation and Video script translation | English ->Korean video translation |
Janssen Korea |
Year-end Message from Kris Sterkens | English ->Korean |
Janssen Korea |
Stelara EUPI data | English ->Korean |
Janssen Korea |
JK innovation framework training_ver1.1 | Korean ->English |
Janssen Korea |
Let’s begin this emergency meeting. video dictation and translation | Korean ->English Video translaion |
Janssen Korea |
Making Your Ideas BIGR Every Day Facilitator Guide FINAL | English ->Korean |
Janssen Korea |
EHS&S Generic Equipment Specification Minimum EHS&S requirements -Ronny Briers, Occupational Safety Fellow | English ->Korean |
Janssen Korea |
FIRST Study Objection Handler - Medical and HEMAR Analyses | English ->Korean |
Janssen Korea |
AS APP operation manual [幸福無僵APP 系統操作手冊] | Chinese->Korean |
Janssen Korea |
ASAP project - Taiwan presentation data | English ->Korean |
Janssen Korea |
Jurnista® - Product information | German->Korean |
Janssen Korea |
Clinical Overview - Treatment of Adults with Moderately to Severely Active Crohn’s Disease : STELARA® (ustekinumab) | English ->Korean |
Janssen Korea |
STELARA® (ustekinumab) Clinical Study Report CNTO1275CRD3001 SYNOPSIS | English ->Korean summary translation |
Janssen Korea |
STELARA® (ustekinumab) Clinical Study Report CNTO1275CRD3002 SYNOPSIS | English ->Korean summary translation |
Janssen Korea |
STELARA® (ustekinumab) 44-Week Clinical Study Report CNTO1275CRD3003 SYNOPSIS | English ->Korean |
Janssen Korea |
Qualitative Hazard Identification and Risk Assessment- Job Safety Analysis - Technical Standard TS_01.2_001 | English ->Korean |
Janssen Korea |
Non-Routine Permit-To-Work - Technical Safety Standard TSS_24_006 | English ->Korean |
Janssen Korea |
J&J 2015 Citizenship & Sustainability Report | English ->Korean |
Janssen Korea |
Clinical Overview - Sirukumab (Subcutaneous) for the Treatment of Rheumatoid Arthritis (52-Week Submission) CNTO 136 (sirukumab) | English ->Korean |
Janssen Korea |
Clinical Overview - Bioavailability and Bioequivalence Studies to Support ZYTIGA® 500-mg Film-Coated Tablet Formulation JNJ-212082 (abiraterone acetate) | English ->Korean |
Janssen Korea |
Summary of Biopharmaceutic Studies and Associated Analytical Methods - ZYTIGA® 250-mg and 500-mg Film-coated Tablet Formulations JNJ-212082 (abiraterone acetate) | English ->Korean |
Janssen Korea |
Clinical Overview - Infliximab dose intensification for severe active Crohn’s disease in children with loss of response to 5 mg/kg q8 weeks REMICADE ® (infliximab) | English ->Korean |
Janssen Korea |
Hye-sook Jeon claimed, "The distribution of these defamatory leaflets by the Korean Association of Pediatric Practitioners is an attempt to blame others for their own errors" | Korean ->English |
Janssen Korea |
Construction Safety Assessment / Peer Review | English ->Korean |
Janssen Korea |
Celltrion's Remsima biosimilar proven interchangeably safe with original drug | English ->Korean |
Janssen Korea |
New Mental Health Integration Index confirms substantial gaps exist in policy and support for patients across Asia Pacific | English ->Korean |
Janssen Korea |
Clinical Overview - Paliperidone Palmitate 3-Month Prolonged Release Suspension for Injection for the Maintenance Treatment of Schizophrenia Extension Marketing Authorization Application R092670 (paliperidone palmitate) | English ->Korean |
Janssen Korea |
SYNOPSIS A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects with Schizophrenia | English ->Korean summary translation |
Janssen Korea |
SYNOPSIS A Randomized, Multicenter, Double-Blind, Relapse Prevention Study of Paliperidone Palmitate 3-Month Formulation for the Treatment of Subjects with Schizophrenia | English ->Korean summary translation |
Janssen Korea |
“Global pharmaceutical companies will be attracted to Changdong Depot” said Park Won-soon / News 1 (Sep. 22, 2016) | Korean ->English |
Janssen Korea |
CASe Pre-Read report | English ->Korean |
Janssen Korea |
Sirukumab m2 data 18 files | English ->Korean |
Janssen Korea |
CNTO136 (Sirukumab) Clinical Study Report CNTO136ARA3001 SYNOPSIS | English ->Korean summary translation |
Janssen Korea |
CNTO136 (sirukumab) 52-Week Clinical Study Report CNTO136ARA3002 SYNOPSIS | English ->Korean summary translation |
Janssen Korea |
CNTO 136 (sirukumab) 52-Week Clinical Study Report CNTO136ARA3003 SYNOPSIS | English ->Korean summary translation |
Janssen Korea |
CNTO 136 (sirukumab) 24-Week Clinical Study Report CNTO136ARA3005 SYNOPSIS | English ->Korean summary translation |
Janssen Korea |
JANSSEN KOREA’S REMICADE® TEAM GOES GLOBAL AT THE JAMES E. BURKE MARKETING AWARDS | English ->Korean |
Janssen Korea |
Request for Orphan Drug Designation - Use of Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Waldenstrom’s Macroglobulinemia Ibrutinib (JNJ-54179060) | English ->Korean |
Janssen Korea |
Distributor Self-Assessment Form - TV-eFRM-00507 Version 1.0 | English ->Korean |
Janssen Korea |
J&J Company Quality Agreement | English ->Korean |
Janssen Korea |
Korean MFDS approves INVEGA TRINZATM, a long-acting injection (LAI) for schizophrenia | Korean ->English |
Janssen Korea |
Food Drug Information Service Ministry of Food and Drug Safety - Permission of Change of Narcotics and Other Analogous Substance Dealer & Notice on Permission of Change of Drug Product Manufacture | Korean ->English |
Janssen Korea |
SYNOPSIS Summary translation : JNJ-54767414 (daratumumab) Clinical Study Report GEN501 | English ->Korean summary translation |
Janssen Korea |
2016 PA Presurvey | Korean ->English |
Janssen Korea |
Aspects Impacts and Hazards Risks identification and assessment tool, Contractor Qualification Checklist (as of Sept. 1 2014) & PSSR CHECKLIST AND APPROVAL FORMS | English ->Korean |
Janssen Korea |
Process Safety Management (PSM) Program - Janssen Vacaville Environmental Health & Safety | English ->Korean |
Janssen Korea |
Hearts, Minds and Healthcare Innovation in Korea | English ->Korean |
Janssen Korea |
STELARA MOD Final_v013-HD 1080P-3 Video dictation and translation | English ->Korean video translation |
Janssen Korea |
STELARA MOD Final_v013-HD 1080P-3 Video Editing | English ->Korean Video Editing |
Janssen Korea |
Janssen Korea Employment Contract | English ->Korean |
Janssen Korea |
Long Acting Antipsychotics Treatment for Schizophrenia: Paliperidone Palmitate 3-month Formulation Advisory Board Meeting data | English ->Korean |
Janssen Korea |
National Policy Coordination Meeting - For a happy life, a healthy society COMPREHENSIVE PLAN FOR MENTAL HEALTH / February 25, 2016 | Korean ->English |
Janssen Korea |
Career Conversation with APLTs held in Seoul | Korean ->English |
Janssen Korea |
Grünenthal : Trendanalyse mikrobiologisches Monitoring und Partikelkontrolle 4. Qualtal 2015 | German->Korean |
Janssen Korea |
Health Authority Response - Response to Korean Health Authority Dated 11 January 2016 Pediatric Psoriasis STELARA (ustekinumab) | English ->Korean |
Janssen Korea |
STELARA MOD Final_v013-HD_1080P Video dictation and translation | English ->Korean video translation |
Janssen Korea |
Grünenthal : Standardarbeitsanweisung / HQ-PH-045-V051-04 & User Requirement Specification (URS) RLT-Anlagen 010/011 und 020/021, Campus, Gebaude 604/608 | German->Korean |
Janssen Korea |
World Number 1, J&J, draws its future strategy in Seoul - `Bio Korea` Enjoys Growing Presence in the Global Market / Seeking to cooperate with Korean firms | Korean ->English |
Janssen Korea |
Clinical Overview - Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma JNJ-54179060 (Ibrutinib) | English ->Korean |
Janssen Korea |
Invega Sustenna Video Story Board (Animation + Actual Images) | English ->Korean |
Janssen Korea |
WHAT IS SCHIZOPHRENIA? - Website L10N | English ->Korean |
Janssen Korea |
Clinical Overview - Daratumumab for the Treatment of Relapsed and Refractory Multiple Myeloma JNJ54767414 (daratumumab) | English ->Korean |
Janssen Korea |
SYNOPSIS Summary translation :JNJ-54767414 (daratumumab Clinical Study Report 54767414MMY2002 | English ->Korean summary translation |
Janssen Korea |
2.5 CLINICAL OVERVIEW - VELCADE® (bortezomib) for Injection | English ->Korean |
Janssen Korea |
SYNOPSIS Summary translation : JNJ-26866138 (VELCADE** [bortezomib] for Injection) Clinical Study Report 26866138-LYM-3002 | English ->Korean summary translation |
Janssen Korea |
SYNOPSIS Summary translation : VELCADE: Clinical Protocol 26866138-LYM-2034 – Amendment INT-3 | English ->Korean summary translation |
Janssen Korea |
2.5 Clinical Overview - VELCADE Retreatment VELCADE® (bortezomib) for Injection | English ->Korean |
Janssen Korea |
SYNOPSIS Summary translation : JNJ-26866138 (bortezomib) for Injection) Clinical Study Report 26866138MMY2036 | English ->Korean summary translation |
Janssen Korea |
Janssen Asia Pacific Innovation Fund 2016 Application Form | Korean ->English |
Janssen Korea |
Final Market Research Report - January 2015 / Shaping a competitively differentiated positioning / messaging for SIMPONI in RA | English ->Korean |
Janssen Korea |
Grünenthal: Standardarbeitsanweisung Grünenthal, 52099 Aachen, Deutschland / HQ-QA-171-F001-03 | German->Korean |
Janssen Korea |
This guideline has been prepared to support the sponsor and investigator who are designing the initial stages of a clinical study for cell therapy products and gene therapy products. | Korean ->English |
Janssen Korea |
Grünenthal - GIO-DE- PRODUCTION - PACKAGING CENTER REINIGUNGSVALIDIERUNG DER VERPACKUNGSLINIEN VALIDIERUNGSPLAN 30.07.2013 | German->Korean |
Janssen Korea |
Operation of the manufacturing and quality management standards (GMP) for cell therapy products | Korean ->English |
Janssen Korea |
일본통증클리닉학회 - 비암성 만성 (동)통에 대한 오피오이드 진통제 처방 가이드라인 <- Japanese | Japanese->Korean |
Janssen Korea |
Grünenthal Template 01 zu SOP GL-QO-170-A002-01- B-0-1 Risikoanalyse Reinigung Packaging Center-R-01 .doc | German->Korean |
Janssen Korea |
Grünenthal Standardbeitsanweisung - HQ-PH-045-G002-04 - 01. AUG. 2015 | German->Korean |
Janssen Korea |
Grünenthal Standardbeitsanweisung - HQ-PH-045-V0552-03 - 15. JUNI. 2015 | German->Korean |
Janssen Korea |
INVEGA SUSTENNA POST MARKETING SURVEILLANCE (4) & INVEGA SUSTENNA POST MARKETING SURVEILLANCE (5) | Korean ->English |
Janssen Korea |
CAELYX® Janssen-Cilag AG Eigenschaften/Wirkungen - WIRKUNGSMECHANISMUS/PHARMAKODYNAMIK - Doxorubicinhydrochlorid, der Wirkstoff von Caelyx, ist ein zytotoxisches Anthrazyclin-Antibiotikum, das aus Streptomyces peucetius var. caesius gewonnen wird. | German->Korean |
Janssen Korea |
日本標準商品分類番号 874235 - 抗悪性腫瘍剤 DOXIL Injection ドキソルビシン塩酸塩 リポソーム注射剤 | Japanese->Korean |
Janssen Korea |
SLAQ Information Packet_DrShin | English ->Korean |
Janssen Korea |
Janssen Research & Development - Clinical Overview - REMICADE® (infliximab) - 4 November 2015 | English ->Korean |
Janssen Korea |
Module 2.5 Clinical Overview - psoriasis adult patient who inadequately respond to q12w Stelara® (ustekinumab) | English ->Korean |
Janssen Korea |
Pledge for Protection of Medical Information and Request for Use of Information System For Clinical Research Associate (CRA) | Korean ->English |
Janssen Korea |
Request for Issue of Personal Number - (Sponsor, Overseas Medical Scientist) | Korean ->English |
Janssen Korea |
Janssen Research & Development - Briefing Book in Support of Pre-Submission National Consultations for Daratumumab as a Treatment for Relapsed and Refractory Multiple Myeloma | English ->Korean |
Janssen Korea |
Dr. Nelson Speech - What is the neurobiological correlates of corollary discharge and aberrant salience? | English ->Korean video dictation & documentation |
Janssen Korea |
Dr. Howes Speech - The next question is: What is the mechanism linking increased dopamine and abhorrent stimuli processing? | English ->Korean video dictation & documentation |
Janssen Korea |
Dr. Kim -remote medical Examination and treatment | English ->Korean video dictation & documentation |
Janssen Korea |
Sterile Needle - The definition of a sterile needle (A53010.02) in accordance with the [Regulations for Product Classification of Medical Device and Class by Product]: - a sterilized needle used for injecting medical supplies into the human body, or drawi | Korean ->English |
Janssen Korea |
Grünenthal : Anhang 4 SOP HQ-QC-170.-G049 | German->Korean |
Janssen Korea |
Grünenthal : HQ-QC-170-Q049-05_BBDE.1 | German->Korean |
Janssen Korea |
Grünenthal Standardarbeitsanweisung : HQ-PH-045-G001-03 - Luftströmungskontrolle Kopfstationen - Air Flow Check of Head Stations | German->Korean |
Janssen Korea |
Grünenthal Standardarbeitsanweisung : HQ-QC-170-G001-05_F970.1 | German->Korean |
Janssen Korea |
Grünenthal Standardarbeitsanweisung : HQ-QC-170-G005-05_35DA.1 | German->Korean |
Janssen Korea |
Grünenthal Standardarbeitsanweisung : HQ-QC-170-Q029-01_BFD4.1 | German->Korean |
Janssen Korea |
Meßplan Partikelmessung at rest, Packaging Center; Präfix Messorte: DEIC-PZE | German->Korean |
Janssen Korea |
Meßplan Meßart A/L, Packing Center; W5 Präfix Messorte: DEIC - | German->Korean |
Janssen Korea |
[Interview] President of Janssen Korea, Kim Ok-Yeon, who is also the President of KRPIA and a Health and Medical Industry in Asia-Pacific area -The fair agreement between KRPIA, Korea Pharmaceutical Manufacturers Association and Korea Medical Industry Ass | Korean ->English |
Janssen Korea |
Tapentadol QOS for GRT ER & Tapentadol QOS for GRT IR | English ->Korean |
Janssen Korea |
KDDF Press Release Oct. 22, 2015 - KDDF launches global technical transfer acceleration project in partnership with J&J Shanghai Innovation Center | Korean ->English |
Janssen Korea |
[Meet Korea’s First Women] ② Kim Ok-yeon, CEO of Janssen Korea - The first female chairperson of Korea Research-based Pharmaceutical Industry Association (KRPIA) – A warm-hearted ‘sympathetic’ leader | Korean ->English |
Janssen Korea |
Janssen Research & Development, LLC - R092670PSY3011 CSR Synopsis - (paliperidone palmitate) 10 June 2015 | English ->Korean |
Janssen Korea |
Grünenthal - GIO-DE- PRODUCTION - PACKAGING CENTER REINIGUNGSVALIDIERUNG DER VERPACKUNGSLINIEN VALlDIERUNGSBERICHT VERTRAULlCH B.0.1.1 19.11.2013 | German->Korean |
Janssen Korea |
Grünenthal Standardarbeitsanweisung : HQ-PH-045-G002-04 - Hygieneplan des Verpackungsbereiches für Räume und Maschinen in der RK E und angrenzende Bereiche | German->Korean |
Janssen Korea |
Grünenthal Standardarbeitsanweisung : HQ-PH-045-G003-0 1 - Hygieneplan des Verpackungsbereiches für Räume und Maschinen in der RK F und angrenzende Bereiche | German->Korean |
Janssen Korea |
Grünenthal - GIO-DE- PRODUCTION - QUALlFIZIERUNGSPLAN VERTRAULlCH B.4.C.12.1 .1.2 - Qualifizierung (PQ) Einsiegelmaschine und Kartonierer (81330/ C2205) 21.11.2011 | German->Korean |
Janssen Korea |
Grünenthal - GIO-DE- PRODUCTION - QUALlFIZIERUNGSBERICHT VERTRAULlCH B .4.C.12.1.1.2 - Leistungsqualifizierung (PQ) Einsiegelmaschine und Kartonierer (81330 / C2205) 12.01.2012 | German->Korean |
Janssen Korea |
Grünenthal - GIO-DE- PRODUCTION - QUALlFIZIERUNGSPLAN 8.4.C.12.2.1.2 - Leistungsqualifizierung (PQ) Einsiegelmaschine und Kartonierer (81330/ C2205) 21.03.2012 | German->Korean |
Janssen Korea |
Grünenthal - GIO-DE- PRODUCTION - QUALlFIZIERUNGSBERICHT VERTRAULlCH B.4.C.12.2.1.2 - Leistungsqualifizierung (PQ) Einsiegelmaschine und Kartonierer (81330 / C2205) 17.04.2012 | German->Korean |
Janssen Korea |
Ibrutinib Learning System - Introduction to Mantle Cell Lymphoma | English ->Korean |
Janssen Korea |
Ibrutinib Learning System - Introduction to Ibrutinib | English ->Korean |
Janssen Korea |
Ibrutinib Learning System - Mantle Cell Lymphoma Treatment Landscape | English ->Korean |
Janssen Korea |
Daratumumab - Application for Orphan Medicinal Product Designation – Scientific Annex - 11 April 2013 | English ->Korean |
Janssen Korea |
Factors associated with response to pharmacotherapy in Korean youth with attention-deficit/hyperactivity disorder: a 52-week prospective observational study | Korean ->English |
Janssen Korea |
Janssen Research & Development - JNJ-61186372 - Investigator's Brochure - Edition 1 9 September 2015 | English ->Korean |
Janssen Korea |
IMBRUVICA Objection handler | English ->Korean |
Janssen Korea |
SYLVANT™ (Siltuximab) Powder for Concentrate for Solution 100 mg and 400 mg – HA Response Document | English ->Korean |
Janssen Korea |
Module 2.5 Clinical Overview - psoriasis adult patient who inadequately respond to q12w Stelara® (ustekinumab) 28 August 2015 | English ->Korean |
Janssen Korea |
Ministry of Health and Welfare Press Release Aug. 28, 2015- Clinical Trials Global Competitiveness Reinforcement Initiative Announced - Aiming to Become one of the Top 5 Clinical Trial Powerhouses by 2020 | Korean ->English |
Janssen Korea |
Module 2.5 Clinical Overview - psoriasis adult patient who inadequately respond to q12w Stelara® (ustekinumab) 28 August 2015 | Korean ->English |
Janssen Korea |
Paliperidone Palmitate 3-Month Injection: Module 2.2 Introduction | English ->Korean |
Janssen Korea |
Janssen Research & Development Nonclinical Overview MODULE 2.4 R092670 (Paliperidone Palmitate, JNJ-16977831) 3-Month Injection | English ->Korean |
Janssen Korea |
Janssen Research & Development - Toxicology Tabulated Summary MODULE 2.6.7 R092670 (Paliperidone Palmitate, JNJ-16977831) 3-Month Injection | English ->Korean |
Janssen Korea |
Janssen Research & Development - Summary of Biopharmaceutic Studies and Associated Analytical Methods R092670 (paliperidone palmitate) 3-month formulation R092670 (paliperidone palmitate) | English ->Korean |
Janssen Korea |
Janssen Research & Development - Paliperidone Palmitate 3-Month Formulation (F015) 2.3 Introduction | English ->Korean |
Janssen Korea |
Technical Safety Standard TSS_24_004 - Line Breaking Permit-To- Work Issue Date: April 17th,2015 | English ->Korean |
Janssen Korea |
Technical Safety Standard TSS_24_005- Critical Lift Permit-To- Work Issue Date: April 17th,2015 | English ->Korean |
Janssen Korea |
Technical Safety Standard TSS_24_006- Contractor Safety Permit To Work Issue Date: April 28th ,2015 | English ->Korean |
Janssen Korea |
Technical Safety Standard TSS_24_007 - Working at Height Permit To Work Issue Date: April 10th, 2015 | English ->Korean |
Janssen Korea |
Janssen Research & Development, LLC Global Medical Safety - REMICADE® (infliximab) Supporting Document for the Addition of Cervical Cancer - 16 June 2015 | English ->Korean |
Janssen Korea |
Janssen Research & Development, LLC Global Medical Safety - REMICADE® (infliximab) Supporting Document for the Addition of Cerebrovascular Accident in the Context of an Infusion Reaction - 11 June 2015 | English ->Korean |
Janssen Korea |
Janssen Research & Development, LLC STELARA® (ustekinumab) Pediatric psoriasis Module 2.5 Clinical Overview - 2 December 2014 | English ->Korean |
Janssen Korea |
Janssen Research & Development, LLC STELARA (ustekinumab) Clinical Study Report CNTO1275PSO3006 SYNOPSIS - 16 June 2014 | English ->Korean |
Janssen Korea |
INVEGA TRINZA™ IFU Data | English ->Korean |
Janssen Korea |
Germany - Switzerland ATC-Browser | Drugs A-Z | Recent Registrations Information for professionals for Livostin® Nasenspray: Indikationen/Anwendungsmöglichkeiten Saisonale, allergische Rhinitis. Die Therapiedauer beträgt maximal 2 Monate. | German->Korean |
Janssen Korea |
DARUNAVIR/COBICISTAT MODULE 2.6.6 TOXICOLOGY WRITTEN SUMMARY | English ->Korean |
Janssen Korea |
GILEAD GS-9350 - FINAL CLINICAL STUDY REPORT - GS-US-216-0115 | English ->Korean |
Janssen Korea |
TMC114IFD1001 Clinical Study Report Synopsis 22-Feb-2012 | English ->Korean |
Janssen Korea |
DRV/COBI (darunavir/cobicistat) fixed dose combination - Clinical Study Report TMC114IFD1003 25 January 2013 | English ->Korean |
Janssen Korea |
Darunavir/Cobicistat Week 48 Safety and Efficacy Summary GS-US-216-0130 17 February 2015 | English ->Korean |
Janssen Korea |
GILEAD GS-US-216-0130 - CLINICAL STUDY REPORT - Cobicistat-boosted Darunavir (DRV+COBI) | English ->Korean |
Janssen Korea |
TMC114-C211 Clinical Research Report | English ->Korean |
Janssen Korea |
TMC114-TiDP31-C229 Clinical Research Report Synopsis | English ->Korean |
Janssen Korea |
Eidgenössisches Departement des Innern EDI Bundesamt für Gesundheit BAG Direktionsbereich Kranken- und Unfallversicherung Allgemeine - Bestimmungen zur Spezialitätenliste | German->Korean |
Janssen Korea |
Doxil Inspection Report AIFA 2014 - GlaxoSmithKline Manufacturing Spa S. Polo di Torrile - Parma 7~10.04.2014 | English ->Korean |
Janssen Korea |
Profile Feature as seen in Nature 25th June 2015 - Janssen InsideView_Anuk Das | English ->Korean |
Janssen Korea |
Janssen Research & Development - TMC435 simeprevir Chronic Hepatitis C / 20150042043 Health Authority Response Korea 29 June 2015 | English ->Korean |
Janssen Korea |
Message from Scott - June draft 0 2_DDM edits | English ->Korean |
Janssen Korea |
Grünenthal - Validierungsbericht - Bestimmung der Restlösungsmittel in CG5503 07. Dezember 2007 | German->English |
Janssen Korea |
Janssen Research & Development Drug Safety Sciences - DARUNAVIR/COBICISTAT MODULE 2.4 NONCLINICAL OVERVIEW Issue/Report Date: 16 October 2013 | English ->Korean |
Janssen Korea |
SIMPONI® IV (golimumab) and SIMPONI® (golimumab) Global Brand Book - Janssen Biotech, Inc. 2015 | English ->Korean |
Janssen Korea |
Integrity Board Game Chutes and Ladders Cards: Updated Content - 24 06 2015 | English ->Korean |
Janssen Korea |
Korean Pharmaceutical Manufacturers Association - 3. Regulation on the Safety of Drugs, etc Article 78 (Range of advertising for drugs, etc.) ① Advertisement media or advertisement means for drugs as set forth in Paragraph 6, Article 68 of this Regulation | Korean ->English |
Janssen Korea |
Janssen AP Medical Affairs Functional (MAF) Competency Model | English ->Korean Editing & Proofreading |
Janssen Korea |
Fuji DS-SOP-16637 - Standard Operating Procedure - セキュリティ監視カメラのモニタリングとデジタル記録保存 Monitoring Security Surveillance Equipment and Digital Recording Retention 30-Mar-2015 | English ->Korean |
Janssen Korea |
Fuji DS-SOP-16636 - Standard Operating Procedure - 富士工場のセキュリティFuji Plant Security Guidelines 30-Mar-2015 | English ->Korean |
Janssen Korea |
SIMPONI® I.V. (golimumab) Product Monograph. Janssen Inc. - BIO ADVANCE - SIMPONI® I.V. Administration Protocol | English ->Korean |
Janssen Korea |
Guideline for the implementation of a “Powered Industrial Vehicles (PIV) Program” | English ->Korean |
Janssen Korea |
Janssen Research & Development - Clinical Overview - Paliperidone Palmitate 3-Month Injection for the Treatment of Schizophrenia New Drug Application R092670 (paliperidone palmitate) 23 October 2014 | English ->Korean |
Janssen Korea |
Janssen Research & Development - R092670 (paliperidone palmitate) Clinical Study Report R092670PSY3012 SYNOPSIS 2 September 2014 | English ->Korean |
Janssen Korea |
Johnson & Johnson - Employee Online Activity Quick Tips Infographic | English ->Korean |
Janssen Korea |
Johnson & Johnson - Guidelines on Employee Mentions of Johnson & Johnson, its Operating Companies, and its Brands in Social Media (Last Updated: 2/26/2015) | English ->Korean |
Janssen Korea |
Johnson & Johnson - Q&A with Jake Feldman and Leah Olverd Topic: The New Guidelines on Employee Mentions of J&J in Social Media | English ->Korean |
Janssen Korea |
Ministry of Food and Drug Safety - Guidelines for the Evaluation of Stem Cell Therapy Products (Guideline for Quality, Non-clinical and Clinical Assessment of Stem Cell Therapy Products) Dec. 2014 | Korean ->English |
Janssen Korea |
Ministry of Food and Drug Safety - Guideline on the Evaluation of Cell Therapy Products Containing Scaffolds Nov. 2014 (Tentative) | Korean ->English |
Janssen Korea |
Janssen Research & Development - Clinical Overview - (5 January 2015 [Version 010] CCDS Update) R092670 (paliperidone palmitate) | English ->Korean |
Janssen Korea |
Geron Corporation - Imetelstat Investigator’s Brochure, Edition 11.0 Release Date: 25 February 2015 | English ->Korean |
Janssen Korea |
Johnson & Johnson, Janssen Korea's global mother company, has a corporate philosophy called 'Our Credo.' | English ->Korean video dictation & translation |
Janssen Korea |
Asian Ankylosing Spondylitis Patient Advocacy Council (AASPAC) AASPAC Leadership Conference 28 – 29 March 2015 Guangzhou, China Meeting Report | English ->Korean |
Janssen Korea |
Janssen Research & Development - Clinical Overview - Treatment of Non-radiographic Axial Spondyloarthritis (24-Week Submission) SIMPONI ® (golimumab) 5 November 2014 | English ->Korean |
Janssen Korea |
Janssen Research & Development - MK-8259 (Golimumab) CLINICAL STUDY REPORT P006 (24-WEEK CSR) SYNOPSIS | English ->Korean |
Janssen Korea |
Stakeholders Engagement - Kris Sterkens_Severance - Briefing Document for Proposed Site Visits with Kris Sterkens during Korea visit 15-16 April, 2015 | Korean ->English |
Janssen Korea |
HaTCH – Inspiring Innovation in Australian Healthcare - “ The best way to predict the future is to invent it” Alan Kay | English ->Korean |
Janssen Korea |
Asian Ankylosing Spondylitis Patient Advocacy Council (AASPAC) Leadership Conference - Thank You Letter - 1 April 2015 | English ->Korean |
Janssen Korea |
Ibrutinib Frequently Asked Questions (FAQs) Master Document - November 2014 | English ->Korean |
Janssen Korea |
Ketamine abuse Video 5 files dictation & translation | English ->Korean video dictation & translation |
Janssen Korea |
Press Release - Janssen Korea’s ‘Simponi,’ a treatment for autoimmune diseases, is now covered by Korea’s National Insurance benefits for ulcerative colitis patients - - Simponi increases the remission rate of ulcerative colitis with its excellent mucous | Korean ->English |
Janssen Korea |
Janssen Research & Development - Clinical Overview - (Darunavir/Cobicistat 800/150 mg Fixed Dose Combination Tablet for the Treatment of HIV-1 Infection in Adults DRV/COBI (darunavir/cobicistat) 16 October 2013 | English ->Korean |
Janssen Korea |
The president of KOAS (Korean Organization Ankylosing Spondylitis ) Presentation - Advocacy in Korea | Korean ->English |
Janssen Korea |
Tell us how you’ve shone as a Janssen Asia Pacific Leading Light - Leading Lights Entry Form | English ->Korean |
Janssen Korea |
Launch announcement email from Kris Sterkens Date of release: 6 April, 2015 | English ->Korean |
Janssen Korea |
Mid-campaign reminder email from Kris Sterkens Date of release: 1 May, 2015 | English ->Korean |
Janssen Korea |
Janssen Research & Development - Bridging Study Evaluation - Position Paper for Bridging Study Evaluation in South Korea Regarding Use of Simeprevir in Asian Subjects TMC435 (simeprevir) 13 February 2015 | English ->Korean |
Janssen Korea |
Janssen Research & Development - Clinical Overview - Multicentric Castleman’s Disease Siltuximab (CNTO 328) 25 July 2013 | English ->Korean |
Janssen Korea |
Janssen Research & Development - SILTUXIMAB MODULE 2.4 NONCLINICAL OVERVIEW 29 JULY 2013 | English ->Korean |
Janssen Korea |
Janssen Research & Development - Summary of Clinical Efficacy - Multicentric Castleman’s Disease Siltuximab (CNTO 328) 17 July 2013 | English ->Korean |
Janssen Korea |
Janssen Research & Development - Summary of Clinical Safety -Multicentric Castleman’s Disease Siltuximab (CNTO 328) 9 August 2013 | English ->Korean |
Janssen Korea |
Janssen Research & Development - Clinical Overview - (5 January 2015 [Version 010] CCDS Update) R092670 (paliperidone palmitate) 8 January 2015 | English ->Korean |
Janssen Korea |
Janssen Scientific Affairs, LLC - R092670 (paliperidone palmitate) - Clinical Study Report R092670-SCA-3004 SYNOPSIS 10 March 2014 | English ->Korean |
Janssen Korea |
Innovation Fund Application Project - Heart and Will Final & Mothers of patients argue not to use the term ‘Jeongshinboonyeoljeung (schizophrenia)’ carelessly | Korean ->English |
Janssen Korea |
Shire-Movetis NV SPD555-302 Version 1.0, FINAL 21 Mar 2014 - STUDY SYNOPSIS | English ->Korean |
Janssen Korea |
2015-R1 Innovation Fund Application Form (Come Together Project) - : An alternative caregiver pool operating project in order to improve accessibility to health care services for the disadvantaged in society | Korean ->English |
Janssen Korea |
World Health Organization (WHO) EXECUTIVE BOARD 136th session Provisional agenda item 15.1 19 December 2014 - Reports of advisory bodies Expert committees and study groups1 Report by the Secretariat | English ->Korean |
Janssen Korea |
Janssen STANDARD OPERATING PROCEDURE SOP-CPA-001-JK Version: 1.0 - JK’s Social Participation Activity Fund, NANUM Impl. Date: Mar 2014 | Korean ->English |
Janssen Korea |
Arzneimittel A-Z | ATC-Browser | Neuregistrierungen Fachinformation zu Nizoral® Crème: Zusammensetzung Wirkstoff: Ketoconazolum. Hilfsstoffe: Propylenglycolum, Antioxidans E 221 (Natriumsulfit). Galenische Form und Wirkstoffmenge pro Einheit Crème: 20 mg | German->Korean |
Janssen Korea |
ATC-Browser | Drugs Germany - Switzerland Information for professionals for Livostin® Nasenspray: Zusammensetzung Wirkstoff: Levocabastinum ut Levocabastini hydrochloridum. Hilfsstoffe: Propylenglycolum, Conserv.: Benzalkonii chloridum, Excipiens ad suspe | German->Korean |
Janssen Korea |
Recording telephone conversation auido file dictation - running time: 42:00 min. | English Audio dictation |
Janssen Korea |
Pharmacyclics, Inc. PCI-32765 (ibrutinib) Clinical Study Report PCYC-1104-CA SYNOPSIS 22 May 2013 | English ->Korean |
Janssen Korea |
Pharmacyclics, Inc. Ibrutinib (PCI-32765) Clinical Study Report PCYC-04753 SYNOPSIS 27 February 2013 | English ->Korean |
Janssen Korea |
Janssen Research & Development - Module 2.5 Clinical Overview Addendum - Chronic Hepatitis C Infection simeprevir (TMC435) 14 July 2014 | English ->Korean |
Janssen Korea |
Janssen Research & Development - Clinical Overview - Update to the Product Information Regarding (January 2014 CCDS Version 02 Update) simeprevir (TMC435) 29 January 2014 | English ->Korean |
Janssen Korea |
Janssen Research & Development - Module 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods - Chronic Hepatitis C Infection TMC435 (simeprevir) 4 February 2013 | English ->Korean |
Janssen Korea |
Janssen Research & Development - Module 2.7.2 Summary of Clinical Pharmacology Studies - Chronic Hepatitis C Infection TMC435 (simeprevir) 7 March 2013 | English ->Korean |
Janssen Korea |
Janssen Research & Development - Module 2.7.2 Special Studies (Virology Summary) - Chronic Hepatitis C Infection TMC435 (simeprevir) 25 June 2013 | English ->Korean |
Janssen Korea |
Janssen Asia Pacific Medical Affairs - Clinical Study Report - CONSIST Observational Study Protocol PRUCOP4003; Phase 4 26 August 2014 | English ->Korean |
Janssen Korea |
Janssen Research & Development - Module 2.5 Clinical Overview - Chronic Hepatitis C Infection simeprevir (TMC435) 14 March 2013 | English ->Korean |
Janssen Korea |
Conference call - Company Insight Management Learning from Janssen Australia-- the first Insight workshop in APEX | English ->Korean video dictation & translation |
Janssen Korea |
Janssen Asia Pacific - Communication & Public Affairs Policies Section 1: Communicating with the Media (updated February 2014) | English ->Korean |
Janssen Korea |
Janssen Asia Pacific - Communication & Public Affairs Policies Section 2: Photography, Filming and Recording | English ->Korean |
Janssen Korea |
Janssen Asia Pacific - Communication & Public Affairs Policies Section 3: Issues & Crisis Communication (updated November 2013) | English ->Korean |
Janssen Korea |
Janssen Asia Pacific - Communication & Public Affairs Policies Section 3: Media Message Map/Q&A Document Subject to ongoing legal and regulatory review | English ->Korean |
Janssen Korea |
Janssen Asia Pacific - Communication & Public Affairs Policies Section 4: Approval Process for Communication Material (updated November 2013) | English ->Korean |
Janssen Korea |
Janssen Asia Pacific - Communication & Public Affairs Policies Section 5: Working with Patient Groups | English ->Korean |
Janssen Korea |
Janssen Asia Pacific - Communication & Public Affairs Policies Section 5: Patient Group Promise | English ->Korean |
Janssen Korea |
Janssen Asia Pacific - Communication & Public Affairs Policies Section 5: SPONSORSHIP AGREEMENT (v Mar2014 Amended) | English ->Korean |
Janssen Korea |
Janssen Asia Pacific - Communication & Public Affairs Policies Section 5: Photo & Film Consent and Release Form Template - CONSENT AND RELEASE | English ->Korean |
Janssen Korea |
Janssen Asia Pacific - Communication & Public Affairs Policies Section 6: Product Communications to Stakeholders other than HCPs | English ->Korean |
Janssen Korea |
Janssen Asia Pacific - Communication & Public Affairs Policies Section 7: Managing PR Agencies | English ->Korean |
Janssen Korea |
Janssen Asia Pacific - Communication & Public Affairs Policies Section 7: Communication Agency Briefing Document - Project Brief: [Name of Project] | English ->Korean |
Janssen Korea |
Janssen Asia Pacific - Communication & Public Affairs Policies Section 7: Score Sheet for Agency Pitches and Proposals | English ->Korean |
Janssen Korea |
EVONIK TECHNOCHEMIE Dossenheim - STANDARD OPERATING PROCEDURE - Pest Control No.: VA4.2.2-02 Status: Version 4 | English ->Korean |
Janssen Korea |
Janssen Korea Releases Caelyx, Chemotherapy Drug for Advanced Ovarian Cancer - October 19, 2014 | Korean ->English |
Janssen Korea |
Press Release - Velcade, a treatment for multiple myeloma, expands its indications as the first-line induction therapy before stem cell transplantation - October, 00, 2014 | Korean ->English |
Janssen Korea |
Simpony ARIA - Simpony ARIA Dosing and Administration Guide | English ->Korean |
Janssen Korea |
Simpony ARIA - Simpony ARIA gorimumab for Infusion - I am able | English ->Korean |
Janssen Korea |
Simpony ARIA - IN ADDITION TO SIMPTOM IMPROVEMENT... | English ->Korean |
Janssen Korea |
Janssen STANDARD OPERATING PROCEDURE CODE: SOP-CPA-002-JK Version: 1.0 - Charitable Contributions - IMPL. DATE: 1 Oct 2014 | Korean ->English |
Janssen Korea |
Press Release - Janssen Korea - ‘NUCYNTA®’, a new narcotic analgesic is approved in Korea - August 18, 2014 | Korean ->English |
Janssen Korea |
Evonik Technochemie (ETC) - Historie der Rattenköderstationen seit 06/2012 - History of the rat traps since June 2012 | German->Korean |
Janssen Korea |
EVONIK TECHNOCHEMIE Dossenheim - Checkliste Sichtkontrolle - Pest Control - FB 4.2.2-08 07-14 | German->Korean |
Janssen Korea |
Evonik Technochemie GmbH - F+M Schädlingsbekämpfungs - Wir sichern Ihren guten Ruf ! - Servicebericht - 03.06.2014 | German->Korean |
Janssen Korea |
Römer Wartung + Service Gebäudemanagement - Wartungsliste / Checkliste - Evonik Geb. PW 2 • Dossenheim - Zuluft + Ablllftgerät mit KV-WRG | German->Korean |
Janssen Korea |
EVONIK TECHNOCHEMIE Dossenheim - Installations-Qualifizierung OQ- Plan und -Bericht - Bezug auf Dokument: DQ-PQ 0024 Design Qualifizierung Erweiterung Stickstoffsystem - Ident-Nr.: OQ-PQ-0024 | German->Korean |
Janssen Korea |
AQura GmbH - Prüfbericht Nr. A140012564 nach DIN EN ISO/IEC 17025 23.07.2014 - Auftrags-/Produktbezeichnung: AQ-AG14-2399: Stickstoffanalytik (GMP) | German->Korean |
Janssen Korea |
AQura GmbH - Prüfbericht Nr. A140012565 nach DIN EN ISO/IEC 17025 23.07.2014 - Auftrags-/Produktbezeichnung: AQ-AG14-2399: Stickstoffanalytik (GMP) Prüfzeitraum: 31.07. bis 11.08.2014 | German->Korean |
Janssen Korea |
EVONIK TECHNOCHEMIE Dossenheim - VERFAHRENSANWEISUNG Klimaüberwachung in der Technochemie - Ident-Nr.: VA 6.6-05 | German->Korean |
Janssen Korea |
Janssen Research & Development - Clinical Protocol - JNJ-212082 (abiraterone acetate): Clinical Protocol 212082PCR2007 - Amendment INT-5 - 26 August 2014 | English ->Korean |
Janssen Korea |
World Health Organization (WHO) Expert Committee on Drug Dependence Thirty‐sixth Meeting Geneva, 16‐20 June 2014 - Expert peer review No.1 - Agenda item 6.1: Tramadol | English ->Korean |
Janssen Korea |
World Health Organization (WHO) Expert Committee on Drug Dependence Thirty‐sixth Meeting Geneva, 16‐20 June 2014 - Expert peer review No.2 - Agenda item 6.1: Tramadol | English ->Korean |
Janssen Korea |
World Health Organization (WHO) Expert Committee on Drug Dependence Thirty‐sixth Meeting Geneva, 16‐20 June 2014 - Expert peer review No.3 - Agenda item 6.1: Tramadol | English ->Korean |
Janssen Korea |
IFPMA comments and supplementary data - 28 May 2014 | English ->Korean |
Janssen Korea |
World Health Organization (WHO) Expert Committee on Drug Dependence Thirty‐sixth Meeting Geneva, 16‐20 June 2014 - Tramadol Update Review Report - Agenda item 6.1 - 36th ECDD (2014) Agenda item 6.1 | English ->Korean |
Janssen Korea |
ACMD Advisory Council on the Misuse of Drugs - ACMD consideration of tramadol - February 2013 | English ->Korean |
Janssen Korea |
U.S. Department of Justice Drug Enforcement Administration - Schedules of Controlled Substances: Placement of Tramadol into Schedule IV - Background, Data, and Analysis: - Eight Factors Determinative of Control and Findings Pursuant to 21 U.S.C. 812(b) Ma | English ->Korean |
Janssen Korea |
Janssen Research & Development - Knowledge Book For Rheumatic Diseases - Last Updated: March, 2014 | English ->Korean |
Janssen Korea |
Janssen Research & Development - Request for Supplementary Information - JNJ-26866138 (VELCADE® (bortezomib) VELCADE as Induction Treatment Prior to Transplant - Response to Requested Supplementation 15 August 2014 | English ->Korean |
Janssen Korea |
Real relief from nail psoriasis with Stelara®1 - Effects on nail disease in patients with moderate to severe psoriasis: subanalysis from PHOENIX I study | English ->Korean |
Janssen Korea |
STELARA® 45 mg and 90 mg solution for injection in pre-filled syringe - Is it time for a change of direction in PsA? | English ->Korean |
Janssen Korea |
Major adverse cardiovascular events included myocardinal infarction and stroke. - Proportion of patients achieving ACR20 response according to prior anti-TNF therapy at Week 243 | English ->Korean |
Janssen Korea |
Stelara® 3D MoA video script | English ->Korean |
Janssen Korea |
INVEGA® (paliperidone) authorization data - U.S.A & Europe | English ->Korean |
Janssen Korea |
Janssen Research & Development - CNTO 1959 (guselkumab) - Investigator's Brochure - Edition 5 - 09 May 2014 | English ->Korean |
Janssen Korea |
TEP Experience-Janssen Express-editted | English ->Korean |
Janssen Korea |
Food and Drug Administration Department of Health, Executive Yuan, R.O.C. - GMP Audit Report - 2012/07/12-13 | English ->Korean |
Janssen Korea |
Cambridge Major Laboratories, Inc. Establishmcnt Inspection Report - This routine inspection of this Active Pharmaceutical lngredient (API) and fine chemicals manufacturer was conducted as part of the MIN-DO FYl3 work plan and as a follow-up to the Decemb | English ->Korean |
Janssen Korea |
Department of Health and Human Services F'ood and Drug Administration Establishment Inspection Report - December 10, 2013 | English ->Korean |
Janssen Korea |
MHRA Janssen Gurabo site inspection report - Corrected to include packaging - 10-15 November 2010 | English ->Korean |
Janssen Korea |
David Rubin's Presentation Video data - Lunch symposium on optimizing biological therapy - Video dictation, translation & subtitling | English ->Korean video dictation, translation & subtitling |
Janssen Korea |
Janssen Asia Pacific - Alex Vdeo (Script) v2- Integrity is an absolutely important part of our global growth story and I am truly inspired by the way that all of you across Janssen Asia Pacific have embraced this Credo value. | English ->Korean video script translation |
Janssen Korea |
Johnson & Johnson - J&J_Credo Survey English into Korean Proofreading | English ->Korean Proofreading |
Janssen Korea |
Janssen Research & Development - DS-WI-19330 Version: 0.11 - Artwork Review and Approval at Local Operating Companies - 01-Jul-2014 | English ->Korean |
Janssen Korea |
Pharmacyclics, Inc. Ibrutinib (PCI-32765) Clinical Study Report PCYC-1112-CA SYNOPSIS - 25 Mar 2014 | English ->Korean |
Janssen Korea |
Janssen Korea advertising video script dictation & translation | Korean ->English Video dictation & translaion |
Janssen Korea |
Janssen Korea Compnay Introduction brochure - for print | Korean ->English |
Janssen Korea |
Talking Points at a meeting with the Minister of MHW | Korean ->English |
Janssen Korea |
Janssen Worldwide Chairman’s Request for Face-to-Face Talk with the Minister - Apr. 25, 2014, Pharmaceutical Industry Team | Korean ->English |
Janssen Korea |
Inspektionsbericht RHI 23 - 27 01 2012 schwarz for customers - Regionales Heilmitlelinspektorat der Nordwestschweiz | German->Korean |
Janssen Korea |
Anatomical Therapeutic Chemical (ATC) / Pharmacotherapeutic group for abiraterone - MODULE 2.2 INTRODUCTION | English ->Korean |
Janssen Korea |
Anatomical Therapeutic Chemical (ATC) / Pharmacotherapeutic group for abiraterone - Module 2.4 – Nonclinical Overview of JNJ-212082 (abiraterone acetate) 25 May 2012 | English ->Korean |
Janssen Korea |
Anatomical Therapeutic Chemical (ATC) / Pharmacotherapeutic group for abiraterone - Module 2.5 Clinical Overview - JNJ-212802 (abiraterone acetate) | English ->Korean |
Janssen Korea |
Janssen Research & Development - Module 2.6 - Nonclinical Written and Tabulated Summaries - Nonclinical Pharmacology, Pharmacokinetics, and Toxicology JNJ-212082 (abiraterone acetate) 25 MAY 2012 | English ->Korean |
Janssen Korea |
Janssen Research & Development - MODULE 2.6.3 - PHARMACOLOGY TABULATED SUMMARY - JNJ-212082 (abiraterone acetate) | English ->Korean |
Janssen Korea |
Janssen Research & Development - MODULE 2.6.2 Abiraterone Acetate: 2.6.2 Pharmacology Written Summary | English ->Korean |
Janssen Korea |
Janssen Research & Development - MODULE 2.6.5 PHARMACOKINETICS TABULATED SUMMARY - JNJ-212082 (abiraterone acetate) | English ->Korean |
Janssen Korea |
Janssen Research & Development - MODULE 2.6.4 Abiraterone Acetate: 2.6.4 Pharmacokinetics Written Summary | English ->Korean |
Janssen Korea |
Janssen Research & Development - MODULE 2.6.4 TOXICOLOGY TABULATED SUMMARY - JNJ-212082 (abiraterone acetate) | English ->Korean |
Janssen Korea |
Janssen Research & Development - MODULE 2.6.6 Abiraterone Acetate: 2.6.6 Toxicology Written Summary | English ->Korean |
Janssen Korea |
Janssen Research & Development - Module 2.7.5 Clinical Summary Literature References - JNJ-212082 (abiraterone acetate) | English ->Korean |
Janssen Korea |
Janssen Research & Development - Module 2.7.3 Summary of Clinical Efficacy - JNJ-212082 (abiraterone acetate) | English ->Korean |
Janssen Korea |
Janssen Research & Development - MODULE 2.7.2 Summary of Clinical Pharmacology Studies - JNJ-212082 (abiraterone acetate) | English ->Korean |
Janssen Korea |
Janssen Research & Development - Module 2.7.2 Summary of Clinical Pharmacology Studies - Chronic Hepatitis C Infection TMC435 (simeprevir) 7 March 2013 | English ->Korean |
Janssen Korea |
Janssen Research & Development - Module 2.7.4 Summary of Clinical Safety - JNJ-212082 (abiraterone acetate) | English ->Korean |
Janssen Korea |
Janssen Research & Development - Clinical Study Report COU-AA-302 - JNJ-212082 (abiraterone acetate) | English ->Korean |
Janssen Korea |
Janssen Research & Development - Abiraterone Acetate Tablet 2.3 Introduction - Zytiga M 2.3 quality | English ->Korean |
Janssen Korea |
Ibrutinib Frequently Asked Questions (FAQs) - Mar. 2014 | English ->Korean |
Janssen Korea |
Janssen Research & Development - JNJ-54767414 (daratumumab) - Investigator's Brochure - Edition 10 16 December 2013 | English ->Korean |
Janssen Korea |
HIGHLIGHTS OF PRESCRIBING INFORMATION - IMBRUVICATM (ibrutinib) capsules, for oral use Initial U.S. Approval: 2013 | English ->Korean |
Janssen Korea |
Simponi (golimumab) 50 mg FVP (IV) - 2.3.A.1 Facilities and Equipment Cilag | English ->Korean |
Janssen Korea |
Simponi (golimumab) 50 mg FVP (IV) - Module 2.3.A.1 Facilities and Equipment Leiden | English ->Korean |
Janssen Korea |
Simponi (golimumab) 50 mg FVP (IV) - Module 2.3.A.2 Adventitious Agents Safety Evaluation Non Viral Adventitious Agents | English ->Korean |
Janssen Korea |
Simponi (golimumab) 50 mg FVP (IV) - Module 2.3.A.2 Adventitious Agents Safety Evaluation Viral Adventitious Agents | English ->Korean |
Janssen Korea |
Simponi (golimumab) 50 mg FVP (IV) - 2.3.P.1 Description and Composition of the Drug Product | English ->Korean |
Janssen Korea |
Simponi (golimumab) 50 mg FVP (IV) - 2.3.P.2 Pharmaceutical Development | English ->Korean |
Janssen Korea |
Simponi (golimumab) 50 mg FVP (IV) - 2.3.P.3 Manufacture | English ->Korean |
Janssen Korea |
Simponi (golimumab) 50 mg FVP (IV) - 2.3.P.4 Control of Excipients | English ->Korean |
Janssen Korea |
Simponi (golimumab) 50 mg FVP (IV) - 2.3.P.5 Control of Drug Product | English ->Korean |
Janssen Korea |
Simponi (golimumab) 50 mg FVP (IV) - 2.3.P.6 Reference Standards or Materials | English ->Korean |
Janssen Korea |
Simponi (golimumab) 50 mg FVP (IV) - 2.3.P.7 Container Closure System | English ->Korean |
Janssen Korea |
Simponi (golimumab) 50 mg FVP (IV) - 2.3.P.8 Stability | English ->Korean |
Janssen Korea |
Project name: Paul Stoffels Academic Award | Korean ->English |
Janssen Korea |
Food and Drug General Information Service Ministry of Food and Drug Safety - Response to the first Preliminary Review of Pharmaceuticals, etc. (One case in addition to Janssen Korea-Ultracet Tab.) 3 April 2014 | Korean ->English |
Janssen Korea |
Janssen Research & Development - Aragon Pharmaceuticals, Inc. CTA response JNJ-56021927 (ARN-509) Protocol: ARN-509-003 2 April 2014 | English ->Korean |
Janssen Korea |
JNJ-26866138 (bortezomib) Clinical Study Report 26866138MMY2045 SYNOPSIS 6 September 2012 | English ->Korean |
Janssen Korea |
VELCADE (bortezomib): Clinical Study Report Synopsis 26866138-MMY-3021 SYNOPSIS 17 FEBRUARY 2011 | English ->Korean |
Janssen Korea |
SYNOPSIS - Study Protocol No.: DOXIL-MMY-3001 - R031059, DOXIL®/CAELYX® | English ->Korean |
Janssen Korea |
Janssen Research & Development - SIMPONI (golimumab) Clinical Overview - Intravenous Golimumab for the Treatment of Rheumatoid Arthritis (52-Week Submission) 21 Dec 2012 | English ->Korean |
Janssen Korea |
Janssen Korea - Purchase Procedures and Regulations | Korean ->English |
Janssen Korea |
Use of Topiramate monotherapy in pediatrics | Korean ->English |
Janssen Korea |
Janssen Research & Development - Ibrutinib (PCI-32765 - Request for Orphan Drug Designation - Use of Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia 10 March 2014 | English ->Korean |
Janssen Korea |
DACOGEN (decitabine) Response Document - Reference No.: 20130175958 | English ->Korean |
Janssen Korea |
Latina Standard Operating Procedure - DS-SOP-9528 - Flussi personale/materiali-norme generali di comportamento - 07-Jan-2014 | Italian ->Korean |
Janssen Korea |
Latina Standard Operating Procedure - DS-SOP-9548 - Addestramento del personale - 9-Nov-2013 | Italian ->Korean |
Janssen Korea |
Latina Standard Operating Procedure - DS-SOP-9942- Norme generali di pulizia in produzione - 09-Jul-2013 | Italian ->Korean |
Janssen Korea |
JANSSEN CILAG - DS-WI-10824 - Pulizia aree, stanze e linee di confezionamento - 09 Sep. 2011 | Italian ->Korean |
Janssen Korea |
Latina Standard Operating Procedure - DS-WI-14885 - Re-processing - 24-Apr-2013 | Italian ->Korean |
Janssen Korea |
Homonal and metabolic changes induced by flunarizine therapy : preliminary results - Pietro Cortelli | English ->Korean |
Janssen Korea |
Acta Neurol Scand., 1988:77:289-292 - Neuroendocrinological evidence of an anti--dopaminenergic effect of flunarizine - Pietro Cortelli | English ->Korean |
Janssen Korea |
Flunarizine and migraine in childhood - An evaluation of endocrine function - Vincenzo Guidetti | English ->Korean |
Janssen Korea |
Prophylactic Drugs and Cytokine and Leptin Levels in Children With Migraine - Tugba Hirfanoglu | English ->Korean |
Janssen Korea |
Safety and efficacy of flunarizine in childhood migraine: 11 years' experience, with emphasis on its effect in hemiplegic migraine - BASHEER PEER MOHAMED | English ->Korean |
Janssen Korea |
Flunarizine v. placevo in childhood migraine. A double-blind study - Fulvio Sorge, Enrico Marano | English ->Korean |
Janssen Korea |
Flunarizine in prophylaxis of childhood migraine A double-blind, placebo-controlled, crossover study - Fulvio Sorge, Roberto De Simone, Enrico Marano, Maria Noiano, Giuseppe Orefice, Pietro Carrieri | English ->Korean |
Janssen Korea |
The Act on Combating Bribery of Foreign Public Officials in International Business Transactions - [Enforced on March 24, 2010] [Act No. 10178, March 24, 2010, Partial Amendment] Ministry of Justice (International Criminal Affairs Division) | Korean ->English |
Janssen Korea |
Janssen Research & Development - siltuximab (CNTO-328)- Request for Orphan Drug Designation 24 December 2013 | English ->Korean |
Janssen Korea |
Media Fact Sheet: Canagliflozin Phase 3 Program | English ->Korean |
Janssen Korea |
Canagliflozin Pre-Reading - Diabetes: Detection and Diagnosis | English ->Korean |
Janssen Korea |
Canagliflozin Pre-Reading - Diabetes: Introduction and Overview | English ->Korean |
Janssen Korea |
Canagliflozin Pre-Reading - Module 3: Complications of Diabetes | English ->Korean |
Janssen Korea |
Canagliflozin Pre-Reading - Module 4 : Treatment of Diabetes | English ->Korean |
Janssen Korea |
Janssen Research & Development -STELARA® (ustekinumab) - Clinical Overview - MOW - Treatment of Adult Patients with Active Psoriatic Arthritis – 1-Year Submission 1 August 2013 | English ->Korean |
Janssen Korea |
Janssen Research & Development - STELARA® (ustekinumab) - 52-Week CNTO1275PSA3001 Clinical Study Report SYNOPSIS 2 May 2013 | English ->Korean |
Janssen Korea |
Janssen Research & Development - STELARA® (ustekinumab) - 60-Week Clinical Study Report CNTO1275PSA3002 SYNOPSIS 30 May 2013 | English ->Korean |
Janssen Korea |
OROS® Hydromorphone: Clinical Study Report NMT 1077-301 - SYNOPSIS (SEPARATE DOCUMENT) | English ->Korean |
Janssen Korea |
Janssen-Cilag EMEA Medical Affairs - Clinical Study Report - Protocol 42801PAI3001; Phase IIIb AP-77 (OROS® Hydromorphone hydrochloride) Date effective:31 OCT 2008 | English ->Korean |
Janssen Korea |
FINAL CLINICAL STUDY REPORT - A REPEATEO-DOSE PHARMACOKINETIC EVALUATION OF DILAUDID@ SR TABLETS (HYDROMORPHONE HCL) IN PATIENTS WITH CHRONIC PAIN - 19 Nov. 1999 | English ->Korean |
Janssen Korea |
ABBREVIATED FINAL REPORT for PROTOCOL DO-118X - Safety and Tolerability of Long-term Administration of Dilaudid SR (Hydromorphone HCl) in Cancer Pain (DO-118X) 21 October 2005 | English ->Korean |
Janssen Korea |
OROS® Hydromorphone HCl Extended-Release Tablets - DO-127/DO-127X, SYNOPSIS REPORT - 05 December 2005 | English ->Korean |
Janssen Korea |
An_ Esp. Pediatr.. 32. 3 (213-21 R). 1990 - Flunarizine or dihydroergotamine for the treatment of migraine in childhood. Randomized study of 50 patients - L LASTRA MARTINEZ. J HERRANZ FERNANDEZ and R ARTEAGA MANJON-CABEZA | English ->Korean |
Janssen Korea |
Migraine Prevention with Flunarizine and Acetylsalicylic Acid A Double Blind Study - R. Pothmann Pediatric Clinic (Director: Prof. Dr. W. Mortier), Wuppertal Childhood Migraine Prophylaxis with Calcium Antagonist Flunarizine and Acetylsalicylic Acid. A Do | English ->Korean |
Janssen Korea |
Schweiz. med. Wschr. 1990, 120:1731-1736 - Treatment of Pediatric Migraine with Flunarizine and Propranolol - J. Lütschg, F. Vassella Pediatric Clinic, Canton Hospital Bruderholz University Pediatric Clinic, Bern | English ->Korean |
Janssen Korea |
Korea Food & Drug Administration - Title: Approval of Handling Exceptional Drugs of Drug Handler - Morphine Alkaloid, Hydromorphone N-Oxide, 2.2-Bishydromorphone, Dihydromorphine - From the date of approval to the 31st of Dec., 2013 | Korean ->English |
Janssen Korea |
Korea Food & Drug Administration - Title: Approval of Handling Exceptional Drugs of Drug Handler - Hydromorphone HCL Hydromorphone HCL standard (USP) | Korean ->English |
Janssen Korea |
Cell to Sell Anti-TNF Platform - Module 1: Basic immunology & immunological diseases | English ->Korean |
Janssen Korea |
Cell to Sell Anti-TNF Platform - Module 2: Immunology | English ->Korean |
Janssen Korea |
Cell to Sell Anti-TNF Platform - Module 3: Monoclonal antibodies | English ->Korean |
Janssen Korea |
Cell to Sell Anti-TNF Platform - Module 4: TNFα and anti-TNFs | English ->Korean |
Janssen Korea |
Cell to Sell Dermatology Expertise - Module 1: Anatomy and physiology | English ->Korean |
Janssen Korea |
Cell to Sell Dermatology Expertise - Module 2: Disease states | English ->Korean |
Janssen Korea |
Cell to Sell Dermatology Expertise - Module 3: Management of psoriasis | English ->Korean |
Janssen Korea |
Cell to Sell Dermatology Expertise - Module 4: Remicade® in the treatment of psoriasis | English ->Korean |
Janssen Korea |
Cell to Sell Dermatology Expertise - Module 6: Dermatology Competitive Overview | English ->Korean |
Janssen Korea |
Cell to Sell Gastroenterology Expertise - Module 1: Anatomy and physiology | English ->Korean |
Janssen Korea |
Cell to Sell Gastroenterology Expertise - Module 2: Diseases of the gastrointestinal tract – Crohn's disease and ulcerative colitis | English ->Korean |
Janssen Korea |
Cell to Sell Gastroenterology Expertise - Module 2: Management of inflammatory bowel diseases (IBD) | English ->Korean |
Janssen Korea |
Cell to Sell Gastroenterology Expertise - Module 4: Remicade® clinical efficacy and tolerability | English ->Korean |
Janssen Korea |
Cell to Sell Gastroenterology Expertise - Module 5: Competition in Gastroenterology | English ->Korean |
Janssen Korea |
Cell to Sell Gastroenterology Expertise - Module 6: Gastroenterology Competitive Overview | English ->Korean |
Janssen Korea |
Cell to Sell Rheumatology Expertise - Module 1: Anatomy and physiology | English ->Korean |
Janssen Korea |
Cell to Sell Rheumatology Expertise - Module 2: Diseases of the musculoskeletal system | English ->Korean |
Janssen Korea |
Cell to Sell Rheumatology Expertise - Module 3: Management of rheumatological disorders | English ->Korean |
Janssen Korea |
Cell to Sell Rheumatology Expertise - Module 4: Remicade® clinical efficacy and tolerability | English ->Korean |
Janssen Korea |
Cell to Sell Rheumatology Expertise - Module 5: Competition in Rheumatology | English ->Korean |
Janssen Korea |
Cell to Sell Rheumatology Expertise - Module 6: Rheumatology Competitive Overview | English ->Korean |
Janssen Korea |
Cell to Sell Rheumatology Expertise - Module 7: Simponi Expertise Training module | English ->Korean |
Janssen Korea |
Answers to the Most Common Objections for Golimumab_Sep. 12_53 min. Video dictation & translation | English ->Korean video dictation & translation |
Janssen Korea |
Answers to the Most Common Objections for Infliximab_Oct. 2012_74 min. Video dictation & translation | English ->Korean video dictation & translation |
Janssen Korea |
TERMS AND CONDITIONS OF PURCHASE - These Terms and Conditions of Purchase form a part of the Award Contract (as defined below) and constitutes the entire agreement between Buyer and Seller. | English ->Korean |
Janssen Korea |
Johnson & Johnson Pte Ltd Singapore - Johnson & Johnson International Safety, Health and Environmental Policy | English ->Korean |
Janssen Korea |
Johnson & Johnson Pte Ltd Singapore - Conflict of Interest Policy | English ->Korean |
Janssen Korea |
Johnson & Johnson Quality Standard STD - 005 - Pallet Management - Issue Date: August 3, 2011 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pte Ltd Singapore - Annexure F – Change Control - Dear Valued Supplier, | English ->Korean |
Janssen Korea |
TMC207 – MODULE 2.4 Nonclinical Overview - Issued Date: 08-May-2012 | English ->Korean |
Janssen Korea |
Janssen Research & Development - Ibrutinib (PCI-32765) - Request for Orphan Drug Designation - Use of Ibrutinib for the Treatment of Mantle Cell Lymphoma 20 November 2013 | English ->Korean |
Janssen Korea |
Janssen Korea - Clinical Study Report - Tolerability improvement of Ultracet by titration in Korean OA patients : Multicenter, randomized, double-blind study Clinical Study Protocol ULT-KOR-04; Phase-IV November 5, 2013 | Korean ->English |
Janssen Korea |
CILAG AG Chemical Operation - FABRIKATIONSVORSCHRIFT - 465660 Blocked Aminotriazine ChemOp-FV465660-HB01 Endprodukt(e): 75333 Oecitabine (0-150) | German->Korean |
Janssen Korea |
CILAG AG Chemical Operation - FABRIKATIONSVORSCHRIFT - 465660 Blocked Aminotriazine ChemOp-FV465660-HB01 Endprodukt(e): 75333 Decitabine (D-150) | German->Korean |
Janssen Korea |
CILAG AG Chemical Operation - Original-Ghargenblatt - 465660 Blocked Aminotriazine | German->Korean |
Janssen Korea |
CILAG AG Chemical Operation - FABRIKATIONSVORSCHRIFT - 465670 D-150 Grude ChemOp-FV465670-HA02 Endprodukt(e): 75333 Decitabine (D-150) | German->Korean |
Janssen Korea |
CILAG AG Chemical Operation - FABRIKATIONSVORSCHRIFT - 75333 Decitabine (D-150) ChemOp-FV75333-HA02 Endprodukt(e): 75333 Decitabine (D-150) | German->Korean |
Janssen Korea |
Janssen Research & Development - COMPANY CORE DATA SHEET - Ibrutinib (TRADENAME) 14 June 2013 VERSION 01 | English ->Korean |
Janssen Korea |
Janssen Korea - Clinical Study Report - Rapid onset of action of Ultracet in orthopedic surgical pain: Randomized, double-blind, placebo-controlled study - Clinical Study Protocol ULT-KOR-12; Phase-IV Tramadol HCl / Acetaminophen October 31, 2013 | Korean ->English |
Janssen Korea |
Janssen Research & Development - Flunarizine (Sibelium ) MODULE 2.5 Clinical Overview - Approved, Date: 6 September 2013 | English ->Korean |
Janssen Korea |
UNODC/HONLAP/34/6 - Report of the Thirty-fourth Meeting of Heads of National Drug Law Enforcement Agencies, Asia and the Pacific, held in Bangkok from 30 November to 3 December 2010 - 10 December 2010 | English ->Korean |
Janssen Korea |
Janssen Korea - Clinical Study Report - The efficacy and safety of Tramadol/Acetaminophen versus Celecoxib for the treatment of chronic low back pain - Clinical Study Protocol ULT-KOR-013; Phase-IV Tramadol HCl / Acetaminophen October 25, 2013 | Korean ->English |
Janssen Korea |
Janssen Korea - Clinical Study Report - The efficacy of Ultracet for the treatment of low back pain in patients receiving a NSAID or a Cox-2 selective inhibitor - Clinical Study Protocol ULT-KOR-11; Phase-IV Tramadol HCl / Acetaminophen October 22, 2013 | Korean ->English |
Janssen Korea |
Janssen Korea - Clinical Study Report - Clinical usefulness and Quality of life of OROS® hydromorphone in strong opioid-naïve cancer pain patients; Multicenter, prospective, open-label and observational study - Clinical Study Protocol HYD-KOR-5011; Observ | Korean ->English |
Janssen Korea |
Berna a Crucell Company - Product Monograph - HEPAVAX-GENE® Recombinant hepatitis B vaccine HEPAVAX-GENE® TF Thiomersal-free, recombinant hepatitis B vaccine | English ->Korean |
Janssen Korea |
Grünenthal GmbH - Synopsis HP5503/03 of August 30, 2001 | English ->Korean |
Janssen Korea |
Grünenthal GmbH - Synopsis HP5503/04 of December 01, 2000 | English ->Korean |
Janssen Korea |
Grünenthal GmbH - CG5503 SGS Biopharma # B100514 Study HP5503/05 (PK449; HU268) SYNOPSIS | English ->Korean |
Janssen Korea |
Grünenthal GmbH - Synopsis HP5503/07 October 2003 | English ->Korean |
Janssen Korea |
Grünenthal GmbH - Synopsis HP5503/10 10 August 2004 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1007; HP5503/14 Study Period: Start: 13 June 2005; Completed: 26 Sept 2005 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1006 (HP5503/15) Study Period: 14 November 2005 – 11 May 2006 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1002 (HP5503/16) Study Period: Clinical Conduct: 16 November 2005 to 9 June 2006 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1008 (HP5503/19) Study Period: 09 October 2006 to 19 December 2006 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1009 (HP5503/20) Study Period: Clinical Conduct: 28 Sep 2005 – 16 Nov 2005 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1010 (HP5503/21) Study Period: Clinical Conduct: 15 November 2005 – 12 December 2005 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1011 (HP5503/22) Study Period: 19 May 2006 to 23 August 2006 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1013 (HP5503/23) Study Period: 06 September 2006 to 29 September 2006 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1018; HP5503/25 Study Period: 07 May 2007 - 31 August 2007 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1019 (HP5503/30) Study Period: Clinical Conduct: 31 Aug 2006 to 07 Feb 2007 | English ->Korean |
Janssen Korea |
Grünenthal GmbH - Synopsis HP 5503/01 Protocol-No.: Grünenthal GmbH study HP 5503/01 - IPHAR 96/313a Time of Clinical Part: 30.01.1997 - 07.10.1997 | English ->Korean |
Janssen Korea |
Grünenthal GmbH - Synopsis HP5503/02 March 28, 2001 | English ->Korean |
Janssen Korea |
Grünenthal GmbH - Synopsis HP5503/06 November 2003 | English ->Korean |
Janssen Korea |
Grünenthal GmbH - Synopsis HP5503/09 9 August 2004 | English ->Korean |
Janssen Korea |
Grünenthal GmbH - Synopsis HP5503/11 23 December 2004 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1005 (HP5503/13) Study Period: Clinical Conduct: 8 June 2005 – 6 October 2005 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333 PAI 1016 (HP5503/24) Study Period: Start: 11 April 2006; Completion: 26 April 2006 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1014 (HP5503/34) Study Period: Clinical Conduct: 06 March 2007 to 25 March 2007 | English ->Korean |
Janssen Korea |
Grünenthal GmbH - Synopsis KF5503/01 Studied period (years): 0.8 years | English ->Korean |
Janssen Korea |
Grünenthal GmbH - Synopsis KF5503/08 Study Period (years): 10 September 2001 – 20 November 2001 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1027 (HP5503) Study Period: 30 April 2007 to 27 May 2007 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1024 (HP5503/35) Study Period: 19 July 2007 to 22 August 2007 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1025 (HP5503/29) Study Period: 26 June 2007 to 08 August 2007 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1026 Study Period: 01 May 2007 to 11 June 2007 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333–PAI–1028 (HP5503/44) Study Period: 15 September 2008 to 12 December 2008; Database lock: 19 December 2008 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333–PAI–1033 (HP5503/31) Study Period: 15 September 2008 to 27 October 2008, Database lock: 12 December 2008 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1034 (HP5503/42) Study Period: 15 September 2008 to 24 October 2008, Database lock: 4 December 2008 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1035 (HP5503/39) Study Period: 05 November 2008 to 23 December 2008; Database lock date: 27 January 2009 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333–PAI–1036 (HP5503/38) Study Period: 19 September 2008 to 13 October 2008, Database lock: 20 November 2008 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1037 (HP5503/57) Study Period: 21 November 2008 until 24 December 2008; Database lock date: 02 February 2009 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1038 (HP5503/58) Study Period: 1 December 2008 to 19 January 2009; Database lock: 16 February 2009 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1046 (HP5503/61) Study Period: 04 March 2009 to 05 May 2009, Database lock: 12 May 2009 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1047 (HP5503/62) Study Period: First subject enrolled: 12 May 2009 Last subject completed: 27 May 2009 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1055 (HP5503/67) Study Period: 04 August 2009 (first subject in) to 25 September 2009 (last subject out) | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1057 (HP5503/80) Study Period: 13 May 2010 to 07 June 2010, Database lock: 23 June 2010 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1058 (HP5503/81) Study Period: 20 May 2010 to 24 June 2010, Database lock: 06 June 2010 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1059; (HP5503/82) Study Period: 30 July 2010 to 25 August 2010, Database lock: 3 September 2010 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1060; HP5503/83 Study Period: 21 July 2010 to 17 August 2010 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-1061; HP5503/84 Study Period: 13 July 2010 to 11 August 2010, Database lock: 25 August 2010 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-3007 (KF5503/24) Study Period: 14 November 2006 – 25 July 2008 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-3016 (KF5503/35/A) 15 October 2008 Version 5.0 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-3018 (KF5503/38) Study Period: 28 January 2008 – 3 October 2008 | English ->Korean |
Janssen Korea |
Janssen Research & Development - JNJ-28431754 (Canagliflozin) Treatment of Adults with T2DM MODULE 2.5 Clinical Overview - Approved, Date: 3 January 2013 | English ->Korean |
Janssen Korea |
Janssen Research & Development - JNJ-28431754 (Canagliflozin) Treatment of Adults with T2DM Module 2.4 Nonclinical Overview- Issue/Report Date: 23 OCTOBER 2012 | English ->Korean |
Janssen Korea |
Janssen Korea - Clinical Study Report - Ultracet for the treatment of pain of rheumatoid arthritis: Randomized, double-blind, placebo controlled add-on therapy - Clinical Study Protocol ULT-KOR-02; Phase-IV Tramadol HCl / Acetaminophen Date of Issue: Octo | Korean ->English |
Janssen Korea |
Janssen Korea - Clinical Study Report - A randomized, prospective comparison of omeprazole versus rabeprazole in the treatment of peptic ulcer disease Clinical Study Protocol RAB-KOR-13; Phase-IV Date of Issue: October 1, 2013 | Korean ->English |
Janssen Korea |
CNTO 1275 Psoriatic Arthritis Module 5.3 Clinical Study Report - Synopsis (C0743T10) Studied Period: 21 Dec 2005/20 Sep 2007 | English ->Korean |
Janssen Korea |
STELARA® (ustekinumab) Clinical Study Report C0743T26 - Issue Date: 25 Oct 2011 Study Period: 21 Oct 2008—09 Dec 2010 | English ->Korean |
Janssen Korea |
STELARA® (ustekinumab) 24-Week CNTO1275PSA3001 Clinical Study Report - SYNOPSIS Issue Date: 17 Jan 2013 Study Period: Through Week 24 | English ->Korean |
Janssen Korea |
STELARA® (ustekinumab) Clinical Study Report CNTO1275PSA3002 24-Week CSR - SYNOPSIS Issue Date: 17 Jan 2013 Study Period: Through Week 24 | English ->Korean |
Janssen Korea |
Grünenthal GmbH - Module no. 2.6.1 Introduction Tapentadol | English ->Korean |
Janssen Korea |
Grünenthal GmbH - Module no. 2.6.2 Pharmacology Written Summary Tapentadol | English ->Korean |
Janssen Korea |
Grünenthal GmbH - Module no. 2.6.4 Pharmacokinetics Written Summary Tapentadol | English ->Korean |
Janssen Korea |
Grünenthal GmbH - Module no. 2.6.6 Toxicology Written Summary Tapentadol | English ->Korean |
Janssen Korea |
The quality management system of CILAG AG | English ->Korean |
Janssen Korea |
Decitabine - 2.3.S.7 Stability 1. STABILITY SUMMARY AND CONCLUSIONS | English ->Korean |
Janssen Korea |
R076477 (paliperidone) Clinical Protocol R076477BIP3002 Pending Review, Date: 6 September 2013 | English ->Korean |
Janssen Korea |
Centocor, Inc - CNTO 148 (golimumab) Rheumatoid Arthritis Module 5.3 Clinical Study Report (48-Week) Synopsis (C0524T12 GO LIVE) Approved 23 Jul 2009 | English ->Korean |
Janssen Korea |
Janssen Research & Development - SIMPONI® (golimumab) 52-Week CNTO148ART3001 Clinical Study Report SYNOPSIS Issue Date: 13 Jul 2012 | English ->Korean |
Janssen Korea |
Immunobiology Research - CNTO 148 (golimumab) Module 4.2.1.1 Discovery Report: DIS.RES.DRR.011.ds.A.doc Title: Effect of Golimumab in the Tg197 Transgenic Mouse Experimental Arthritis Model July 9, 2007 | English ->Korean |
Janssen Korea |
Centocor, Inc - CNTO 148 (golimumab) Module 4.2.2.2 P-2000-016 Report Body (MULTIPLE INTRAVENOUS DOSE PHARMACOKINETIC STUDY IN CYNOMOLGUS MONKEYS WITH rTNV148B (Anti-human TNFa Monoclonal Antibody) REVISED SUMMARY REPORT July 12,2007 | English ->Korean |
Janssen Korea |
Centocor Research & Development - Golimumab: Clinical Study Report C0524T16 SYNOPSIS Issue Date: 13 May 2010 | English ->Korean |
Janssen Korea |
Janssen Research & Development - CNTO 148 (golimumab) Ulcerative colitis Module 5.3 C0524T17 Clinical Study Report SYNOPSIS Issue Date: 11 Aug 2011 | English ->Korean |
Janssen Korea |
Janssen Research & Development - SIMPONI® (golimumab) 54-Week Clinical Study Report C0524T18 SYNOPSIS Issue Date: 12 Jun 2012 | English ->Korean |
Janssen Korea |
Chonnam National University Hospital - Janssen Korea Bioequivalence Test Report for “Risperdal OD Tab. 1mg” | Korean ->English |
Janssen Korea |
Chonnam National University Hospital - Janssen Korea Bioequivalence Test Report for “Risperdal OD Tab. 2mg” | Korean ->English |
Janssen Korea |
Janssen Korea Post Marketing Surveillance - EVRATM (norelgestromin. ethinyl estradiol) Annual Report of Use Performance Surveys | Korean ->English |
Janssen Korea |
Janssen Korea Post Marketing Surveillance - Use Survey and Special Re-examination Report for RISPERDAL CONSTA® (January 8, 2005 - January 7, 2009) | Korean ->English |
Janssen Korea |
Janssen Korea Post Marketing Surveillance - Use Survey and Special Re-examination Report for Sporanox Injection (November 1, 2003 ~ November 21, 2008) | Korean ->English |
Janssen Korea |
Janssen Korea Post Marketing Surveillance - Use Survey and Special Re-examination Report for Ultracet Tab. (December 19, 2001 ~ December 18, 2007) | Korean ->English |
Janssen Korea |
Gilead Sciences, Inc. - Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Study GS-US-264-0103 Final Clinical Study Report - Study Period: 12 February 2010 (First subject screened) 12 April 2010 (Last subject observation) | English ->Korean |
Janssen Korea |
Gilead Sciences, Inc. - Emtricitabine/rilpivirine/tenofovir disoproxil fumarate Study GS-US-264-0101 Final Clinical Study Report - Study Period: 28 September 2009 (First subject screened) 03 December 2009 (Last subject observation) | English ->Korean |
Janssen Korea |
Mallinckrodt Inc. ("Mallinckrodt"), a Covidien company and the McNeil Consumer Healthcare Division of McNEIL-PPC, Inc. (“McNeil") - AMENDED AND REST ATED APAP SUPPLY AGREEMENT | English ->Korean |
Janssen Korea |
Grünenthal GmbH - Synopsis KF5503/02 - STUDY PERIOD First patient enrolled: 03 MAY, 2000 Last patient completed: 07 NOV, 2000 | English ->Korean |
Janssen Korea |
Grünenthal GmbH - Synopsis KF5503/04 - Study Period (years): 09 April 2001 to 14 August 2001 | English ->Korean |
Janssen Korea |
Grünenthal GmbH - Synopsis KF5503/05 - Study Period (years): 02 April 2001 – 30 July 2001 | English ->Korean |
Janssen Korea |
Grünenthal GmbH - Synopsis KF5503/09 - Study Period (years): July 2002 – January 2003 | English ->Korean |
Janssen Korea |
Grünenthal GmbH - Synopsis KF5503/10 - Study Period (years): May 2002 – November 2002 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: KF5503/19 (R331333-PAI-2001) Study Period: 14 July 2004 – 18 August 2005 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: KF5503/20 (R331333-PAI-2002)Study Initiation/Completion Dates: Start: 13 May 2004; Completed: 07 April 2005 | English ->Korean |
Janssen Korea |
Grünenthal GmbH - Synopsis KF5503/21 - 14 Feb 2007 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-2003 (KF5503/22) Study Period: 28 January 2005 to 19 August 2005 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-3003 (KF5503/32) Study Period: 02 August 2006 to 23 May 2007 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-3002 (KF5503/33) Study Period: 24 October 2006 to 22 August 2007 | English ->Korean |
Janssen Korea |
Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development - CLINICAL STUDY REPORT SYNOPSIS Protocol No.: R331333-PAI-3004 (KF5503/34) Study Period: 31 July 2006 to 17 July 2007 | English ->Korean |
Janssen Korea |
RATIONALE FOR ORPHAN DRUG DESIGNATION OF IBRUTINIB IN MCL AND CLL/SLL | English ->Korean |
Janssen Korea |
Hydromorphone: Clinical Study Report 42801-PAI-1008 | English ->Korean |
Janssen Korea |
Hydromorphone: Clinical Study Report 42801-PAI-1009 | English ->Korean |
Janssen Korea |
Pharmacyclics, Inc.; Janssen Research & Development, LLC - Ibrutinib (PCI-32765) MCL and CLL/SLL Module 2.5 Clinical Overview 13 June 2013 | English ->Korean |
Janssen Korea |
Pharmacyclics, Inc.; Janssen Research & Development, LLC - PCI-32765 (IBRUTINIB) MODULE 2.4 NONCLINICAL OVERVIEW 6 June 2013 | English ->Korean |
Janssen Korea |
Pharmacyclics, Inc. - Ibrutinib (PCI-32765) Clinical Study Report PCYC-1102-CA Synopsis 7 May 2013 | English ->Korean |
Janssen Korea |
Pharmacyclics, Inc. - PCI-32765 (ibrutinib) Clinical Study Report PCYC-1104-CA Synopsis 22 May 2013 | English ->Korean |
Janssen Korea |
Pharmacyclics, Inc. - Ibrutinib (PCI-32765) Clinical Study Report PCYC-04753 Synopsis 27 February 2013 | English ->Korean |
Janssen Korea |
Stichting Hemato-Oncologie, Erasmus Medical Center / Janssen Research & Development - VELCADE (bortezomib) Clinical Study Report 26866138-MMY-3003 Study Period: 04 May 2005 to 28 March 2011. Clinical cutoff: 12 April 2011 | English ->Korean |
Janssen Korea |
The PETHEMA Foundation/Janssen Research & Development - VELCADE (bortezomib) Clinical Study Report 26866138-MMY-3010 Study Period: 09 April 2006 to 12 July 2011 | English ->Korean |
Janssen Korea |
Intergroupe Francophone du Myélome (IFM), Service d’Hématologie Clinique, Nantes, cedex; France / Janssen Research & Development, LLC. - VELCADE (bortezomib) Clinical Study Report IFM 2005-01 Study Period: 04 July 2005 to 05 June 2009. | English ->Korean |
Janssen Korea |
Janssen Research & Development - R331333 (tapentadol) Acute Pain in Adults - Bridging Study Evaluation Approved, Date: 8 July 2013 | English ->Korean |
Janssen Korea |
F-MARC - THE "11+" Manual - A complete warm-up programme to prevent injuries | English ->Korean |
Janssen Korea |
FIFA 11+ - PART 1 RUNNING EXERCISES · 8 MINUTES PART 2 STRENGTH · PLYOMETRICS · BALANCE · 10 MINUTES PART 3 RUNNING EXERCISES · 2 MINUTES | English ->Korean |
Janssen Korea |
FIFA 11+ IMPLEMENTATION - 11 steps to implement the FIFA 11+ | English ->Korean |
Janssen Korea |
THE JOURNAL OF UROLOGY®, December 2002 - PHASE III STUDY OF MITOXANTRONE PLUS LOW DOSE PREDNISONE VERSUS LOW DOSE PREDNISONE ALONE IN PATIENTS WITH ASYMPTOMATIC HORMONE REFRACTORY PROSTATE CANCER - WILLIAM BERRY | English ->Korean |
Janssen Korea |
American Society of Clinical Oncology Clin Oncol 17:2506-2513. 1999 - Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study - By Philip W. Kantoff | English ->Korean |
Janssen Korea |
Chemotherapy With Mitoxantrone Plus Prednisone or Prednisone Alone for Symptomatic Hormone-Resistant Prostate Cancer: A Canadian Randomized Trial With Palliative End Points - By Ian F. Tannock 1996 | English ->Korean |
Janssen Korea |
Gilead Sciences, Inc. - Tenofovir (PMPA) Study GS-96-701 Clinical Study Report - November 13, 2000 | English ->Korean |
Janssen Korea |
Gilead Sciences, Inc. - Tenofovir Disoproxil Fumarate Study 901 Final Clinical Study Report - April 18, 2001 | English ->Korean |
Janssen Korea |
Tibotec Pharmaceuticals Ltd. - TMC278-TiDP6-C131 - Clinical Research Report - 0143385, Final, 23-Nov-2008 | English ->Korean |
Janssen Korea |
Tibotec Pharmaceuticals Ltd. - TMC278-TiDP6-C151 - Clinical Research Report - 0257412, Final, 23-Nov-2008 | English ->Korean |
Janssen Korea |
Tibotec Pharmaceuticals Ltd. - TMC278-TiDP6-C152 - Clinical Research Report - Issued Date: 10-Feb-2010 | English ->Korean |
Janssen Korea |
Exprimo/Tibotec - Rilpivirine TMC278 Ph III Pop PK final 25 June 2010 | English ->Korean |
Janssen Korea |
Exprimo/Tibotec - Rilpivirine TMC278-C204 Population PK 4 May 2007 | English ->Korean |
Janssen Korea |
Exprimo/Tibotec - TMC278-C204 96 wks Bayesian Feedback 19 March 2008 | English ->Korean |
Janssen Korea |
Gilead Sciences, Inc. - Viread (tenofovir disoproxil fumarate) Renal Impairment Data Summary (Studies GS-104-0235, GS-99-903, and GS-01-934) Final - 17 April 2006 | English ->Korean |
Janssen Korea |
Gilead Sciences, Inc. - Tenofovir Disoproxil Fumarate Study 902 Clinical Study Report Final - January 18, 2002 | English ->Korean |
Janssen Korea |
Gilead Sciences, Inc. - Tenofovir Disoproxil Fumarate Study GS-99-903 Open-Label Extension Week 192 Interim CSR - 13 November 2008 | English ->Korean |
Janssen Korea |
Gilead Sciences, Inc. - Tenofovir Disoproxil Fumarate Study GS-99-907 Clinical Study Report Final - March 18, 2002 | English ->Korean |
Janssen Korea |
Gilead Sciences, Inc. - Tenofovir Disoproxil Fumarate Study GS-99-910 Clinical Study Report Final - 24 July 2003 | English ->Korean |
Janssen Korea |
Gilead Sciences, Inc. - Emtricitabine/tenofovir disoproxil fumarate Final CSR GS-DE-164-0106 - 01 June 2007 | English ->Korean |
Janssen Korea |
Gilead Sciences, Inc. - Emtricitabine/tenofovir disoproxil fumarate Study GS-ES-164-0154 Abbreviated Clinical Study Report Final - 28 September 2009 | English ->Korean |
Janssen Korea |
Gilead Sciences, Inc. - Emtricitabine/tenofovir disoproxil fumarate Study GS-MC-164-0111 Final Clinical Study Report Final - 21 May 2008 | English ->Korean |
Janssen Korea |
Gilead Sciences, Inc. - Emtricitabine and Tenofovir Disoproxil Fumarate Final CSR GS-US-164-0107 - 23 August 2006 | English ->Korean |
Janssen Korea |
Gilead Sciences, Inc. - Emtricitabine/Tenofovir disoproxil fumarate + Atazanavir/ritonavir GS-US-164-0115 - SYNOPTIC CLINICAL STUDY REPORT - 25 March 2008 | English ->Korean |
Janssen Korea |
Abbott Laboratories. - ABT-378 M02-418 Clinical Study Report R&D/05/001 - 07 July 2005 | English ->Korean |
Janssen Korea |
Tibotec Pharmaceuticals Ltd. - NPR-TiDP -20060022-VRR - Virology Research Report - 0104540, Final, 19-Jan-2010 | English ->Korean |
Janssen Korea |
Gilead Sciences, Inc. - FTC/RPV/TDF FDC Nonclinical Report No. PC-264-2005 Virology Study Report for the Truvada Subset of the TMC278-TiDP6-C209 and TMC278-TiDP6-C215 Clinical Trial Virologic Failures by Week 48 Final - 3 August 2010 | English ->Korean |
Janssen Korea |
Tibotec Pharmaceuticals Ltd. - R278474-C201 - Clinical Research Report - Date: 21-Mar-2005 | English ->Korean |
Janssen Korea |
Tibotec Pharmaceuticals Ltd. - R278474-C202 - Clinical Research Report - Date: 28-Feb-2006 | English ->Korean |
Janssen Korea |
Tibotec Pharmaceuticals Ltd. - TMC278-TiDP6 - Pharmacokinetic/Pharmacodynamic Report - Date: 10-June-2010 | English ->Korean |
Janssen Korea |
QualityMetric. - CO-083029, Report for Trial C209 CRR- Date: 26 May 2010 | English ->Korean |
Janssen Korea |
QualityMetric. - CO-083029, Report for Trial C215 CRR - Date: 26 May 2010 | English ->Korean |
Janssen Korea |
Tibotec Pharmaceuticals Ltd. - TMC278-TiDP6-C906- Statistical Analysis Plan - Date: 28-Sep-2009 | English ->Korean |
Janssen Korea |
Tibotec Pharmaceuticals Ltd. - TMC278-IV1-AVMR - Antiviral Microbiology Report- Date: 16-Feb-2010 | English ->Korean |
Janssen Korea |
Tibotec Pharmaceuticals Ltd. - TMC278-IV2-AVMR - Antiviral Microbiology Report- Date: 26-May-2010 | English ->Korean |
Janssen Korea |
Triangle Pharmaceuticals, Inc.- Protocol No. FTC-301A: WEEK 24 INTERIM CLINICAUSTATISTICAL REPORT - August 26,2002 | English ->Korean |
Janssen Korea |
Triangle Pharmaceuticals, Inc.- Protocol Number-FTC-302: FINAL CLINICAL STUDY REPORT - August 9,2002 | English ->Korean |
Janssen Korea |
Triangle Pharmaceuticals, Inc.- Protocol No.: FTC-303 : FINAL CLINICAL STUDY REPORT - June 10,2002 | English ->Korean |
Janssen Korea |
Gilead Sciences, Inc. - Emtricitabine-Tenofovir DF Study GS-01-934 Interim Report (Week 144) - 02 May 2007 | English ->Korean |
Janssen Korea |
Exprimo/Tibotec - Rilpivirine TMC278 Ph III Pop PK - 25 June 2010 | English ->Korean |
Janssen Korea |
Exprimo/Tibotec - TMC278 48-week GAM analysis of Phase-III studies - 26 June 2010 | English ->Korean |
Janssen Korea |
Tibotec Pharmaceuticals Ltd. - TMC278-C204-W192-AVMR - Antiviral Microbiology Report- Date: 18-Mar-2010 | English ->Korean |
Janssen Korea |
Tibotec Pharmaceuticals Ltd. - TMC278-C209-C215-C904-W48-AVMR - Antiviral Microbiology Report- Date: 04-Jun-2010 | English ->Korean |
Janssen Korea |
Tibotec Pharmaceuticals Ltd. - TMC278-C904-LLV-AVMR - Antiviral Microbiology Report- Date: 28-May-2010 | English ->Korean |
Janssen Korea |
QualityMetric. - CO-083029, Report for pooled Trials C209 & C215 - Date: 14 June 2010 | English ->Korean |
Janssen Korea |
FTC/RPV/TDF Tablets 3.2.P.8.1 Stability Summary and Conclusions Final (RoW) (Purple Tablet) - May 2013 | English ->Korean |
Janssen Korea |
Emtricitabine 3.2.S.6 Container Closure System Final - RoW FTC | English ->Korean |
Janssen Korea |
Emtricitabine 3.2.S.1.3 General Properties Final - RoW FTC | English ->Korean |
Janssen Korea |
Patheon GMP Document | English ->Korean |
Janssen Korea |
2.7.3.4.1. Doses of FDC | English ->Korean |
Janssen Korea |
EVONIC TECHNOCHEMIC - RICHTLlNIE Reinigungsvalidierung - 20.02.2012 | German->Korean |
Janssen Korea |
Evonik Technochemie Dossenheim - IMS Übersicht-Richtlinien - Druckdatum: 30.01.2013 | German->Korean |
Janssen Korea |
Evonik Technochemie Dossenheim - RICHTLlNIE Validation Master Plan - Druckdatum: 04.02.2013 | German->Korean |
Janssen Korea |
Evonik Technochemie Dossenheim - RICHTLlNIE Validation Master Plan Anhang IT Qualifizierung und Validierung - Druckdatum: 04.02.2013 | German->Korean |
Janssen Korea |
Janssen Korea - Clinical Study Report - Safety and Efficacy of Topamax vs Carbamazepine in Benign rolandic epilepsy - TOP-KOR-18 ; Phase IV / Topiramate May 15, 2013 | Korean ->English |
Janssen Korea |
Janssen Research & Development - TMC207-C208-Stage 2-Final - Clinical Study Report Synopsis - Issued Date: 08-Nov-2012 | English ->Korean |
Janssen Korea |
Janssen Research & Development - TMC207-C209-W24- Clinical Study Report Synopsis - Issued Date: 15-May-2012 | English ->Korean |
Janssen Korea |
Janssen Research & Development - TMC207-C208-Stage 2-Interim Analysis - Clinical Study Report Synopsis - Issued Date: 09-May-2012 | English ->Korean |
Janssen Korea |
Decitabine (DACOGEN) authorization data | Korean ->English |
Janssen Korea |
Janssen Research and Development, Janssen-Cilag Limited, on behalf of Janssen-Cilag International N.V. - JNJ-212082 (abiraterone acetate) Module 2.5 Clinical Overview - Approved, Date: 10 June 2012 | English ->Korean |
Janssen Korea |
Janssen Research and Development, Janssen-Cilag Limited, on behalf of Janssen-Cilag International N.V. - JNJ-212082 (abiraterone acetate) MODULE 2.2 INTRODUCTION- Approved, Date: 10 June 2012 | English ->Korean |
Janssen Korea |
Janssen Research and Development, Janssen-Cilag Limited, on behalf of Janssen-Cilag International N.V. - JNJ-212082 (abiraterone acetate) Module 2.4 – Nonclinical Overview- 25 May 2012 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Grünenthal GmbH - Tapentadol ER: Clinical Overview - Tapentadol ER in the Management of Moderate to Severe Chronic Pain - Issue/Report Date: 23 NOVEMBER 2011 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development Grünenthal GmbH - Module 2.5 - Clinical Overview - Tapentadol IR in the Treatment of Moderate to Severe Acute Pain J&JPRD R331333; Grünenthal CG5503 (Tapentadol HCl) 12 AUGUST 2011 | English ->Korean |
Janssen Korea |
Grünenthal GmbH - Nonclinical Overview Tapentadol - AUGUST 2011 | English ->Korean |
Janssen Korea |
Janssen Korea - Clinical Study Report - Naturalistic dose optimization study of topiramate monotherapy in newly diagnosed pediatric patients - Clinical Study Protocol TOP-KOR-20; Phase-IV Topiramate April 30, 2013 | Korean ->English |
Janssen Korea |
Janssen Research & Development - Canagliflozin (JNJ-28431754) Treatment of Adults with T2DM Module 2.7.4 Summary of Clinical Safety - 19 May 2012 | English ->Korean |
Janssen Korea |
Janssen Korea - Clinical Study Report - The efficacy of Galantamine on the attention and frontal function of patients with Dementia of Alzheimer type - GAL-KOR-15; Observational study Galantamine May 2, 2013 | Korean ->English |
Janssen Korea |
Janssen Korea - Clinical Study Report - A randomized, comparative study of rabeprazole vs. ranitidine maintenance therapies for reflux esophagitis - Clinical Study Protocol RAB-KOR-09; Phase IV Rabeprazole April 30, 2013 | Korean ->English |
Janssen Korea |
KFDA Regulation -The purpose of these “Regulations for Labeling of Drug” (“Regulations”) is to prevent medication errors and to provide accurate and easy to understand information about the drug by deciding the type, method and registration procedures of | Korean ->English |
Janssen Korea |
Janssen Research & Development, LLC - Canagliflozin (JNJ-28431754) Treatment of Adults with T2DM Module 2.6.6 Toxicology Written Summary - 19 OCTOBER 2012 | English ->Korean |
Janssen Korea |
Janssen Research & Development, LLC - Canagliflozin (JNJ-28431754) Treatment of Adults with T2DM Module 2.6.2 Pharmacology Written Summary - 16 April 2012 | English ->Korean |
Janssen Korea |
Janssen Research & Development, LLC - Canagliflozin (JNJ-28431754) Treatment of Adults with T2DM Module 2.6.4 Pharmacokinetics Written Summary - 10 SEPTEMBER 2012 | English ->Korean |
Janssen Korea |
Janssen Research & Development, LLC - Canagliflozin (JNJ-28431754) Type 2 Diabetes Mellitus Module 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods - 14 May 2012 | English ->Korean |
Janssen Korea |
Janssen Research & Development, LLC - Canagliflozin (JNJ-28431754) Treatment of Adults with T2DM Module Module 2.7.3 Summary of Clinical Efficacy - 17 May 2012 | English ->Korean |
Janssen Korea |
Janssen Research & Development, LLC - JNJ-28431754 (Canagliflozin) - Position Paper for Bridging Study Evaluation in Korea Regarding Use of Canagliflozin in Asian Subjects - 19 March 2013 | English ->Korean |
Janssen Korea |
Janssen Korea - Clinical Study Report - A prospective, open-labeled, multicenter study of optimal dosages of OROS-methylphenidate in treating children and adolescents with Attention-Deficit Hyperactivity Disorder - CON-KOR-012 ; Phase IV Concerta (Methyl | Korean ->English |
Janssen Korea |
FTC/RPV/TDF Tablets 2.3.P Quality Overall Summary (QOS) Final - RoW (Tibotec) | English ->Korean |
Janssen Korea |
Emtricitabine 2.3.S Quality Overall Summary (QOS) [Emtricitabine] Final - FTC QoS RoW | English ->Korean |
Janssen Korea |
Tenofovir Disproxil Fumarate 2.3.S Quality Overall Summary (QOS) [Tenofovir Disoproxil Fumarate] Final - TDF QoS RoW | English ->Korean |
Janssen Korea |
HAVAS WORLDWIDE LIFE MEDICOM - Food articles for vaccinate-me com | English ->Korean |
Janssen Korea |
The Castleman's Study - Regarding: CNTO328MCD2001 top line results and publication planning - 5 April 2013 | English ->Korean |
Janssen Korea |
Janssen Inc. - Economic Evaluation of Abiraterone Acetate as Treatment for Metastatic Castration Resistant Prostate Cancer After Failure of Docetaxel - April 5, 2012 | English ->Korean |
Janssen Korea |
Gilead Sciences International Limited - Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Section 2.5 Clinical Overview Final - 18 August 2010 | English ->Korean |
Janssen Korea |
Gilead Sciences International Limited - Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Section 2.4 Nonclinical Overview Final - 17 August 2010 | English ->Korean |
Janssen Korea |
KFDA Public Document -Request to supply information - Implemented Pharmaceutical Management Division - 1254 (02.18 2013) | Korean ->English |
Janssen Korea |
Korea Food & Drug Administration (KFDA) - Request for data supplementation about the GMP appraisal results per item [Janssen Korea Co., Ltd. - Simponi Auto Injector 50mg (golimumab, genetic recombination)] Enforced, Bio Medicine Quality Control Bureau -35 | Korean ->English |
Janssen Korea |
Mx – A World of Opportunity Quick Reference Guide | English ->Korean |
Janssen Korea |
Overview: Mx – A World of Opportunity | English ->Korean |
Janssen Korea |
Mx – A World of Opportunity Simulation Workbook | English ->Korean |
Janssen Korea |
Congratulations on being named to the Litelia™ brand team! | English ->Korean |
Janssen Korea |
INVESTMENT RESULTS Cards - Simulation Activity | English ->Korean |
Janssen Korea |
Welcome to Mx – A World of Opportunity Training | English ->Korean |
Janssen Korea |
KFDA Documents for submission - Case: 1:13-cv-00154 Doc #: 1-1 Filed: 01/22/13 1 of 47. PageID #: 10 - CONSENT DECREE OF PERMANENT INJUCTION | English ->Korean |
Janssen Korea |
Janssen Korea - Clinical Protocol - R076477 (paliperidone) Protocol insert number(s); Phase 3 - 22 January 2013 | English ->Korean |
Janssen Korea |
Psoriasis-- The illness that brings indescribable misery and agony to patients as well as their families. Some 1.5 million are estimated to be suffering from psoriasis in the country, even denied the dignity of their life. - Video script translatoin | Korean ->English Video translaion |
Janssen Korea |
Invega Benefits and effects, Dosage & Invega - Dosage | Korean ->English |
Janssen Korea |
Janssen Research & Development - JNJ-28431754 (Canagliflozin) Treatment of Adults with T2DM Module 2.5 Clinical Overview- Issue/Report Date: 3 January 2013 | English ->Korean |
Janssen Korea |
Janssen Research & Development - JNJ-28431754 (Canagliflozin) Treatment of Adults with T2DM Module 2.4 Nonclinical Overview- Issue/Report Date: 23 October 2012 | English ->Korean |
Janssen Korea |
Centocor Ortho Biotech Inc. - Understanding prostate canser | English ->Korean |
Janssen Korea |
STUDY SYNOPSIS - Protocol Number: GLM-KOR-3001 - Study Title: A randomized, placebo-controlled, double blind study for the comparison of treatment response between golimumab and placebo groups for refractory intestinal Behçet’s disease (Phase III) -Kim, W | English ->Korean |
Janssen Korea |
STUDY SYNOPSIS - Protocol Number: INF-KOR-5005 - Study Title: Clinical course and prognostic factors with newly diagnosed moderate to severe UC in tertiary referral hospital setting in Korea. Principal Investigator/investigational site: Kim, HyoJong | English ->Korean |
Janssen Korea |
Zitiga (abiraterone acetate) 250 mg tablets brochure - For your urology practice - Oral theraphy - For patients with metastatic castration-resistant prostate cancer (mCRPC) who have received prior chemotheraphy containing docetaxel... | English ->Korean |
Janssen Korea |
Motilium-M - General Precautions | Korean ->English |
Janssen Korea |
Sibelium (5 ~ 10mg/day) - General Precautions | Korean ->English |
Janssen Korea |
Janssen Research & Development, LLC - TMC207 Module 2.5 Clinical overview - 11-June-2012 | English ->Korean |
Janssen Korea |
Janssen Research & Development, LLC - TMC207 5 OVERVIEW OF SAFETY- 11-June-2012 | English ->Korean |
Janssen Korea |
Janssen Korea Ltd - Protocol 26866138-LYM-3002 - Participant Information and Informed Consent Form & PLANNING OF VISITS AND STUDY PROCEDURES | English ->Korean |
Janssen Korea |
The Cochrane Collaboration - Adverse effects of biologics: a network meta-analysis and Cochrane overview (Review) - Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, MacDonald JK | English ->Korean |
Janssen Korea |
Effectiveness of Biologic Therapies for Rheumatoid Arthritis: An Indirect Comparisons Approach - Emily Beth Devine, Pharm .D. , M.B.A.. , Ph.D. , Rarael Alfonso-Cristanacho | English ->Korean |
Janssen Korea |
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA - J L Nam,1 | English ->Korean |
Janssen Korea |
Rheumatology Advance Access published March 16, 2012 - Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis - Xenofon Baraliakos1 | English ->Korean |
Janssen Korea |
A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis - Zoe Ash | English ->Korean |
Janssen Korea |
ARTHRITIS & RHEUMATISM Vol. 46, No. 6, June 2002 - The Relationship of Serum Infliximab Concentrations to Clinical Improvement in Rheumatoid Arthritis - Results From ATTRACT, a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial - E. William S | English ->Korean |
Janssen Korea |
Janssen Research & Development, LLC - COMPANY CORE DATA SHEET - Bedaquiline Tablets 24/May/2012 VERSION 01 | English ->Korean |
Janssen Korea |
Infliximab (chimeric anti-tumour necrosis factor monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial - Ravinder Maini, E William St Clair | English ->Korean |
Janssen Korea |
Rationale for Introducing One-day Durogesic Patches in Korea | Korean ->English |
Janssen Korea |
The Safety of Infliximab, Combined With Background Treatments, Among Patients With Rheumatoid Arthritis and Various Comorbidities A Large, Randomized, Placebo-Controlled Trial - Rene Westhovens | English ->Korean |
Janssen Korea |
Ann Rheum Dis 2007;66:1233–1238. doi: 10.1136/ard.2006.065995 - Double-blinded infliximab dose escalation in patients with rheumatoid arthritis - Mahboob U Rahman | English ->Korean |
Janssen Korea |
THERAPEUTIC EFFICACY OF MULTIPLE INTRAVENOUS INFUSIONS OF ANTI-TUMOR NECROSIS FACTOR CI! MONOCLONAL ANTIBODY COMBINED WITH LOW-DOSE WEEKLY METHOTREXATE IN - RHEUMATOID ARTHRITIS RAVINDER N. | English ->Korean |
Janssen Korea |
Grünenthal GmbH - Tapentadol COMPANY CORE DATA SHEET - 18 Nov 2011 Version 5.0 | English ->Korean |
Janssen Korea |
Ortho Biotech Oncology Research & Development, Unit of Johnson & Johnson Pharmaceutical Research & Development - Clinical Overview - DACOGEN for the Treatment of Adult Patients With Acute Myeloid Leukemia JNJ-30979754 (decitabine) - 13 MAY 2011 | English ->Korean |
Janssen Korea |
Zytiga(Abiraterone acetate) Frequently Asked Questions - August 2012 Version 5 EMEA Medical Affairs | English ->Korean |
Janssen Korea |
Janssen Research & Development, LLC - JNJ-40346527 Clinical Protocol 40346527ARA2001 Amendment 1 Issue/Report Date: 05 Aug 2012 | English ->Korean |
Janssen Korea |
Janssen Research & Development, LLC - NONCLINICAL SAFETY STUDY REPORT - TMC435 spiked with 5% T003010 TOX9694 - Report date: October 28, 2010 | English ->Korean |
Janssen Korea |
Huntingdon Life Science - Report TMC435350 + 5% T003010: In Vitro Mutation Test using Mouse Lymphoma L5178Y Cells - Sponsor’s Reference Number: 1986_0016574 J&JPRD Reference Number: TOX9698 - Issue Date: 30 November 2010 | English ->Korean |
Janssen Korea |
Tibotec Pharmaceuticals Ltd. - FINAL REPORT – Study Title - In Vitro Mammalian Chromosome Aberration Test of JNJ-38940642-AAA (T003010) Test Article JNJ-38940642-AAA Also known as T003010 (R493943) - 18 January 2012 | English ->Korean |
Janssen Korea |
Janssen Research & Development, LLC - FINAL REPORT - NON-CLINICAL SAFETY STUDY REPORT - TOX7895 Report date: December 18, 2006 | English ->Korean |
Janssen Korea |
TMC435-TiDP16 - Response to Korea Hea1th Authority (KFDA) - Request for Information Dated 12 and 13 Ju\y 2012 | English ->Korean |
Janssen Korea |
MASTER SUPPLY AGREEMENT - BETWEEN JOHNSON & JOHNSON PTE. LTD AND [FULL SUPPLIER NAME] - 12 OCTOBER 2011 | English ->Korean |
Janssen Korea |
Round Table Meeting with Dr. Ryan | English ->Korean |
Janssen Korea |
Janssen Research and Development, LLC - Protocol CNTO1275ARA2001 - Covance Central Laboratory Procedures presented by Alvin Yeong Investigator Training Center August 2012 | English ->Korean |
Janssen Korea |
Janssen Research and Development, LLC - CNTO1275ARA2001 IWRS Asia - August 2012 | English ->Korean |
Janssen Korea |
Janssen Research and Development, LLC - CNTO1275ARA2001 Welcome and Introduction - Andrew Greenspan, MD Senior Director, Immunology Janssen R&D - July 18 2012 | English ->Korean |
Janssen Korea |
Janssen Research and Development, LLC - CNTO1275ARA2001 Rheumatoid Arthritis - Andrew Greenspan, MD Senior Director, Immunology Janssen R&D - July 18 2012 | English ->Korean |
Janssen Korea |
Janssen Research and Development, LLC - CNTO1275ARA2001 Investigator Meeting - eResearchTechnology, Inc. (ERT), Centralized Digital 12-Lead ECG Services | English ->Korean |
Janssen Korea |
Motilium-M - Instructions for Use / General Precautions | Korean ->English |
Janssen Korea |
Janssen Research & Development, LLC - SIMPONI® (golimumab) GCP Inspection - Response to Korea KFDA Request Dated 13 Jun 2012 | English ->Korean |
Janssen Korea |
Centocor Research & Development, Inc. - SIMPONI™ (golimumab) Treatment of Rheumatoid Arthritis (52-Week and 104-Week Submission) Module 2.5 – Clinical Overview Date: 21 Sep 2010 | English ->Korean |
Janssen Korea |
Centocor Research & Development, Inc. - SIMPONI™ (golimumab) Treatment of Rheumatoid Arthritis (52-Week and 104-Week Submission) Module 2.5 – Clinical Overview Date: 17 Nov 2010 | English ->Korean |
Janssen Korea |
Centocor Inc. - SIMPONI™ (golimumab) Rheumatoid Arthritis Module 2.7.6 Synopsis of C0524T05 52wk Module 5.3 Clinical Study Report (52-Week) Approved 15 Oct 2009 | English ->Korean |
Janssen Korea |
Centocor Inc. - SIMPONI™ (golimumab) Rheumatoid Arthritis Module 2.7.6 Synopsis of C0524T05 104wk Module 5.3 Clinical Study Report (104-Week) Approved 15 Oct 2009 | English ->Korean |
Janssen Korea |
Centocor Inc. - SIMPONI™ (golimumab) Rheumatoid Arthritis Module 2.7.6 Synopsis of C0524T06 52wk Module 5.3 Clinical Study Report (52-Week) Approved 15 Oct 2009 | English ->Korean |
Janssen Korea |
Centocor Inc. - SIMPONI™ (golimumab) Rheumatoid Arthritis Module 2.7.6 Synopsis of C0524T06 104wk Module 5.3 Clinical Study Report (104-Week) Approved 15 Oct 2009 | English ->Korean |
Janssen Korea |
Centocor Inc. - SIMPONI™ (golimumab) Rheumatoid Arthritis Module 2.7.6 Synopsis of C0524T12 48wk Module 5.3 Clinical Study Report (48-Week) Approved 23 Jul 2009 | English ->Korean |
Janssen Korea |
Centocor Inc. - SIMPONI™ (golimumab) Rheumatoid Arthritis Module 2.7.6 Synopsis of C0524T14 Module 5.3 C0524T14 Clinical Study Report (Final) Date of Report: 08 Oct 2009 | English ->Korean |
Janssen Korea |
Centocor Inc. - SIMPONI™ (golimumab) Rheumatoid Arthritis Module 2.7.6Synopsis of C0524T08 Module 5.3 Clinical Study Report (52-Week) Approved 23 Sep 2010 | English ->Korean |
Janssen Korea |
ratiopharm GmbH - Midazolam-ratiopharm 2 mg/ml Lösung - Fachinformation (Zusammenfassung der Merkmale des Arzneimittels/SPC) | German->Korean |
Janssen Korea |
LINDO PHARM - Fachinformation - Percoffedrinol® N 50mg Tabletten | German->Korean |
Janssen Korea |
Janssen Research & Development, LLC - REMICADE® (infliximab) Shortened Infusion (across all adult indications Module 2.5 Clinical Overview - 14 May 2012 | English ->Korean |
Janssen Korea |
PDR_concise monograph - Zytiga ( abiraterone acetate ) – Janssen - THERAPEUTIC CLASS Nonsteroidal antiandrogen | English ->Korean |
Janssen Korea |
Harrison's Online_mCRPC - METASTATIC DISEASE: CASTRATE | English ->Korean |
Janssen Korea |
DeVita, Hellman (1) - Abiraterone Acetate / DeVita, Hellman (2) - Androgen Synthesis Inhibitors | English ->Korean |
Janssen Korea |
Bope and Kellerman.doc, Basic & Clinical Pharmacology.doc, Goodman & Gilman's.doc, Wein- Campbell-Walsh Urology.doc | English ->Korean |
Janssen Korea |
The Oncologist 2010;15:1073–1082 - Tolerability, Efficacy, and Safety of Pegylated Liposomal Doxorubicin in Combination with Carboplatin Versus Gemcitabine–Carboplatin for the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review - | English ->Korean |
Janssen Korea |
The new england journal of medicine may 26, 2011 - Abiraterone and Increased Survival in Metastatic Prostate Cancer - Johann S. de Bono, M.B. | English ->Korean |
Janssen Korea |
www.thelancet.com Vol 376 October 2, 2010 - Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial - Johann Sebastian de Bono | English ->Korean |
Janssen Korea |
Centocor Inc. - Psoriasis REMICADE® (infliximab) Module 2.5 Clinical Overview Date: 30 Mar 2007 | English ->Korean |
Janssen Korea |
Centocor Inc. - REMICADE® (infliximab) Ulcerative Colitis Module 5.3 Synopsis (C0168T37 ACT 1) Approved 18 Aug 2008 | English ->Korean |
Janssen Korea |
Centocor Research & Development, Inc. - Remicade® (infliximab) Pediatric Ulcerative Colitis Module 2.5 – Clinical Overview Date: 30 Nov 2010 | English ->Korean |
Janssen Korea |
Korea Food & Drug Administration (KFDA) Drug Safety Policy Department- Risk Evaluation and Mitigation Strategy (REMS) Reporting Guideline (Proposal) August 2011 | Korean ->English |
Janssen Korea |
Janssen Research & Development, LLC - CNTO 136 (Sirukumab) Module 1 Investigator’s Brochure - Release Date: 27 Apr 2012 | English ->Korean |
Janssen Korea |
Centocor Research & Development, Inc. - Remicade® (infliximab) Moderate Crohn’s Disease Module 2.5 – Clinical Overview Date: 24 Jun 2010 | English ->Korean |
Janssen Korea |
Centocor Ortho Biotech Inc. - Remicade® (infliximab) Moderate Crohn’s Disease Synopsis (C0168T67 SONIC) FINAL: 03 May 2010 | English ->Korean |
Janssen Korea |
The purpose of this Notification is to provide the criteria and procedure for designation of orphan drugs in accordance with the provisions of Article 31 and Article 42 of the Pharmaceutical Affairs Act | Korean ->English |
Janssen Korea |
JANSSEN PHARMCEUTICA - SOP-GEEL-103 - WERKINSTRUCTIE Beheer van referentieproducten binnen het labo | Danish->English |
Janssen Korea |
Tibotec Pharmaceuticals Ltd. - TMC435 Investigator’s Brochure Edition 6 - October 2011 Appendix 2: Nonclinical Single Dose Pharmacokinetics – Approved, Issued Date: 24-Oct-2011 | English ->Korean |
Janssen Korea |
Tibotec Pharmaceuticals Ltd. - TMC435 Investigator’s Brochure Edition 6 – October 2011 Appendix 3: Nonclinical Repeated Dose Pharmacokinetics – Approved, Issued Date: 24-Oct-2011 | English ->Korean |
Janssen Korea |
Tibotec Pharmaceuticals Ltd. - TMC435 Investigator’s Brochure Edition 6 – October 2011 – Appendix 10: Reproductive Developmental Toxicity - Approved, Issued Date: 24-Oct-2011 | English ->Korean |
Janssen Korea |
Tibotec Pharmaceuticals Ltd. - TMC435 Investigator’s Brochure Edition 6 – October 2011 – Appendix 9: Genotoxicity - Approved, Issued Date: 24-Oct-2011 | English ->Korean |
Janssen Korea |
Tibotec Pharmaceuticals Ltd. - TMC435 Investigator’s Brochure Edition 6 – October 2011 –Appendix 1: Nonclinical Safety Pharmacology - Approved, Issued Date: 24-Oct-2011 | English ->Korean |
Janssen Korea |
Tibotec Pharmaceuticals Ltd. - TMC435 Investigator’s Brochure Edition 6 – October 2011 –Antiviral Activity of TMC435 in Genotype 1a and 1b Replicons- Approved, Issued Date: 24-Oct-2011 | English ->Korean |
Janssen Korea |
Tibotec Pharmaceuticals Ltd. - TMC435 Investigator’s Brochure Edition 6 - October 2011 PHARMACOKINETICS AND METABOLISM IN ANIMALS – Approved, Issued Date: 24-Oct-2011 | English ->Korean |
Janssen Korea |
Good evening. Thank you Professor Yu for your kind introduction. - Video script dictation | English ->English video dictation |
Janssen Korea |
1. Hello, I am Moon, Yongwoon, the director of OOO. 2. I am so glad to be here to take part in ‘Peace In Mind.’ 3. Hello, I am Choi, Woo Suk from the OOO division. 4. Red team and Blue team, please come together. | Korean ->English |
Janssen Korea |
Peace In Mind’ started to overcome prejudice about people with schizophrenia and to help their return to society. | Korean ->English |
Janssen Korea |
Tibotec Pharmaceuticals Ltd. - TMC435 Investigator’s Brochure Edition 6 – October 2011 – SUMMARY - Approved, Issued Date: 24-Oct-2011 | English ->Korean |
Janssen Korea |
Korea/Standard Document/SOP/09. QQI - QQI001 - In-process control procedure, General | Korean ->English |
Janssen Korea |
Korea/Standard Document/SOP/10. QQL - QQL001 - Sampling Procedures | Korean ->English |
Janssen Korea |
Korea/Standard Document/SOP/10. QQL - QQL002 - Control Procedures of Reference Standards | Korean ->English |
Janssen Korea |
Korea/Standard Document/SOP/10. QQL006 - Calibration Program | Korean ->English |
Janssen Korea |
Korea/Standard Document/SOP/10. QQL007 - Stability Monitoring Program | Korean ->English |
Janssen Korea |
Korea/Standard Document/SOP/10. QQL008 - Objective - The purpose of this procedure is to validate the manufacturing process for the products manufactured by Janssen Korea in order to maintain repeatable and high quality standards. | Korean ->English |
Janssen Korea |
Korea/Standard Document/SOP/10. QQL010 - Objective-The purpose is to check that all equipment, systems and facilities used for manufacturing products in Janssen Korea are properly installed for continuous and stable operation without performance changes w | Korean ->English |
Janssen Korea |
Korea/Standard Document/SOP/10. QQL011 - Objective - The purpose of this procedure is validation and evaluation for standard equipment cleaning procedures to check whether the cleaned equipment used for medicine manufacturing process can be used for the n | Korean ->English |
Janssen Korea |
Korea/Standard Document/SOP/10. QQL012 -Validation of Analytical Methods - Objective - This purpose is to prove those different analysis devices, reagent and other raw materials don’t affect the analysis result during the test according to test method pro | Korean ->English |
Janssen Korea |
Korea/Standard Document/SOP/10. QQL013 - Policy for Handling Result of Out-Of-Specification and Out-Of-Trend - Objective -This is to establish criteria for re-testing and final decision by preparing investigation and procedure of decision in case test res | Korean ->English |
Janssen Korea |
Korea/Standard Document/SOP/11. QQM001 -Microbiological Testing Policy - Objective - The purpose of this procedure is to regulate test criteria for microorganisms, the method of how to collect the specimen, test frequency, the evaluation of test result an | Korean ->English |
Janssen Korea |
Korea/Standard Document/SOP/10. QQM002 - Objective - The purpose of this document is to specify the type and criteria of the water used in Janssen Korea, manage the supply of water that meets the quality requirements and test the water used for manufactur | Korean ->English |
Janssen Korea |
Korea/Standard Document/SOP/10. QQM003 - Microbiological Testing Policy - Objective - This is to define throughout microbial environment monitoring tests, which include microbial testing criteria for workplace where all non-sterile products produced by Ja | Korean ->English |
Janssen Korea |
Korea/Standard Document/SOP/10. QQM007 - Preservative Efficacy Test- Objective - This procedure is to keep the functionality and stability of preservatives used at Janssen Korea. | Korean ->English |
Janssen Korea |
Official Letter for Drug Safety - Issued date : March 6, 2012 - US FDA amended the permits for combined administration with “Statin" drug and recommended good care in its administration | Korean ->English |
Janssen Korea |
Asan Medical Center Institutional Review Board - Health related quality of life in female patients with chronic constipation - Protocol prepared on March 27, 2012, Version 1.0 | Korean ->English |
Janssen Korea |
Korean Institute of Tuberculosis Microbiology Department - Tubercular Bacilli Test SOP (Acid-fast Bacilli Smear and Culture Tests), 2008 | Korean ->English |
Janssen Korea |
Korean Institute of Tuberculosis Microbiology Department - [External Quality Control SOP], 2008 | Korean ->English |
Janssen Korea |
Korean Institute of Tuberculosis Microbiology Department - [Internal Quality Control SOP], 2008 | Korean ->English |
Janssen Korea |
Korea/Standard Document/SOP/08. QQG010 - Discard Procedure - Objective - This is to define the procedure for discarding raw materials and products. | Korean ->English |
Janssen Korea |
Korea/Standard Document/SOP/08. QQG011 - GMP assessment and Self audit procedure - Objective -This procedure is to define GMP assessment procedure, which is to assess whether Janssen Korea’s entire production and quality system are being operated effectiv | Korean ->English |
Janssen Korea |
Korea/Standard Document/SOP/08. QQG012 - Objective -This procedure is to receive quality of APIs and to ensure consistent quality of products being sold by Janssen Korea by defining procedures required for selection, evaluation and control of suppliers of | Korean ->English |
Janssen Korea |
Korea/Standard Document/SOP/08. QQG013 - Control procedure of packaging material’s artwork & specification | Korean ->English |
Janssen Korea |
Korea/Standard Document/SOP/08. QQG019 - Annual Product Review - Objective - This guideline is to evaluate the quality of products and to confirm and review if products meet the requirements of the law and OC by recording and reviewing relevant records re | Korean ->English |
Janssen Korea |
Korea/Standard Document/SOP/08. QQG021 - Change Control Procedure - Objective - The purpose of this statement is to maintain the product quality and compliance to Korean regulations and J&J criteria by regulating the procedures necessary for management of | Korean ->English |
Janssen Korea |
Korea/Standard Document/SOP/08. QQG023 - Printed Material Control for Obsolete Products- QQG-023 Attachment 1 (010523) - Printed Material Control for Obsolete Products | Korean ->English |
Janssen Korea |
Korea/Standard Document/SOP/08. QQG024 - Quality Assurance Manual / Validation Policy - Objective - The purpose of this procedure is to define the procedure for preparing, revising and maintaining the general procedures and requirements for the validatio | Korean ->English |
Janssen Korea |
Korea/Standard Document/SOP/08. QQG025 - Procedure for Computerized System Validation and Management - Objective - This standard is to verify if the computer system and the administration process that Janssen Korea Ltd. is using are appropriate for the J& | Korean ->English |
Janssen Korea |
Korea/Standard Document/SOP/08. QQG027 - Quality Risk Management Procedure - Objective - The purpose of this procedure is to propose procedures and measures to minimize the effectof risk by checking, evaluating and managing all potential risk that may aff | Korean ->English |
Janssen Korea |
Korea/Standard Document/SOP/08. QQG028 - Corrective Action and Preventive Action Procedure - Objective - The purpose of this procedure is to trace and manage CAPA efficiently by regulating a range of application for corrective action and preventive action | Korean ->English |
Janssen Korea |
Korea/Standard Document/SOP/08. QQG030 - Event and Deviation Management - Objective - The purpose of this procedure is, with regard to all the events and deviations that take place in the course of GMP-related activities conducted by Janssen Korea (inclu | Korean ->English |
Janssen Korea |
Johnson & Johnson - Business Partner Risk Assessment Process Applicaton Questionnaire - Based on 2009 IAPPs v7.0 | English ->Korean |
Janssen Korea |
Johnson & Johnson - Business Partner Risk Assessment Process - Comprehensive Risk Assessment Questionnaire - Based on 2009 I APPs v7.0 | English ->Korean |
Janssen Korea |
Johnson & Johnson - Business Partner Risk Assessment Process - Guideline Version 2.0 - Based on 2009 IAPPs v7.0 | English ->Korean |
Janssen Korea |
Johnson & Johnson - Business Partner Risk Assessment Process - Personal Computing Device Access Risk Assessment Questionnaire - Based on 2009 IAPPs v7.0 | English ->Korean |
Janssen Korea |
Johnson & Johnson - Business Partner Risk Assessment Process - Screening Questionnaire - Based on 2009 IAPPs v7.0 | English ->Korean |
Janssen Korea |
Johnson & Johnson - Business Partner Risk Assessment Process - Summary Form - Based on 2009 IAPPs v7.0 | English ->Korean |
Janssen Korea |
Johnson & Johnson - IAPP Internal Assessment Process - Questionnaire for Deployed Applications v1.0 - Based on 2009 IAPPs v7.0 | English ->Korean |
Janssen Korea |
Johnson & Johnson - IAPP Internal Assessment Process - Physical Security of Infomation Assets Questionnaire v1.1 - Based on 2009 IAPPs v7.0 and Security Standard for the Physical Protection of Infomation Assets v 1.3 (26 May 2010) | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.- R076477 (Paliperidone) Clinical Overview - Paliperidone Extended Release Tablets in the Treatment of Schizophrenia in Adolescents- Issue/Report Date: 20 October 2010 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.- R076477 (Paliperidone) Module 2.2 Introduction- Issue/Report Date: 20 October 2010 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.- R076477 Paliperidone ER in Adolescents: MODULE 2.7.2 Summary of Clinical Pharmacology Studies - Issue/Report Date: 5 NOVEMBER 2010 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.- Paliperidone (R076477) Extended Release Tablets MODULE 2.7.3 Paliperidone ER: Summary of Clinical Efficacy- Issue/Report Date: 20 October 2010 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.- Paliperidone (R076477) Extended Release MODULE 2.7.4 Paliperidone ER: Summary of Clinical Safety - Issue/Report Date: 20 October 2010 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.- Paliperidone (R076477) Extended Release - Paliperidone ER: ADR Determination- Issue/Report Date: 17 AUGUST 2010 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.- R076477 (Paliperidone) Module 2.4. Nonclinical overview- Issue/Report Date: 08 SEPTEMBER 2010 | English ->Korean |
Janssen Korea |
STUDY SYNOPSIS - Protocol Number: FEN-KOR-4053 Study Title: The effectiveness and safety of Fentanyl Matrix with gabapentin in Chemotherapy-induced neuropathic pain - Principal Investigator: KeonUk Park, KyeMyung university dongsan Hospital | Korean ->English |
Janssen Korea |
STUDY SYNOPSIS - Protocol Number: ULTER-KOR-5010 (Local ID) Study Title: A multicenter, open-label, prospective, observational study to investigate pain related sleep quality and health-related quality of life in patients administering Tramadol HCl (75mh | Korean ->English |
Janssen Korea |
Cautions for Use - Infliximab (gene recombination) single pill (injection) | Korean ->English |
Janssen Korea |
ARTHRITIS & RHEUMATISM - Efficacy and Safety of Golimumab in Patients With Ankylosing Spondylitis - Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial - Robert D. Inman | English ->Korean |
Janssen Korea |
Arthritis Care & Research - Golimumab Reduces Sleep Disturbance in Patients With Active Ankylosing Spondylitis: Results From a Randomized, Placebo-Controlled Trial - ATUL DEODHAR | English ->Korean |
Janssen Korea |
ARTHRITIS & RHEUMATISM - Golimumab, a New Human Tumor Necrosis Factor Antibody, Administered Every Four Weeks as a Subcutaneous Injection in Psoriatic Arthritis - Twenty-Four–Week Efficacy and Safety Results of a Randomized, Placebo-Controlled Study - A | English ->Korean |
Janssen Korea |
ARTHRITIS & RHEUMATISM - Significant Improvement in Synovitis, Osteitis, and Bone Erosion Following Golimumab and Methotrexate Combination Therapy as Compared With Methotrexate Alone - A Magnetic Resonance Imaging Study of 318 Methotrexate-Naïve Rheumatoi | English ->Korean |
Janssen Korea |
BMJ Journals - Assessment b y MRI of infl ammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial - Philip G Conaghan | English ->Korean |
Janssen Korea |
ARTHRITIS & RHEUMATISM - The Effects of Golimumab on Radiographic Progression in Rheumatoid Arthritis - Results of Randomized Controlled Studies of Golimumab Before Methotrexate Therapy and Golimumab After Methotrexate Therapy - Paul Emery | English ->Korean |
Janssen Korea |
ARTHRITIS & RHEUMATISM -Golimumab, a New Human Anti–Tumor Necrosis Factor α Antibody, Administered Intravenously in Patients With Active Rheumatoid Arthritis - Forty-Eight–Week Efficacy and Safety Results of a Phase III Randomized, Double-Blind, Placebo-C | English ->Korean |
Janssen Korea |
ARTHRITIS & RHEUMATISM - Golimumab, a Human Anti–Tumor Necrosis Factor α Monoclonal Antibody, Injected Subcutaneously Every Four Weeks in Methotrexate-Naive Patients With Active Rheumatoid Arthritis - Paul Emery | English ->Korean |
Janssen Korea |
BMJ Journals - Golimumab, a human antibody to tumour necrosis factor a given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study - E C Keystone | English ->Korean |
Janssen Korea |
BMJ Journals - Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study - Edward Keystone, Mark C Genovese, Lars Klareskog, et al. | English ->Korean |
Janssen Korea |
CNTO 328 Module 5.3 Multiple Myeloma Revised Protocol EudraCT No.: 2008-007157-12 CNTO328MMY2001 - Approved 15 Mar 2012 Am3 | English ->Korean |
Janssen Korea |
Tylenol ER Tab. Dosage & Administration, Efficacy & Effectiveness & Caution for Use | Korean ->English |
Janssen Korea |
A case with a patient of mine that illustrates the challenges of managing spondylarthritis very well indeed - Video dictation | English ->English video dictation |
Janssen Korea |
How do we assess a disease modifying therapy in ankylosing spondylitis. - Video dictation | English ->English video dictation |
Janssen Korea |
As you know ankylosing spondilytis is a key disease in the middle of a number of spondylarthritis which are you could say sharing some clinical radiographic and genetic features. - Video dictation | English ->English video dictation |
Janssen Korea |
Notice of Protection of Personal Information for Johnson & Johnson and Its Subsidiaries | Korean ->English |
Janssen Korea |
List of Documents for Compliance with the Personal Information Protection Act (2012. 03. 09.) | Korean ->English |
Janssen Korea |
Janssen Korea (“JK”) Departments’ Questions and K&C’s Answers | Korean ->English |
Janssen Korea |
Conditions of Personal Information Protection Act (PIPA) | Korean ->English |
Janssen Korea |
PIPA Issues (Info Sharing among Affiliates) | English ->Korean |
Janssen Korea |
Janssen Korea is continuing its efforts as a pain treatment solution partner in 2012. | Korean ->English |
Janssen Korea |
JANSSEN RESEARCH PRODUCTS INFORMATION SERVICE - In vitro receptor binding and neurotransmitter uptake Inhibition profile of R093877 - m4-2-1-1-1-prim-pd-n125486 | English ->Korean |
Janssen Korea |
JANSSEN RESEARCH FOUNDATION- NON-CLINICAL RESEARCH REPORT -R - number: R093877 - m4-2-1-1-2-prim-pd-n150986 | English ->Korean |
Janssen Korea |
Janssen Research Foundation, B-2340 Beerse, Belgium - PRECLJNICAL RESEARCH REPORT -Protocol/Study Number: R093877- m4-2-1-1-3-prim-pd-n106503 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NON-CLINICAL RESEARCH REPORT-R - number: R093877 -5 JAN 2000 - m4-2-1-1-4-prim-pd-n147710 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NON-CLINICAL RESEARCH REPORT - R - number: R093877 -September 1997- m4-2-1-1-5-prim-pd-n125413 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - PRECLINICAL RESEARCH REPORT- Protocol/Study Number: R093877 -February 1996- m4-2-1-1-6-prim-pd-n122100 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development -Nonclinical Pharmacology Research Report- R093877 (prucalopride) R018553 (loperamide) -January 2007 - m4-2-1-1-7-prim-pd-n230285 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development -Nonclinical Pharmacology Research Report- Prucalopride (R093877) -December 2007- m4-2-1-1-8-prim-pd-edms-psbd-6544735 | English ->Korean |
Janssen Korea |
Janssen Research Foundation -NON-CLINICAL RESEARCH REPORT- R - number: R093877 -13 JAN 2000- m4-2-1-1-9-prim-pd-n148145 | English ->Korean |
Janssen Korea |
Janssen Research Foundation -NON-CLINICAL RESEARCH REPORT- R - number: R093877 -April 4th, 1997- m4-2-1-1-10-prim-pd-n125154 | English ->Korean |
Janssen Korea |
Janssen Research Foundation -NON-CLINICAL RESEARCH REPORT- R - number: R093877 -April 4th. 1997- m4-2-1-1-11-prim-pd-n125155 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development -Nonclinical Pharmacology Research Report - Prucalopride (R093877) -November 2007- m4-2-1-1-12-prim-pd-edms-bebe-5885488 | English ->Korean |
Janssen Korea |
Janssen Research Foundation -PRECLINICAL RESEARCH REPORT - Protocol/Study Number: R093877 -January 1996- m4-2-1-1-13-prim-pd-n113237 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development -Nonclinical Pharmacology Research Report- Prucalopride (R093877)-November 2007- m4-2-1-1-14-prim-pd-edms-bebe-1823858 | English ->Korean |
Janssen Korea |
Janssen Research Foundation -Preclinical Research Report- R-number: 093877 -February, 1996- m4-2-1-1-15-prim-pd-n113195 | English ->Korean |
Janssen Korea |
Janssen Research Foundation -NON-CLINICAL PHARMACODYNAMICS - R-number: R51619 R 93777 R93877 -28 JAN 1997- m4-2-1-1-16-prim-pd-n125075 | English ->Korean |
Janssen Korea |
Janssen Research Foundation -NON-CLINICAL RESEARCH REPORT - R-number: R051619 R093877 R149524 R093777 R149402 -3 July 2000- m4-2-1-1-17-prim-pd-n154173 | English ->Korean |
Janssen Korea |
JANSSEN PHARMACEUTICA -PRECLINICAL R&D REPORT- Substance: R 093877 -September 2,1997 - m4-2-1-1-18-prim-pd-n136283 | English ->Korean |
Janssen Korea |
JANSSEN PHARMACEUTICA -PRECLINICAL R&D REPORT- Substance : R093877 -September 1997 - m4-2-1-1-19-prim-pd-n129273 | English ->Korean |
Janssen Korea |
JANSSEN PHARMACEUTICA -PRECLINICAL R&D REPORT- Substance : R093877 -September 1997 - m4-2-1-1-20-prim-pd-129272 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NON-CLINICAL RESEARCH REPORT- R - number : R093877 -27 Nov 1997- m4-2-1-1-21-prim-pd-n126995 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NON-CLINICAL RESEARCH REPORT- R - number : R093877 -10-Apr-2000- m4-2-1-1-22-prim-pd-n152544 | English ->Korean |
Janssen Korea |
Department of Physiology University of Cambridge Alberto J. Kaumann investigator - Comparison of the effects of R149402, R108512 (prucalopride) and R149524 (norcisapride) on porcine and human atrial myocardium - m4-2-1-2-1-sec-pd-n153805 | English ->Korean |
Janssen Korea |
Department of Physiology University of Cambridge Alberto J. Kaumann investigator - Comparison of the effects of R199715, R155144, cisapride and RI08512 (prucalopride) on porcine and human atrial myocardium - m4-2-1-2-2-sec-pd-n161966 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NON-CLINICAL RESEARCH REPORT - R - number R149524, R051619, R159597, R108511, Report date: 23 May 2001 - m4-2-1-2-3-sec-pd-n164966 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NON-CLINICAL RESEARCH REPORT - R - number 093877, Report date: 07-Apr-2000- m4-2-1-2-4-sec-pd-n151647 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Preclinical Research Report- Serial number R93877, Report date: September 1997- m4-2-1-2-5-sec-pd-n126628 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - PRECLINICAL RESEARCH REPORT- Protocol/Study Number: R093877, Report date: April 1996- m4-2-1-2-6-sec-pd-n122102 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NON-CLINICAL RESEARCH REPORT - R number: R093877, Report date: 10 Dec 1996- m4-2-1-2-7-sec-pd-n122435 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NON-CLINICAL RESEARCH REPORT -R- number: R093877, Report date: SEP 1999 - m4-2-1-2-8-sec-pd-n135746 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - PRECLINICAL RESEARCH REPORT- - Protocol/Study Number: R093877, Report date: May 1996 - m4-2-1-2-9-sec-pd-n122101 | English ->Korean |
Janssen Korea |
James Black Foundation U.K. N-Shankley. - Experiment: Effect of R093877 (1OpM) on basal and pentagastrinstimulated acid secretion in the immature rat stomach assay (JBF experimental reference EB 18x004) - m4-2-1-2-10-sec-pd-139793 | English ->Korean |
Janssen Korea |
Janssen Research Foundation -NON-CLINICAL RESEARCH REPORT- R - number: R093877 -08 SEP 1999- m4-2-1-2-11-sec-pd-n144540 | English ->Korean |
Janssen Korea |
Janssen Research Foundation -Preclinical Research Report - R - number: R093877 -Date: February 1995- m4-2-1-2-12-sec-pd-n114864 | English ->Korean |
Janssen Korea |
Janssen Research Foundation -NON-CLINICAL RESEARCH REPORT - R - number: R093877 -Date: 21 December 2000 - m4-2-1-2-13-sec-pd-n161242 | English ->Korean |
Janssen Korea |
Janssen Research Foundation -NON-CLINICAL RESEARCH REPORT - R - number: R093877 -Date: 26 AUG 1998- m4-2-1-2-14-sec-pd-n135745 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Preclinical Research Report- Serial number: R108512 -Date: April 1996 - m4-2-1-2-15-sec-pd-n119532 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Preclinical Research Report- Serial number: R093877-Date: January 1995- m4-2-1-2-16-sec-pd-n109171 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NON-CLINICAL RESEARCH REPORT - R - number: R108512 -Date: April 2000- m4-2-1-2-19-sec-pd-n152546 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NON-CLINICAL RESEARCH REPORT - R - number: R108512 R093877 -Date: 10-Apr-2000 - m4-2-1-2-20-sec-pd-n152547 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NON-CLINICAL RESEARCH REPORT - R - number: R108512 -Date: December 1999 - m4-2-1-3-1-safety-pharmacol-n147361 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NON-CLINICAL RESEARCH REPORT - R - number: R093877 -Date: October 1998- m4-2-1-3-2-safety-pharmacol-n135800 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NON-CLINICAL RESEARCH REPORT - R - number: R108512 -Date: March 1998- m4-2-1-3-3-safety-pharmacol-n126875 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NON-CLINICAL RESEARCH REPORT - R - number: R108512 -Date: 7 August 2000 - m4-2-1-3-4-safety-pharmacol-n156600 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Preclinical Research Report - Interim Report - Serial number: R093877 -Date: September 1995 - m4-2-1-3-5-safety-pharmacol-n115227 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NON-CLINICAL RESEARCH REPORT- R number: R108512-Date: October 1998- m4-2-1-3-6-safety-pharmacol-n135773 | English ->Korean |
Janssen Korea |
Hondegheni Pharmaceutica.l Consulting N.V. Hondeg hem, L.M. - ELECTROPHYSIOLOGICAL EFFECTS OF PRUCALOPRIDE IN ISOLATED, WORKING RABBIT HEARTS (LANGENDORFF MODE). -27 August, 1999- m4-2-1-3-7-safety-pharmacol-n143434 | English ->Korean |
Janssen Korea |
Hondeghem Pharmaceutical Consulting N.V. JANSSEN PHARMACEUTICA JAN0001-4 August 30, 2000- Electrophysiological Effects Of Prucalopride In The Presence And Absence Of Erythromycin or Ketoconazole On The Monophasic Action Potential Of The Langendorff Perfus | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NON-CLINICAL RESEARCH REPORT- R - number : R093877 -March 1998- m4-2-1-3-9-safety-pharmacol-n126893 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NON-CLINICAL RESEARCH REPORT- R - number : R108512. R093877 - March 1999- m4-2-1-3-10-safety-pharmacol-n136344 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NON-CLINICAL RESEARCH REPORT- R - number : R108512. R093877 - March 1999- m4-2-1-3-11-safety-pharmacol-n136366 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NON-CLINICAL RESEARCH REPORT- R - number : R108512. R093877 - June 1998 - m4-2-1-3-12-safety-pharmacol-n135519 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NON-CLINICAL RESEARCH REPORT- R - number : R108512. R093877 - September 1999- m4-2-1-3-13-safety-pharmacol-n139584 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NON-CLINICAL RESEARCH REPORT- R - number : R108512. - August 1999 - m4-2-1-3-14-safety-pharmacol-n136280 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NON-CLINICAL RESEARCH REPORT- R - number : R093877 R108512. - August 1998 - m4-2-1-3-15-safety-pharmacol-n135547 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NON-CLINICAL RESEARCH REPORT- R - number : R093877 R108512. - September 1999 - m4-2-1-3-16-safety-pharmacol-n136000 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Pilot Research Report - Serial Number: R93877. - Date: June 1993 - m4-2-1-3-17-safety-pharmacol-n092871 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NON-CLINICAL RESEARCH REPORT- R - number : R108512. R093877 - March 1999 - m4-2-1-3-18-safety-pharmacol-n136391 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Preclinical Research Report - Protocol/Study Number: R 93877/CPFl - December 1993 - m4-2-1-3-19-safety-pharmacol-n101078 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development -Nonclinical Pharmacology Research Report - JNJ-437580-AEO (prucalopride; R108512) -July 2007- m4-2-1-3-20-safety-pharmacol-edms-psdb-7025921 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Preclinical Research Report- Serial number R93877, Report date: February 1996 - m4-2-1-3-21-safety-pharmacol-n113240 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report Final Report - Report number: R093877IFK1788, Report date: AUGUST 16 1999 - m4-2-2-1-1-analyt-met-val-n106667 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report Final Report - Report number: R093877/FK2040, Report date: AUGUST 16 1997 - m4-2-2-1-2-analyt-met-val-n126509 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report Final Report - Report number: R093877lFK 1787, Report date: MAY 23 1995 - m4-2-2-1-3-analyt-met-val-n111729 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report Final Report - Report number: R093877lFK1927, Report date: AUGUST 25 1995 - m4-2-2-1-4-analyt-met-val-n111686 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development -Nonclinical Pharmacology Research Report - R-number(s): R108512 - Report date: January 28, 2002- m4-2-2-1-5-analyt-met-val-n169568 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development -Nonclinical Pharmacology Research Report - R-number(s): R108512 - Report date: January 28, 2002- m4-2-2-1-6-analyt-met-val-n169470 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report Final Report- Report number: R093877fFK1740 -Date: June 7 1995 - m4-2-2-2-1-absorp-n111732 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report Final Report- R-number(s): R108512 -Date:03 APR 2000 - m4-2-2-2-2-absorp-n149366 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Identification of original report NON-CLINICAL PHARMACOKINETICS REPORT- R-number(s): R108512 -Date: 03 MAY 2001 - m4-2-2-2-3-absorp-n149617 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report Final Report - Report number : R093877lFK1780 -Date: AUGUST 24 1995 - m4-2-2-2-4-absorp-n111684 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report Final Report - Report number: R093877lFK1495 -Date: AUGUST 21 1995 - m4-2-2-2-5-absorp-n111720 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Note - Report number : R 93877lFK1524 -Date: JUNE 25 1983 - m4-2-2-2-6-absorp-n111747 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report - R-number(s): R1085 12-Date: 10 DEC 1998 - m4-2-2-2-7-absorp-n132879 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report - R-number(s): R108512, R103451 Date: 11 APR 2001- m4-2-2-2-8-absorp-n160988 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report - R-number(s): R 108512 - Date: 1ODEC 1998 - m4-2-2-2-9-absorp-n132878 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report Final Report - Report number: R093877lFK 191 3 -Date: MAY 19 1995 - m4-2-2-3-1-distrib-n111726 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report - R-number(s): R108512 - Date: 07 AUG 2001 - m4-2-2-3-2-distrib-n164020 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report Final Report- Report number: R1085 12FK2349 - Date: JULY 02 1997- m4-2-2-3-3-distrib-n125384 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report - R-number@): R108512 - Date: 28 MAY 1999 - m4-2-2-3-4-distrib-n139830 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report Final Report- Report number: R093877/FK1897- Date: JUNE 25 1995- m4-2-2-4-1-metab-n113041 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report Final Report- Report number: R093877m1475- Date: JUNE 2 1995- m4-2-2-4-2-metab-n111730 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report - R-number(s): R 1085 12- Date: 03 NOV 1997- m4-2-2-4-3-metab-n125217 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report - R-number(s): R 108512- Date: 29 OCT 2001 - m4-2-2-4-4-metab-n167668 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report - R-number(s): R093877- Date: 10 AUG 1999 - m4-2-2-4-5-metab-n111650 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report - R-number(s): R108512- Date: 07 MAY 2001 - m4-2-2-4-6-metab-n161829 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report Final Report - Report number: R093877lFK1778 -Date: MAY 29 1995 - m4-2-2-4-7-metab-n111728 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development -NON-CLINICAL PHARMACOKINETICS REPORT- R-number(s): R108512 - Report date: 16 OCT 2007- m4-2-2-4-8-metab-n183717 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report Final Report - Report number: R093877lFK2035, Report date: SEMTEMBER 18 1997 - m4-2-2-4-9-metab-n126538 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report - R-number(s): R108512, Report date: 30 May 2001- m4-2-2-4-10-metab-n161982 | English ->Korean |
Janssen Korea |
Aptuit - Preclinical Final Report - Study Sponsor: Movetis NV - The Disposition of Total Radioactivity in the Mouse Following Single Oral Administration of [14C] R108512 - March 2009 - m4-2-2-4-11-metab-ZNA24737.001 | English ->Korean |
Janssen Korea |
CellzDirect Invitrogen Corporation Final Report Issue Date: Feb 2 2009 - In Vitro Assessment of the Induction Potential of Various New Chemical Entities in Primary Cultures of Wistar Hanover Rat Hepatocytes - m4-2-2-4-12-metab-3200-1066-1800 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report - R-number(s): R129160/R102694 R041232/R072075- Date: 20 JAN 1999- m4-2-2-6-1-pk-drug-interact-n136308 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report - R-number(s): R108512- Date: 26 APR 2001- m4-2-2-6-2-pk-drug-interact-n161063 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report - R-number(s): R093877, R041400 R051211, R063373- Date: 27 Oct 1997- m4-2-2-6-3-pk-drug-interact-n126559 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Acute oral toxicity of R93877 in mice (pilot study) - Preclinical Research Report- R-number(s): R93877 - Date: March 1993- m4-2-3-1-1-single-dose-tox-n092765 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - The acute oral toxicity of the enterokinetic R93877 in mice. - Preclinical Research Report- Serial number: R93877 - Date: June 1995- m4-2-3-1-2-single-dose-tox-n112651 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - A pilot study on the acute intravenous toxicity of the enterokinetic compound R93877 in mice- Preclinical Research Report- Serial number: R93877 - Date: March 1993- m4-2-3-1-3-single-dose-tox-n092767 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - The acute intravenous toxicity of the enterokinetic R 93 877 in mice. - Preclinical Research Serial number: R93877 - Date: June 1995- m4-2-3-1-4-single-dose-tox-n112649 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - A pilot study on the acute oral toxicity of the enterokinetic compound R 93877 in rats.. - Preclinical Research Serial number: R93877 - Date: March 1993- m4-2-3-1-5-single-dose-tox-n092766 | English ->Korean |
Janssen Korea |
Janssen Research Foundation -The acute oral toxicity of the enterokinetic R93877 in rats.. - Preclinical Research Report- Serial number: R93877 - Date: June 1995- m4-2-3-1-6-single-dose-tox-n112650 | English ->Korean |
Janssen Korea |
Janssen Research Foundation -A pilot study on the acute intravenous toxicity of the enterokinetic compound R93877 in rats. - Preclinical Research Report- Serial number: R93877 - Date: March 1993- m4-2-3-1-7-single-dose-tox-n092768 | English ->Korean |
Janssen Korea |
Janssen Research Foundation -The acute intravenous toxicity of the enterokinetic R93877 in rats. - Preclinical Research Report- Serial number: R93877 - Date: June 1995- m4-2-3-1-8-single-dose-tox-n112648 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. -Single Dose Subcutaneous Toxicity Study in the Wistar Rat - TOXICOLOGY REPORT- R - number: R108512 - Report date: May 26, 2000 - m4-2-3-1-9-single-dose-tox-n152550 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. -Single Dose Subcutaneous Toxicity Study in the Wistar Rat- TOXICOLOGY REPORT- R - number: R108512 - Report date: May 26, 2000- m4-2-3-1-10-single-dose-tox-n151689 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. -Single Dose Subcutaneous Toxicity Study in the Wistar Rat- TOXICOLOGY REPORT- R - number: R108512 - Report date: May 26, 2000- m4-2-3-1-11-single-dose-tox-n151688 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. -Single dose escalation subcutaneous toxicity study in the beagle dog.- TOXICOLOGY REPORT- R - number: R108512 - Report date: May 18, 2000- m4-2-3-1-12-single-dose-tox-n151691 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development -NON-CLINICAL PHARMACOKINETICS REPORT FINAL REPORT- R-number(s): R108512 - Report date: 17-OCT-2007- m4-2-3-1-13-single-dose-tox-fk3500 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NONCLINICAL LABORATORY STUDY Final reDort (pilot study) -ONE-MONTH TOXICITY STUDY IN SPF WISTAR RATS - R-number(s): R93877 - Date: June 21 1993- m4-2-3-2-1-repeat-dose-tox-n099959 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report Final Report- Report number: R093877lFK1483- Date: May 1995- m4-2-3-2-2-repeat-dose-tox-n111680 | English ->Korean |
Janssen Korea |
Janssen Research Foundation -Toxicology Report Final Report- Report number: R093877 R1085123- Date: Oct 24 1997- m4-2-3-2-3-repeat-dose-tox-n119599 | English ->Korean |
Janssen Korea |
Janssen Research Foundation -Non-clinical Pharmacokinetics Report Addendum to the Toxicity Report- R1085 12/R093877/FK2169 - Date: Oct 02 1996- m4-2-3-2-4-repeat-dose-tox-n122206 | English ->Korean |
Janssen Korea |
Janssen Research Foundation -NONCLINICAL LABORATORY STUDY EVALUATION OF THE TOXICITY POTENTIAL OF R093877 Experiment No. 3156 CHRONIC TOXICITY STUDY Date: May 19 1995- m4-2-3-2-5-repeat-dose-tox-n106682 | English ->Korean |
Janssen Korea |
Janssen Research Foundation -Non-clinical Pharrnacokinetics Report Final Report Report number: R093877fFK1759 - Date: May 11 1995- m4-2-3-2-6-repeat-dose-tox-n111723 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. -TOXICOLOGY REPORT Final Report - Report number: R108512 - Date: October 29, 1999- m4-2-3-2-6-repeat-dose-tox-n111723 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation -NON-CLINICAL PHARMACOKINETICS REPORT ADDENDUM TO THE TOXICOLOGY REPORT EXP. NO. 4094- R number: R108512 - Date: 04 JAN 2001- m4-2-3-2-8-repeat-dose-tox-n158854 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation -NONCLINICAL LABORATORY STUDY R 93877 Experiment No. 3170 ONE-MONTH TOXICITY STUDY IN SPF WISTAR RATS - Date: 14 JAN 1994- m4-2-3-2-9-repeat-dose-tox-n109283 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation -Non-clinical Pharmacokinetics Report Final Repart - Report number: R093877lFK1621 - Date: April 27 1995- m4-2-3-2-10-repeat-dose-tox-n111685 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation -NONCLINICAL LABORATORY STUDY R093877 EXPERIMENT No. 3583 SUBCHRONIC TOXICITY STUDY - Date: Nov 24 1995- m4-2-3-2-11-repeat-dose-tox-n113136 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation -Non-clinical Phmacokinetics Report Final Report - Report number: R093877lFK1974 - Date: Oct 13 1995- m4-2-3-2-12-repeat-dose-tox-n113096 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - Pilot. study NONCLINICAL LABORATORY STUDY R 93877 Experiment No.2998 ONE-MONTH TOXICITY STUDY IN BEAGLE DOGS - Date: June 17 1995- m4-2-3-2-13-repeat-dose-tox-n092923 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - Non-clinical Pharmacokinetics Report Final Report- Report number: R093877lFK1484 - Date: May 10 1995- m4-2-3-2-14-repeat-dose-tox-n111679 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - TOXICOLOGY FINAL REPORT GLP STUDY - Report number: R093877 R108512 - Date: Oct 24 1997- m4-2-3-2-15-repeat-dose-tox-n119600 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - Non-clinical Pharmacokinetics Report Addendum to the Toxicity Report Exp. No. 3834- Report number: R1085 121R093 8771FK2 1 68 - Date: Oct 02 1994- m4-2-3-2-16-repeat-dose-tox-n122205 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - NONCLINICAL LABORATORY STUDY EVALUATION OF THE TOXICITY POTENTIAL OF R093877 Experiment No. 3157 - Date: May 19 1995- m4-2-3-2-17-repeat-dose-tox-n106683 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - Non-clinical Pharmacokinetics Report Final Report - Report number: R093877FK1760 - Date: May 19 1995- m4-2-3-2-18-repeat-dose-tox-n111724 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - TOXICOLOGY REPORT FINAL REPORT - Report number: R108512 - Date:December 18, 1998 - m4-2-3-2-19-repeat-dose-tox-n134120 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Johnson & Johnson Pharmaceutical Research & Development- NON-CLINICAL PHARMACOKINETICES REPORT- Report number: R108512 - Date:17-OCT-2007- m4-2-3-2-20-repeat-dose-tox-fk2375 | English ->Korean |
Janssen Korea |
JANSSEN RESEARCH FOUNDATION - Pilot study NONCLINICAL LABORATORY STUDY R 93877 Experirnent No.3171 ONE-MONTH TOXICITY STUDY IN BEA'GLE DOGS- Date:17-Jan 18 1994 - m4-2-3-2-21-repeat-dose-tox-n109284 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report Addendum to the Toxicity Report Exp. No. 3171 Final Report Report number: R093877lFK1633 - Date:17-May 9 1995 - m4-2-3-2-22-repeat-dose-tox-n111682 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NONCLINICAL LABORATORY STUDY EVALUATION OF THE TOXICITY POTENTIAL OF R 93877 Exp. No. 3584 ONE-MONTH TOXICITY STUDY IN BEAGLE DOGS - Date: Nov 24 1995 - m4-2-3-2-23-repeat-dose-tox-n113137 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report Final Report - Report number: R093877FK1970 - Date: Nov 13 1995 - m4-2-3-2-24-repeat-dose-tox-n113146 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NONCLNICAL LABORATORY STUDY PILOT STUDY - NON GLP R93877 Experiment No. 3011 - Date: June 24 1993- m4-2-3-3-1-1-in-vitro-n092911 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NONCLNICAL LABORATORY STUDY GLP STUDY R93877 Experiment No. 3543 - Date: June 15 1995- m4-2-3-3-1-2-in-vitro-n111745 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NONCLNICAL LABORATORY STUDY GLP STUDY Experiment No. 3544 - Date: Sep 28 1995- m4-2-3-3-1-3-in-vitro-n115226 | English ->Korean |
Janssen Korea |
JANSSEN PHARMACEUTICA N.V. - GENETIC AND IN VITRO TOXICOLOGY REPORT - R - number: R108512 - Date: October 23, 2001 - m4-2-3-3-1-4-in-vitro-n168084 | English ->Korean |
Janssen Korea |
JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT - GENETIC AND IN VITRO TOXICOLOGY REPORT FINAL STUDY REPORT – NON-GLP - R - number: R108512 - Date: August 30, 2002- m4-2-3-3-1-5-in-vitro-n178015 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - GENETIC AND IN VITRO TOXICOLOGY REPORT FINAL STUDY REPORT – NON-GLP - R - number: R108512 - Date: October 02, 2001, 2002- m4-2-3-3-1-6-in-vitro-n167659 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - REPORT EVALUATION OF THE MUTAGENIC ACTIVITY OF R 09877 IN AN IN VITRO MAMMALIAN CELL GENE MUTATION TESTWITH L5178Y MOUSE LYMPHOMA CELLS- Date: 01 13 1995- m4-2-3-3-1-7-in-vitro-n109250 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NONCLINICAL LABORATORY STLDY R093877 Experiment No. 3375 Final Report- Date: Feb 04 13 1995- m4-2-3-3-1-8-in-vitro-n109219 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - REPORT EVALUATION OF DNA REPAIR INDUCING ABILITY OF R 09877 I N A PRIMARY CULTURE DF RAT HEPATOCYTES (WITH INDEPENDENT REPEAT) - Date: Sep 05 1994- m4-2-3-3-1-9-in-vitro-n109001 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. -Unscheduled DNA synthesis in mammalian cells in vitro -TOXICOLOGY REPORT- R - number: R108512 - Report date: June 14, 2001 - m4-2-3-3-1-10-in-vitro-n162985 | English ->Korean |
Janssen Korea |
BIORELIANCE CORPORATION - Janssen Research Foundation Philippe Vanparys, Ph.D. - Date: 13 July 2000 - m4-2-3-3-1-11-in-vitro-jacobson-kram-2000 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Derek for Windows Report -Date: Monday, 2 March 2009 - stud-rep-derekanalysis | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - NONCLINICAL LABORATORY STUDY NON GLP STLIDY R093877 Experiment No. 3179 - Date: Sep 19 1994- m4-2-3-3-2-1-in-vivo-n106737 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - NONCLINICAL LABORATORY STUDY Final Report R093877 Experiment No. 3545 - Date: June 13 1995 - m4-2-3-3-2-2-in-vivo-n111746 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - NONCLINICAL LABORATORY STUDY Final Report R093877 Experiment No. 3425 - Date: Dec 19 1995 - m4-2-3-3-2-3-in-vivo-n111721 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - Non-clinical Pharmacokinetics Report Addendum to the Report on NOTOX Project 129318 Final Report - R number: R093877lFK 1 832- Date: Feb 24 1995 - m4-2-3-3-2-4-in-vivo-n111526 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development - Toxicology Report FINAL TOXICOLOGY REPORT - R108512 (prucalopride succinate) Exp.No : 5580- Date: 26 MARCH 2003- m4-2-3-3-2-5-in-vivo-n182875 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development - Report - Assay for the Detection of DNA Damage and Adduct Formation by R108512-in Mice and Rats - Date: 19 JUNE 2003 - m4-2-3-3-2-6-in-vivo-n185033 | English ->Korean |
Janssen Korea |
Silicos NV - Report - Polarity vs Chromatographic Retention Time -Author(s): Wilfried Langenaeker, Gert Thijs - Date: 2/26/2009 - polarity- vs-chromatographic-retention-time | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - Toxicity Report - Report number: R108512 - Date: Seotember 15.1998 - m4-2-3-4-1-1-lt-stud-n135577 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - Non-clinical Pharmacokinetics Report Final Report Report number: R1085 12FK2178 - Date: July 02.1997 - m4-2-3-4-1-2-lt-stud-n125359 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - TOXICOLOGY REPORT -Report number: R108512 - Date: 13 August 1998- m4-2-3-4-1-3-lt-stud-n133755 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - Non-clinical Pharmacokinetics Report Addendum to the Toxicity Report Exp. No. 3904 -Report number: R1085 12/FK2211- Date: August 26 1994- m4-2-3-4-1-4-lt-stud-n126507 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - TOXICOLOGY REPORT R - number: R108512 - Date: May 26, 2000 - m4-2-3-4-1-5-lt-stud-n154830 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - Non-clinical Pharmacokinetics Report Addendum to the Toxicity Report Exp. No. 3843 - Report number: R1085 12/FK2 167- Date: Aug 26, 1997 - m4-2-3-4-1-6-lt-stud-n126508 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - Identification of original report Toxicity Report - Report number: R1085 12/FK2 167- Date: April 25, 2000- m4-2-3-4-1-7-lt-stud-n156599 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology - EXPERIMENT: 4045 24-Month Carcinogenicity Study R108512 - OR/GAV - MOUSE - m4-2-3-4-1-7-lt-stud-n156599-app1 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology - CLINICAL OBSERVATIONS -Experiment: 4045 24-Month Carcinogenicity Study R108512 - ORlGA V - MOUSE - m4-2-3-4-1-7-lt-stud-n156599-app1 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology - BODY WEIGHT Detailed Results -Experiment: 4045 24-Month Carcinogenicity Study R108512 - OR/GAV - MOUSE - Date: 22-Aug-1997 - m4-2-3-4-1-7-lt-stud-n156599-app3 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology - FOOD CONSUMPTION Detailed Results -Experiment: 4045 24-Month Carcinogenicity Study R108512 - OR/GAV - MOUSE - Date: 29-Aug-1997- m4-2-3-4-1-7-lt-stud-n156599-app4 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology -Detailed Results -Experiment: 4045 24-Month Carcinogenicity Study R108512 - OR/GAV - MOUSE - Date: 29-Aug-1997- m4-2-3-4-1-7-lt-stud-n156599-app5 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology -GROSS PATHOLOGY HISTOPATHOLOGY Experiment: 4045 24-Month Carcinogenicity Study R108512 - OR/GAV - MOUSE - Date: Dec 07 1999- m4-2-3-4-1-7-lt-stud-n156599-app6 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology -NON-CLINICAL PHARMACOKINETICS REPORT ADDENDUM TO THE TOXICOLOGY REPORT EXP. NO. 4045 R-number(s): R108512 - Date: 05 DEC 2000- m4-2-3-4-1-8-lt-stud-n157965 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology -HISTORICAL DATA SUPPORTING THE TUMOUR INCIDENCES OF THE MOUSE CARCINOGEN ICITY STUDY WITH PRUCALOPRIDE- Date: August 17, 2007- m4-2-3-4-1-9-lt-stud-van-deun-2007a | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology -TOXICOLOGY REPORT - R - number: R108512 - Report date: March 2, 2000 - m4-2-3-4-1-10-lt-stud-n147317 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology -AMENDMENT TO THE FINAL REPORT- 24-month oral carcinogenicity study in the Wistar Rat - R - number: R108512 - Report date: May 3, 2000- m4-2-3-4-1-10-lt-stud-n147317-am3 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology -Detailed Results -Experiment: 4044 24-Month Carcinogenicity Study R108512 - OR/GAV - RAT - m4-2-3-4-1-10-lt-stud-n147317-app1 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology -FOOD CONSUMPTION Detailed Results -Experiment: 4044 24-Month Carcinogenicity Study R108512 - OR/GAV - RAT -m4-2-3-4-1-10-lt-stud-n147317-app2 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology -GROSS PATHOLOGY HISTOPATHOLOGY Experiment: 4044 24-Month Carcinogenicity Study R108512 - OR/GAV - RAT - Date: 16-Jan-2000- m4-2-3-4-1-10-lt-stud-n147317-app3 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology -GROSS PATHOLOGY HISTOPATHOLOGY Experiment: 4044 24-Month Carcinogenicity Study R108512 - OR/GAV - RAT - Date: 28-Jan-2000- m4-2-3-4-1-10-lt-stud-n147317-app4 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - Non-clinical Pharmacokinetics Report ADDENDUM TO THE TOXICOLOGY REPORT EXP. NO. 4044 - Report number: R108512- Date: 10 Jul 2000- m4-2-3-4-1-11-lt-stud-n154462 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - HISTORICAL DATA SUPPORTING THE TUMOUR INCIDENCES OF THE RAT CARCINOGEN ICITY STUDY WITH PRUCALOPRIDE- - Date: August 17, 2007- m4-2-3-4-1-12-lt-stud-van-deun-2007b | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology -TOXICOLOGY REPORT - R - number: R108512 - Report date: December 20, 2001- m4-2-3-4-2-1-smt-stud-n168376 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology -NON-CLINICAL PHARMACOKINETICS REPORT ADDENDUM TO THE TOXICOLOGY REPORT EXP. NO. 5390 R-number(s): R108512 - Date: 30 OCT 2001- m4-2-3-4-2-2-smt-stud-n167671 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology -TOXICOLOGY REPORT - R - number: R108512 - Report date: February 26, 1999- m4-2-3-4-2-3-smt-stud-n122398 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - Non-clinical Pharmacokinetics Report Addendum to the Toxicity Report Exp. No. 3920 Final Report - Report number: R1085 12RK2268- Date: April 22 1997 - m4-2-3-4-2-4-smt-stud-n125186 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology -TOXICOLOGY REPORT - R - number: R108512 - Report date: April 5, 2000 - m4-2-3-4-2-5-smt-stud-n152829 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology -Detailed Results -Carcinogenicity Study in the Neonatal Mouse Study R108512 - OR/GAV - m4-2-3-4-2-5-smt-stud-n152829-app | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - Non-clinical Pharmacokinetics Report Addendum to the Toxicity Report Exp. No. 4540 -R-number(s): R108512- Date: 04 DEC 2000- m4-2-3-4-2-6-smt-stud-n157949 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology -TOXICOLOGY REPORT - R - number: R108512 - Report date: April 26, 1999 - m4-2-3-5-1-1-fert-embryo-dev-n136372 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - NONCLINICAL LABORATORY STUDY Assessment of potential effects on male and female fertility Final Report R093877 Experiment No. 3597 - Nov 23 1995 - m4-2-3-5-1-2-fert-embryo-dev-n113139 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - NONCLINICAL LABORATORY STUDY Assessment of the potential embryotoxicity and teratogenicity Final Report R093877 Experiment No. 3244 - Feb 07 1995 - m4-2-3-5-2-1-embryo-fetal-dev-n109245 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - Non-clinical Pharmacokinetics Report Addendum to the Toxicity Report Exp. No. 3244 -Report number: R093877lFK177- Date: May 10 1995 - m4-2-3-5-2-2-embryo-fetal-dev-n111681 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology -TOXICOLOGY REPORT - R - number: R108512 - Report date: March 7, 2000 - m4-2-3-5-2-3-embryo-fetal-dev-n147719 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology -NON-CLINICAL PHARMACOKINETICS REPORT R-number(s): R108512 - Date: 15-OCT-2007 - m4-2-3-5-2-4-embryo-fetal-dev-fk3339 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - NONCLINICAL LABORATORY STUDY Final Report R093877 Experiment No. 3587 - Date: Nov 22 1995 - m4-2-3-5-2-5-embryo-fetal-dev-n113138 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - Non-clinical Pharmacokinetics Report Addendum to the Toxicity Report Exp. No. 3587 - Report number: R093877lFK198 1- Date: Oct 11, 1995 - m4-2-3-5-2-6-embryo-fetal-dev-n113095 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NONCLNICAL LABORATORY STUDY PILOT STUDY - NON GLP R93877 Experiment No. 3442 - Date: Nov 07 1994- m4-2-3-5-2-7-embryo-fetal-dev-n109076 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - NONCLINICAL LABORATORY STUDY R093877 Experiment No. 3245 EMBRYOTOXICITY AND TERATOGENICITY STUDY IN ALBINO RABBITS- Aug 02 1994- m4-2-3-5-2-8-embryo-fetal-dev-n106707 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - NONCLINICAL LABORATORY STUDY Final Report R093877 Experiment No. 3443 - Date: April 26 1995 - m4-2-3-5-2-9-embryo-fetal-dev-n111687 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - Non-clinical Pharmacokinetics Report Addendum to the Toxicity Report Exp. No. 3443 - Report number: R093877/FK188 1- Date: May 17 1995 - m4-2-3-5-2-10-embryo-fetal-dev-n111725 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NONCLNICAL LABORATORY STUDY Assessment of the potential embryotoxicity and teratogenicity R093877 Experiment No. 3588 - Date: Jan 30 1996- m4-2-3-5-2-11-embryo-fetal-dev-n113194 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - Non-clinical Pharmacokinetics Report Addendum to the Toxicity Report Exp. No. 3588 -Report number: R093877IFK2028- Date: Feb 29 1996- m4-2-3-5-2-12-embryo-fetal-dev-n113238 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology -TOXICOLOGY REPORT FINAL REPORT - R - number: R108512 - Report date: Aug 25, 1998 - m4-2-3-5-3-1-pre-postnatal-dev-n126894 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology -TOXICOLOGY REPORT - R - number: R108512 - Report date: July 01 1999 - m4-2-3-5-4-1-juv-n139711 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - Non-clinical Pharmacokinetics Report - Report number: R108512 - Date: 10 SEP 1999- m4-2-3-5-4-2-juv-n144656 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development - Toxicology Report -R - number: R108512- Date: July 8, 2002- m4-2-3-5-4-3-juv-n176277 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology - EXPERIMENT: 5002 1-Month Repeated Dose Toxicity Study RI08512 - ORlGAV - NEONATAL RAT - m4-2-3-5-4-3-juv-n176277-app1 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology - EXPERIMENT: 5002 1-Month Repeated Dose Toxicity Study R108512 - OR/GAV - RAT- Date: 2-Aug-2000 - m4-2-3-5-4-3-juv-n176277-app2 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development -NON-CLINICAL PHARMACOKINETICS REPORT- R-number(s): R108512 - Report date: 15-OCT-2007- m4-2-3-5-4-4-juv-fk3314 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology -TOXICOLOGY REPORT - R - number: R108512 - Report date: July 1, 1999 - m4-2-3-5-4-5-juv-n139825 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology -NON-CLINICAL PHARMACOKINETICS REPORT R-number(s): R108512 - Date: 10 SEP 1999 - m4-2-3-5-4-6-juv-n144655 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - Identification of original report Toxicity Report - Report number: R10851 - Date: June 19, 2001- m4-2-3-5-4-7-juv-n162991 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Janssen Research Foundation - NONCLINICAL LABORATORY STUDY EVALUATION OF PARENTERAL IRRITATION OF R093877 Experiment No. 3494 - Date: Feb 22 1995 - m4-2-3-5-2-5-embryo-fetal-dev-n113138 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology -TOXICOLOGY REPORT - R - number: R108512 - Report date: November 19,1998 - m4-2-3-6-2-loc-tol-n135772 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology -TOXICOLOGY REPORT - R - number: R108512 - Report date: April 25, 2001- m4-2-3-7-3-1-mechan-stud-n161465 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology -TOXICOLOGY REPORT - R - number: R108512 - Report date: September 24, 1999 - m4-2-3-7-3-2-mechan-stud-n139838 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology -TOXICOLOGY REPORT - R - number: R108512 - Report date: October 11, 1999 - m4-2-3-7-3-3-mechan-stud-n144646 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development - Toxicology Report -R - number: R108512- Date: March 28, 2003- m4-2-3-7-3-4-mechan-stud-n183157 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development -NON-CLINICAL PHARMACOKINETICS REPORT ADDENDUM TO THE TOXICOLOGY REPORT EXP. NO. 5276- R-number(s): R108512 - Report date: 31 OCT, 2001- m4-2-3-7-3-5-mechan-stud-n167669 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development - Toxicology Report -R - number: R108512- Date: March 31, 2003 - m4-2-3-7-3-6-mechan-stud-n162305 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology - CLINICAL OBSERVATIONS DetaHed results per animal EXPERIMENT: 5103 l-Month R.D. Toxicity Study with 6-Weeks Recovery R108512 - OR/GAV - RAT- m4-2-3-7-3-6-mechan-stud-n162305-app1 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V. Department of toxicology -GROSS PATHOLOGY HISTOPATHOLOGY Experiment: 5103 1-Month R. D. Toxicity Study with 6 Weeks Recovery R108512 - OR/GAV - RAT - Date: 22-May-2000- m4-2-3-7-3-6-mechan-stud-n162305-app2 | English ->Korean |
Janssen Korea |
Johnson and Johnson Pharmaceutical Research and Development -Toxicology Report Final Report- Report number: R1085123- Date: April 11, 2003- m4-2-3-7-3-7-mechan-stud-n183170 | English ->Korean |
Janssen Korea |
Janssen Pharmaceutica N.V.- TOXICOLOGY REPORT - R - number: R108512 - Report date: November 19, 2001- m4-2-3-7-3-8-mechan-stud-n168177 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development - Toxicology Report -R - number: R108512- Date: April 17, 2003 - m4-2-3-7-3-9-mechan-stud-n183443 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development - Toxicology Report -R - number: R108512- Date: April 5, 2002- m4-2-3-7-3-10-mechan-stud-n173939 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development -NON-CLINICAL PHARMACOKINETICS REPORT ADDENDUM TO THE TOXICOLOGY REPORT EXP. NO. 5365- R-number(s): R108512 - Report date: 5 APR 2002- m4-2-3-7-3-11-mechan-stud-n171812 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report Final Report- Report number: R093877PFK 1857- Date: April 12 1995 - m4-2-3-7-5-1-metab-n111649 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - NON-CLINICAL PHARMACOKINETICS REPORT- R-number(s): R 108512- Date: 15 OCT 2001- m4-2-3-7-5-2-metab-n168079 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report Final Report- R-number(s): R108512 - Date: 10 August 2001- m4-2-3-7-5-3-metab-n169569 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report - R-number(s): R 108512 - Date: 27 APR 2001- m4-2-3-7-5-4-metab-n161330 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report - R-number(s): R108512, R129531 R112718, R107504 - Date: 18 APR 2001- m4-2-3-7-5-5-metab-n161181 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report - R-number(s): R 108512 - Date: 29 OCT 2001- m4-2-3-7-5-6-metab-n167449 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report - R-number(s): R 108512- Date: 13 AUG 2001 - m4-2-3-7-5-7-metab-n164373 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report - R-number(s): R 108512- Date: 11 APR 2001- m4-2-3-7-5-8-metab-n161263 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report - R-number(s): R 108512- Date: 07 AUG 2001- m4-2-3-7-5-9-metab-n164022 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report - R-number(s): R 108512- Date: 3 Apr 2002- m4-2-3-7-5-10-metab-n171594 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Non-clinical Pharmacokinetics Report - R-number(s): R 108512- Date: 14-OCT-2002- m4-2-3-7-5-11-metab-n178399 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development -NON-CLINICAL SAFETY STUDY REPORT FINAL REPORT- R-number(s): R108512 - Report date: May 23, 2003 - m4-2-3-7-6-1-imp-n184637 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development -NON-CLINICAL SAFETY STUDY REPORT FINAL REPORT- R-number(s): R108512 - Report date: May 23, 2003- m4-2-3-7-6-2-imp-n136074 | English ->Korean |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development -TOXICOLOGRYEP ORT FINAL REPORT- R-number(s): R108512 -R 149706 -R103451- R102390 Report date: September 30, 1999- m4-2-3-7-6-3-imp-n143464 | English ->Korean |
Janssen Korea |
JANSSEN STUDY NO.: RMD 260 -RCC - CCR PROJECT 643001- SALMONELLA TYPHlMURlUM AND ESCHERlCHlA COLl REVERSE MUTATION ASSAY WITH T001830 REPORT December 20: 1999 - m4-2-3-7-7-3-other-rmd260 | English ->Korean |
Janssen Korea |
PROJECT ID OF CONTRACTING INSTITUTE RCC PROJECT 741532 RCC-CCR PROJECT 643002 Janssen Project No. RMD261 IN VlTRO CHROMOSOME ABERRATION ASSAY IN CHINESE HAMSTER V79 CELLS WITH T001830 REPORT March 17, 2000 -m4-2-3-7-7-4-other-rmd261 | English ->Korean |
Janssen Korea |
Safepharm Laboratories Limited - T1830 MICRONUCLEUS TEST IN THE MOUSE SPL PROJECT NUMBER: 1827/104 AUTHOR: R Durward - Date: 06 Oct 2004 - m4-2-3-7-7-5-other-spl1827-104 | English ->Korean |
Janssen Korea |
RCC - CCR STUDY NUMBER 1125801 CHROMOSOME ABERRATION TEST IN HUMAN LYMPHOCYTES IN VITRO WITH T1830 JANSSEN-RCC STUDY NO. 070 FINAL REPORT Date: December 10, 2007 - m4-2-3-7-7-6-other-1125801 | English ->Korean |
Janssen Korea |
JANSSEN STUDY NO.: RMD288 RCC - CCR PROJECT 642901 SALMONELLA TYPHIMURIUM AND ESCHERICHIA COLI REVERSE MUTATION ASSAY WITH T1874 REPORT Date:February 29, 2000- m4-2-3-7-7-7-other-rmd288 | English ->Korean |
Janssen Korea |
PROJECT ID OF CONTRACTING INSTITUTE RCC PROJECT 741868 RCC-CCR PROJECT 642902 Janssen Project No. RMD289 IN VlTRO CHROMOSOME ABERRATION ASSAY IN CHINESE HAMSTER V79 CELLS WITH T001874 REPORT Dec 14,1999-m4-2-3-7-7-8-other-rmd289 | English ->Korean |
Janssen Korea |
JANSSEN STUDY NO.: RMD 315-RCC - CCR PROJECT 657400- MICRONUCLEUS ASSAY IN BONE MARROW CELLS OF THE MOUSE WITH T001874 REPORT June 23, 2000- m4-2-3-7-7-9-other-rmd315 | English ->Korean |
Janssen Korea |
RCC - CCR STUDY NUMBER 1125802 CHROMOSOME ABERRATION TEST IN HUMAN LYMPHOCYTES IN VITRO WITH T1874 REPORT Date: December 11, 2007 - m4-2-3-7-7-10-other-1125802 | English ->Korean |
Janssen Korea |
Janssen Pharrnaceutica - Lisec - Final Report - Acute toxicity of R108512 for Daphnia magna study no WE-01 -21 5 Date: Mar 18 1999 - m4-2-3-7-7-1-other-n139585 | English ->Korean |
Janssen Korea |
Janssen Pharrnaceutica - Lisec - Final Report - Biodegradation study Manometric respirometry test of R108512 study no WB-08-073 Date: Aug 22 1998 - m4-2-3-7-7-2-other-n139596 | English ->Korean |
Janssen Korea |
Movetis NV -Charles River Laboratories Final Report - Charles River Laboratories Study No. BOV00030 Single Dosage Phototoxicity Study to Determine the Effects of Oral (Gavage) Administration of Prucalopride on Eyes and Skin in Pigmented Rats Date: Feb 09 | English ->Korean |
Janssen Korea |
SUPPLY OF SERVICES AGREEMENT by and between Johnson & Johnson Medical Asia Pacific, a division of Johnson & Johnson Pte Limited | English ->Korean |
Janssen Korea |
Janssen Korea Quality Control Guide - Preservative Efficacy Test | Korean ->English |
Janssen Korea |
Janssen Korea Quality Control Guide - Method of Environmental Control | Korean ->English |
Janssen Korea |
Janssen Korea Quality Control Guide - Organism Counting Method | Korean ->English |
Janssen Korea |
Janssen Korea Quality Control Guide - Dry heat sterilization of glasses | Korean ->English |
Janssen Korea |
Janssen Korea Quality Control Guide - Decontamination of Hazardous Microbiological waste | Korean ->English |
Janssen Korea |
Janssen Korea - Standard Operating Procedure - Culture Media Performance Test | Korean ->English |
Janssen Korea |
Janssen Korea - Standard Operating Procedure - Use and Management of BI | Korean ->English |
Janssen Korea |
Janssen Korea Quality Control Guide - Objectionable organismsObjectionable organisms | Korean ->English |
Janssen Korea |
Janssen Korea Quality Control Guide - Microbiological Analysis of Water | Korean ->English |
Janssen Korea |
Janssen Korea Quality Control Guide - Microbiological Test method for Equipment Cleaning ValidationMicrobiological Test method for Equipment Cleaning Validation | Korean ->English |
Janssen Korea |
Janssen Korea Quality Control Guide - Sterility Test | Korean ->English |
Janssen Korea |
Janssen Korea Quality Control Guide - Use and Test of Pall Filter for Compressed Air | Korean ->English |
Janssen Korea |
Janssen Korea Quality Control Guide - Evaluation of Autoclave Sterilizer | Korean ->English |
Janssen Korea |
Janssen Korea Quality Control Guide - Control of Membrane Filtration System (Microfil™ system) | Korean ->English |
Janssen Korea |
Janssen Korea Quality Control Guide - Cleaning and Sanitization Program for the Microbiological lab & Sampling Room | Korean ->English |
Janssen Korea |
Janssen Korea - Standard Operating Procedure - Validation and Transfer of Microbiological Test | Korean ->English |
Janssen Korea |
Janssen Korea - Quality Control Standard Operating Procedure - Sampling Techniques & Sample Handing for Microbiological Tests | Korean ->English |
Janssen Korea |
Janssen Korea - Quality Control Standard Operating Procedure - Microbiological Monitoring Testing Frequency | Korean ->English |
Janssen Korea |
Janssen Korea - Operating Rule/Standard Operating Procedure - Management of Purchased Reagents & Culture Mediums at Microbiological Lab | Korean ->English |
Janssen Korea |
Janssen Korea - Operating Rule/Standard Operating Procedure - Compounding & Managing of Media and Buffers | Korean ->English |
Janssen Korea |
Janssen Korea - SOP/Guideline - Procedure of Handling OOS/OOT for Microbial Test | Korean ->English |
Janssen Korea |
Janssen Korea - SOP/Guideline - Management of Strains | Korean ->English |
Janssen Korea |
Janssen Korea - SOP/Guideline - Microbial Limit Test | Korean ->English |
Janssen Korea |
Janssen Korea - SOP/Guideline - Microbial Identification | Korean ->English |
Janssen Korea |
Janssen Korea - SOP/Guideline - Using and Managing Disinfectant | Korean ->English |
Janssen Korea |
PROFESSIONAL SERVICES AGREEMENT - JK call center agmt_DIRI_Janssen_final -990115v4 | English ->Korean |
Janssen Korea |
Seoul Regional Korea Food & Drug Administration - Instruction for submission of import drug’s overseas manufacturer history card - 02-16 2012 | Korean ->English |
Janssen Korea |
Seoul Regional Korea Food & Drug Administration - [Attachment 1] History Card - Overseas Manufacturer History Card | Korean ->English |
Janssen Korea |
Janssen Korea - Standard Operating Procedure - Prevention of cross contamination | Korean ->English |
Janssen Korea |
Cougar Biotechnology, Inc. - JNJ-212082 (abiraterone acetate) Module 2.5 Clinical Overview - Issue/Report Date: 11 January 2011 | English ->Korean |
Janssen Korea |
Cougar Biotechnology, Inc. - Module 2.4 – Nonclinical Overview Nonclinical Overview of JNJ-212082 (abiraterone acetate) - Issue/Report Date: 19 November 2010 | English ->Korean |
Janssen Korea |
Interview-Video-STELARA-Patient-PatrickStarega-Internal-Aug-2010, Interview, Development Process-Video-STELARA-Inform-Internal-JohnsonMedal, STELARA News Segment Video 3 files dictation, translation & subtitling | English ->Korean video dictation, translation & subtitling |
Janssen Korea |
Lancet 2011; 378: 238–46 - Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial - Jean-Michel Molina | English ->Korean |
Janssen Korea |
Lancet 2011; 378: 229–37 - Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial - Calvin J Cohen | English ->Korean |
Janssen Korea |
Curr Infect Dis Rep (2011) 13:1–3 - Clinical Trial Report: TMC278 (Rilpivirine) Versus Efavirenz as Initial Therapy in Treatment-Naïve, HIV-1–Infected Patients - Rodger D. MacArthur | English ->Korean |
Janssen Korea |
Korea Food and Drug Administration (KFDA) - Notification of Import Item License for Drug [Janssen Korea Ltd. – Edurant pill 25mg (Rilpivirine Hydrochloride)] - 05. 16 2011. | Korean ->English |
Janssen Korea |
Agreement for Marketing and Sales Service | Korean ->English |
Janssen Korea |
Biotech Training Video - This is intended to provide an overview on the history of the company and its products for educational/informational purposes only. - Video dictation, translation & subtitling | English ->Korean video dictation, translation & subtitling |
Janssen Korea |
KFDA Regulation - Detailed Operational Guideline for Drug Approval – Patent Linkage System | Korean ->English |
Janssen Korea |
SALES AGREEMENT (WHOLESALE BUSINESS CONTRACT) | Korean ->English |
Janssen Korea |
日本標準商品分類番号 8 7 8 2 1 9 - 経皮吸収型 持続性癌疼痛治療剤 ワンデュロパッチ0.84mg （案）OneDuro Patch フェンタニル経皮吸収型製剤 | Japanese->Korean |
Janssen Korea |
試驗報告書 (No. ROC-09-079) OD錠 0.5mg | Japanese->Korean |
Janssen Korea |
건강 21 시리즈⑭ - 궤양성대장염/크론병 환자의 식사 - 조시영양대학 출판부 - Japanese into Korean translation | Japanese->Korean |
Janssen Korea |
ゴリムマブ（シンポニー®）使用成績調査の中間解析結果からみる安全性について - 前田喜一、上堀雅由、川村佐代子 、矢島勉、川岸朋代、藤野明子 ヤンセンファーマ株式会社 研究開発本部 | Japanese->Korean |
Janssen Korea |
다나베미쓰비시제약(田辺三菱製薬) - 의료∙복지제도 가이드북 - 류마티스 관절염 환자와 가족 여러분께 - (2010년 8월 개정) - Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
Janssen Korea Website Localization Project Part1 - REMICADE®1_MAIN Page | English ->Korean |
Janssen Korea |
Janssen Korea Website Localization Project Part1 - REMICADE®1_CHOOSE ANOTHER CONDITION Page | English ->Korean |
Janssen Korea |
Janssen Korea Website Localization Project Part1 - REMICADE®1_Managing Treatment Page | English ->Korean |
Janssen Korea |
Janssen Korea Website Localization Project Part1 - REMICADE®1_Registration_Country Name Page | English ->Korean |
Janssen Korea |
Janssen Korea Website Localization Project Part1 - REMICADE®1_SUPPORT Page | English ->Korean |
Janssen Korea |
Janssen Korea Website Localization Project Part1 - REMICADE®1_Specialist Locator Page | English ->Korean |
Janssen Korea |
Janssen Korea Website Localization Project Part1 - REMICADE®1_Understanding RA Page | English ->Korean |
Janssen Korea |
Janssen Korea Website Localization Project Part1 - REMICADE®1_R-TM Page | English ->Korean |
Janssen Korea |
Janssen Korea Website Localization Project Part1 - REMICADE®1_Understanding PsO Page | English ->Korean |
Janssen Korea |
Janssen Korea Website Localization Project Part1 - REMICADE®_Part2_R-TM Page | English ->Korean |
Janssen Korea |
Janssen Korea Website Localization Project Part2 - REMICADE®2_About REMICADE.Page | English ->Korean |
Janssen Korea |
Janssen Korea Website Localization Project Part2 - REMICADE®2_Managing Treatment.Page | English ->Korean |
Janssen Korea |
Janssen Korea Website Localization Project Part2 - REMICADE®2_Understanding CD.Page | English ->Korean |
Janssen Korea |
Janssen Korea Website Localization Project Part2 - REMICADE®3_CHOOSE ANOGHER CONDITION.Page | English ->Korean |
Janssen Korea |
Janssen Korea Website Localization Project Part2 - REMICADE®3_Dosing.Page | English ->Korean |
Janssen Korea |
Janssen Korea Website Localization Project Part2 - REMICADE®3_Patient Profiles.Page | English ->Korean |
Janssen Korea |
Janssen Korea Website Localization Project Part2 - REMICADE®3_Professional Support.Page | English ->Korean |
Janssen Korea |
Janssen Korea Website Localization Project Part2 - REMICADE®3_RENUCADE EFFUCACY.Page | English ->Korean |
Janssen Korea |
Janssen Korea Website Localization Project Part2 - REMICADE®3_Safety.Page | English ->Korean |
Janssen Korea |
Janssen Korea Website Localization Project Part2 - REMICADE®4_Appointment PrepGuide.Page | English ->Korean |
Janssen Korea |
Janssen Korea Website Localization Project Part2 - REMICADE®4_Clinical Date.Page | English ->Korean |
Janssen Korea |
Janssen Korea Website Localization Project Part2 - REMICADE®4_Dosign and Admisistraion.Page | English ->Korean |
Janssen Korea |
Janssen Korea Website Localization Project Part2 - REMICADE®4._Professional Support.Page | English ->Korean |
Janssen Korea |
Janssen Korea Website Localization Project Part2 - REMICADE®4_Safety.Page | English ->Korean |
Janssen Korea |
Janssen Korea Website Localization Project Part2 - REMICADE®_Part2_R-TM.Page | English ->Korean |
Janssen Korea |
武州製薬株式会社 品質保証部 - 改善計画書 - 添付資料 - ・ KFDAアクションプラン2頁 ・添付資料11頁 - ヤンセンファーマ株式会社 アジア太平洋地域 委託製造管理シニアマネージャー 井越伸和様 | Japanese->Korean |
Janssen Korea |
ヤンセンファーマ株式会社富士研究所 研究報告書 - 和文主題. !Jスペ!JドンOD錠規格及び試験方法の検討(2) [Study of Specification and Test Method of Risperidone OD Tablets (2)], 副題: 溶出試験の分析法ノザデーション[Analytical Method Validation of Dissolution Test] | Japanese->Korean |
Janssen Korea |
Risperdal OD GMP_deficency letter - KFDA(食品医薬品安全庁) - (経由) タイトル：品目別GMP評価結果補完資料の要請[(株)韓国ヤンセン‐リスパダールOD錠1mg (リスペリドン)その他1件] - 2011.5.20 | Korean ->Japanese |
Janssen Korea |
武州製薬株式会社 分類番号:RIS-000.5mg-CLV-PL ~2007-039 - ベリフィケーション実施計画書 / 品名 - リスパダーjレOD錠O.5mg | Japanese->Korean |
Janssen Korea |
武州製薬株式会社 - リスパダールOD錠0.5mg PV包装品の安定性試験結果 - 試験計画書No.：PQC-09-079 | Japanese->Korean |
Janssen Korea |
武州製薬株式会社 - 製造標準書/製造指댐記錄書 - 10.26.2009 | Japanese->Korean |
Janssen Korea |
武州製薬株式会社 - 試驗成績書 - 檢훌指因No. 檢훌指因No. 000000000052595 品名 OD鎬O. 5mg- 使用期限 2012年10月31 日 | Japanese->Korean |
Janssen Korea |
武州製薬株式会社 - 製品換겉좋指因記錄書 - 檢f졸指因Na. 檢훌指因No. 000000000052859 表示 使用期限 2012.10 | Japanese->Korean |
Janssen Korea |
武州製薬株式会社 - 製造標準書/製造指因記錄書 - 改訂日 2010年12 月28 日 | Japanese->Korean |
Janssen Korea |
武州製薬株式会社 - 製造標準書 - 包裝 | Japanese->Korean |
Janssen Korea |
武州製薬株式会社 - 中間製品規格及'(}試嚴方法 - 分類짧뭉 - IS-184.50-00-01 | Japanese->Korean |
Janssen Korea |
武州製薬株式会社 分類짧뭉 RIS-ODO.5mg-PSV-PL -2008 -1 01.xls - 案施計固書 - Process Validation Plan | Japanese->Korean |
Janssen Korea |
武州製薬株式会社 分類짧뭉 RIS-ODO.5mg-PSV-PL -2008 -1 01.xls - 案施報告書 - Process Validation Report | Japanese->Korean |
Janssen Korea |
Janssen Japan SOP - 리스페달 OD정 0.5mg 제조방법에 관한 자료 4 files - 얀센파머 주식회사 - Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP - 004_제품표준서 리스페달오디정1mg (코드 184.60-0007)_kor - Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP - 005_제품표준서 리스페달오디정1mg (코드 184.60-0007)_kor - Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP - 006_HPMC20%액 코드 418.42-01 05_kor - Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP - 007_무수인산수수칼슘(GS)(사과) 코드 503.49-01 02]_kor - Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP - 008_무수인산수소칼슘(경질)(사과) 코드 503.48-01 02_kor - Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP - 009_카멜로우스NS-300(사과) 코드 503.51-01 02_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP - 010_결정셀룰로오스PH102(사과) 코드 503.50-01 04_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP - 011_카프렉스67(사과) 코드 503.37-01 05_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP - 012_리스페달오디정2mg 코드 184.30-00 01_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -019_로트번호 G05481_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -022_로트번호 G03974_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -034_중간제품규격시험방법_리스페달오디정1mg_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -034_중간제품규격시험방법_리스페달오디정1mg_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -035_중간제품규격시험방법_리스페달오디정2mg_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -036_원료규격시험방법_무수인산수소칼슘_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -037_원료규격시험방법_결정셀룰로오스_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -038_원료규격시험방법_카멜로오스_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -039_원료규격시험방법_스테아르산마그네슘_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -040_원료규격시험방법_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -041_원료규격시험방법_함수이산화규소(카프렉스67)_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -042_원료규격시험방법_아세설팜칼륨_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -043_원료규격시험방법_히프로멜로오스(HPME TC-5E)_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -044_원료규격시험방법_카멜로오스칼슘(CMC칼슘)_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -133_포장벨리데이션계획서 1mg_PL-2007-026_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -134_포장벨리데이션계획서1mg_RS-2007-026_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -135_포장벨리데이션계획서2mg_PL-2007-027_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -136_포장벨리데이션계획서2mg_RS-2007-027_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -143_품질관리기록서_G0766_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -146_품질관리기록서_G5414_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -170_공정벨리데이션_RIS-OD1mg-PSV-PL-2006-101_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -171_공정벨리데이션_RIS-OD1mg-PSV-RS-2006-101_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -172_공정벨리데이션_RIS-OD2mg-PSV-PL-2006-102_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -173_공정벨리데이션_RIS-OD2mg-PSV-PL-2006-102_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -174_세척벨리데이션_RIS-OD-2mg-CLV-PL-2006-118_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -175_세척벨리데이션_RIS-OD-2mg-CLV-RS-2006-118_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -176_세척벨리데이션_RIS-OD-1mg-CLV-RS-2006-118-2_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -177_세척벨리데이션_RIS-OD-2mg-CLV-PL-2006-119_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -178_세척벨리데이션_RIS-OD2mg-CLV-RS-2006-119_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -179_세척벨리데이션_RIS-OD-2mg-CLV-PL-2007-024_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -180_세척벨리데이션_RIS-OD-2mg-CLV-RS-2007-024_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -181_세척벨리데이션_RIS-OD-2mg-CLV-RS-2007-024-2_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -182_세척벨리데이션_RIS-OD-2mg-CLV-RS-2007-024-2_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -183_제품표준서(포장) 1mg_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
부슈제약(주) 가와고에 공장 SOP -184_제품표준서(포장) 2mg_kor- Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
Janssen 얀센파머주식회사 - Invega®정을 복용하시는 분과 가족분들께 - 이 책자는 여러분이 드시는 약(Invega®정)에 대해 설명한 것입니다. - Japanese into Korean Translation | Japanese->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - R093877-BEL-4 - Part I: Pharmacokinetics | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF-PRU-BEL-14 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF--PRU-BEL-32 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF--PRU-BEL-33 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF--Trial R093 877-BEL-l 2 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF--PRU-BEL-29 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF--Trial PRU-BEL-30 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF--PRU-BEL-31 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF--PRU-USA-29 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary -JRF--PRU-USA-31 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary -JRF-PRU-USA 32 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary -JRF--Trial PRU-BEL-I / Part I | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary -R093877-BEL-2 Part I: Pharmacokinetics | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary -R093877-BEL-3 Part I: Pharmacokinetics | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary -R093877-BEL-5 - Part I: Pharmacokinetics | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary -R093877-BEL-9 - Part I: Phannacokinetics | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary -JRF--R093877-BEL-10 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary -JRF--Trial PRU-BEL-15 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary -JRF--Trial R093877-BEC 16 1 Part I: Pharmacokinetics | English ->Korean |
Janssen Korea |
Movetis NV - SYNOPSIS Clinical Study Report PRU-GBR-9 - Final, 22 February 2008 | English ->Korean |
Janssen Korea |
Movetis NV - SYNOPSIS Clinical Study Report PRU-GBR-10 - 11 February 2008 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - CLINICAL RESEARCH REPORT - R - number: R093877 - Report Date: 22 December 1999 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - SYNOPSIS Trial identification and protocol summary - REPORT : 23019712466 TRIAL : R093877-NED-5 | English ->Korean |
Janssen Korea |
Movetis NV - SYNOPSIS Clinical Study Report PRU-RSA-1 - REPORT : 27 JUL 2007 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary -JRF-PRU-USA-6 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF Clinical Research Report -- PRU-USA-12 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF Clinical Research Report -- PRU-USA-24 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF-Trial PRU-BEL-20 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF--Trial PRU-BEL-25 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - REPORT : CPl9910633 TRIAL : PRU-NED-6 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - REPORT : CP/99/0418 TRIAL : PRU-NED-7 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - REPORT : CPl9910986 TRIAL : PRU-NED-11 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - REPORT : CP/99/1207 TRIAL : PRU-NED-12 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF Trial -- PRU-NED-14 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF--Trial PRU-BEL-27 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - Clinical Trial Report, R093877-NED-l | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF—PRU-NED-8 | English ->Korean |
Janssen Korea |
Movetis NV - Synopsis Clinical Study Report PRU-NED-15 - 10 October 2007 | English ->Korean |
Janssen Korea |
Movetis NV - Synopsis Clinical Study Report PRU-USA-7 - 23 JUL 2007 | English ->Korean |
Janssen Korea |
Movetis NV - Synopsis Clinical Study Report M0001-C102 - 15 June 2009 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF--R093877-GBR-1 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF-R093877-GBR-2. | English ->Korean |
Janssen Korea |
Movetis NV - Synopsis Clinical Study Report PRU-FRA-1 - 17 July 2007 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF R093877-NED-2 | English ->Korean |
Janssen Korea |
Movetis NV - Synopsis Abbreviated Clinical Study Report PRU-NED-13 - 17 OCT 2007 | English ->Korean |
Janssen Korea |
Movetis NV - Synopsis Abbreviated Clinical Study Report PRU-USA-21 - 24 July 2007 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF--R093877-BEL-6 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF--Trial PRU-GBR-4 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF--R93877-INT-1 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF--R93877-INT-2 | English ->Korean |
Janssen Korea |
Movetis NV - Synopsis Clinical Study Report PRU-INT-6 - 05 SEP 2007 | English ->Korean |
Janssen Korea |
Movetis NV - Synopsis Clinical Study Report PRU-INT-12 - 05 OCT 2007 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF Clinical Research Report -- PRU-USA-3 | English ->Korean |
Janssen Korea |
Movetis NV - Synopsis Clinical Study Report PRU-USA-11 - 17 SEP 2007 | English ->Korean |
Janssen Korea |
Movetis NV - Synopsis Clinical Study Report PRU-USA-13 - Final, 04 OCT 2007 | English ->Korean |
Janssen Korea |
Movetis NV - Synopsis Clinical Study Report PRU-USA-25 - 16 JAN 2008 | English ->Korean |
Janssen Korea |
Movetis NV - Synopsis Clinical Study Report PRU-USA-26 - Final, 15 February 2008 | English ->Korean |
Janssen Korea |
Movetis NV - Synopsis Clinical Study Report PRU-USA-28 - Final, 21 DEC 2007 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF-PRU-BEL-8 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF -- CRR PRU-INT-3 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF--Trial PRU-INT-4 | English ->Korean |
Janssen Korea |
Movetis NV - Synopsis Clinical Study Report PRU-INT-10 - 12 February 2008 | English ->Korean |
Janssen Korea |
Movetis NV - Synopsis Abbreviated Clinical Study Report PRU-INT-13 - 22 FEB 2008 | English ->Korean |
Janssen Korea |
Movetis NV - Synopsis Clinical Study Report PRU-NED-4 - 07 FEB 2008 | English ->Korean |
Janssen Korea |
Movetis NV - Synopsis Clinical Study Report PRU-SWE-2 - 18 February 2008 | English ->Korean |
Janssen Korea |
Movetis NV - Synopsis Clinical Study Report PRU-USA-22 - 29 February 2008 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF—R093877-BEL-18 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF—R093877-BEL-19 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary -JRF--Trial R093877-DEN-2 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF -- PRU-GBR-7 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - R093877-GBR-1 | English ->Korean |
Janssen Korea |
Janssen Research Foundation - Synopsis Trial identification and protocol summary - JRF--PRU-INT-8 | English ->Korean |
Janssen Korea |
Movetis NV - Synopsis Clinical Study Report PRU-INT-9 - 19 OCT 2007 | English ->Korean |
Janssen Korea |
Centocor Research & Development, Inc. - CNTO 1959: Investigator's Brochure - Edition 2 - 25 May 2011 | English ->Korean |
Janssen Korea |
Movetis NV - Synopsis Clinical Study Report PRU-INT-14 - 22 FEB 2008 | English ->Korean |
Janssen Korea |
Movetis NV - Synopsis Abbreviated Clinical Study Report PRU-INT-17- 29 February 2008 | English ->Korean |
Janssen Korea |
Movetis NV - Synopsis Clinical Study Report PRU-USA-8 - 24 JAN 2008 | English ->Korean |
Janssen Korea |
Movetis NV - Synopsis Clinical Study Report PRU-USA-27 - 2 February 2008 | English ->Korean |
Janssen Korea |
The Catholic University of Korea, Seoul St. Mary’s Hospital - Informed Consent Form - [ULTER-KOR-3003] 01-S-001 (1/11) - 06-04- 2009 | Korean ->English |
Janssen Korea |
Centocor Research & Development, Inc. - STELARA®(ustekinumab) Module 1 Investigator's Brochure - Edition 12 - 12 Apr 2011 | English ->Korean |
Janssen Korea |
Crohn’s Disease Drug - REMICADE® Each country Dose and Dosage | English ->Korean |
Janssen Korea |
Crohn’s Disease Drug - REMICADE® Indication Each country comparative table | English ->Korean |
Janssen Korea |
Pharmaceutical Seminar Simultaneous interpreting & Interpreting eqipments lease services - Marriott Hotel, Banpo-dong, Seoul, Dec. 02 2011 | English->Korean Simultaneous interpreting & Interpreting eqipments services |
Janssen Korea |
Zytiga (abiraterone acetate) - Data proving that the safety or efficacy of the medicine is a great improvement over existing alternative pharmaceuticals - Answer: | Korean ->English |
Janssen Korea |
Korea Food & Drug Administration(KFDA) Public Document - Notice on acceptance of declaration for drug substance [Janssen Korea Co., Ltd. - Rilpivirine hydrochloride] - 10.28.2011 | Korean ->English |
Janssen Korea |
Korea Food & Drug Administration(KFDA) Public Document - Approval of clinical trial plan [Janssen Korea Co., Ltd.– Tapentadol IR Tab ] - 10.28.2011 | Korean ->English |
Janssen Korea |
Centocor Ortho Biotech, Inc & Janssen-Cilag International N. V. - STELARA®,™ (ustekinumab) and REMICADE® (infliximab) Protocol Synopsis - C0168Z03 - Approved 19 Aug 2009 | English ->Korean |
Janssen Korea |
Original Article - Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma - Robert A. Baiocchi, MD | English ->Korean |
Janssen Korea |
47TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, ATLANTA, GEORGIA, USA, DECEMBER 10-13, 2005 BLOOD 106 (11, PART 1), P.147A, 2005. - LYMPHOMA: THERAPY WITH BIOLOGIC AGENTS, EXCLUDING PRECLINICAL MODELS III | English ->Korean |
Janssen Korea |
49TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY (ASH), ATLANTA, GEORGIA, USA, DECEMBER 8-11, 2007 BLOOD 110 (11, PART 1), P.760A, 2007. - NEW AGENTS AND TREATMENT APPROACHES IN'NON-HODGKIN LYMPHOMA | English ->Korean |
Janssen Korea |
49TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY (ASH), ATLANTA, GEORGIA, USA, DECEMBER 8-11, 2007. BLOOD 110 (11, PART 1), P.754A, 2007.- NEW AGENTS AND TREATMENT APPROACHES IN NON-HODGKIN LYMPHOMA | English ->Korean |
Janssen Korea |
99TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR), SAN DIEGO, CALIFORNIA, USA, APRIL 12-16, 2008. - EXPERIMENTAL AND MOLECULAR THERAPEUTICS 33 | English ->Korean |
Janssen Korea |
JOURNAL OF CLINICAL ONCOLOGY VOLUME 29 NUMBER 6 FEBRUARY 20 2011- Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma - Jia Ruan, Peter Martin | English ->Korean |
Janssen Korea |
From bloodjournal.hematologylibrary.org at ORTHO CLINICAL DIAGNOSTICS on June 8, 2011. - The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma - Jonathan W. Friedberg | English ->Korean |
Janssen Korea |
Original Articles - Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma - Wolfgang Lamm | English ->Korean |
Janssen Korea |
2009 Blackwell Publishing Ltd, British Journal of Haematology, 148, 805–814 - Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma - Enrico Orciuolo | English ->Korean |
Janssen Korea |
2010 Blackwell Publishing Ltd, British Journal of Haematology, 151, 47–53 - Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma - Jorge E | English ->Korean |
Janssen Korea |
2010 Blackwell Publishing Ltd, British Journal of Haematology, 151, 346–353 - Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstro¨m macroglobulinaem | English ->Korean |
Janssen Korea |
[mAbs 1:1, 31-40; January/February 2009]; ©2009 Landes Bioscience- Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma - Lapo Alinari | English ->Korean |
Janssen Korea |
NIH Public Access Author Manuscript Br J Haematol. 2009 October ; 147(1): 89–96. - Phase I Trial of Fludarabine, Bortezomib and Rituximab for Relapsed and Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma - Paul M. Barr | English ->Korean |
Janssen Korea |
K Alexander_Papp-01-Kor_track, K Alexander_Papp-02-R2_Kor_track, K Alexander_Papp-QA-R2_Korean_track - English into Korean Proofreading (comparative table writing) - Medical Seminar Vidio script proofreading | English ->Korean video script proofreading |
Janssen Korea |
German Formulary - Magen-Darm-Mittel 60 306 - 돔페리돈- 1 A Pharma 10mg 정 | German->Korean |
Janssen Korea |
Stem Cell Transplantation • Research Paper - haematologica 2004; 89(11):November 2004 - Infliximab treatment for steroid-refractory acute graft-versus-host disease - FRANCESCA PATRIARCA | English ->Korean |
Janssen Korea |
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS BLOOD, 1 AUGUST 2004 VOLUME 104, NUMBER 3 - Tumor necrosis factor- blockade for the treatment of acute GVHD -Daniel Couriel | English ->Korean |
Janssen Korea |
Nature Publishing Group Bone Marrow Transplantation (2001) 28, 47–49 - Graft-versus-host disease - Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNF antibody - G Kobbe | English ->Korean |
Janssen Korea |
Am J Health-Syst Pharm. 2002; 59:1271-5- DRUG EXPERIENCE - Infliximab in graft-versus-host disease - ANASTASIA M. RIVKINA AND LISA S. STUMP | English ->Korean |
Janssen Korea |
CLlN1CAL CARE • ACUTE GVHD AND lNFECT10US COMPLlCATI0NS OF TRANSPLANTATION - Alloreactive CD8+ Repertoire for GVT Effect after Non-Myeloablative Hematopoietic Stem Cell Transplantation Patient with Metastatic Colon Cancer. Sumiko Kobayashi | English ->Korean |
Janssen Korea |
A Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of the Extended-release Tramadol Hcl/Acetaminophen Fixed-dose Combination Tablet for the Treatment of Chronic Lower Back Pain - Jae Hyup Lee, MD, PhD | Korean ->English |
Janssen Korea |
Sejong Claim Adjusting & Survey Co., Ltd.- Report of Insurance Cover | Korean ->English |
Janssen Korea |
REMICADE® (infliximab) Treatment of Graft versus Host Disease - Date: Sep 3, 2010 | English ->Korean |
Janssen Korea |
STELARA Prefilled Syringe (Ustekinumab) Korea Protocol - 1 Korea Post-Marketing Surveillance Protocol | Korean ->English |
Janssen Korea |
Stelara MOA Transcription Video dictation, translation & dubbing | English ->Korean video dictation, translation & dubbing |
Janssen Korea |
Johnson & Johnson Pharmaceutical Research & Development - R108512 (prucalopride) Prucalopride: Position Paper for South Korean Authorities - Issue Date: 27 July 2011 | English ->Korean |
Janssen Korea |
Barn Dance Questions | English ->Korean |
Janssen Korea |
Behaviour Cardsred. | English ->Korean |
Janssen Korea |
Behaviour Cards yellow | English ->Korean |
Janssen Korea |
Venue Specifications for 5 Conversations Training including TTT - Room specifications and set up details | English ->Korean |
Janssen Korea |
Leading Coaching and the 5 Conversations Train the Trainer Run Sheet and Trainer Notes – V3 | English ->Korean |
Janssen Korea |
Leading Coaching and the 5 Conversations Administration Checklist | English ->Korean |
Janssen Korea |
Leading Coaching and the 5 Conversations Train the Trainer Run Sheet and Trainer Notes – V3 - Agenda Overview – Day One | English ->Korean |
Janssen Korea |
Driving Employee Engagement to Improve Financial Performance – 2007 WorkCanada™ Survey Report – Watson Wyatt Worldwide | English ->Korean |
Janssen Korea |
Conversations Flow Diagram Wall chart | English ->Korean |
Janssen Korea |
Conversations Models Pyramid Wall chart | English ->Korean |
Janssen Korea |
Leading Coaching & the 5 Conversations – You’re the one | English ->Korean |
Janssen Korea |
Macklin Holdings Pty. Ltd - Purpose - Build regional HR capability in delivery and support of the Leading Coaching and the 5 Conversations program. - Learning Outcomes | English ->Korean |
Janssen Korea |
Leading Coaching & the 5 Conversations - Pre Reading Overview | English ->Korean |
Janssen Korea |
2011 Performance & Development (P&D) – 9-point scale | English ->Korean |
Janssen Korea |
German Formulary - [제품명] 로페린캅셀(염산로페라미드)수출명:이모디움캅셀(염산로페라미드), 로페린시럽(염산로페라미드)[수출용:이모디움시럽(염산로페라미드)], 리보스틴점안액(레보카바스틴염산염), 틴세트정30밀리그람(옥사토마이드), 리보스틴네잘스프레이(레보카바스틴염산염), 파리에트정10, 20밀리그람(라베프라졸) | German->Korean |
Janssen Korea |
Leading Coaching and the 5 Conversations Handouts - A SMART Goal Setting - Review the following goals. Are they A SMART? How would you improve each goal? | English ->Korean |
Janssen Korea |
Macklin Holdings Pty Ltd. - Leading Coaching & the 5 Conversations – You’re the one - “The single biggest problem in communication is the illusion that it has taken place.” George Bernard Shaw | English ->Korean |
Janssen Korea |
Leading Coaching & the 5 Conversations – Train the Trainer | English ->Korean |
Janssen Korea |
German Formulary - [제품명] 파리에트정20밀리그람(라베프라졸), , 아레스탈정(로페라미드옥사이드), 모티리움-엠정(돔페리돈말레산염), 니조랄액1%(케토코나졸), 니조랄크림(케토코나졸), 니조랄액(케토코나졸), 후루버말정(플루벤다졸) | German->Korean |
Janssen Korea |
Health Technology Assessment 2006; Vol. 10: No. 46 - Etanercept and efalizumab for the treatment of psoriasis: a systematic review - N Woolacott - Health Technology Assessment HTA NHS R&D HTA Programme | English ->Korean |
Janssen Korea |
Medical Staff Survey & Patient Survey - This nationwide survey is conducted by the Korean Society For Hospice and Palliative Care. The purpose of this survey is to obtain basic data for pain management and recognition of cancer patients. | Korean ->English |